DRUG,TYPE OF DRUG_GENE INTERACTION,DRUG_CLASS,Level of Evidence,GENE/GENE_COMBINATION,SINGLE PROFILE,GENE 1,GENE 2,GENE 3,Additional Information,Professional Guidelines,Phenotype/RS_ID,Phenotype 1,RS_ID/GENOTYPE1,Score 1A,Score 1B,Score 1C,Score 1D,Score 1E,Score 1F,Score 1G,Score 1H,Score 1I,Score 1J,Score 1K,Phenotype 2,RS_ID/GENOTYPE2,Score 2A,Phenotype 3,RS_ID/GENOTYPE3,Score 3A,Drug_Gene interaction,Type of Action,Phenotype_Category,Icon,Recommendation,Other not recommended Drugs,Recommended Drug,COMMENT_ARTI
Loratadine,Actionable,ALLERGY,Level 2C,CYP2D6 + CYP3A4,No,CYP2D6,CYP3A4,-,-,-,CYP2D6: Ultrarapid Metabolizer (>2)| CYP3A4: Intermediate Metabolizer,Ultrarapid Metabolizer,-,>2,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,-,-,-,-,Exposure Can't be determined,Use with Caution,PK,‚ö†Ô∏è,-,-,-,"CYP3A4 and CYP2D6 both are responsible for metabolizing loratadine to descarboethoxyloratadine. This primary metabolite is 4 times more pharmacologically active than loratadine. So, both have beeb included for prediction purposes."
Loratadine,Actionable,ALLERGY,Level 2C,CYP2D6 + CYP3A4,No,CYP2D6,CYP3A4,-,-,-,CYP2D6: Ultrarapid Metabolizer (>2)| CYP3A4: Poor Metabolizer,Ultrarapid Metabolizer,-,>2,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,-,-,-,-,Exposure Can't be determined,Use with Caution,PK,‚ö†Ô∏è,-,-,-,"CYP3A4 and CYP2D6 both are responsible for metabolizing loratadine to descarboethoxyloratadine. This primary metabolite is 4 times more pharmacologically active than loratadine. So, both have beeb included for prediction purposes."
Loratadine,Actionable,ALLERGY,Level 2C,CYP2D6 + CYP3A4,No,CYP2D6,CYP3A4,-,-,-,CYP2D6: Ultrarapid Metabolizer (>2)| CYP3A4: Normal Metabolizer,Ultrarapid Metabolizer,-,>2,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,-,-,-,-,Decreased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,"CYP3A4 and CYP2D6 both are responsible for metabolizing loratadine to descarboethoxyloratadine. This primary metabolite is 4 times more pharmacologically active than loratadine. So, both have beeb included for prediction purposes."
Loratadine,Actionable,ALLERGY,Level 2C,CYP2D6 + CYP3A4,No,CYP2D6,CYP3A4,-,-,-,"CYP2D6: Normal metabolizer (1, 1.5 and 2)| CYP3A4: Intermediate Metabolizer",Normal metabolizer,-,1,1.5,2,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,-,-,-,-,Increased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,"CYP3A4 and CYP2D6 both are responsible for metabolizing loratadine to descarboethoxyloratadine. This primary metabolite is 4 times more pharmacologically active than loratadine. So, both have beeb included for prediction purposes."
Loratadine,Actionable,ALLERGY,Level 2C,CYP2D6 + CYP3A4,No,CYP2D6,CYP3A4,-,-,-,CYP2D6: Normal metabolizer (1.5 and 2)| CYP3A4: Poor Metabolizer,Normal metabolizer,-,1.5,2,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,-,-,-,-,Increased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,"CYP3A4 and CYP2D6 both are responsible for metabolizing loratadine to descarboethoxyloratadine. This primary metabolite is 4 times more pharmacologically active than loratadine. So, both have beeb included for prediction purposes."
Loratadine,Actionable,ALLERGY,Level 2C,CYP2D6 + CYP3A4,No,CYP2D6,CYP3A4,-,-,-,CYP2D6: Normal metabolizer (1.5 and 2)| CYP3A4: Normal Metabolizer,Normal metabolizer,-,1.5,2,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,"CYP3A4 and CYP2D6 both are responsible for metabolizing loratadine to descarboethoxyloratadine. This primary metabolite is 4 times more pharmacologically active than loratadine. So, both have beeb included for prediction purposes."
Loratadine,Actionable,ALLERGY,Level 2C,CYP2D6 + CYP3A4,No,CYP2D6,CYP3A4,-,-,-,CYP2D6: Intermediate Metabolizer | CYP3A4: Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,-,-,-,-,Increased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,"CYP3A4 and CYP2D6 both are responsible for metabolizing loratadine to descarboethoxyloratadine. This primary metabolite is 4 times more pharmacologically active than loratadine. So, both have beeb included for prediction purposes."
Loratadine,Actionable,ALLERGY,Level 2C,CYP2D6 + CYP3A4,No,CYP2D6,CYP3A4,-,-,-,CYP2D6: Intermediate Metabolizer | CYP3A4: Poor Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,-,-,-,-,Increased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,"CYP3A4 and CYP2D6 both are responsible for metabolizing loratadine to descarboethoxyloratadine. This primary metabolite is 4 times more pharmacologically active than loratadine. So, both have beeb included for prediction purposes."
Loratadine,Actionable,ALLERGY,Level 2C,CYP2D6 + CYP3A4,No,CYP2D6,CYP3A4,-,-,-,CYP2D6: Intermediate Metabolizer | CYP3A4: Normal Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,-,-,-,-,Increased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,"CYP3A4 and CYP2D6 both are responsible for metabolizing loratadine to descarboethoxyloratadine. This primary metabolite is 4 times more pharmacologically active than loratadine. So, both have beeb included for prediction purposes."
Loratadine,Actionable,ALLERGY,Level 2C,CYP2D6 + CYP3A4,No,CYP2D6,CYP3A4,-,-,-,CYP2D6: Poor Metabolizer | CYP3A4: Intermediate Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,-,-,-,-,Increased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,"CYP3A4 and CYP2D6 both are responsible for metabolizing loratadine to descarboethoxyloratadine. This primary metabolite is 4 times more pharmacologically active than loratadine. So, both have beeb included for prediction purposes."
Loratadine,Actionable,ALLERGY,Level 2C,CYP2D6 + CYP3A4,No,CYP2D6,CYP3A4,-,-,-,CYP2D6: Poor Metabolizer | CYP3A4: Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,-,-,-,-,Increased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,"CYP3A4 and CYP2D6 both are responsible for metabolizing loratadine to descarboethoxyloratadine. This primary metabolite is 4 times more pharmacologically active than loratadine. So, both have beeb included for prediction purposes."
Loratadine,Actionable,ALLERGY,Level 2C,CYP2D6 + CYP3A4,No,CYP2D6,CYP3A4,-,-,-,CYP2D6: Poor Metabolizer | CYP3A4: Normal Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,-,-,-,-,Increased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,"CYP3A4 and CYP2D6 both are responsible for metabolizing loratadine to descarboethoxyloratadine. This primary metabolite is 4 times more pharmacologically active than loratadine. So, both have beeb included for prediction purposes."
Alfentanil,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 2B,OPRM1,Yes,OPRM1,-,-,-,CPIC (No recommendation),Asn/Asn isoform,-,Asn/Asn isoform,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Response,Use as Directed,-,‚úÖ,-,-,-,"Alfentanil undergoes significant metabolism by CYP3A4 through two main pathways, resulting in the formation of noralfentanil and N-phenylpropionamide. While there are no reported instances of CYP3A4 polymorphism causing changes in pharmacokinetics (PK), there seems to be some predictive value in OPRM1 polymorphism for determining its action. So, only OPRM1 is included in the evidence database."
Alfentanil,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 2B,OPRM1,Yes,OPRM1,-,-,-,CPIC (No recommendation),Asn/Asp isoform,-,Asn/Asp isoform,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Reduced Response (Analgesic),Use with Caution,Efficacy,‚ö†Ô∏è,-,-,-,"Alfentanil undergoes significant metabolism by CYP3A4 through two main pathways, resulting in the formation of noralfentanil and N-phenylpropionamide. While there are no reported instances of CYP3A4 polymorphism causing changes in pharmacokinetics (PK), there seems to be some predictive value in OPRM1 polymorphism for determining its action. So, only OPRM1 is included in the evidence database."
Alfentanil,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 2B,OPRM1,Yes,OPRM1,-,-,-,CPIC (No recommendation),Asp/Asp isoform,-,Asp/Asp isoform,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Reduced Response (Analgesic),Use with Caution,Efficacy,‚ö†Ô∏è,-,-,-,"Alfentanil undergoes significant metabolism by CYP3A4 through two main pathways, resulting in the formation of noralfentanil and N-phenylpropionamide. While there are no reported instances of CYP3A4 polymorphism causing changes in pharmacokinetics (PK), there seems to be some predictive value in OPRM1 polymorphism for determining its action. So, only OPRM1 is included in the evidence database."
Buprenorphine,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 2B,CYP3A4,Yes,CYP3A4,-,-,-,CPIC (No recommendation),Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Response,Use as Directed,-,‚úÖ,-,-,-,"PharmGKB provides information about the analgesic response to buprenorphine through rs2740574. However, this particular study conducted at the University Hospital of Salamanca focused specifically on individuals of African American/Afro-Caribbean descent. Therefore, although the data from this study has not been included in the database, it may still be relevant for patients belonging to that ethnic region."
Buprenorphine,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 2B,CYP3A4,Yes,CYP3A4,-,-,-,CPIC (No recommendation),Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Reduced Response,Use with Caution,Efficacy,‚ö†Ô∏è,-,-,-,"PharmGKB provides information about the analgesic response to buprenorphine through rs2740574. However, this particular study conducted at the University Hospital of Salamanca focused specifically on individuals of African American/Afro-Caribbean descent. Therefore, although the data from this study has not been included in the database, it may still be relevant for patients belonging to that ethnic region."
Buprenorphine,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 2B,CYP3A4,Yes,CYP3A4,-,-,-,CPIC (No recommendation),Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Reduced Response,Use with Caution,Efficacy,‚ö†Ô∏è,-,-,-,"PharmGKB provides information about the analgesic response to buprenorphine through rs2740574. However, this particular study conducted at the University Hospital of Salamanca focused specifically on individuals of African American/Afro-Caribbean descent. Therefore, although the data from this study has not been included in the database, it may still be relevant for patients belonging to that ethnic region."
Carisoprodol,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 1BB,CYP2C19,Yes,CYP2C19,-,-,FDA evidence,-,Ultrarapid Metabolizer,Ultrarapid Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,"PharmGKB offers information on pharmacokinetics (PK) supported by level 4 evidence. In order to account for genotypic variations and exercise caution, certain genotypes associated with differential functional variants of genes were specifically flagged."
Carisoprodol,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 1BB,CYP2C19,Yes,CYP2C19,-,-,FDA evidence,-,Rapid Metabolizer,Rapid Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,"PharmGKB offers information on pharmacokinetics (PK) supported by level 4 evidence. In order to account for genotypic variations and exercise caution, certain genotypes associated with differential functional variants of genes were specifically flagged."
Carisoprodol,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 1BB,CYP2C19,Yes,CYP2C19,-,-,FDA evidence,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,"PharmGKB offers information on pharmacokinetics (PK) supported by level 4 evidence. In order to account for genotypic variations and exercise caution, certain genotypes associated with differential functional variants of genes were specifically flagged."
Carisoprodol,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 1BB,CYP2C19,Yes,CYP2C19,-,-,FDA evidence,-,Likely Intermediate Metabolizer,Likely Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal or Increased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,"PharmGKB offers information on pharmacokinetics (PK) supported by level 4 evidence. In order to account for genotypic variations and exercise caution, certain genotypes associated with differential functional variants of genes were specifically flagged."
Carisoprodol,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 1BB,CYP2C19,Yes,CYP2C19,-,-,FDA evidence,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,"PharmGKB offers information on pharmacokinetics (PK) supported by level 4 evidence. In order to account for genotypic variations and exercise caution, certain genotypes associated with differential functional variants of genes were specifically flagged."
Carisoprodol,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 1BB,CYP2C19,Yes,CYP2C19,-,-,FDA evidence,-,Likely Poor Metabolizer,Likely Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,"PharmGKB offers information on pharmacokinetics (PK) supported by level 4 evidence. In order to account for genotypic variations and exercise caution, certain genotypes associated with differential functional variants of genes were specifically flagged."
Carisoprodol,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 1B,CYP2C19,Yes,CYP2C19,-,-,FDA evidence,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,"PharmGKB offers information on pharmacokinetics (PK) supported by level 4 evidence. In order to account for genotypic variations and exercise caution, certain genotypes associated with differential functional variants of genes were specifically flagged."
Carisoprodol,Actionable,ANALGESIC / ANESTHESIOLOGY,n/a,CYP2C19,Yes,CYP2C19,-,-,FDA evidence,-,Indeterminate,Indeterminate,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,n/a,-,n/a,-,-,-,-,"PharmGKB offers information on pharmacokinetics (PK) supported by level 4 evidence. In order to account for genotypic variations and exercise caution, certain genotypes associated with differential functional variants of genes were specifically flagged."
Codeine,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 1A (Strong),CYP2D6,Yes,CYP2D6,-,-,Professional guideline; FDA evidence,"CPIC, DPWG",Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure; Reduced Response (diminished analgesia),Increased Caution/Avoid,Efficacy,üõë,"Avoid Codeine use. If opioid use is warranted, consider a non-tramadol opioid.","-Do not select tramadol, as this is also metabolised by CYP2D6. ","Morphine is not metabolised by CYP2D6. Oxycodone is metabolised by CYP2D6 to a limited extent, but this does not result in differences in analgesia in patients.",-
Codeine,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 1A (Moderate),CYP2D6,Yes,CYP2D6,-,-,Professional guideline; FDA evidence,"CPIC, DPWG",Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure,Use with Caution,Efficacy,‚ö†Ô∏è,"Use codeine label dosing. If no response and opioid use is warranted, consider a non-tramadol opioid.","-Do not select tramadol, as this is also metabolised by CYP2D6. ","Morphine is not metabolised by CYP2D6. Oxycodone is metabolised by CYP2D6 to a limited extent, but this does not result in differences in analgesia in patients.",-
Codeine,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 1A (Strong),CYP2D6,Yes,CYP2D6,-,-,Professional guideline; FDA evidence,"CPIC, DPWG",Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,Use codeine label recommended dosing.,-,-,-
Codeine,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 1A (Strong),CYP2D6,Yes,CYP2D6,-,-,Professional guideline; FDA evidence,"CPIC, DPWG",Ultrarapid Metabolizer (>2),Ultrarapid Metabolizer,-,>2,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure; Increased Risk of ADR,Increased Caution/Avoid,Toxicity,üõë,"Avoid codeine use. If opioid use is warranted, consider a non-tramadol opioid.","- For PAIN: do not select tramadol, as this is also metabolised by CYP2D6. 
","-FOR PAIN: Morphine is not metabolized by CYP2D6. Oxycodone is metabolized by CYP2D6 to a limited extent, but this does not result in differences in side effects in patients.- For COUGH: noscapine is not metabolized by CYP2D6. 
-For COUGH: noscapine is not metabolized by CYP2D6.",-
Codeine,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 1A (No recommendation),CYP2D6,Yes,CYP2D6,-,-,Professional guideline; FDA evidence,"CPIC, DPWG",Indeterminate,Indeterminate,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,n/a,Use as Directed,-,-,No recommendation,-,-,-
Cyclobenzaprine,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 2C,CYP1A2,Yes,CYP1A2,-,-,-,-,Extensive Metabolizer,Extensive Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Cyclobenzaprine,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 2C,CYP1A2,Yes,CYP1A2,-,-,-,-,High Inducibility,High Inducibility,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Cyclobenzaprine,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 2C,CYP1A2,Yes,CYP1A2,-,-,-,-,Slow metabolizers; *1C heterozygous,Slow metabolizers,*1C Heterozygous,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with caution,PK,‚ö†Ô∏è,-,-,-,-
Cyclobenzaprine,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 2C,CYP1A2,Yes,CYP1A2,-,-,-,-,Intermediate metabolizer,Intermediate metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with caution,PK,‚ö†Ô∏è,-,-,-,-
Cyclobenzaprine,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 2C,CYP1A2,Yes,CYP1A2,-,-,-,-,Slow metabolizers; *1C Homozygous,Slow metabolizers,*1C Homozygous,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with caution,PK,‚ö†Ô∏è,-,-,-,-
Cyclobenzaprine,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 2C,CYP1A2,Yes,CYP1A2,-,-,-,-,Poor metabolizer,Poor metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with caution,PK,‚ö†Ô∏è,-,-,-,-
Cyclobenzaprine,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 2C,CYP3A4,Yes,CYP3A4,-,-,-,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Cyclobenzaprine,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 2C,CYP3A4,Yes,CYP3A4,-,-,-,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with caution,PK,‚ö†Ô∏è,-,-,-,-
Cyclobenzaprine,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 2C,CYP3A4,Yes,CYP3A4,-,-,-,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with caution,PK,‚ö†Ô∏è,-,-,-,-
Cyclobenzaprine,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 2C,CYP1A2 + CYP3A4,No,CYP1A2,CYP3A4,-,-,-,CYP1A2: Extensive Metabolizer + CYP3A4: Poor Metabolizer,Extensive Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,-,-,-,-,Increased Exposure,Use with caution,PK,‚ö†Ô∏è,-,-,-,-
Cyclobenzaprine,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 2C,CYP1A2 + CYP3A4,No,CYP1A2,CYP3A4,-,-,-,CYP1A2: High Inducibility + CYP3A4: Poor Metabolizer,High Inducibility,-,-,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,-,-,-,-,Increased Exposure,Use with caution,PK,‚ö†Ô∏è,-,-,-,-
Cyclobenzaprine,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 2C,CYP1A2 + CYP3A4,No,CYP1A2,CYP3A4,-,-,-,CYP1A2: Slow metabolizers; *1C heterozygous  + CYP3A4: Poor Metabolizer,Slow metabolizers,*1C Heterozygous,-,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,-,-,-,-,Increased Exposure,Use with caution,PK,‚ö†Ô∏è,-,-,-,-
Cyclobenzaprine,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 2C,CYP1A2 + CYP3A4,No,CYP1A2,CYP3A4,-,-,-,CYP1A2: Intermediate metabolizer  + CYP3A4: Poor Metabolizer,Intermediate metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,-,-,-,-,Increased Exposure,Use with caution,PK,‚ö†Ô∏è,-,-,-,-
Cyclobenzaprine,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 2C,CYP1A2 + CYP3A4,No,CYP1A2,CYP3A4,-,-,-,CYP1A2: Slow metabolizers; *1C Homozygous + CYP3A4: Poor Metabolizer,Slow metabolizers,*1C Homozygous,-,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,-,-,-,-,Increased Exposure,Use with caution,PK,‚ö†Ô∏è,-,-,-,-
Cyclobenzaprine,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 2C,CYP1A2 + CYP3A4,No,CYP1A2,CYP3A4,-,-,-,CYP1A2: Poor metabolizer + CYP3A4: Poor Metabolizer,Poor metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,-,-,-,-,Increased Exposure,Use with caution,PK,‚ö†Ô∏è,-,-,-,-
Cyclobenzaprine,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 2C,CYP1A2 + CYP3A4,No,CYP1A2,CYP3A4,-,-,-,CYP1A2: Extensive Metabolizer + CYP3A4: Normal Metabolizer,Extensive Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Cyclobenzaprine,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 2C,CYP1A2 + CYP3A4,No,CYP1A2,CYP3A4,-,-,-,CYP1A2: High Inducibility + CYP3A4: Normal Metabolizer,High Inducibility,-,-,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Cyclobenzaprine,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 2C,CYP1A2 + CYP3A4,No,CYP1A2,CYP3A4,-,-,-,CYP1A2: Slow metabolizers; *1C heterozygous + CYP3A4: Normal Metabolizer,Slow metabolizers,*1C Heterozygous,-,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,-,-,-,-,Increased Exposure,Use with caution,PK,‚ö†Ô∏è,-,-,-,-
Cyclobenzaprine,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 2C,CYP1A2 + CYP3A4,No,CYP1A2,CYP3A4,-,-,-,CYP1A2: Intermediate metabolizer + CYP3A4: Normal Metabolizer,Intermediate metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,-,-,-,-,Increased Exposure,Use with caution,PK,‚ö†Ô∏è,-,-,-,-
Cyclobenzaprine,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 2C,CYP1A2 + CYP3A4,No,CYP1A2,CYP3A4,-,-,-,CYP1A2: Slow metabolizers; *1C Homozygous + CYP3A4: Normal Metabolizer,Slow metabolizers,*1C Homozygous,-,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,-,-,-,-,Increased Exposure,Use with caution,PK,‚ö†Ô∏è,-,-,-,-
Cyclobenzaprine,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 2C,CYP1A2 + CYP3A4,No,CYP1A2,CYP3A4,-,-,-,CYP1A2: Poor metabolizer + CYP3A4: Normal Metabolizer,Poor metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,-,-,-,-,Increased Exposure,Use with caution,PK,‚ö†Ô∏è,-,-,-,-
Cyclobenzaprine,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 2C,CYP1A2 + CYP3A4,No,CYP1A2,CYP3A4,-,-,-,CYP1A2: Extensive Metabolizer + CYP3A4: Intermediate Metabolizer,Extensive Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,-,-,-,-,Increased Exposure,Use with caution,PK,‚ö†Ô∏è,-,-,-,-
Cyclobenzaprine,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 2C,CYP1A2 + CYP3A4,No,CYP1A2,CYP3A4,-,-,-,CYP1A2: High Inducibility + CYP3A4: Intermediate Metabolizer,High Inducibility,-,-,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,-,-,-,-,Increased Exposure,Use with caution,PK,‚ö†Ô∏è,-,-,-,-
Cyclobenzaprine,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 2C,CYP1A2 + CYP3A4,No,CYP1A2,CYP3A4,-,-,-,CYP1A2: Slow metabolizers; *1C heterozygous + CYP3A4: Intermediate Metabolizer,Slow metabolizers,*1C Heterozygous,-,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,-,-,-,-,Increased Exposure,Use with caution,PK,‚ö†Ô∏è,-,-,-,-
Cyclobenzaprine,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 2C,CYP1A2 + CYP3A4,No,CYP1A2,CYP3A4,-,-,-,CYP1A2: Intermediate metabolizer + CYP3A4: Intermediate Metabolizer,Intermediate metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,-,-,-,-,Increased Exposure,Use with caution,PK,‚ö†Ô∏è,-,-,-,-
Cyclobenzaprine,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 2C,CYP1A2 + CYP3A4,No,CYP1A2,CYP3A4,-,-,-,CYP1A2: Slow metabolizers; *1C Homozygous + CYP3A4: Intermediate Metabolizer,Slow metabolizers,*1C Homozygous,-,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,-,-,-,-,Increased Exposure,Use with caution,PK,‚ö†Ô∏è,-,-,-,-
Cyclobenzaprine,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 2C,CYP1A2 + CYP3A4,No,CYP1A2,CYP3A4,-,-,-,CYP1A2: Poor metabolizer + CYP3A4: Intermediate Metabolizer,Poor metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,-,-,-,-,Increased Exposure,Use with caution,PK,‚ö†Ô∏è,-,-,-,-
Fentanyl,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,CPIC (No recommendation),Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,Dosing,‚úÖ,-,-,-,Studies done in East Asian Population shows role of rs2242480 in predicting the analgesic responses. It hasn't been incorporated in this report but can be done based on ethnicity.
Fentanyl,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,CPIC (No recommendation),Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,Dosing,‚ö†Ô∏è,-,-,-,Studies done in East Asian Population shows role of rs2242480 in predicting the analgesic responses. It hasn't been incorporated in this report but can be done based on ethnicity.
Fentanyl,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,CPIC (No recommendation),Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,Dosing,‚ö†Ô∏è,-,-,-,Studies done in East Asian Population shows role of rs2242480 in predicting the analgesic responses. It hasn't been incorporated in this report but can be done based on ethnicity.
Hydrocodone,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 1A(Optional),CYP2D6,Yes,CYP2D6,-,-,Professional guideline,CPIC,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure,Use with Caution,Efficacy,‚ö†Ô∏è,"Use hydrocodone label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider non-codeine and non-tramadol opioid.",-,-,-
Hydrocodone,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 1A(Optional),CYP2D6,Yes,CYP2D6,-,-,Professional guideline,CPIC,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure,Use with Caution,Efficacy,‚ö†Ô∏è,"Use hydrocodone label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider non-codeine and non-tramadol opioid.",-,-,-
Hydrocodone,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 1A(Strong),CYP2D6,Yes,CYP2D6,-,-,Professional guideline,CPIC,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,Use hydrocodone label recommended age- or weight-specific dosing.,-,-,-
Hydrocodone,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 1A(No Recommendation),CYP2D6,Yes,CYP2D6,-,-,Professional guideline,CPIC,Ultrarapid Metabolizer (>2),Ultrarapid Metabolizer,-,>2,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure; Minimal Evidence for Clinical Impact,Use with Caution,Efficacy,‚ö†Ô∏è,No recommendation for hydrocodone therapy because of minimal evidence regarding adverse events or analgesia.,-,-,-
Hydrocodone,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 1A(No Recommendation),CYP2D6,Yes,CYP2D6,-,-,Professional guideline,CPIC,Indeterminate,Indeterminate,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,n/a,Use as Directed,-,-,No recommendation,-,-,-
Hydromorphone,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 2C,Liver Phase 2(Glucuronidation),Yes,Liver Phase 2(Glucuronidation),-,-,-,CPIC (No recommendation),Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,"Hydromorphone is subject to phase 2 elimination, which involves no  participation of cytochrome P450 (CYP) enzymes."
Ibuprofen,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 1A(Moderate),CYP2C9,Yes,CYP2C9,-,-,Professional guideline,CPIC,"Poor Metabolizer (0.0, 0.5)",Poor Metabolizer,-,0,0.5,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,Initiate therapy with 25-50% of the lowest recommended starting dose and titrate dose upward to clinical effect or consider an alternate therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo [CPIC],-,"Alternative therapies not primarily metabolized by CYP2C9 include aspirin, ketorolac, naproxen and sulindac. Selection of therapy will depend on individual patient treatment goals and risks for toxicity.","While there is no alteration in the recommendation for intermediate metabolizer (IM), caution is advised due to the patient's genotype, as it may interact with other risk factors and potentially increase the likelihood of adverse events compared to individuals with normal metabolism."
Ibuprofen,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 1A(Moderate),CYP2C9,Yes,CYP2C9,-,-,Professional guideline,CPIC,Intermediate Metabolizer (1.0),Intermediate Metabolizer,-,1,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,Toxicity,‚ö†Ô∏è,"Initiate therapy with lowest recommended starting dose. Titrate dose upward to clinical effect or maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Carefully monitor adverse events such as blood pressure and kidney function during course of therapy.",-,-,"While there is no alteration in the recommendation for intermediate metabolizer (IM), caution is advised due to the patient's genotype, as it may interact with other risk factors and potentially increase the likelihood of adverse events compared to individuals with normal metabolism."
Ibuprofen,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 1A(Moderate),CYP2C9,Yes,CYP2C9,-,-,Professional guideline,CPIC,Intermediate Metabolizer(1.5),Intermediate Metabolizer,-,1.5,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use with Caution,Toxicity,‚ö†Ô∏è,"Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.",-,-,"While there is no alteration in the recommendation for intermediate metabolizer (IM), caution is advised due to the patient's genotype, as it may interact with other risk factors and potentially increase the likelihood of adverse events compared to individuals with normal metabolism."
Ibuprofen,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 1A(Strong),CYP2C9,Yes,CYP2C9,-,-,Professional guideline,CPIC,Normal Metabolizer(2.0),Normal Metabolizer,-,2,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,"Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.",-,-,"While there is no alteration in the recommendation for intermediate metabolizer (IM), caution is advised due to the patient's genotype, as it may interact with other risk factors and potentially increase the likelihood of adverse events compared to individuals with normal metabolism."
Ibuprofen,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 1A(No Recommendation),CYP2C9,Yes,CYP2C9,-,-,Professional guideline,CPIC,Indeterminate(n/a),Indeterminate,-,n/a,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,No recommendation,-,-,"While there is no alteration in the recommendation for intermediate metabolizer (IM), caution is advised due to the patient's genotype, as it may interact with other risk factors and potentially increase the likelihood of adverse events compared to individuals with normal metabolism."
Ketamine,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 2C,CYP2B6,Yes,CYP2B6,-,-,-,-,Indeterminate,Indeterminate,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,"When it comes to Ketamine, both CYP3A4 and CYP2B6 enzymes carry similar significance. Therefore, the course of action should be determined based on the genotypes of both enzymes."
Ketamine,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 2C,CYP2B6,Yes,CYP2B6,-,-,-,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,"When it comes to Ketamine, both CYP3A4 and CYP2B6 enzymes carry similar significance. Therefore, the course of action should be determined based on the genotypes of both enzymes."
Ketamine,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 2C,CYP2B6,Yes,CYP2B6,-,-,-,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,"When it comes to Ketamine, both CYP3A4 and CYP2B6 enzymes carry similar significance. Therefore, the course of action should be determined based on the genotypes of both enzymes."
Ketamine,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 2C,CYP2B6,Yes,CYP2B6,-,-,-,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,"When it comes to Ketamine, both CYP3A4 and CYP2B6 enzymes carry similar significance. Therefore, the course of action should be determined based on the genotypes of both enzymes."
Ketamine,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 2C,CYP2B6,Yes,CYP2B6,-,-,-,-,Rapid Metabolizer,Rapid Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,"When it comes to Ketamine, both CYP3A4 and CYP2B6 enzymes carry similar significance. Therefore, the course of action should be determined based on the genotypes of both enzymes."
Ketamine,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 2C,CYP2B6,Yes,CYP2B6,-,-,-,-,Ultrarapid Metabolizer,Ultrarapid Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,"When it comes to Ketamine, both CYP3A4 and CYP2B6 enzymes carry similar significance. Therefore, the course of action should be determined based on the genotypes of both enzymes."
Ketamine,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 2C,CYP3A4,Yes,CYP3A4,-,-,-,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,"When it comes to Ketamine, both CYP3A4 and CYP2B6 enzymes carry similar significance. Therefore, the course of action should be determined based on the genotypes of both enzymes."
Ketamine,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 2C,CYP3A4,Yes,CYP3A4,-,-,-,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,"When it comes to Ketamine, both CYP3A4 and CYP2B6 enzymes carry similar significance. Therefore, the course of action should be determined based on the genotypes of both enzymes."
Ketamine,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 2C,CYP3A4,Yes,CYP3A4,-,-,-,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,"When it comes to Ketamine, both CYP3A4 and CYP2B6 enzymes carry similar significance. Therefore, the course of action should be determined based on the genotypes of both enzymes."
Ketamine,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 2C,CYP2B6 + CYP3A4,No,CYP2B6,CYP3A4,-,-,-,CYP2B6: Indeterminate + CYP3A4: Normal Metabolizer,Indeterminate,-,-,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,-,-,-,-,na,-,-,-,-,-,-,"When it comes to Ketamine, both CYP3A4 and CYP2B6 enzymes carry similar significance. Therefore, the course of action should be determined based on the genotypes of both enzymes."
Ketamine,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 2C,CYP2B6 + CYP3A4,No,CYP2B6,CYP3A4,-,-,-,CYP2B6: Intermediate Metabolizer + CYP3A4: Normal Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,-,-,-,-,Increased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,"When it comes to Ketamine, both CYP3A4 and CYP2B6 enzymes carry similar significance. Therefore, the course of action should be determined based on the genotypes of both enzymes."
Ketamine,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 2C,CYP2B6 + CYP3A4,No,CYP2B6,CYP3A4,-,-,-,CYP2B6: Normal Metabolizer + CYP3A4: Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,"When it comes to Ketamine, both CYP3A4 and CYP2B6 enzymes carry similar significance. Therefore, the course of action should be determined based on the genotypes of both enzymes."
Ketamine,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 2C,CYP2B6 + CYP3A4,No,CYP2B6,CYP3A4,-,-,-,CYP2B6: Poor Metabolizer + CYP3A4: Normal Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,-,-,-,-,Increased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,"When it comes to Ketamine, both CYP3A4 and CYP2B6 enzymes carry similar significance. Therefore, the course of action should be determined based on the genotypes of both enzymes."
Ketamine,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 2C,CYP2B6 + CYP3A4,No,CYP2B6,CYP3A4,-,-,-,CYP2B6: Rapid Metabolizer + CYP3A4: Normal Metabolizer,Rapid Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,-,-,-,-,Decreased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,"When it comes to Ketamine, both CYP3A4 and CYP2B6 enzymes carry similar significance. Therefore, the course of action should be determined based on the genotypes of both enzymes."
Ketamine,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 2C,CYP2B6 + CYP3A4,No,CYP2B6,CYP3A4,-,-,-,CYP2B6: Ultrarapid Metabolizer + CYP3A4: Normal Metabolizer,Ultrarapid Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,-,-,-,-,Decreased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,"When it comes to Ketamine, both CYP3A4 and CYP2B6 enzymes carry similar significance. Therefore, the course of action should be determined based on the genotypes of both enzymes."
Ketamine,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 2C,CYP2B6 + CYP3A4,No,CYP2B6,CYP3A4,-,-,-,CYP2B6: Indeterminate + CYP3A4: Intermediate Metabolizer,Indeterminate,-,-,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,-,-,-,-,Increased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,"When it comes to Ketamine, both CYP3A4 and CYP2B6 enzymes carry similar significance. Therefore, the course of action should be determined based on the genotypes of both enzymes."
Ketamine,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 2C,CYP2B6 + CYP3A4,No,CYP2B6,CYP3A4,-,-,-,CYP2B6: Intermediate Metabolizer + CYP3A4: Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,-,-,-,-,Increased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,"When it comes to Ketamine, both CYP3A4 and CYP2B6 enzymes carry similar significance. Therefore, the course of action should be determined based on the genotypes of both enzymes."
Ketamine,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 2C,CYP2B6 + CYP3A4,No,CYP2B6,CYP3A4,-,-,-,CYP2B6: Normal Metabolizer + CYP3A4: Intermediate Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,-,-,-,-,Increased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,"When it comes to Ketamine, both CYP3A4 and CYP2B6 enzymes carry similar significance. Therefore, the course of action should be determined based on the genotypes of both enzymes."
Ketamine,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 2C,CYP2B6 + CYP3A4,No,CYP2B6,CYP3A4,-,-,-,CYP2B6: Poor Metabolizer + CYP3A4: Intermediate Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,-,-,-,-,Increased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,"When it comes to Ketamine, both CYP3A4 and CYP2B6 enzymes carry similar significance. Therefore, the course of action should be determined based on the genotypes of both enzymes."
Ketamine,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 2C,CYP2B6 + CYP3A4,No,CYP2B6,CYP3A4,-,-,-,CYP2B6: Rapid Metabolizer + CYP3A4: Intermediate Metabolizer,Rapid Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,-,-,-,-,Increased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,"When it comes to Ketamine, both CYP3A4 and CYP2B6 enzymes carry similar significance. Therefore, the course of action should be determined based on the genotypes of both enzymes."
Ketamine,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 2C,CYP2B6 + CYP3A4,No,CYP2B6,CYP3A4,-,-,-,CYP2B6: Ultrarapid Metabolizer + CYP3A4: Intermediate Metabolizer,Ultrarapid Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,-,-,-,-,Increased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,"When it comes to Ketamine, both CYP3A4 and CYP2B6 enzymes carry similar significance. Therefore, the course of action should be determined based on the genotypes of both enzymes."
Ketamine,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 2C,CYP2B6 + CYP3A4,No,CYP2B6,CYP3A4,-,-,-,CYP2B6: Indeterminate + CYP3A4: Poor Metabolizer,Indeterminate,-,-,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,-,-,-,-,Increased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,"When it comes to Ketamine, both CYP3A4 and CYP2B6 enzymes carry similar significance. Therefore, the course of action should be determined based on the genotypes of both enzymes."
Ketamine,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 2C,CYP2B6 + CYP3A4,No,CYP2B6,CYP3A4,-,-,-,CYP2B6: Intermediate Metabolizer + CYP3A4: Poor Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,-,-,-,-,Increased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,"When it comes to Ketamine, both CYP3A4 and CYP2B6 enzymes carry similar significance. Therefore, the course of action should be determined based on the genotypes of both enzymes."
Ketamine,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 2C,CYP2B6 + CYP3A4,No,CYP2B6,CYP3A4,-,-,-,CYP2B6: Normal Metabolizer + CYP3A4: Poor Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,-,-,-,-,Increased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,"When it comes to Ketamine, both CYP3A4 and CYP2B6 enzymes carry similar significance. Therefore, the course of action should be determined based on the genotypes of both enzymes."
Ketamine,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 2C,CYP2B6 + CYP3A4,No,CYP2B6,CYP3A4,-,-,-,CYP2B6: Poor Metabolizer + CYP3A4: Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,-,-,-,-,Increased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,"When it comes to Ketamine, both CYP3A4 and CYP2B6 enzymes carry similar significance. Therefore, the course of action should be determined based on the genotypes of both enzymes."
Ketamine,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 2C,CYP2B6 + CYP3A4,No,CYP2B6,CYP3A4,-,-,-,CYP2B6: Rapid Metabolizer + CYP3A4: Poor Metabolizer,Rapid Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,-,-,-,-,Increased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,"When it comes to Ketamine, both CYP3A4 and CYP2B6 enzymes carry similar significance. Therefore, the course of action should be determined based on the genotypes of both enzymes."
Ketamine,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 2C,CYP2B6 + CYP3A4,No,CYP2B6,CYP3A4,-,-,-,CYP2B6: Ultrarapid Metabolizer + CYP3A4: Poor Metabolizer,Ultrarapid Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,-,-,-,-,Increased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,"When it comes to Ketamine, both CYP3A4 and CYP2B6 enzymes carry similar significance. Therefore, the course of action should be determined based on the genotypes of both enzymes."
Lidocaine,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 1B,G6PD,Yes,G6PD,-,-,-,-,Normal,Normal,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Risk of ADR (acute hemolytic anemia),Use as Directed,-,‚úÖ,-,-,-,"According to the study, the primary enzyme involved in the metabolic processing of lidocaine in individuals with normal liver function is CYP1A2. However, apart from the metabolic enzyme, G6PD also plays a role in determining lidocaine toxicity. Therefore, it is advisable to consider both CYP1A2 and G6PD when assessing lidocaine."
Lidocaine,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 1B,G6PD,Yes,G6PD,-,-,-,-,Deficient,Deficient,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Risk of ADR (acute hemolytic anemia),Use with Caution,Toxicity,‚ö†Ô∏è,-,-,-,"According to the study, the primary enzyme involved in the metabolic processing of lidocaine in individuals with normal liver function is CYP1A2. However, apart from the metabolic enzyme, G6PD also plays a role in determining lidocaine toxicity. Therefore, it is advisable to consider both CYP1A2 and G6PD when assessing lidocaine."
Lidocaine,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 1B,G6PD,Yes,G6PD,-,-,-,-,Deficient with CNSHA,Deficient with CNSHA,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Risk of ADR (acute hemolytic anemia),Use with Caution,Toxicity,‚ö†Ô∏è,-,-,-,"According to the study, the primary enzyme involved in the metabolic processing of lidocaine in individuals with normal liver function is CYP1A2. However, apart from the metabolic enzyme, G6PD also plays a role in determining lidocaine toxicity. Therefore, it is advisable to consider both CYP1A2 and G6PD when assessing lidocaine."
Lidocaine,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 1B,G6PD,Yes,G6PD,-,-,-,-,Variable,Variable,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Risk of ADR (acute hemolytic anemia),Use as Directed,-,‚úÖ,-,-,-,"According to the study, the primary enzyme involved in the metabolic processing of lidocaine in individuals with normal liver function is CYP1A2. However, apart from the metabolic enzyme, G6PD also plays a role in determining lidocaine toxicity. Therefore, it is advisable to consider both CYP1A2 and G6PD when assessing lidocaine."
Lidocaine,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 1B,G6PD,Yes,G6PD,-,-,-,-,Indeterminate,Indeterminate,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Unknown Risk of ADR (acute hemolytic anemia),-,-,-,-,-,-,"According to the study, the primary enzyme involved in the metabolic processing of lidocaine in individuals with normal liver function is CYP1A2. However, apart from the metabolic enzyme, G6PD also plays a role in determining lidocaine toxicity. Therefore, it is advisable to consider both CYP1A2 and G6PD when assessing lidocaine."
Lidocaine / prilocaine,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 1B,G6PD,Yes,G6PD,-,-,FDA evidence,-,Normal,Normal,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Risk of ADR (acute hemolytic anemia),Use as Directed,-,‚úÖ,-,-,-,"According to the study, the primary enzyme involved in the metabolic processing of lidocaine in individuals with normal liver function is CYP1A2. However, apart from the metabolic enzyme, G6PD also plays a role in determining lidocaine toxicity. Therefore, it is advisable to consider both CYP1A2 and G6PD when assessing lidocaine."
Lidocaine / prilocaine,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 1B,G6PD,Yes,G6PD,-,-,FDA evidence,-,Deficient,Deficient,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Risk of ADR (acute hemolytic anemia),Use with Caution,Toxicity,‚ö†Ô∏è,-,-,-,"According to the study, the primary enzyme involved in the metabolic processing of lidocaine in individuals with normal liver function is CYP1A2. However, apart from the metabolic enzyme, G6PD also plays a role in determining lidocaine toxicity. Therefore, it is advisable to consider both CYP1A2 and G6PD when assessing lidocaine."
Lidocaine / prilocaine,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 1B,G6PD,Yes,G6PD,-,-,FDA evidence,-,Deficient with CNSHA,Deficient with CNSHA,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Risk of ADR (acute hemolytic anemia),Use with Caution,Toxicity,‚ö†Ô∏è,-,-,-,"According to the study, the primary enzyme involved in the metabolic processing of lidocaine in individuals with normal liver function is CYP1A2. However, apart from the metabolic enzyme, G6PD also plays a role in determining lidocaine toxicity. Therefore, it is advisable to consider both CYP1A2 and G6PD when assessing lidocaine."
Lidocaine / prilocaine,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 1B,G6PD,Yes,G6PD,-,-,FDA evidence,-,Variable,Variable,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Risk of ADR (acute hemolytic anemia),Use as Directed,-,‚úÖ,-,-,-,"According to the study, the primary enzyme involved in the metabolic processing of lidocaine in individuals with normal liver function is CYP1A2. However, apart from the metabolic enzyme, G6PD also plays a role in determining lidocaine toxicity. Therefore, it is advisable to consider both CYP1A2 and G6PD when assessing lidocaine."
Lidocaine / prilocaine,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 1B,G6PD,Yes,G6PD,-,-,FDA evidence,-,Indeterminate,Indeterminate,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Unknown Risk of ADR (acute hemolytic anemia),-,-,-,-,-,-,"According to the study, the primary enzyme involved in the metabolic processing of lidocaine in individuals with normal liver function is CYP1A2. However, apart from the metabolic enzyme, G6PD also plays a role in determining lidocaine toxicity. Therefore, it is advisable to consider both CYP1A2 and G6PD when assessing lidocaine."
Lidocaine and tetracaine,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 1B,G6PD,Yes,G6PD,-,-,FDA evidence,-,Normal,Normal,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Risk of ADR (acute hemolytic anemia),Use as Directed,-,‚úÖ,-,-,-,"According to the study, the primary enzyme involved in the metabolic processing of lidocaine in individuals with normal liver function is CYP1A2. However, apart from the metabolic enzyme, G6PD also plays a role in determining lidocaine toxicity. Therefore, it is advisable to consider both CYP1A2 and G6PD when assessing lidocaine."
Lidocaine and tetracaine,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 1B,G6PD,Yes,G6PD,-,-,FDA evidence,-,Deficient,Deficient,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Risk of ADR (acute hemolytic anemia),Use with Caution,Toxicity,‚ö†Ô∏è,-,-,-,"According to the study, the primary enzyme involved in the metabolic processing of lidocaine in individuals with normal liver function is CYP1A2. However, apart from the metabolic enzyme, G6PD also plays a role in determining lidocaine toxicity. Therefore, it is advisable to consider both CYP1A2 and G6PD when assessing lidocaine."
Lidocaine and tetracaine,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 1B,G6PD,Yes,G6PD,-,-,FDA evidence,-,Deficient with CNSHA,Deficient with CNSHA,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Risk of ADR (acute hemolytic anemia),Use with Caution,Toxicity,‚ö†Ô∏è,-,-,-,"According to the study, the primary enzyme involved in the metabolic processing of lidocaine in individuals with normal liver function is CYP1A2. However, apart from the metabolic enzyme, G6PD also plays a role in determining lidocaine toxicity. Therefore, it is advisable to consider both CYP1A2 and G6PD when assessing lidocaine."
Lidocaine and tetracaine,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 1B,G6PD,Yes,G6PD,-,-,FDA evidence,-,Variable,Variable,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Risk of ADR (acute hemolytic anemia),Use as Directed,-,‚úÖ,-,-,-,"According to the study, the primary enzyme involved in the metabolic processing of lidocaine in individuals with normal liver function is CYP1A2. However, apart from the metabolic enzyme, G6PD also plays a role in determining lidocaine toxicity. Therefore, it is advisable to consider both CYP1A2 and G6PD when assessing lidocaine."
Lidocaine and tetracaine,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 1B,G6PD,Yes,G6PD,-,-,FDA evidence,-,Indeterminate,Indeterminate,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Unknown Risk of ADR (acute hemolytic anemia),-,-,-,-,-,-,"According to the study, the primary enzyme involved in the metabolic processing of lidocaine in individuals with normal liver function is CYP1A2. However, apart from the metabolic enzyme, G6PD also plays a role in determining lidocaine toxicity. Therefore, it is advisable to consider both CYP1A2 and G6PD when assessing lidocaine."
Methadone,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 2A,CYP2B6,Yes,CYP2B6,-,-,-,CPIC (No recommendation),Indeterminate,Indeterminate,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,"When it comes to methadone, both CYP3A4 and CYP2B6 appear to have significant roles, indicating that both enzymes should be considered primary factors when making recommendations regarding appropriate actions."
Methadone,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 2A,CYP2B6,Yes,CYP2B6,-,-,-,CPIC (No recommendation),Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,"When it comes to methadone, both CYP3A4 and CYP2B6 appear to have significant roles, indicating that both enzymes should be considered primary factors when making recommendations regarding appropriate actions."
Methadone,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 2A,CYP2B6,Yes,CYP2B6,-,-,-,CPIC (No recommendation),Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,"When it comes to methadone, both CYP3A4 and CYP2B6 appear to have significant roles, indicating that both enzymes should be considered primary factors when making recommendations regarding appropriate actions."
Methadone,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 2A,CYP2B6,Yes,CYP2B6,-,-,-,CPIC (No recommendation),Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,"When it comes to methadone, both CYP3A4 and CYP2B6 appear to have significant roles, indicating that both enzymes should be considered primary factors when making recommendations regarding appropriate actions."
Methadone,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 2A,CYP2B6,Yes,CYP2B6,-,-,-,CPIC (No recommendation),Rapid Metabolizer,Rapid Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure,Use as Directed,-,‚úÖ,-,-,-,"When it comes to methadone, both CYP3A4 and CYP2B6 appear to have significant roles, indicating that both enzymes should be considered primary factors when making recommendations regarding appropriate actions."
Methadone,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 2A,CYP2B6,Yes,CYP2B6,-,-,-,CPIC (No recommendation),Ultrarapid Metabolizer,Ultrarapid Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,"When it comes to methadone, both CYP3A4 and CYP2B6 appear to have significant roles, indicating that both enzymes should be considered primary factors when making recommendations regarding appropriate actions."
Midazolam,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure; Minimal Evidence for Clinical Impact,Use as Directed,-,‚úÖ,-,-,-,-
Midazolam,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure; Minimal evidence for clinical impact,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Midazolam,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure; Minimal evidence for clinical impact,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Tramadol,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 1A(Strong),CYP2D6,Yes,CYP2D6,-,-,Professional guideline; FDA evidence,"CPIC, DPWG",Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure; Reduced Efficacy (analgesia),Increased Caution/Avoid,Efficacy,üõë,"Avoid tramadol use because of possibility of diminished analgesia. If opioid use is warranted, consider a non-codeine opioid.","Do not select codeine, as this is also metabolised by CYP2D6. ","Morphine is not metabolised by CYP2D6. Oxycodone is metabolised by CYP2D6 to a limited extent, but this does not result in differences in analgesia in patients.",-
Tramadol,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 1A(Optional),CYP2D6,Yes,CYP2D6,-,-,Professional guideline; FDA evidence,"CPIC, DPWG",Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure,Use with Caution,Efficacy,‚ö†Ô∏è,"Use tramadol label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider non-codeine opioid.",-,-,-
Tramadol,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 1A(Strong),CYP2D6,Yes,CYP2D6,-,-,Professional guideline; FDA evidence,"CPIC, DPWG",Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,Use tramadol label recommended age- or weight-specific dosing.,-,-,-
Tramadol,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 1A(Strong),CYP2D6,Yes,CYP2D6,-,-,Professional guideline; FDA evidence,"CPIC, DPWG",Ultrarapid Metabolizer (>2),Ultrarapid Metabolizer,-,>2,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure; Increased Risk of ADR,Increased Caution/Avoid,Toxicity,üõë,"Avoid tramadol use because of potential for toxicity. If opioid use is warranted, consider a non-codeine opioid.","Do not select codeine, as this is also metabolised by CYP2D6. ","Morphine is not metabolised by CYP2D6. Oxycodone is metabolised by CYP2D6 to a limited extent, but this does not result in differences in analgesia in patients.",-
Tramadol,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 1A(No Recommendation),CYP2D6,Yes,CYP2D6,-,-,Professional guideline; FDA evidence,"CPIC, DPWG",Indeterminate,Indeterminate,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,n/a,-,-,-,No recommendation,-,-,-
Tramadol And Acetaminophen ,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 2A,CYP2D6,Yes,CYP2D6,-,-,FDA evidence (Doubt),-,Ultrarapid Metabolizer (>2),Ultrarapid Metabolizer,-,>2,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure; Increased Risk of ADR,Increased Caution/Avoid,Toxicity,üõë,-,-,-,-
Tramadol And Acetaminophen ,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 2A,CYP2D6,Yes,CYP2D6,-,-,FDA evidence (Doubt),-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Tramadol And Acetaminophen ,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 2A,CYP2D6,Yes,CYP2D6,-,-,FDA evidence (Doubt),-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure,Use with Caution,Efficacy,‚ö†Ô∏è,-,-,-,-
Tramadol And Acetaminophen ,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 2A,CYP2D6,Yes,CYP2D6,-,-,FDA evidence (Doubt),-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure; Reduced Efficacy (analgesia),Use with Caution,Efficacy,‚ö†Ô∏è,-,-,-,-
Morphine,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 2B,OPRM1,Yes,OPRM1,-,-,-,CPIC (No recommendation),Asn/Asn isoform,-,Asn/Asn isoform,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Response,Use as Directed,-,‚úÖ,-,-,-,-
Morphine,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 2B,OPRM1,Yes,OPRM1,-,-,-,CPIC (No recommendation),Asn/Asp isoform,-,Asn/Asp isoform,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Reduced Response,Use with Caution,Efficacy,‚ö†Ô∏è,-,-,-,-
Morphine,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 2B,OPRM1,Yes,OPRM1,-,-,-,CPIC (No recommendation),Asp/Asp isoform,-,Asp/Asp isoform,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Reduced Response,Use with Caution,Efficacy,‚ö†Ô∏è,-,-,-,-
Oxycodone,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 2B,OPRM1,Yes,OPRM1,-,-,-,"CPIC (No recommendation), DPWG (No recommendation)",Asn/Asn isoform,-,Asn/Asn isoform,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Response,Use as Directed,-,‚úÖ,-,-,-,"Oxycodone undergoes metabolism by both CYP3A4 and CYP3A5, resulting in the formation of noroxycodone, which is further metabolized by CYP2D6 to noroxymorphone. According to CPIC, the role of the CYP2D6 pathway in oxycodone metabolism is considered relatively minor, and it is not considered a significant drug-gene interaction. On the other hand, CYP3A4 plays an important role in oxycodone metabolism. Therefore, it is advisable to consider both CYP3A4 and OPRM1together for better actionability."
Oxycodone,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 2B,OPRM1,Yes,OPRM1,-,-,-,"CPIC (No recommendation), DPWG (No recommendation)",Asn/Asp isoform,-,Asn/Asp isoform,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Reduced Response,Use with Caution,Efficacy,‚ö†Ô∏è,-,-,-,"Oxycodone undergoes metabolism by both CYP3A4 and CYP3A5, resulting in the formation of noroxycodone, which is further metabolized by CYP2D6 to noroxymorphone. According to CPIC, the role of the CYP2D6 pathway in oxycodone metabolism is considered relatively minor, and it is not considered a significant drug-gene interaction. On the other hand, CYP3A4 plays an important role in oxycodone metabolism. Therefore, it is advisable to consider both CYP3A4 and OPRM1together for better actionability."
Oxycodone,Actionable,ANALGESIC / ANESTHESIOLOGY,Level 2B,OPRM1,Yes,OPRM1,-,-,-,"CPIC (No recommendation), DPWG (No recommendation)",Asp/Asp isoform,-,Asp/Asp isoform,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Reduced Response,Use with Caution,Efficacy,‚ö†Ô∏è,-,-,-,"Oxycodone undergoes metabolism by both CYP3A4 and CYP3A5, resulting in the formation of noroxycodone, which is further metabolized by CYP2D6 to noroxymorphone. According to CPIC, the role of the CYP2D6 pathway in oxycodone metabolism is considered relatively minor, and it is not considered a significant drug-gene interaction. On the other hand, CYP3A4 plays an important role in oxycodone metabolism. Therefore, it is advisable to consider both CYP3A4 and OPRM1together for better actionability."
Apixaban,Actionable,ANTICOAGULANT / ANTIPLATELET,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,"Apixaban undergoes metabolism primarily through CYP3A enzymes, with CYP3A4 identified as the primary gene according to label information and AGS reports. However, PharmGKB provides information on pharmacokinetic changes related to CYP3A5 based on studies conducted in the East Asian population. It is important to note that the total score for CYP3A5 is 1, and the population in question is not specifically Central Asian. Therefore, the actionability of apixaban is determined based on CYP3A4."
Apixaban,Actionable,ANTICOAGULANT / ANTIPLATELET,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure; Minimal Information for Clinical Effect,Use with Caution,PK,‚ö†Ô∏è,-,-,-,"Apixaban undergoes metabolism primarily through CYP3A enzymes, with CYP3A4 identified as the primary gene according to label information and AGS reports. However, PharmGKB provides information on pharmacokinetic changes related to CYP3A5 based on studies conducted in the East Asian population. It is important to note that the total score for CYP3A5 is 1, and the population in question is not specifically Central Asian. Therefore, the actionability of apixaban is determined based on CYP3A4."
Apixaban,Actionable,ANTICOAGULANT / ANTIPLATELET,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure; Minimal Information for Clinical Effect,Use with Caution,PK,‚ö†Ô∏è,-,-,-,"Apixaban undergoes metabolism primarily through CYP3A enzymes, with CYP3A4 identified as the primary gene according to label information and AGS reports. However, PharmGKB provides information on pharmacokinetic changes related to CYP3A5 based on studies conducted in the East Asian population. It is important to note that the total score for CYP3A5 is 1, and the population in question is not specifically Central Asian. Therefore, the actionability of apixaban is determined based on CYP3A4."
Cilostazol,Actionable,ANTICOAGULANT / ANTIPLATELET,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,PK,‚úÖ,-,-,-,"The label and AGS report indicate that CYP3A4 is the primary gene involved in the metabolism of Cilostazol. However, PharmGKB includes clinical annotation for CYP3A5, demonstrating PK changes with a total score of 2, based on studies conducted in the East Asian population. As its not central asian population it has not been taken into consideration for the current analysis."
Cilostazol,Actionable,ANTICOAGULANT / ANTIPLATELET,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure; Minimal Information for Clinical Effect,Use with Caution,PK,‚ö†Ô∏è,-,-,-,"The label and AGS report indicate that CYP3A4 is the primary gene involved in the metabolism of Cilostazol. However, PharmGKB includes clinical annotation for CYP3A5, demonstrating PK changes with a total score of 2, based on studies conducted in the East Asian population. As its not central asian population it has not been taken into consideration for the current analysis."
Cilostazol,Actionable,ANTICOAGULANT / ANTIPLATELET,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure; Minimal Information for Clinical Effect,Use with Caution,PK,‚ö†Ô∏è,-,-,-,"The label and AGS report indicate that CYP3A4 is the primary gene involved in the metabolism of Cilostazol. However, PharmGKB includes clinical annotation for CYP3A5, demonstrating PK changes with a total score of 2, based on studies conducted in the East Asian population. As its not central asian population it has not been taken into consideration for the current analysis."
Clopidogrel,Actionable,ANTICOAGULANT / ANTIPLATELET,n/a,CYP2C19,Yes,CYP2C19,-,-,FDA evidence,"CPIC, DPWG",Indeterminate,Indeterminate,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,n/a,-,n/a,-,No recommendation,-,-,"Both the DPWG and CPIC have not provided any dosage change recommendations for ultra-rapid metabolizers (UM). Therefore, for individuals classified as rapid metabolizers, it was given as ""Use as directed""."
Clopidogrel,Actionable,ANTICOAGULANT / ANTIPLATELET,Level 1A(Strong),CYP2C19,Yes,CYP2C19,-,-,FDA evidence,"CPIC, DPWG",Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure; Reduced Response (increased on-treatment platelet reactivity); Increased Risk of ADR (cardiac and cerebrovascular events),Increased Caution/Avoid,Toxicity,üõë,Avoid standard dose (75 mg). Use prasugrel or ticagrelor at standard dose if no contraindication.,-,-,"Both the DPWG and CPIC have not provided any dosage change recommendations for ultra-rapid metabolizers (UM). Therefore, for individuals classified as rapid metabolizers, it was given as ""Use as directed""."
Clopidogrel,Actionable,ANTICOAGULANT / ANTIPLATELET,Level 1A(Strong),CYP2C19,Yes,CYP2C19,-,-,FDA evidence,"CPIC, DPWG",Likely Intermediate Metabolizer,Likely Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure; Reduced Response (increased on-treatment platelet reactivity); Increased Risk of ADR (cardiac and cerebrovascular events),Increased Caution/Avoid,Toxicity,üõë,Avoid standard dose (75 mg). Use prasugrel or ticagrelor at standard dose if no contraindication.,-,-,"Both the DPWG and CPIC have not provided any dosage change recommendations for ultra-rapid metabolizers (UM). Therefore, for individuals classified as rapid metabolizers, it was given as ""Use as directed""."
Clopidogrel,Actionable,ANTICOAGULANT / ANTIPLATELET,Level 1A(Strong),CYP2C19,Yes,CYP2C19,-,-,FDA evidence,"CPIC, DPWG",Likely Poor Metabolizer,Likely Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure; Reduced Response (increased on-treatment platelet reactivity); Increased Risk of ADR (cardiac and cerebrovascular events),Increased Caution/Avoid,Toxicity,üõë,Avoid standard dose (75 mg). Use prasugrel or ticagrelor at standard dose if no contraindication.,-,-,"Both the DPWG and CPIC have not provided any dosage change recommendations for ultra-rapid metabolizers (UM). Therefore, for individuals classified as rapid metabolizers, it was given as ""Use as directed""."
Clopidogrel,Actionable,ANTICOAGULANT / ANTIPLATELET,Level 1A(Strong),CYP2C19,Yes,CYP2C19,-,-,FDA evidence,"CPIC, DPWG",Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,Use standard dose,-,-,"Both the DPWG and CPIC have not provided any dosage change recommendations for ultra-rapid metabolizers (UM). Therefore, for individuals classified as rapid metabolizers, it was given as ""Use as directed""."
Clopidogrel,Actionable,ANTICOAGULANT / ANTIPLATELET,Level 1A(Strong),CYP2C19,Yes,CYP2C19,-,-,FDA evidence,"CPIC, DPWG",Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure; Reduced Response (increased on-treatment platelet reactivity); Increased Risk of ADR (cardiac and cerebrovascular events),Increased Caution/Avoid,Toxicity,üõë,Significantly reduced clopidogrel active metabolite formation; increased on-treatment platelet reactivity; increased risk for adverse cardiac and cerebrovascular events; Avoid standard dose (75 mg). Use prasugrel or ticagrelor at standard dose if no contraindication.,-,-,"Both the DPWG and CPIC have not provided any dosage change recommendations for ultra-rapid metabolizers (UM). Therefore, for individuals classified as rapid metabolizers, it was given as ""Use as directed""."
Clopidogrel,Actionable,ANTICOAGULANT / ANTIPLATELET,Level 1A (Strong),CYP2C19,Yes,CYP2C19,-,-,FDA evidence,"CPIC, DPWG",Rapid Metabolizer,Rapid Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal or Increased Exposure,Use as Directed,-,‚úÖ,Use standard dose,-,-,"Both the DPWG and CPIC have not provided any dosage change recommendations for ultra-rapid metabolizers (UM). Therefore, for individuals classified as rapid metabolizers, it was given as ""Use as directed""."
Clopidogrel,Actionable,ANTICOAGULANT / ANTIPLATELET,Level 1A(Strong),CYP2C19,Yes,CYP2C19,-,-,FDA evidence,"CPIC, DPWG",Ultrarapid Metabolizer,Ultrarapid Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,Toxicity,‚ö†Ô∏è,Use standard dose,-,-,"Both the DPWG and CPIC have not provided any dosage change recommendations for ultra-rapid metabolizers (UM). Therefore, for individuals classified as rapid metabolizers, it was given as ""Use as directed""."
Rivaroxaban,Actionable,ANTICOAGULANT / ANTIPLATELET,Level 2A,CYP3A4,Yes,CYP3A4,-,-,FDA evidence (Its for F5),-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,"Within PharmGKB, the variant annotation includes studies that explore both the involvement and lack of involvement of CYP3A5 in the metabolism of Rivaroxaban. Because of inconclusive nature of CYP3A5, it not included in database."
Rivaroxaban,Actionable,ANTICOAGULANT / ANTIPLATELET,Level 2A,CYP3A4,Yes,CYP3A4,-,-,FDA evidence (Its for F5),-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure; Minimal Information for Clinical Effect,Use with Caution,PK,‚ö†Ô∏è,-,-,-,"Within PharmGKB, the variant annotation includes studies that explore both the involvement and lack of involvement of CYP3A5 in the metabolism of Rivaroxaban. Because of inconclusive nature of CYP3A5, it not included in database."
Rivaroxaban,Actionable,ANTICOAGULANT / ANTIPLATELET,Level 2A,CYP3A4,Yes,CYP3A4,-,-,FDA evidence (Its for F5),-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure; Minimal Information for Clinical Effect,Use with Caution,PK,‚ö†Ô∏è,-,-,-,"Within PharmGKB, the variant annotation includes studies that explore both the involvement and lack of involvement of CYP3A5 in the metabolism of Rivaroxaban. Because of inconclusive nature of CYP3A5, it not included in database."
Ticagrelor,Actionable,ANTICOAGULANT / ANTIPLATELET,Level 1B + Level 2A,CYP2C19 + CYP3A4,No,CYP2C19,CYP3A4,-,FDA evidence,-,CYP2C19: Ultrarapid Metabolizer + CYP3A4: Normal Metabolizer,Ultrarapid Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,"Ticagrelor metabolism and the formation of its major active metabolite are primarily mediated by the enzyme CYP3A4. In contrast, CYP2C19 does not play a significant role in the metabolism of ticagrelor. Therefore, when making final recommendations, i have included both CYP3A4 and CYP2C19."
Ticagrelor,Actionable,ANTICOAGULANT / ANTIPLATELET,Level 1BB + Level 2A,CYP2C19 + CYP3A4,No,CYP2C19,CYP3A4,-,FDA evidence,-,CYP2C19: Rapid Metabolizer + CYP3A4: Normal Metabolizer,Rapid Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,"Ticagrelor metabolism and the formation of its major active metabolite are primarily mediated by the enzyme CYP3A4. In contrast, CYP2C19 does not play a significant role in the metabolism of ticagrelor. Therefore, when making final recommendations, i have included both CYP3A4 and CYP2C19."
Ticagrelor,Actionable,ANTICOAGULANT / ANTIPLATELET,Level 1BB + Level 2A,CYP2C19 + CYP3A4,No,CYP2C19,CYP3A4,-,FDA evidence,-,CYP2C19: Normal Metabolizer + CYP3A4: Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,"Ticagrelor metabolism and the formation of its major active metabolite are primarily mediated by the enzyme CYP3A4. In contrast, CYP2C19 does not play a significant role in the metabolism of ticagrelor. Therefore, when making final recommendations, i have included both CYP3A4 and CYP2C19."
Ticagrelor,Actionable,ANTICOAGULANT / ANTIPLATELET,Level 1BB + Level 2A,CYP2C19 + CYP3A4,No,CYP2C19,CYP3A4,-,FDA evidence,-,CYP2C19: Likely Intermediate Metabolizer + CYP3A4: Normal Metabolizer,Likely Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,"Ticagrelor metabolism and the formation of its major active metabolite are primarily mediated by the enzyme CYP3A4. In contrast, CYP2C19 does not play a significant role in the metabolism of ticagrelor. Therefore, when making final recommendations, i have included both CYP3A4 and CYP2C19."
Ticagrelor,Actionable,ANTICOAGULANT / ANTIPLATELET,Level 1BB + Level 2A,CYP2C19 + CYP3A4,No,CYP2C19,CYP3A4,-,FDA evidence,-,CYP2C19: Intermediate Metabolizer + CYP3A4: Normal Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,"Ticagrelor metabolism and the formation of its major active metabolite are primarily mediated by the enzyme CYP3A4. In contrast, CYP2C19 does not play a significant role in the metabolism of ticagrelor. Therefore, when making final recommendations, i have included both CYP3A4 and CYP2C19."
Ticagrelor,Actionable,ANTICOAGULANT / ANTIPLATELET,Level 1BB + Level 2A,CYP2C19 + CYP3A4,No,CYP2C19,CYP3A4,-,FDA evidence,-,CYP2C19: Likely Poor Metabolizer + CYP3A4: Normal Metabolizer,Likely Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,"Ticagrelor metabolism and the formation of its major active metabolite are primarily mediated by the enzyme CYP3A4. In contrast, CYP2C19 does not play a significant role in the metabolism of ticagrelor. Therefore, when making final recommendations, i have included both CYP3A4 and CYP2C19."
Ticagrelor,Actionable,ANTICOAGULANT / ANTIPLATELET,Level 1BB + Level 2A,CYP2C19 + CYP3A4,No,CYP2C19,CYP3A4,-,FDA evidence,-,CYP2C19: Poor Metabolizer + CYP3A4: Normal Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,"Ticagrelor metabolism and the formation of its major active metabolite are primarily mediated by the enzyme CYP3A4. In contrast, CYP2C19 does not play a significant role in the metabolism of ticagrelor. Therefore, when making final recommendations, i have included both CYP3A4 and CYP2C19."
Ticagrelor,Actionable,ANTICOAGULANT / ANTIPLATELET,Level 1BB + Level 2A,CYP2C19 + CYP3A4,No,CYP2C19,CYP3A4,-,FDA evidence,-,CYP2C19: Indeterminate + CYP3A4: Normal Metabolizer,Indeterminate,-,-,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,"Ticagrelor metabolism and the formation of its major active metabolite are primarily mediated by the enzyme CYP3A4. In contrast, CYP2C19 does not play a significant role in the metabolism of ticagrelor. Therefore, when making final recommendations, i have included both CYP3A4 and CYP2C19."
Ticagrelor,Actionable,ANTICOAGULANT / ANTIPLATELET,Level 1B + Level 2A,CYP2C19 + CYP3A4,No,CYP2C19,CYP3A4,-,FDA evidence,-,CYP2C19: Ultrarapid Metabolizer + CYP3A4: Intermediate Metabolizer,Ultrarapid Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,-,-,-,-,-,Use with Caution,-,‚ö†Ô∏è,-,-,-,"Ticagrelor metabolism and the formation of its major active metabolite are primarily mediated by the enzyme CYP3A4. In contrast, CYP2C19 does not play a significant role in the metabolism of ticagrelor. Therefore, when making final recommendations, i have included both CYP3A4 and CYP2C19."
Ticagrelor,Actionable,ANTICOAGULANT / ANTIPLATELET,Level 1BB + Level 2A,CYP2C19 + CYP3A4,No,CYP2C19,CYP3A4,-,FDA evidence,-,CYP2C19: Rapid Metabolizer + CYP3A4: Intermediate Metabolizer,Rapid Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,-,-,-,-,-,Use with Caution,-,‚ö†Ô∏è,-,-,-,"Ticagrelor metabolism and the formation of its major active metabolite are primarily mediated by the enzyme CYP3A4. In contrast, CYP2C19 does not play a significant role in the metabolism of ticagrelor. Therefore, when making final recommendations, i have included both CYP3A4 and CYP2C19."
Ticagrelor,Actionable,ANTICOAGULANT / ANTIPLATELET,Level 1BB + Level 2A,CYP2C19 + CYP3A4,No,CYP2C19,CYP3A4,-,FDA evidence,-,CYP2C19: Normal Metabolizer + CYP3A4: Intermediate Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,-,-,-,-,-,Use with Caution,-,‚ö†Ô∏è,-,-,-,"Ticagrelor metabolism and the formation of its major active metabolite are primarily mediated by the enzyme CYP3A4. In contrast, CYP2C19 does not play a significant role in the metabolism of ticagrelor. Therefore, when making final recommendations, i have included both CYP3A4 and CYP2C19."
Ticagrelor,Actionable,ANTICOAGULANT / ANTIPLATELET,Level 1BB + Level 2A,CYP2C19 + CYP3A4,No,CYP2C19,CYP3A4,-,FDA evidence,-,CYP2C19: Likely Intermediate Metabolizer + CYP3A4: Intermediate Metabolizer,Likely Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,-,-,-,-,-,Use with Caution,-,‚ö†Ô∏è,-,-,-,"Ticagrelor metabolism and the formation of its major active metabolite are primarily mediated by the enzyme CYP3A4. In contrast, CYP2C19 does not play a significant role in the metabolism of ticagrelor. Therefore, when making final recommendations, i have included both CYP3A4 and CYP2C19."
Ticagrelor,Actionable,ANTICOAGULANT / ANTIPLATELET,Level 1BB + Level 2A,CYP2C19 + CYP3A4,No,CYP2C19,CYP3A4,-,FDA evidence,-,CYP2C19: Intermediate Metabolizer + CYP3A4: Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,-,-,-,-,-,Use with Caution,-,‚ö†Ô∏è,-,-,-,"Ticagrelor metabolism and the formation of its major active metabolite are primarily mediated by the enzyme CYP3A4. In contrast, CYP2C19 does not play a significant role in the metabolism of ticagrelor. Therefore, when making final recommendations, i have included both CYP3A4 and CYP2C19."
Ticagrelor,Actionable,ANTICOAGULANT / ANTIPLATELET,Level 1BB + Level 2A,CYP2C19 + CYP3A4,No,CYP2C19,CYP3A4,-,FDA evidence,-,CYP2C19: Likely Poor Metabolizer + CYP3A4: Intermediate Metabolizer,Likely Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,-,-,-,-,-,Use with Caution,-,‚ö†Ô∏è,-,-,-,"Ticagrelor metabolism and the formation of its major active metabolite are primarily mediated by the enzyme CYP3A4. In contrast, CYP2C19 does not play a significant role in the metabolism of ticagrelor. Therefore, when making final recommendations, i have included both CYP3A4 and CYP2C19."
Ticagrelor,Actionable,ANTICOAGULANT / ANTIPLATELET,Level 1BB + Level 2A,CYP2C19 + CYP3A4,No,CYP2C19,CYP3A4,-,FDA evidence,-,CYP2C19: Poor Metabolizer + CYP3A4: Intermediate Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,-,-,-,-,-,Use with Caution,-,‚ö†Ô∏è,-,-,-,"Ticagrelor metabolism and the formation of its major active metabolite are primarily mediated by the enzyme CYP3A4. In contrast, CYP2C19 does not play a significant role in the metabolism of ticagrelor. Therefore, when making final recommendations, i have included both CYP3A4 and CYP2C19."
Ticagrelor,Actionable,ANTICOAGULANT / ANTIPLATELET,Level 1BB + Level 2A,CYP2C19 + CYP3A4,No,CYP2C19,CYP3A4,-,FDA evidence,-,CYP2C19: Indeterminate + CYP3A4: Intermediate Metabolizer,Indeterminate,-,-,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,-,-,-,-,-,Use with Caution,-,‚ö†Ô∏è,-,-,-,"Ticagrelor metabolism and the formation of its major active metabolite are primarily mediated by the enzyme CYP3A4. In contrast, CYP2C19 does not play a significant role in the metabolism of ticagrelor. Therefore, when making final recommendations, i have included both CYP3A4 and CYP2C19."
Ticagrelor,Actionable,ANTICOAGULANT / ANTIPLATELET,Level 1B + Level 2A,CYP2C19 + CYP3A4,No,CYP2C19,CYP3A4,-,FDA evidence,-,CYP2C19: Ultrarapid Metabolizer + CYP3A4: Poor Metabolizer,Ultrarapid Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,-,-,-,-,-,Use with Caution,-,‚ö†Ô∏è,-,-,-,"Ticagrelor metabolism and the formation of its major active metabolite are primarily mediated by the enzyme CYP3A4. In contrast, CYP2C19 does not play a significant role in the metabolism of ticagrelor. Therefore, when making final recommendations, i have included both CYP3A4 and CYP2C19."
Ticagrelor,Actionable,ANTICOAGULANT / ANTIPLATELET,Level 1BB + Level 2A,CYP2C19 + CYP3A4,No,CYP2C19,CYP3A4,-,FDA evidence,-,CYP2C19: Rapid Metabolizer + CYP3A4: Poor Metabolizer,Rapid Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,-,-,-,-,-,Use with Caution,-,‚ö†Ô∏è,-,-,-,"Ticagrelor metabolism and the formation of its major active metabolite are primarily mediated by the enzyme CYP3A4. In contrast, CYP2C19 does not play a significant role in the metabolism of ticagrelor. Therefore, when making final recommendations, i have included both CYP3A4 and CYP2C19."
Ticagrelor,Actionable,ANTICOAGULANT / ANTIPLATELET,Level 1BB + Level 2A,CYP2C19 + CYP3A4,No,CYP2C19,CYP3A4,-,FDA evidence,-,CYP2C19: Normal Metabolizer + CYP3A4: Poor Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,-,-,-,-,-,Use with Caution,-,‚ö†Ô∏è,-,-,-,"Ticagrelor metabolism and the formation of its major active metabolite are primarily mediated by the enzyme CYP3A4. In contrast, CYP2C19 does not play a significant role in the metabolism of ticagrelor. Therefore, when making final recommendations, i have included both CYP3A4 and CYP2C19."
Ticagrelor,Actionable,ANTICOAGULANT / ANTIPLATELET,Level 1BB + Level 2A,CYP2C19 + CYP3A4,No,CYP2C19,CYP3A4,-,FDA evidence,-,CYP2C19: Likely Intermediate Metabolizer + CYP3A4: Poor Metabolizer,Likely Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,-,-,-,-,-,Use with Caution,-,‚ö†Ô∏è,-,-,-,"Ticagrelor metabolism and the formation of its major active metabolite are primarily mediated by the enzyme CYP3A4. In contrast, CYP2C19 does not play a significant role in the metabolism of ticagrelor. Therefore, when making final recommendations, i have included both CYP3A4 and CYP2C19."
Ticagrelor,Actionable,ANTICOAGULANT / ANTIPLATELET,Level 1BB + Level 2A,CYP2C19 + CYP3A4,No,CYP2C19,CYP3A4,-,FDA evidence,-,CYP2C19: Intermediate Metabolizer + CYP3A4: Poor Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,-,-,-,-,-,Use with Caution,-,‚ö†Ô∏è,-,-,-,"Ticagrelor metabolism and the formation of its major active metabolite are primarily mediated by the enzyme CYP3A4. In contrast, CYP2C19 does not play a significant role in the metabolism of ticagrelor. Therefore, when making final recommendations, i have included both CYP3A4 and CYP2C19."
Ticagrelor,Actionable,ANTICOAGULANT / ANTIPLATELET,Level 1BB + Level 2A,CYP2C19 + CYP3A4,No,CYP2C19,CYP3A4,-,FDA evidence,-,CYP2C19: Likely Poor Metabolizer + CYP3A4: Poor Metabolizer,Likely Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,-,-,-,-,-,Use with Caution,-,‚ö†Ô∏è,-,-,-,"Ticagrelor metabolism and the formation of its major active metabolite are primarily mediated by the enzyme CYP3A4. In contrast, CYP2C19 does not play a significant role in the metabolism of ticagrelor. Therefore, when making final recommendations, i have included both CYP3A4 and CYP2C19."
Ticagrelor,Actionable,ANTICOAGULANT / ANTIPLATELET,Level 1BB + Level 2A,CYP2C19 + CYP3A4,No,CYP2C19,CYP3A4,-,FDA evidence,-,CYP2C19: Poor Metabolizer + CYP3A4: Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,-,-,-,-,-,Use with Caution,-,‚ö†Ô∏è,-,-,-,"Ticagrelor metabolism and the formation of its major active metabolite are primarily mediated by the enzyme CYP3A4. In contrast, CYP2C19 does not play a significant role in the metabolism of ticagrelor. Therefore, when making final recommendations, i have included both CYP3A4 and CYP2C19."
Ticagrelor,Actionable,ANTICOAGULANT / ANTIPLATELET,Level 1BB + Level 2A,CYP2C19 + CYP3A4,No,CYP2C19,CYP3A4,-,FDA evidence,-,CYP2C19: Indeterminate + CYP3A4: Poor Metabolizer,Indeterminate,-,-,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,-,-,-,-,-,Use with Caution,-,‚ö†Ô∏è,-,-,-,"Ticagrelor metabolism and the formation of its major active metabolite are primarily mediated by the enzyme CYP3A4. In contrast, CYP2C19 does not play a significant role in the metabolism of ticagrelor. Therefore, when making final recommendations, i have included both CYP3A4 and CYP2C19."
Ticagrelor,Actionable,ANTICOAGULANT / ANTIPLATELET,Level 1B + Level 2A,CYP2C19,Yes,CYP2C19,-,-,FDA evidence,DPWG (No recommendation),Ultrarapid Metabolizer,Ultrarapid Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,"Ticagrelor metabolism and the formation of its major active metabolite are primarily mediated by the enzyme CYP3A4. In contrast, CYP2C19 does not play a significant role in the metabolism of ticagrelor. Therefore, when making final recommendations, i have included both CYP3A4 and CYP2C19."
Ticagrelor,Actionable,ANTICOAGULANT / ANTIPLATELET,Level 1BB + Level 2A,CYP2C19,Yes,CYP2C19,-,-,FDA evidence,DPWG (No recommendation),Rapid Metabolizer,Rapid Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,"Ticagrelor metabolism and the formation of its major active metabolite are primarily mediated by the enzyme CYP3A4. In contrast, CYP2C19 does not play a significant role in the metabolism of ticagrelor. Therefore, when making final recommendations, i have included both CYP3A4 and CYP2C19."
Ticagrelor,Actionable,ANTICOAGULANT / ANTIPLATELET,Level 1BB + Level 2A,CYP2C19,Yes,CYP2C19,-,-,FDA evidence,DPWG (No recommendation),Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,"Ticagrelor metabolism and the formation of its major active metabolite are primarily mediated by the enzyme CYP3A4. In contrast, CYP2C19 does not play a significant role in the metabolism of ticagrelor. Therefore, when making final recommendations, i have included both CYP3A4 and CYP2C19."
Ticagrelor,Actionable,ANTICOAGULANT / ANTIPLATELET,Level 1BB + Level 2A,CYP2C19,Yes,CYP2C19,-,-,FDA evidence,DPWG (No recommendation),Likely Intermediate Metabolizer,Likely Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,"Ticagrelor metabolism and the formation of its major active metabolite are primarily mediated by the enzyme CYP3A4. In contrast, CYP2C19 does not play a significant role in the metabolism of ticagrelor. Therefore, when making final recommendations, i have included both CYP3A4 and CYP2C19."
Ticagrelor,Actionable,ANTICOAGULANT / ANTIPLATELET,Level 1BB + Level 2A,CYP2C19,Yes,CYP2C19,-,-,FDA evidence,DPWG (No recommendation),Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,"Ticagrelor metabolism and the formation of its major active metabolite are primarily mediated by the enzyme CYP3A4. In contrast, CYP2C19 does not play a significant role in the metabolism of ticagrelor. Therefore, when making final recommendations, i have included both CYP3A4 and CYP2C19."
Ticagrelor,Actionable,ANTICOAGULANT / ANTIPLATELET,Level 1BB + Level 2A,CYP2C19,Yes,CYP2C19,-,-,FDA evidence,DPWG (No recommendation),Likely Poor Metabolizer,Likely Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,"Ticagrelor metabolism and the formation of its major active metabolite are primarily mediated by the enzyme CYP3A4. In contrast, CYP2C19 does not play a significant role in the metabolism of ticagrelor. Therefore, when making final recommendations, i have included both CYP3A4 and CYP2C19."
Ticagrelor,Actionable,ANTICOAGULANT / ANTIPLATELET,Level 1BB + Level 2A,CYP2C19,Yes,CYP2C19,-,-,FDA evidence,DPWG (No recommendation),Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,"Ticagrelor metabolism and the formation of its major active metabolite are primarily mediated by the enzyme CYP3A4. In contrast, CYP2C19 does not play a significant role in the metabolism of ticagrelor. Therefore, when making final recommendations, i have included both CYP3A4 and CYP2C19."
Ticagrelor,Actionable,ANTICOAGULANT / ANTIPLATELET,Level 1BB + Level 2A,CYP2C19,Yes,CYP2C19,-,-,FDA evidence,DPWG (No recommendation),Indeterminate,Indeterminate,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,n/a,-,n/a,‚úÖ,-,-,-,"Ticagrelor metabolism and the formation of its major active metabolite are primarily mediated by the enzyme CYP3A4. In contrast, CYP2C19 does not play a significant role in the metabolism of ticagrelor. Therefore, when making final recommendations, i have included both CYP3A4 and CYP2C19."
Warfarin,Actionable,ANTICOAGULANT / ANTIPLATELET,Level 1A(Strong),VKORC1 + CYP2C9,No,VKORC1,CYP2C9,-,Professional guideline; FDA evidence,"CPIC, DPWG","VKORC1,GG + CYP2C9*1/*1",-,GG,-,-,-,-,-,-,-,-,-,-,-,-,*1/*1,-,-,-,-,Normal Sensitivity,Use as Directed,-,‚úÖ,Normal Sensitivity. 5-7 mg/day [CPIC],-,-,-
Warfarin,Actionable,ANTICOAGULANT / ANTIPLATELET,Level 1A(Strong),VKORC1 + CYP2C9,No,VKORC1,CYP2C9,-,Professional guideline; FDA evidence,"CPIC, DPWG","VKORC1,GG + CYP2C9*1/*2",-,GG,-,-,-,-,-,-,-,-,-,-,-,-,*1/*2,-,-,-,-,Normal Sensitivity,Use as Directed,-,‚úÖ,Normal Sensitivity. 5-7 mg/day [CPIC],-,-,-
Warfarin,Actionable,ANTICOAGULANT / ANTIPLATELET,Level 1A(Strong),VKORC1 + CYP2C9,No,VKORC1,CYP2C9,-,Professional guideline; FDA evidence,"CPIC, DPWG","VKORC1,GG + CYP2C9*1/*3",-,GG,-,-,-,-,-,-,-,-,-,-,-,-,*1/*3,-,-,-,-,Intermediate sensitivity,Increased Caution/Avoid,-,üõë,Intermediate sensitivity. 3-4 mg/day [CPIC],-,-,-
Warfarin,Actionable,ANTICOAGULANT / ANTIPLATELET,Level 1A(Strong),VKORC1 + CYP2C9,No,VKORC1,CYP2C9,-,Professional guideline; FDA evidence,"CPIC, DPWG","VKORC1,GG + CYP2C9*2/*2",-,GG,-,-,-,-,-,-,-,-,-,-,-,-,*2/*2,-,-,-,-,Intermediate sensitivity,Increased Caution/Avoid,-,üõë,Intermediate sensitivity. 3-4 mg/day [CPIC],-,-,-
Warfarin,Actionable,ANTICOAGULANT / ANTIPLATELET,Level 1A(Strong),VKORC1 + CYP2C9,No,VKORC1,CYP2C9,-,Professional guideline; FDA evidence,"CPIC, DPWG","VKORC1,GG + CYP2C9*2/*3",-,GG,-,-,-,-,-,-,-,-,-,-,-,-,*2/*3,-,-,-,-,Intermediate sensitivity,Increased Caution/Avoid,-,üõë,Intermediate sensitivity. 3-4 mg/day [CPIC],-,-,-
Warfarin,Actionable,ANTICOAGULANT / ANTIPLATELET,Level 1A(Strong),VKORC1 + CYP2C9,No,VKORC1,CYP2C9,-,Professional guideline; FDA evidence,"CPIC, DPWG","VKORC1,GG + CYP2C9*3/*3",-,GG,-,-,-,-,-,-,-,-,-,-,-,-,*3/*3,-,-,-,-,Increased sensitivity,Increased Caution/Avoid,-,üõë,Increased sensitivity. 0.5-2 mg/day [CPIC],-,-,-
Warfarin,Actionable,ANTICOAGULANT / ANTIPLATELET,Level 1A(Strong),VKORC1 + CYP2C9,No,VKORC1,CYP2C9,-,Professional guideline; FDA evidence,"CPIC, DPWG","VKORC1,GA + CYP2C9*1/*1",-,GA,-,-,-,-,-,-,-,-,-,-,-,-,*1/*1,-,-,-,-,Normal Sensitivity,Use as Directed,-,‚úÖ,Normal Sensitivity. 5-7 mg/day [CPIC],-,-,-
Warfarin,Actionable,ANTICOAGULANT / ANTIPLATELET,Level 1A(Strong),VKORC1 + CYP2C9,No,VKORC1,CYP2C9,-,Professional guideline; FDA evidence,"CPIC, DPWG","VKORC1,GA + CYP2C9*1/*2",-,GA,-,-,-,-,-,-,-,-,-,-,-,-,*1/*2,-,-,-,-,Intermediate sensitivity,Increased Caution/Avoid,-,üõë,Intermediate sensitivity. 3-4 mg/day [CPIC],-,-,-
Warfarin,Actionable,ANTICOAGULANT / ANTIPLATELET,Level 1A(Strong),VKORC1 + CYP2C9,No,VKORC1,CYP2C9,-,Professional guideline; FDA evidence,"CPIC, DPWG","VKORC1,GA + CYP2C9*1/*3",-,GA,-,-,-,-,-,-,-,-,-,-,-,-,*1/*3,-,-,-,-,Intermediate sensitivity,Increased Caution/Avoid,-,üõë,Intermediate sensitivity. 3-4 mg/day [CPIC],-,-,-
Warfarin,Actionable,ANTICOAGULANT / ANTIPLATELET,Level 1A(Strong),VKORC1 + CYP2C9,No,VKORC1,CYP2C9,-,Professional guideline; FDA evidence,"CPIC, DPWG","VKORC1,GA + CYP2C9*2/*2",-,GA,-,-,-,-,-,-,-,-,-,-,-,-,*2/*2,-,-,-,-,Intermediate sensitivity,Increased Caution/Avoid,-,üõë,Intermediate sensitivity. 3-4 mg/day [CPIC],-,-,-
Warfarin,Actionable,ANTICOAGULANT / ANTIPLATELET,Level 1A(Strong),VKORC1 + CYP2C9,No,VKORC1,CYP2C9,-,Professional guideline; FDA evidence,"CPIC, DPWG","VKORC1,GA + CYP2C9*2/*3",-,GA,-,-,-,-,-,-,-,-,-,-,-,-,*2/*3,-,-,-,-,Increased sensitivity,Increased Caution/Avoid,-,üõë,Increased sensitivity. 0.5-2 mg/day [CPIC],-,-,-
Warfarin,Actionable,ANTICOAGULANT / ANTIPLATELET,Level 1A(Strong),VKORC1 + CYP2C9,No,VKORC1,CYP2C9,-,Professional guideline; FDA evidence,"CPIC, DPWG","VKORC1,GA + CYP2C9*3/*3",-,GA,-,-,-,-,-,-,-,-,-,-,-,-,*3/*3,-,-,-,-,Increased sensitivity,Increased Caution/Avoid,-,üõë,Increased sensitivity. 0.5-2 mg/day [CPIC],-,-,-
Warfarin,Actionable,ANTICOAGULANT / ANTIPLATELET,Level 1A(Strong),VKORC1 + CYP2C9,No,VKORC1,CYP2C9,-,Professional guideline; FDA evidence,"CPIC, DPWG","VKORC1,AA + CYP2C9*1/*1",-,AA,-,-,-,-,-,-,-,-,-,-,-,-,*1/*1,-,-,-,-,Intermediate sensitivity,Increased Caution/Avoid,-,üõë,Intermediate sensitivity. 3-4 mg/day [CPIC],-,-,-
Warfarin,Actionable,ANTICOAGULANT / ANTIPLATELET,Level 1A(Strong),VKORC1 + CYP2C9,No,VKORC1,CYP2C9,-,Professional guideline; FDA evidence,"CPIC, DPWG","VKORC1,AA + CYP2C9*1/*2",-,AA,-,-,-,-,-,-,-,-,-,-,-,-,*1/*2,-,-,-,-,Intermediate sensitivity,Increased Caution/Avoid,-,üõë,Intermediate sensitivity. 3-4 mg/day [CPIC],-,-,-
Warfarin,Actionable,ANTICOAGULANT / ANTIPLATELET,Level 1A(Strong),VKORC1 + CYP2C9,No,VKORC1,CYP2C9,-,Professional guideline; FDA evidence,"CPIC, DPWG","VKORC1,AA + CYP2C9*1/*3",-,AA,-,-,-,-,-,-,-,-,-,-,-,-,*1/*3,-,-,-,-,Increased sensitivity,Increased Caution/Avoid,-,üõë,Increased sensitivity. 0.5-2 mg/day [CPIC],-,-,-
Warfarin,Actionable,ANTICOAGULANT / ANTIPLATELET,Level 1A(Strong),VKORC1 + CYP2C9,No,VKORC1,CYP2C9,-,Professional guideline; FDA evidence,"CPIC, DPWG","VKORC1,AA + CYP2C9*2/*2",-,AA,-,-,-,-,-,-,-,-,-,-,-,-,*2/*2,-,-,-,-,Increased sensitivity,Increased Caution/Avoid,-,üõë,Increased sensitivity. 0.5-2 mg/day [CPIC],-,-,-
Warfarin,Actionable,ANTICOAGULANT / ANTIPLATELET,Level 1A(Strong),VKORC1 + CYP2C9,No,VKORC1,CYP2C9,-,Professional guideline; FDA evidence,"CPIC, DPWG","VKORC1,AA + CYP2C9*2/*3",-,AA,-,-,-,-,-,-,-,-,-,-,-,-,*2/*3,-,-,-,-,Increased sensitivity,Increased Caution/Avoid,-,üõë,Increased sensitivity. 0.5-2 mg/day [CPIC],-,-,-
Warfarin,Actionable,ANTICOAGULANT / ANTIPLATELET,Level 1A(Strong),VKORC1 + CYP2C9,No,VKORC1,CYP2C9,-,Professional guideline; FDA evidence,"CPIC, DPWG","VKORC1,AA + CYP2C9*3/*3",-,AA,-,-,-,-,-,-,-,-,-,-,-,-,*3/*3,-,-,-,-,Increased sensitivity,Increased Caution/Avoid,-,üõë,Increased sensitivity. 0.5-2 mg/day [CPIC],-,-,-
Celecoxib,Actionable,ANTIINFLAMMATORY ,Level 1A(Moderate),CYP2C9,Yes,CYP2C9,-,-,Professional guideline; FDA evidence,CPIC,"Poor Metabolizer (0.0, 0.5)",Poor Metabolizer,-,0,0.5,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,Initiate therapy with 25-50% of the lowest recommended starting dose and titrate dose upward to clinical effect or consider an alternate therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo [CPIC].,-,-,-
Celecoxib,Actionable,ANTIINFLAMMATORY ,Level 1A(Moderate),CYP2C9,Yes,CYP2C9,-,-,Professional guideline; FDA evidence,CPIC,Intermediate Metabolizer (1.0),Intermediate Metabolizer,-,1,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,Toxicity,‚ö†Ô∏è,"Initiate therapy with lowest recommended starting dose. Titrate dose upward to clinical effect or maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Carefully monitor adverse events such as blood pressure and kidney function during course of therapy.",-,-,-
Celecoxib,Actionable,ANTIINFLAMMATORY ,Level 1A(Moderate),CYP2C9,Yes,CYP2C9,-,-,Professional guideline; FDA evidence,CPIC,Intermediate Metabolizer(1.5),Intermediate Metabolizer,-,1.5,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use with Caution,Toxicity,‚ö†Ô∏è,"Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.",-,-,-
Celecoxib,Actionable,ANTIINFLAMMATORY ,Level 1A(Strong),CYP2C9,Yes,CYP2C9,-,-,Professional guideline; FDA evidence,CPIC,Normal Metabolizer(2.0),Normal Metabolizer,-,2,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,"Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.",-,-,-
Celecoxib,Actionable,ANTIINFLAMMATORY ,Level 1A(No Recommendation),CYP2C9,Yes,CYP2C9,-,-,Professional guideline; FDA evidence,CPIC,Indeterminate(n/a),Indeterminate,-,n/a,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,No recommendation,-,-,-
Flurbiprofen,Actionable,ANTIINFLAMMATORY ,Level 1A(Moderate),CYP2C9,Yes,CYP2C9,-,-,Professional guideline; FDA evidence,CPIC,"Poor Metabolizer (0.0, 0.5)",Poor Metabolizer,-,0,0.5,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,Initiate therapy with 25-50% of the lowest recommended starting dose and titrate dose upward to clinical effect or consider an alternate therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo [CPIC].,-,-,-
Flurbiprofen,Actionable,ANTIINFLAMMATORY ,Level 1A(Moderate),CYP2C9,Yes,CYP2C9,-,-,Professional guideline; FDA evidence,CPIC,Intermediate Metabolizer (1.0),Intermediate Metabolizer,-,1,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,Toxicity,‚ö†Ô∏è,"Initiate therapy with lowest recommended starting dose. Titrate dose upward to clinical effect or maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Carefully monitor adverse events such as blood pressure and kidney function during course of therapy.",-,-,-
Flurbiprofen,Actionable,ANTIINFLAMMATORY ,Level 1A(Moderate),CYP2C9,Yes,CYP2C9,-,-,Professional guideline; FDA evidence,CPIC,Intermediate Metabolizer(1.5),Intermediate Metabolizer,-,1.5,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,Toxicity,‚ö†Ô∏è,"Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.",-,-,-
Flurbiprofen,Actionable,ANTIINFLAMMATORY ,Level 1A(Strong),CYP2C9,Yes,CYP2C9,-,-,Professional guideline; FDA evidence,CPIC,Normal Metabolizer(2.0),Normal Metabolizer,-,2,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,"Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.",-,-,-
Flurbiprofen,Actionable,ANTIINFLAMMATORY ,Level 1A(No Recommendation),CYP2C9,Yes,CYP2C9,-,-,Professional guideline; FDA evidence,CPIC,Indeterminate(n/a),Indeterminate,-,n/a,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,No recommendation,-,-,No recommendation,-,-,-
Meloxicam,Actionable,ANTIINFLAMMATORY ,Level 1A(Strong),CYP2C9,Yes,CYP2C9,-,-,Professional guideline; FDA evidence,CPIC,Normal Metabolizer(2.0),Normal Metabolizer,-,2,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,"Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.",-,-,-
Meloxicam,Actionable,ANTIINFLAMMATORY ,Level 1A(Moderate),CYP2C9,Yes,CYP2C9,-,-,Professional guideline; FDA evidence,CPIC,Intermediate Metabolizer(1.5),Intermediate Metabolizer,-,1.5,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Slightly Increased Exposure,Use with Caution,Toxicity,‚ö†Ô∏è,"Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.",-,-,-
Meloxicam,Actionable,ANTIINFLAMMATORY ,Level 1A(Moderate),CYP2C9,Yes,CYP2C9,-,-,Professional guideline; FDA evidence,CPIC,Intermediate Metabolizer (1.0),Intermediate Metabolizer,-,1,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Initiate therapy with 50% of the lowest recommended starting dose. Titrate dose upward to clinical effect or 50% of the maximum recommended dose with caution. In accordance with the meloxicam prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Upward dose titration should not occur until after steady state is reached (at least 7 days). Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. Alternatively, consider alternative therapy. Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life.",-,-,-
Meloxicam,Actionable,ANTIINFLAMMATORY ,Level 1A(Moderate),CYP2C9,Yes,CYP2C9,-,-,Professional guideline; FDA evidence,CPIC,"Poor Metabolizer (0.0, 0.5)",Poor Metabolizer,-,0,0.5,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life [CPIC].,-,-,-
Meloxicam,Actionable,ANTIINFLAMMATORY ,Level 1A(No Recommendation),CYP2C9,Yes,CYP2C9,-,-,Professional guideline; FDA evidence,CPIC,Indeterminate(n/a),Indeterminate,-,n/a,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,No Recommendation,-,-,No recommendation.,-,-,-
Piroxicam,Actionable,ANTIINFLAMMATORY ,Level 1A(Moderate),CYP2C9,Yes,CYP2C9,-,-,Professional guideline; FDA evidence,CPIC,"Poor Metabolizer (0.0, 0.5)",Poor Metabolizer,-,0,0.5,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure; Increased Risk of ADR,Increased Caution/Avoid,Toxicity,üõë,Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life [CPIC].,-,-,-
Piroxicam,Actionable,ANTIINFLAMMATORY ,Level 1A(Moderate),CYP2C9,Yes,CYP2C9,-,-,Professional guideline; FDA evidence,CPIC,Intermediate Metabolizer (1.0),Intermediate Metabolizer,-,1,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (see CPIC THERAPEUTIC RECOMMENDATIONS FOR CELECOXIB, FLURBIPROFEN, LORNOXICAM, AND IBUPROFEN BASED ON CYP2C9 PHENOTYPE).",-,-,-
Piroxicam,Actionable,ANTIINFLAMMATORY ,Level 1A(Moderate),CYP2C9,Yes,CYP2C9,-,-,Professional guideline; FDA evidence,CPIC,Intermediate Metabolizer(1.5),Intermediate Metabolizer,-,1.5,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,n/a,Use with Caution,Toxicity,‚ö†Ô∏è,"Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.",-,-,-
Piroxicam,Actionable,ANTIINFLAMMATORY ,Level 1A(Strong),CYP2C9,Yes,CYP2C9,-,-,Professional guideline; FDA evidence,CPIC,Normal Metabolizer(2.0),Normal Metabolizer,-,2,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,"Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.",-,-,-
Piroxicam,Actionable,ANTIINFLAMMATORY ,Level 1A(No Recommendation),CYP2C9,Yes,CYP2C9,-,-,Professional guideline; FDA evidence,CPIC,Indeterminate(n/a),Indeterminate,-,n/a,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,No recommendation,-,-,No recommendation,-,-,-
Diclofenac,Actionable,ANTIINFLAMMATORY ,Level 2C,CYP2C9,Yes,CYP2C9,-,-,-,CPIC (No recommendation),"Poor Metabolizer (0.0, 0.5)",Poor Metabolizer,-,0,0.5,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Diclofenac,Actionable,ANTIINFLAMMATORY ,Level 2C,CYP2C9,Yes,CYP2C9,-,-,-,CPIC (No recommendation),Intermediate Metabolizer (1.0),Intermediate Metabolizer,-,1,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Diclofenac,Actionable,ANTIINFLAMMATORY ,Level 2C,CYP2C9,Yes,CYP2C9,-,-,-,CPIC (No recommendation),Intermediate Metabolizer(1.5),Intermediate Metabolizer,-,1.5,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Diclofenac,Actionable,ANTIINFLAMMATORY ,Level 2C,CYP2C9,Yes,CYP2C9,-,-,-,CPIC (No recommendation),Normal Metabolizer(2.0),Normal Metabolizer,-,2,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Diclofenac,Actionable,ANTIINFLAMMATORY ,Level 2C,CYP2C9,Yes,CYP2C9,-,-,-,CPIC (No recommendation),Indeterminate(n/a),Indeterminate,-,n/a,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-
Naproxen,Actionable,ANTIINFLAMMATORY ,Level 2A,CYP2C9,Yes,CYP2C9,-,-,-,CPIC (No recommendation),"Poor Metabolizer (0.0, 0.5)",Poor Metabolizer,-,0,0.5,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure; Minimal Information on clinical impact,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Naproxen,Actionable,ANTIINFLAMMATORY ,Level 2A,CYP2C9,Yes,CYP2C9,-,-,-,CPIC (No recommendation),Intermediate Metabolizer (1.0),Intermediate Metabolizer,-,1,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure; Minimal Information on clinical impact,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Naproxen,Actionable,ANTIINFLAMMATORY ,Level 2A,CYP2C9,Yes,CYP2C9,-,-,-,CPIC (No recommendation),Intermediate Metabolizer(1.5),Intermediate Metabolizer,-,1.5,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Naproxen,Actionable,ANTIINFLAMMATORY ,Level 2A,CYP2C9,Yes,CYP2C9,-,-,-,CPIC (No recommendation),Normal Metabolizer(2.0),Normal Metabolizer,-,2,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Naproxen,Actionable,ANTIINFLAMMATORY ,Level 2A,CYP2C9,Yes,CYP2C9,-,-,-,CPIC (No recommendation),Indeterminate(n/a),Indeterminate,-,n/a,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-
Aliskiren,Actionable,CARDIOVASCULAR,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Aliskiren,Actionable,CARDIOVASCULAR,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal evidence for effect on PK and Clinical Effects,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Aliskiren,Actionable,CARDIOVASCULAR,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal evidence for effect on PK and Clinical Effects,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Amiodarone,Actionable,CARDIOVASCULAR,Level 2B,CYP3A4,Yes,CYP3A4,-,-,-,DPWG (No recommendation),Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Amiodarone,Actionable,CARDIOVASCULAR,Level 2B,CYP3A4,Yes,CYP3A4,-,-,-,DPWG (No recommendation),Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure; Minimal Evidence for Clinical Impact,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Amiodarone,Actionable,CARDIOVASCULAR,Level 2B,CYP3A4,Yes,CYP3A4,-,-,-,DPWG (No recommendation),Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure; Minimal Evidence for Clinical Impact,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Amlodipine,Actionable,CARDIOVASCULAR,Level 2B,CYP3A4,Yes,CYP3A4,-,-,-,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Amlodipine,Actionable,CARDIOVASCULAR,Level 2B,CYP3A4,Yes,CYP3A4,-,-,-,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure; Minimal Information for Clinical Effect,Use with Caution,DD,‚ö†Ô∏è,-,-,-,-
Amlodipine,Actionable,CARDIOVASCULAR,Level 2B,CYP3A4,Yes,CYP3A4,-,-,-,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure; Minimal Information for Clinical Effect,Use with Caution,DD,‚ö†Ô∏è,-,-,-,-
Atorvastatin,Actionable,CARDIOVASCULAR,Level 1A(Strong),SLCO1B1,Yes,SLCO1B1,CYP3A4,-,Professional guideline,"CPIC, DPWG",SLCO1B1: Normal Function + CYP3A4: Poor Metabolizer,Normal Function,-,-,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,-,-,-,-,Normal Exposure,Use with Caution,DD,‚ö†Ô∏è,-,-,-,-
Atorvastatin,Actionable,CARDIOVASCULAR,Level 1A(Moderate),SLCO1B1,Yes,SLCO1B1,CYP3A4,-,Professional guideline,"CPIC, DPWG",SLCO1B1: Poor Function + CYP3A4: Poor Metabolizer,Poor Function,-,-,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,-,-,-,-,Increased Exposure; Increased Risk of ADR (increased myopathy risk),Increased Caution/Avoid,Toxicity,üõë,"Use ‚â§20mg as a starting dose and adjust doses based on disease-specific guidelines. If dose >20mg is needed, consider rosuvastatin or combination therapy",-,-,-
Atorvastatin,Actionable,CARDIOVASCULAR,Level 1A(Moderate),SLCO1B1,Yes,SLCO1B1,CYP3A4,-,Professional guideline,"CPIC, DPWG",SLCO1B1: Possible Decreased Function + CYP3A4: Poor Metabolizer,Possible Decreased Function,-,-,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,-,-,-,-,Increased Exposure; Increased Risk of ADR (increased myopathy risk),Increased Caution/Avoid,Toxicity,üõë,"Use ‚â§40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If dose >40mg needed, consider combination therapy",-,-,-
Atorvastatin,Actionable,CARDIOVASCULAR,Level 1A(Moderate),SLCO1B1,Yes,SLCO1B1,-,-,Professional guideline,"CPIC, DPWG",Decreased Function,Decreased Function,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure; Increased Risk of ADR (increased myopathy risk),Increased Caution/Avoid,Toxicity,üõë,"‚â§40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If dose >40mg needed, consider combination therapy",-,-,-
Atorvastatin,Actionable,CARDIOVASCULAR,Level 1A(Strong),SLCO1B1,Yes,SLCO1B1,-,-,Professional guideline,"CPIC, DPWG",Increased Function,Increased Function,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,Use dosing specified by Label,-,-,-
Atorvastatin,Actionable,CARDIOVASCULAR,n/a,SLCO1B1,Yes,SLCO1B1,-,-,Professional guideline,"CPIC, DPWG",Indeterminate,Indeterminate,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,n/a,No recommendation,Toxicity,-,No recommendation,-,-,-
Atorvastatin,Actionable,CARDIOVASCULAR,Level 1A(Strong),SLCO1B1,Yes,SLCO1B1,-,-,Professional guideline,"CPIC, DPWG",Normal Function,Normal Function,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,Use dosing specified by Label,-,-,-
Atorvastatin,Actionable,CARDIOVASCULAR,Level 1A(Moderate),SLCO1B1,Yes,SLCO1B1,-,-,Professional guideline,"CPIC, DPWG",Poor Function,Poor Function,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure; Increased Risk of ADR (increased myopathy risk),Increased Caution/Avoid,Toxicity,üõë,"Use ‚â§20mg as a starting dose and adjust doses based on disease-specific guidelines. If dose >20mg is needed, consider rosuvastatin or combination therapy",-,-,-
Atorvastatin,Actionable,CARDIOVASCULAR,Level 1A(Moderate),SLCO1B1,Yes,SLCO1B1,-,-,Professional guideline,"CPIC, DPWG",Possible Decreased Function,Possible Decreased Function,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure; Increased Risk of ADR (increased myopathy risk),Increased Caution/Avoid,Toxicity,üõë,"Use ‚â§40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If dose >40mg needed, consider combination therapy",-,-,-
Azilsartan,Actionable,CARDIOVASCULAR,Level 2C,CYP2C9,Yes,CYP2C9,-,-,-,-,"Poor Metabolizer (0.0, 0.5)",Poor Metabolizer,-,0,0.5,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Azilsartan,Actionable,CARDIOVASCULAR,Level 2C,CYP2C9,Yes,CYP2C9,-,-,-,-,Intermediate Metabolizer (1.0),Intermediate Metabolizer,-,1,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Azilsartan,Actionable,CARDIOVASCULAR,Level 2C,CYP2C9,Yes,CYP2C9,-,-,-,-,Intermediate Metabolizer(1.5),Intermediate Metabolizer,-,1.5,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Azilsartan,Actionable,CARDIOVASCULAR,Level 2C,CYP2C9,Yes,CYP2C9,-,-,-,-,Normal Metabolizer(2.0),Normal Metabolizer,-,2,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Azilsartan,Actionable,CARDIOVASCULAR,Level 2C,CYP2C9,Yes,CYP2C9,-,-,-,-,Indeterminate(n/a),Indeterminate,-,n/a,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Use as Directed,-,-,-,-,-,-
Carvedilol,Actionable,CARDIOVASCULAR,Level 1BB,CYP2D6,Yes,CYP2D6,-,-,FDA evidence,DPWG (No recommendation),Ultrarapid Metabolizer (>2),Ultrarapid Metabolizer,-,>2,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure;  Minimal Evidence for Clinical impact,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Carvedilol,Actionable,CARDIOVASCULAR,Level 1BB,CYP2D6,Yes,CYP2D6,-,-,FDA evidence,DPWG (No recommendation),Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Carvedilol,Actionable,CARDIOVASCULAR,Level 1BB,CYP2D6,Yes,CYP2D6,-,-,FDA evidence,DPWG (No recommendation),Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure;  Minimal Evidence for Clinical impact,Use with Caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Carvedilol,Actionable,CARDIOVASCULAR,Level 1B,CYP2D6,Yes,CYP2D6,-,-,FDA evidence,DPWG (No recommendation),Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Risk of ADR (Dizziness).,Use with Caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Clonidine,Actionable,CARDIOVASCULAR,Level 2C,CYP2D6,Yes,CYP2D6,-,-,-,DPWG (No recommendation),Ultrarapid Metabolizer (>2),Ultrarapid Metabolizer,-,>2,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure; Minimal Evidence on clinical impact,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Clonidine,Actionable,CARDIOVASCULAR,Level 2C,CYP2D6,Yes,CYP2D6,-,-,-,DPWG (No recommendation),Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Clonidine,Actionable,CARDIOVASCULAR,Level 2C,CYP2D6,Yes,CYP2D6,-,-,-,DPWG (No recommendation),Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure; Minimal Evidence on clinical impact,Use with Caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Clonidine,Actionable,CARDIOVASCULAR,Level 2C,CYP2D6,Yes,CYP2D6,-,-,-,DPWG (No recommendation),Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure; Minimal Evidence on clinical impact,Use with Caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Diltiazem,Actionable,CARDIOVASCULAR,Level 2A(talks about inducers only),CYP3A4,Yes,CYP3A4,-,-,-,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Diltiazem,Actionable,CARDIOVASCULAR,Level 2A(talks about inducers only),CYP3A4,Yes,CYP3A4,-,-,-,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK and Clinical impact,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Diltiazem,Actionable,CARDIOVASCULAR,Level 2A(talks about inducers only),CYP3A4,Yes,CYP3A4,-,-,-,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK and Clinical impact,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Disopyramide,Actionable,CARDIOVASCULAR,Level 2C,CYP3A4,Yes,CYP3A4,-,-,-,DPWG (No recommendation),Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Disopyramide,Actionable,CARDIOVASCULAR,Level 2C,CYP3A4,Yes,CYP3A4,-,-,-,DPWG (No recommendation),Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK and Clinical impact,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Disopyramide,Actionable,CARDIOVASCULAR,Level 2C,CYP3A4,Yes,CYP3A4,-,-,-,DPWG (No recommendation),Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK and Clinical impact,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Dofetilide,Actionable,CARDIOVASCULAR,Level 2B,CYP3A4,Yes,CYP3A4,-,-,-,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Dofetilide,Actionable,CARDIOVASCULAR,Level 2B,CYP3A4,Yes,CYP3A4,-,-,-,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK and Clinical impact,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Dofetilide,Actionable,CARDIOVASCULAR,Level 2B,CYP3A4,Yes,CYP3A4,-,-,-,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK and Clinical impact,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Dronedarone,Actionable,CARDIOVASCULAR,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Dronedarone,Actionable,CARDIOVASCULAR,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK and Clinical impact,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Dronedarone,Actionable,CARDIOVASCULAR,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK and Clinical impact,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Eplerenone,Actionable,CARDIOVASCULAR,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Eplerenone,Actionable,CARDIOVASCULAR,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK or Clinical Effects,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Eplerenone,Actionable,CARDIOVASCULAR,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK or Clinical Effects,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Felodipine,Actionable,CARDIOVASCULAR,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Felodipine,Actionable,CARDIOVASCULAR,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence on effect on PK and clinical Effects,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Felodipine,Actionable,CARDIOVASCULAR,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence on effect on PK and clinical Effects,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Fluvastatin,Actionable,CARDIOVASCULAR,Level 1A,CYP2C9,Yes,CYP2C9,-,-,Professional guideline,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal risk of ADR (myopathy),Use as Directed,-,‚úÖ,Prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines.,-,-,-
Fluvastatin,Actionable,CARDIOVASCULAR,Level 1A,CYP2C9,Yes,CYP2C9,-,-,Professional guideline,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased risk of ADR (myopathy),Increased Caution/Avoid,Toxicity,üõë,"Prescribe ‚â§20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy).",-,-,-
Fluvastatin,Actionable,CARDIOVASCULAR,Level 1A,CYP2C9,Yes,CYP2C9,-,-,Professional guideline,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased risk of ADR (myopathy),Increased Caution/Avoid,Toxicity,üõë,"Prescribe ‚â§40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >40mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy).",-,-,-
Fluvastatin,Actionable,CARDIOVASCULAR,Level 1A,CYP2C9,Yes,CYP2C9,-,-,Professional guideline,-,Indeterminate,Indeterminate,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-
Fluvastatin,Actionable,CARDIOVASCULAR,Level 1A,SLCO1B1,Yes,SLCO1B1,-,-,Professional guideline,-,Decreased Function,Decreased Function,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,Toxicity,‚ö†Ô∏è,Prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >40mg per day.,-,-,-
Fluvastatin,Actionable,CARDIOVASCULAR,Level 1A,SLCO1B1,Yes,SLCO1B1,-,-,Professional guideline,-,Increased Function,Increased Function,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal risk of ADR (myopathy),Use as Directed,-,‚úÖ,Prescribe desired starting dose and adjust doses based on disease-specific guidelines.,-,-,-
Fluvastatin,Actionable,CARDIOVASCULAR,Level 1A,SLCO1B1,Yes,SLCO1B1,-,-,Professional guideline,-,Indeterminate,Indeterminate,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-
Fluvastatin,Actionable,CARDIOVASCULAR,Level 1A,SLCO1B1,Yes,SLCO1B1,-,-,Professional guideline,-,No Result,No Result,-,n/a,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-
Fluvastatin,Actionable,CARDIOVASCULAR,Level 1A,SLCO1B1,Yes,SLCO1B1,-,-,Professional guideline,-,Normal Function,Normal Function,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal risk of ADR (myopathy),Use as Directed,-,‚úÖ,Prescribe desired starting dose and adjust doses based on disease-specific guidelines.,-,-,-
Fluvastatin,Actionable,CARDIOVASCULAR,Level 1A,SLCO1B1,Yes,SLCO1B1,-,-,Professional guideline,-,Poor Function,Poor Function,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased risk of ADR (myopathy),Increased Caution/Avoid,Toxicity,üõë,"Prescribe ‚â§40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If patient is tolerating 40mg per day but higher potency is needed, a higher dose (>40mg) or an alternative statin (see Figure 1 for recommendations for alternative statins) or combination therapy (i.e. fluvastatin plus non-statin guideline directed medical therapy) could be considered. Prescriber should be aware of possible increased risk for myopathy with fluvastatin especially with doses >40mg per day.",-,-,-
Fluvastatin,Actionable,CARDIOVASCULAR,Level 1A,SLCO1B1,Yes,SLCO1B1,-,-,Professional guideline,-,Possible Decreased Function,Possible Decreased Function,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,Toxicity,‚ö†Ô∏è,Prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >40mg per day.        ,-,-,-
Fluvastatin,Actionable,CARDIOVASCULAR,Level 1A(Optional),CYP2C9 + SLCO1B1,No,CYP2C9,SLCO1B1,-,Professional guideline,"CPIC, DPWG",CYP2C9: Poor Metabolizer (0.0) | SLCO1B1: Decreased Function,Poor Metabolizer,-,0,-,-,-,-,-,-,-,-,-,-,Decreased Function,-,-,-,-,-,Increased risk of ADR (myopathy),Increased Caution/Avoid,Toxicity,üõë,Consider an alternative statin depending on the desired potency.,-,-,-
Fluvastatin,Actionable,CARDIOVASCULAR,Level 1A(Moderate),CYP2C9 + SLCO1B1,No,CYP2C9,SLCO1B1,-,Professional guideline,"CPIC, DPWG",CYP2C9: Poor Metabolizer (0.0) | SLCO1B1: Increased Function,Poor Metabolizer,-,0,-,-,-,-,-,-,-,-,-,-,Increased Function,-,-,-,-,-,Increased risk of ADR (myopathy),Increased Caution/Avoid,Toxicity,üõë,"Consider ‚â§20mg per day as a starting dose and adjust doses based on disease-specific guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (fluvastatin plus non-statin guideline directed medical therapy).",-,-,-
Fluvastatin,Actionable,CARDIOVASCULAR,Level 1A(Moderate),CYP2C9 + SLCO1B1,No,CYP2C9,SLCO1B1,-,Professional guideline,"CPIC, DPWG",CYP2C9: Poor Metabolizer (0.0) | SLCO1B1: Indeterminate,Poor Metabolizer,-,0,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,-,-,-,-,Increased risk of ADR (myopathy),Increased Caution/Avoid,Toxicity,üõë,"Consider ‚â§20mg per day as a starting dose and adjust doses based on disease-specific guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (fluvastatin plus non-statin guideline directed medical therapy).",-,-,-
Fluvastatin,Actionable,CARDIOVASCULAR,Level 1A(Moderate),CYP2C9 + SLCO1B1,No,CYP2C9,SLCO1B1,-,Professional guideline,"CPIC, DPWG",CYP2C9: Poor Metabolizer (0.0) | SLCO1B1: No Result,Poor Metabolizer,-,0,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Increased risk of ADR (myopathy),Increased Caution/Avoid,Toxicity,üõë,"Consider ‚â§20mg per day as a starting dose and adjust doses based on disease-specific guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (fluvastatin plus non-statin guideline directed medical therapy).",-,-,-
Fluvastatin,Actionable,CARDIOVASCULAR,Level 1A(Moderate),CYP2C9 + SLCO1B1,No,CYP2C9,SLCO1B1,-,Professional guideline,"CPIC, DPWG",CYP2C9: Poor Metabolizer (0.0) | SLCO1B1: Normal Function,Poor Metabolizer,-,0,-,-,-,-,-,-,-,-,-,-,Normal Function,-,-,-,-,-,Increased risk of ADR (myopathy),Increased Caution/Avoid,Toxicity,üõë,"Consider ‚â§20mg per day as a starting dose and adjust doses based on disease-specific guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (fluvastatin plus non-statin guideline directed medical therapy).",-,-,-
Fluvastatin,Actionable,CARDIOVASCULAR,Level 1A(Optional),CYP2C9 + SLCO1B1,No,CYP2C9,SLCO1B1,-,Professional guideline,"CPIC, DPWG",CYP2C9: Poor Metabolizer (0.0) | SLCO1B1: Poor Function,Poor Metabolizer,-,0,-,-,-,-,-,-,-,-,-,-,Poor Function,-,-,-,-,-,Increased risk of ADR (myopathy),Increased Caution/Avoid,Toxicity,üõë,Consider an alternative statin depending on the desired potency.,-,-,-
Fluvastatin,Actionable,CARDIOVASCULAR,Level 1A(Optional),CYP2C9 + SLCO1B1,No,CYP2C9,SLCO1B1,-,Professional guideline,"CPIC, DPWG",CYP2C9: Poor Metabolizer (0.0) | SLCO1B1: Possible Decreased Function,Poor Metabolizer,-,0,-,-,-,-,-,-,-,-,-,-,Possible Decreased Function,-,-,-,-,-,Increased risk of ADR (myopathy),Increased Caution/Avoid,Toxicity,üõë,Consider an alternative statin depending on the desired potency.,-,-,-
Fluvastatin,Actionable,CARDIOVASCULAR,Level 1A(Optional),CYP2C9 + SLCO1B1,No,CYP2C9,SLCO1B1,-,Professional guideline,"CPIC, DPWG",CYP2C9: Poor Metabolizer (0.5) | SLCO1B1: Decreased Function,Poor Metabolizer,-,0.5,-,-,-,-,-,-,-,-,-,-,Decreased Function,-,-,-,-,-,Increased risk of ADR (myopathy),Increased Caution/Avoid,Toxicity,üõë,Consider an alternative statin depending on the desired potency.,-,-,-
Fluvastatin,Actionable,CARDIOVASCULAR,Level 1A(Moderate),CYP2C9 + SLCO1B1,No,CYP2C9,SLCO1B1,-,Professional guideline,"CPIC, DPWG",CYP2C9: Poor Metabolizer (0.5) | SLCO1B1: Increased Function,Poor Metabolizer,-,0.5,-,-,-,-,-,-,-,-,-,-,Increased Function,-,-,-,-,-,Increased risk of ADR (myopathy),Increased Caution/Avoid,Toxicity,üõë,"Consider ‚â§20mg per day as a starting dose and adjust doses based on disease-specific guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (fluvastatin plus non-statin guideline directed medical therapy).",-,-,-
Fluvastatin,Actionable,CARDIOVASCULAR,Level 1A(Moderate),CYP2C9 + SLCO1B1,No,CYP2C9,SLCO1B1,-,Professional guideline,"CPIC, DPWG",CYP2C9: Poor Metabolizer (0.5) | SLCO1B1: Indeterminate,Poor Metabolizer,-,0.5,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,-,-,-,-,Increased risk of ADR (myopathy),Increased Caution/Avoid,Toxicity,üõë,"Consider ‚â§20mg per day as a starting dose and adjust doses based on disease-specific guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (fluvastatin plus non-statin guideline directed medical therapy).",-,-,-
Fluvastatin,Actionable,CARDIOVASCULAR,Level 1A(Moderate),CYP2C9 + SLCO1B1,No,CYP2C9,SLCO1B1,-,Professional guideline,"CPIC, DPWG",CYP2C9: Poor Metabolizer (0.5) | SLCO1B1: No Result,Poor Metabolizer,-,0.5,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Increased risk of ADR (myopathy),Increased Caution/Avoid,Toxicity,üõë,"Consider ‚â§20mg per day as a starting dose and adjust doses based on disease-specific guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (fluvastatin plus non-statin guideline directed medical therapy).",-,-,-
Fluvastatin,Actionable,CARDIOVASCULAR,Level 1A(Moderate),CYP2C9 + SLCO1B1,No,CYP2C9,SLCO1B1,-,Professional guideline,"CPIC, DPWG",CYP2C9: Poor Metabolizer (0.5) | SLCO1B1: Normal Function,Poor Metabolizer,-,0.5,-,-,-,-,-,-,-,-,-,-,Normal Function,-,-,-,-,-,Increased risk of ADR (myopathy),Increased Caution/Avoid,Toxicity,üõë,"Consider ‚â§20mg per day as a starting dose and adjust doses based on disease-specific guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (fluvastatin plus non-statin guideline directed medical therapy).",-,-,-
Fluvastatin,Actionable,CARDIOVASCULAR,Level 1A(Optional),CYP2C9 + SLCO1B1,No,CYP2C9,SLCO1B1,-,Professional guideline,"CPIC, DPWG",CYP2C9: Poor Metabolizer (0.5) | SLCO1B1: Poor Function,Poor Metabolizer,-,0.5,-,-,-,-,-,-,-,-,-,-,Poor Function,-,-,-,-,-,Increased risk of ADR (myopathy),Increased Caution/Avoid,Toxicity,üõë,Consider an alternative statin depending on the desired potency.,-,-,-
Fluvastatin,Actionable,CARDIOVASCULAR,Level 1A(Optional),CYP2C9 + SLCO1B1,No,CYP2C9,SLCO1B1,-,Professional guideline,"CPIC, DPWG",CYP2C9: Poor Metabolizer (0.5) | SLCO1B1: Possible Decreased Function,Poor Metabolizer,-,0.5,-,-,-,-,-,-,-,-,-,-,Possible Decreased Function,-,-,-,-,-,Increased risk of ADR (myopathy),Increased Caution/Avoid,Toxicity,üõë,Consider an alternative statin depending on the desired potency.,-,-,-
Fluvastatin,Actionable,CARDIOVASCULAR,Level 1A(Optional),CYP2C9 + SLCO1B1,No,CYP2C9,SLCO1B1,-,Professional guideline,"CPIC, DPWG",CYP2C9: Intermediate Metabolizer (1.0) | SLCO1B1: Decreased Function,Intermediate Metabolizer,-,1,-,-,-,-,-,-,-,-,-,-,Decreased Function,-,-,-,-,-,Increased risk of ADR (myopathy),Increased Caution/Avoid,Toxicity,üõë,"Consider ‚â§20mg per day as a starting dose and adjust doses based on disease-specific guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (fluvastatin plus non-statin guideline directed medical therapy).",-,-,-
Fluvastatin,Actionable,CARDIOVASCULAR,Level 1A(Moderate),CYP2C9 + SLCO1B1,No,CYP2C9,SLCO1B1,-,Professional guideline,"CPIC, DPWG",CYP2C9: Intermediate Metabolizer (1.0) | SLCO1B1: Increased Function,Intermediate Metabolizer,-,1,-,-,-,-,-,-,-,-,-,-,Increased Function,-,-,-,-,-,Increased risk of ADR (myopathy),Increased Caution/Avoid,Toxicity,üõë,"Consider ‚â§40mg per day as a starting dose and adjust doses based on disease-specific guidelines. If dose >40mg needed for desired efficacy, consider an alternative statin or combination therapy (fluvastatin plus non-statin guideline directed medical therapy).",-,-,-
Fluvastatin,Actionable,CARDIOVASCULAR,Level 1A(Moderate),CYP2C9 + SLCO1B1,No,CYP2C9,SLCO1B1,-,Professional guideline,"CPIC, DPWG",CYP2C9: Intermediate Metabolizer (1.0) | SLCO1B1: Indeterminate,Intermediate Metabolizer,-,1,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,-,-,-,-,Increased risk of ADR (myopathy),Increased Caution/Avoid,Toxicity,üõë,"Consider ‚â§40mg per day as a starting dose and adjust doses based on disease-specific guidelines. If dose >40mg needed for desired efficacy, consider an alternative statin or combination therapy (fluvastatin plus non-statin guideline directed medical therapy).",-,-,-
Fluvastatin,Actionable,CARDIOVASCULAR,Level 1A(Moderate),CYP2C9 + SLCO1B1,No,CYP2C9,SLCO1B1,-,Professional guideline,"CPIC, DPWG",CYP2C9: Intermediate Metabolizer (1.0) | SLCO1B1: No Result,Intermediate Metabolizer,-,1,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Increased risk of ADR (myopathy),Increased Caution/Avoid,Toxicity,üõë,"Consider ‚â§40mg per day as a starting dose and adjust doses based on disease-specific guidelines. If dose >40mg needed for desired efficacy, consider an alternative statin or combination therapy (fluvastatin plus non-statin guideline directed medical therapy).",-,-,-
Fluvastatin,Actionable,CARDIOVASCULAR,Level 1A(Moderate),CYP2C9 + SLCO1B1,No,CYP2C9,SLCO1B1,-,Professional guideline,"CPIC, DPWG",CYP2C9: Intermediate Metabolizer (1.0) | SLCO1B1: Normal Function,Intermediate Metabolizer,-,1,-,-,-,-,-,-,-,-,-,-,Normal Function,-,-,-,-,-,Increased risk of ADR (myopathy),Increased Caution/Avoid,Toxicity,üõë,"Consider ‚â§40mg per day as a starting dose and adjust doses based on disease-specific guidelines. If dose >40mg needed for desired efficacy, consider an alternative statin or combination therapy (fluvastatin plus non-statin guideline directed medical therapy).",-,-,-
Fluvastatin,Actionable,CARDIOVASCULAR,Level 1A(Optional),CYP2C9 + SLCO1B1,No,CYP2C9,SLCO1B1,-,Professional guideline,"CPIC, DPWG",CYP2C9: Intermediate Metabolizer (1.0) | SLCO1B1: Poor Function,Intermediate Metabolizer,-,1,-,-,-,-,-,-,-,-,-,-,Poor Function,-,-,-,-,-,Increased risk of ADR (myopathy),Increased Caution/Avoid,Toxicity,üõë,Consider an alternative statin depending on the desired potency.,-,-,-
Fluvastatin,Actionable,CARDIOVASCULAR,Level 1A(Optional),CYP2C9 + SLCO1B1,No,CYP2C9,SLCO1B1,-,Professional guideline,"CPIC, DPWG",CYP2C9: Intermediate Metabolizer (1.0) | SLCO1B1: Possible Decreased Function,Intermediate Metabolizer,-,1,-,-,-,-,-,-,-,-,-,-,Possible Decreased Function,-,-,-,-,-,Increased risk of ADR (myopathy),Increased Caution/Avoid,Toxicity,üõë,"Consider ‚â§20mg per day as a starting dose and adjust doses based on disease-specific guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (fluvastatin plus non-statin guideline directed medical therapy).",-,-,-
Fluvastatin,Actionable,CARDIOVASCULAR,Level 1A(Optional),CYP2C9 + SLCO1B1,No,CYP2C9,SLCO1B1,-,Professional guideline,"CPIC, DPWG",CYP2C9: Intermediate Metabolizer (1.5) | SLCO1B1: Decreased Function,Intermediate Metabolizer,-,1.5,-,-,-,-,-,-,-,-,-,-,Decreased Function,-,-,-,-,-,Increased risk of ADR (myopathy),Increased Caution/Avoid,Toxicity,üõë,"Consider ‚â§20mg per day as a starting dose and adjust doses based on disease-specific guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (fluvastatin plus non-statin guideline directed medical therapy).",-,-,-
Fluvastatin,Actionable,CARDIOVASCULAR,Level 1A(Moderate),CYP2C9 + SLCO1B1,No,CYP2C9,SLCO1B1,-,Professional guideline,"CPIC, DPWG",CYP2C9: Intermediate Metabolizer (1.5) | SLCO1B1: Increased Function,Intermediate Metabolizer,-,1.5,-,-,-,-,-,-,-,-,-,-,Increased Function,-,-,-,-,-,Increased risk of ADR (myopathy),Increased Caution/Avoid,Toxicity,üõë,"Consider ‚â§40mg per day as a starting dose and adjust doses based on disease-specific guidelines. If dose >40mg needed for desired efficacy, consider an alternative statin or combination therapy (fluvastatin plus non-statin guideline directed medical therapy).",-,-,-
Fluvastatin,Actionable,CARDIOVASCULAR,Level 1A(Moderate),CYP2C9 + SLCO1B1,No,CYP2C9,SLCO1B1,-,Professional guideline,"CPIC, DPWG",CYP2C9: Intermediate Metabolizer (1.5) | SLCO1B1: Indeterminate,Intermediate Metabolizer,-,1.5,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,-,-,-,-,Increased risk of ADR (myopathy),Increased Caution/Avoid,Toxicity,üõë,"Consider ‚â§40mg per day as a starting dose and adjust doses based on disease-specific guidelines. If dose >40mg needed for desired efficacy, consider an alternative statin or combination therapy (fluvastatin plus non-statin guideline directed medical therapy).",-,-,-
Fluvastatin,Actionable,CARDIOVASCULAR,Level 1A(Moderate),CYP2C9 + SLCO1B1,No,CYP2C9,SLCO1B1,-,Professional guideline,"CPIC, DPWG",CYP2C9: Intermediate Metabolizer (1.5) | SLCO1B1: No Result,Intermediate Metabolizer,-,1.5,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Increased risk of ADR (myopathy),Increased Caution/Avoid,Toxicity,üõë,"Consider ‚â§40mg per day as a starting dose and adjust doses based on disease-specific guidelines. If dose >40mg needed for desired efficacy, consider an alternative statin or combination therapy (fluvastatin plus non-statin guideline directed medical therapy).",-,-,-
Fluvastatin,Actionable,CARDIOVASCULAR,Level 1A(Moderate),CYP2C9 + SLCO1B1,No,CYP2C9,SLCO1B1,-,Professional guideline,"CPIC, DPWG",CYP2C9: Intermediate Metabolizer (1.5) | SLCO1B1: Normal Function,Intermediate Metabolizer,-,1.5,-,-,-,-,-,-,-,-,-,-,Normal Function,-,-,-,-,-,Increased risk of ADR (myopathy),Increased Caution/Avoid,Toxicity,üõë,"Consider ‚â§40mg per day as a starting dose and adjust doses based on disease-specific guidelines. If dose >40mg needed for desired efficacy, consider an alternative statin or combination therapy (fluvastatin plus non-statin guideline directed medical therapy).",-,-,-
Fluvastatin,Actionable,CARDIOVASCULAR,Level 1A(Optional),CYP2C9 + SLCO1B1,No,CYP2C9,SLCO1B1,-,Professional guideline,"CPIC, DPWG",CYP2C9: Intermediate Metabolizer (1.5) | SLCO1B1: Poor Function,Intermediate Metabolizer,-,1.5,-,-,-,-,-,-,-,-,-,-,Poor Function,-,-,-,-,-,Increased risk of ADR (myopathy),Increased Caution/Avoid,Toxicity,üõë,Consider an alternative statin depending on the desired potency.,-,-,-
Fluvastatin,Actionable,CARDIOVASCULAR,Level 1A(Optional),CYP2C9 + SLCO1B1,No,CYP2C9,SLCO1B1,-,Professional guideline,"CPIC, DPWG",CYP2C9: Intermediate Metabolizer (1.5) | SLCO1B1: Possible Decreased Function,Intermediate Metabolizer,-,1.5,-,-,-,-,-,-,-,-,-,-,Possible Decreased Function,-,-,-,-,-,Increased risk of ADR (myopathy),Increased Caution/Avoid,Toxicity,üõë,"Consider ‚â§20mg per day as a starting dose and adjust doses based on disease-specific guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (fluvastatin plus non-statin guideline directed medical therapy).",-,-,-
Fluvastatin,Actionable,CARDIOVASCULAR,Level 1A(Moderate),CYP2C9 + SLCO1B1,No,CYP2C9,SLCO1B1,-,Professional guideline,"CPIC, DPWG",CYP2C9: Normal Metabolizer (2.0) | SLCO1B1: Decreased Function,Normal Metabolizer,-,2,-,-,-,-,-,-,-,-,-,-,Decreased Function,-,-,-,-,-,Increased risk of ADR (myopathy),Use with Caution,Toxicity,‚ö†Ô∏è,Consider desired starting dose and adjust doses based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >40mg per day.,-,-,-
Fluvastatin,Actionable,CARDIOVASCULAR,Level 1A(Strong),CYP2C9 + SLCO1B1,No,CYP2C9,SLCO1B1,-,Professional guideline,"CPIC, DPWG",CYP2C9: Normal Metabolizer (2.0) | SLCO1B1: Increased Function,Normal Metabolizer,-,2,-,-,-,-,-,-,-,-,-,-,Increased Function,-,-,-,-,-,Normal Risk of ADR,Use as Directed,-,‚úÖ,Use recommended starting dose and adjust doses based on disease-specific guidelines.,-,-,-
Fluvastatin,Actionable,CARDIOVASCULAR,Level 1A(Strong),CYP2C9 + SLCO1B1,No,CYP2C9,SLCO1B1,-,Professional guideline,"CPIC, DPWG",CYP2C9: Normal Metabolizer (2.0) | SLCO1B1: Indeterminate,Normal Metabolizer,-,2,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,-,-,-,-,Normal Risk of ADR,Use as Directed,-,‚úÖ,Use recommended starting dose and adjust doses of fluvastatin based on disease-specific guidelines.,-,-,-
Fluvastatin,Actionable,CARDIOVASCULAR,Level 1A(Strong),CYP2C9 + SLCO1B1,No,CYP2C9,SLCO1B1,-,Professional guideline,"CPIC, DPWG",CYP2C9: Normal Metabolizer (2.0) | SLCO1B1: No Result,Normal Metabolizer,-,2,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Normal Risk of ADR,Use as Directed,-,‚úÖ,Use recommended starting dose and adjust doses of fluvastatin based on disease-specific guidelines.,-,-,-
Fluvastatin,Actionable,CARDIOVASCULAR,Level 1A(Strong),CYP2C9 + SLCO1B1,No,CYP2C9,SLCO1B1,-,Professional guideline,"CPIC, DPWG",CYP2C9: Normal Metabolizer (2.0) | SLCO1B1: Normal Function,Normal Metabolizer,-,2,-,-,-,-,-,-,-,-,-,-,Normal Function,-,-,-,-,-,Normal Risk of ADR,Use as Directed,-,‚úÖ,Consider desired starting dose and adjust doses based on disease-specific guidelines.,-,-,-
Fluvastatin,Actionable,CARDIOVASCULAR,Level 1A(Moderate),CYP2C9 + SLCO1B1,No,CYP2C9,SLCO1B1,-,Professional guideline,"CPIC, DPWG",CYP2C9: Normal Metabolizer (2.0) | SLCO1B1: Poor Function,Normal Metabolizer,-,2,-,-,-,-,-,-,-,-,-,-,Poor Function,-,-,-,-,-,Increased risk of ADR (myopathy),Increased Caution/Avoid,Toxicity,üõë,"Consider ‚â§40mg per day as a starting dose and adjust doses based on disease-specific guidelines. If patient is tolerating 40mg per day but higher potency is needed, consider higher dose (>40mg) or an alternative statin or combination therapy (fluvastatin plus non-statin guideline directed medical therapy). There is possibility of increased risk for myopathy with fluvastatin especially with doses >40mg per day.",-,-,-
Fluvastatin,Actionable,CARDIOVASCULAR,Level 1A(Moderate),CYP2C9 + SLCO1B1,No,CYP2C9,SLCO1B1,-,Professional guideline,"CPIC, DPWG",CYP2C9: Normal Metabolizer (2.0) | SLCO1B1: Possible Decreased Function,Normal Metabolizer,-,2,-,-,-,-,-,-,-,-,-,-,Possible Decreased Function,-,-,-,-,-,Increased risk of ADR (myopathy),Use with Caution,Toxicity,‚ö†Ô∏è,Consider desired starting dose and adjust doses based on disease-specific guidelines. There is possibility of increased risk for myopathy especially for doses >40mg per day.,-,-,-
Fluvastatin,Actionable,CARDIOVASCULAR,Level 1A(Moderate),CYP2C9 + SLCO1B1,No,CYP2C9,SLCO1B1,-,Professional guideline,"CPIC, DPWG",CYP2C9: Indeterminate (n/a) | SLCO1B1: Decreased Function,Indeterminate,-,n/a,-,-,-,-,-,-,-,-,-,-,Decreased Function,-,-,-,-,-,Increased risk of ADR (myopathy),Use with Caution,Toxicity,‚ö†Ô∏è,Use recommended starting dose and adjust doses based on disease-specific guidelines. There is possibility of increased risk for myopathy especially for doses >40mg per day.,-,-,-
Fluvastatin,Actionable,CARDIOVASCULAR,Level 1A(Strong),CYP2C9 + SLCO1B1,No,CYP2C9,SLCO1B1,-,Professional guideline,"CPIC, DPWG",CYP2C9: Indeterminate (n/a) | SLCO1B1: Increased Function,Indeterminate,-,n/a,-,-,-,-,-,-,-,-,-,-,Increased Function,-,-,-,-,-,Normal Risk,Use as Directed,-,‚úÖ,Use recommended starting dose and adjust doses based on disease-specific guidelines.,-,-,-
Fluvastatin,Actionable,CARDIOVASCULAR,n/a,CYP2C9 + SLCO1B1,No,CYP2C9,SLCO1B1,-,Professional guideline,"CPIC, DPWG",CYP2C9: Indeterminate (n/a) | SLCO1B1: Indeterminate,Indeterminate,-,n/a,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,-,-,-,-,No recommendation,No recommendation,-,-,No recommendation,-,-,-
Fluvastatin,Actionable,CARDIOVASCULAR,n/a,CYP2C9 + SLCO1B1,No,CYP2C9,SLCO1B1,-,Professional guideline,"CPIC, DPWG",CYP2C9: Indeterminate (n/a) | SLCO1B1: No Result,Indeterminate,-,n/a,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,No recommendation,No recommendation,-,-,No recommendation,-,-,-
Fluvastatin,Actionable,CARDIOVASCULAR,Level 1A(Strong),CYP2C9 + SLCO1B1,No,CYP2C9,SLCO1B1,-,Professional guideline,"CPIC, DPWG",CYP2C9: Indeterminate (n/a) | SLCO1B1: Normal Function,Indeterminate,-,n/a,-,-,-,-,-,-,-,-,-,-,Normal Function,-,-,-,-,-,Normal Risk,Use as Directed,-,‚úÖ,Use recommended starting dose and adjust doses based on disease-specific guidelines.,-,-,-
Fluvastatin,Actionable,CARDIOVASCULAR,Level 1A(Moderate),CYP2C9 + SLCO1B1,No,CYP2C9,SLCO1B1,-,Professional guideline,"CPIC, DPWG",CYP2C9: Indeterminate (n/a) | SLCO1B1: Poor Function,Indeterminate,-,n/a,-,-,-,-,-,-,-,-,-,-,Poor Function,-,-,-,-,-,Increased risk of ADR (myopathy),Increased Caution/Avoid,Toxicity,üõë,"Consider ‚â§40mg per day as a starting dose and adjust doses based on disease-specific guidelines. If patient is tolerating 40mg per day but higher potency is needed, consider higher dose (>40mg) or an alternative statin or combination therapy (fluvastatin plus non-statin guideline directed medical therapy). There is possibility of increased risk for myopathy especially for doses >40mg per day.",-,-,-
Fluvastatin,Actionable,CARDIOVASCULAR,Level 1A(Moderate),CYP2C9 + SLCO1B1,No,CYP2C9,SLCO1B1,-,Professional guideline,"CPIC, DPWG",CYP2C9: Indeterminate (n/a) | SLCO1B1: Possible Decreased Function,Indeterminate,-,n/a,-,-,-,-,-,-,-,-,-,-,Possible Decreased Function,-,-,-,-,-,Increased risk of ADR (myopathy),Use with Caution,Toxicity,‚ö†Ô∏è,Use recommended starting dose and adjust doses based on disease-specific guidelines. There is possibility of increased risk for myopathy especially for doses >40mg per day.,-,-,-
Fluvastatin,Actionable,CARDIOVASCULAR,Level 1A(Moderate),CYP2C9 + SLCO1B1,No,CYP2C9,SLCO1B1,-,Professional guideline,"CPIC, DPWG",CYP2C9: No Result (No Result) | SLCO1B1: Decreased Function,No Result,-,n/a,-,-,-,-,-,-,-,-,-,-,Decreased Function,-,-,-,-,-,Increased risk of ADR (myopathy),Use with Caution,Toxicity,‚ö†Ô∏è,Use recommended starting dose and adjust doses based on disease-specific guidelines. There is possibility of increased risk for myopathy especially for doses >40mg per day.,-,-,-
Fluvastatin,Actionable,CARDIOVASCULAR,Level 1A(Strong),CYP2C9 + SLCO1B1,No,CYP2C9,SLCO1B1,-,Professional guideline,"CPIC, DPWG",CYP2C9: No Result (No Result) | SLCO1B1: Increased Function,No Result,-,n/a,-,-,-,-,-,-,-,-,-,-,Increased Function,-,-,-,-,-,Normal Risk,Use as Directed,-,‚úÖ,Use recommended starting dose and adjust doses based on disease-specific guidelines.,-,-,-
Fluvastatin,Actionable,CARDIOVASCULAR,n/a,CYP2C9 + SLCO1B1,No,CYP2C9,SLCO1B1,-,Professional guideline,"CPIC, DPWG",CYP2C9: No Result (No Result) | SLCO1B1: Indeterminate,No Result,-,n/a,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,-,-,-,-,No recommendation,No recommendation,-,-,No recommendation,-,-,-
Fluvastatin,Actionable,CARDIOVASCULAR,Level 1A(Strong),CYP2C9 + SLCO1B1,No,CYP2C9,SLCO1B1,-,Professional guideline,"CPIC, DPWG",CYP2C9: No Result (No Result) | SLCO1B1: Normal Function,No Result,-,n/a,-,-,-,-,-,-,-,-,-,-,Normal Function,-,-,-,-,-,Normal Risk,Use as Directed,-,‚úÖ,Use recommended starting dose and adjust doses based on disease-specific guidelines.,-,-,-
Fluvastatin,Actionable,CARDIOVASCULAR,Level 1A(Moderate),CYP2C9 + SLCO1B1,No,CYP2C9,SLCO1B1,-,Professional guideline,"CPIC, DPWG",CYP2C9: No Result (No Result) | SLCO1B1: Poor Function,No Result,-,n/a,-,-,-,-,-,-,-,-,-,-,Poor Function,-,-,-,-,-,Increased risk of ADR (myopathy),Increased Caution/Avoid,Toxicity,üõë,"Consider ‚â§40mg per day as a starting dose and adjust doses based on disease-specific guidelines. If patient is tolerating 40mg per day but higher potency is needed, consider higher dose (>40mg) or an alternative statin or combination therapy (fluvastatin plus non-statin guideline directed medical therapy). There is increased risk for myopathy especially for doses >40mg per day.",-,-,-
Fluvastatin,Actionable,CARDIOVASCULAR,Level 1A(Moderate),CYP2C9 + SLCO1B1,No,CYP2C9,SLCO1B1,-,Professional guideline,"CPIC, DPWG",CYP2C9: No Result (No Result) | SLCO1B1: Possible Decreased Function,No Result,-,n/a,-,-,-,-,-,-,-,-,-,-,Possible Decreased Function,-,-,-,-,-,Increased risk of ADR (myopathy),Use with Caution,Toxicity,‚ö†Ô∏è,Use recommended starting dose and adjust doses based on disease-specific guidelines. There is increased risk for myopathy especially for doses >40mg per day.,-,-,-
Guanabenz,Actionable,CARDIOVASCULAR,Level 2C,CYP1A2,Yes,CYP1A2,-,-,-,-,Extensive Metabolizer,Extensive Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Guanabenz,Actionable,CARDIOVASCULAR,Level 2C,CYP1A2,Yes,CYP1A2,-,-,-,-,High Inducibility,High Inducibility,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure,Use with caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Guanabenz,Actionable,CARDIOVASCULAR,Level 2C,CYP1A2,Yes,CYP1A2,-,-,-,-,Slow metabolizers; *1C heterozygous,Slow metabolizers,*1C Heterozygous,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Guanabenz,Actionable,CARDIOVASCULAR,Level 2C,CYP1A2,Yes,CYP1A2,-,-,-,-,Intermediate metabolizer,Intermediate metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Guanabenz,Actionable,CARDIOVASCULAR,Level 2C,CYP1A2,Yes,CYP1A2,-,-,-,-,Slow metabolizers; *1C Homozygous,Slow metabolizers,*1C Homozygous,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Guanabenz,Actionable,CARDIOVASCULAR,Level 2C,CYP1A2,Yes,CYP1A2,-,-,-,-,Poor metabolizer,Poor metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Irbesartan,Actionable,CARDIOVASCULAR,Level 2B,CYP2C9,Yes,CYP2C9,-,-,-,-,"Poor Metabolizer (0.0, 0.5)",Poor Metabolizer,-,0,0.5,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with caution,PK,‚ö†Ô∏è,-,-,-,-
Irbesartan,Actionable,CARDIOVASCULAR,Level 2B,CYP2C9,Yes,CYP2C9,-,-,-,-,Intermediate Metabolizer (1.0),Intermediate Metabolizer,-,1,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Irbesartan,Actionable,CARDIOVASCULAR,Level 2B,CYP2C9,Yes,CYP2C9,-,-,-,-,Intermediate Metabolizer(1.5),Intermediate Metabolizer,-,1.5,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Irbesartan,Actionable,CARDIOVASCULAR,Level 2B,CYP2C9,Yes,CYP2C9,-,-,-,-,Normal Metabolizer(2.0),Normal Metabolizer,-,2,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Irbesartan,Actionable,CARDIOVASCULAR,Level 2B,CYP2C9,Yes,CYP2C9,-,-,-,-,Indeterminate(n/a),Indeterminate,-,n/a,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-
Losartan,Actionable,CARDIOVASCULAR,Level 2B,CYP2C9,Yes,CYP2C9,-,-,-,-,"Poor Metabolizer (0.0, 0.5)",Poor Metabolizer,-,0,0.5,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Losartan,Actionable,CARDIOVASCULAR,Level 2B,CYP2C9,Yes,CYP2C9,-,-,-,-,Intermediate Metabolizer (1.0),Intermediate Metabolizer,-,1,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Losartan,Actionable,CARDIOVASCULAR,Level 2B,CYP2C9,Yes,CYP2C9,-,-,-,-,Intermediate Metabolizer(1.5),Intermediate Metabolizer,-,1.5,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Losartan,Actionable,CARDIOVASCULAR,Level 2B,CYP2C9,Yes,CYP2C9,-,-,-,-,Normal Metabolizer(2.0),Normal Metabolizer,-,2,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Losartan,Actionable,CARDIOVASCULAR,Level 2B,CYP2C9,Yes,CYP2C9,-,-,-,-,Indeterminate(n/a),Indeterminate,-,n/a,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-
Lovastatin,Actionable,CARDIOVASCULAR,Level 1A(Moderate),SLCO1B1,Yes,SLCO1B1,-,-,Professional guideline,CPIC,Decreased Function,Decreased Function,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure; Increased Risk of ADR (myopathy),Increased Caution/Avoid,Toxicity,üõë,"Use alternative statin. If lovastatin is warranted, limit dose to ‚â§20mg/day.",-,-,-
Lovastatin,Actionable,CARDIOVASCULAR,Level 1A(Strong),SLCO1B1,Yes,SLCO1B1,-,-,Professional guideline,CPIC,Increased Function,Increased Function,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,Prescribe desired starting dose and adjust doses based on disease-specific guidelines.,-,-,-
Lovastatin,Actionable,CARDIOVASCULAR,Level 1A(No Recommendation),SLCO1B1,Yes,SLCO1B1,-,-,Professional guideline,CPIC,Indeterminate,Indeterminate,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,n/a,No recommendation,-,-,No recommendation,-,-,-
Lovastatin,Actionable,CARDIOVASCULAR,Level 1A(Strong),SLCO1B1,Yes,SLCO1B1,-,-,Professional guideline,CPIC,Normal Function,Normal Function,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,Prescribe desired starting dose and adjust doses based on disease-specific guidelines.,-,-,-
Lovastatin,Actionable,CARDIOVASCULAR,Level 1A(Moderate),SLCO1B1,Yes,SLCO1B1,-,-,Professional guideline,CPIC,Poor Function,Poor Function,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure; Increased Risk of ADR (myopathy),Increased Caution/Avoid,Toxicity,üõë,Use alternative statin.,-,-,-
Lovastatin,Actionable,CARDIOVASCULAR,Level 1A(Moderate),SLCO1B1,Yes,SLCO1B1,-,-,Professional guideline,CPIC,Possible Decreased Function,Possible Decreased Function,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure; Increased Risk of ADR (myopathy),Increased Caution/Avoid,Toxicity,üõë,"Use alternative statin. If lovastatin is warranted, limit dose to ‚â§20mg/day.",-,-,-
Metoprolol,Actionable,CARDIOVASCULAR,Level 1A,CYP2D6,Yes,CYP2D6,-,-,Professional guideline; FDA evidence,DPWG,Ultrarapid Metabolizer (>2),Ultrarapid Metabolizer,-,>2,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure; Minimal Evidence for clinical Impact,Increased Caution/Avoid,Efficacy,üõë,1. use the maximum dose for the relevant indication as a target dose. 2. if the effectiveness is still insufficient: increase the dose based on effectiveness and side effects to 2.5 times the standard dose or select an alternative. Possible alternatives include: HEART FAILURE: bisoprolol or carvedilol. Bisoprolol: advantage: not metabolised by CYP2D6; disadvantage: elimination depends on the kidney function. Carvedilol: advantage: elimination does not depend on the kidney function; disadvantage: is metabolised (to a lesser extent than metoprolol) by CYP2D6. OTHER INDICATIONS: atenolol or bisoprolol. Neither is metabolised by CYP2D6.,-,-,-
Metoprolol,Actionable,CARDIOVASCULAR,Level 1A,CYP2D6,Yes,CYP2D6,-,-,Professional guideline; FDA evidence,DPWG,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Metoprolol,Actionable,CARDIOVASCULAR,Level 1A,CYP2D6,Yes,CYP2D6,-,-,Professional guideline; FDA evidence,DPWG,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,"If a GRADUAL REDUCTION in HEART RATE is desired, or in the event of SYMPTOMATIC BRADYCARDIA: 1. use smaller steps in dose titration and/or prescribe no more than 50% of the standard dose. OTHER CASES: 1. no action required",-,-,-
Metoprolol,Actionable,CARDIOVASCULAR,Level 1A,CYP2D6,Yes,CYP2D6,-,-,Professional guideline; FDA evidence,DPWG,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,"If a GRADUAL REDUCTION in HEART RATE is desired, or in the event of SYMPTOMATIC BRADYCARDIA: 1.use smaller steps in dose titration and/or prescribe no more than 25% of the standard dose. OTHER CASES: 1. no action required",-,-,-
Nifedipine,Actionable,CARDIOVASCULAR,Level 2C,CYP3A4,Yes,CYP3A4,-,-,-,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Nifedipine,Actionable,CARDIOVASCULAR,Level 2C,CYP3A4,Yes,CYP3A4,-,-,-,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Nifedipine,Actionable,CARDIOVASCULAR,Level 2C,CYP3A4,Yes,CYP3A4,-,-,-,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Nisoldipine,Actionable,CARDIOVASCULAR,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Nisoldipine,Actionable,CARDIOVASCULAR,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK or Clinical Effects,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Nisoldipine,Actionable,CARDIOVASCULAR,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK or Clinical Effects,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Pravastatin,Actionable,CARDIOVASCULAR,Level 1A(Moderate),SLCO1B1,Yes,SLCO1B1,-,-,Professional guideline,CPIC,Decreased Function,Decreased Function,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure; Increased Risk of ADR (risk of myopathy),Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Pravastatin,Actionable,CARDIOVASCULAR,Level 1A(Strong),SLCO1B1,Yes,SLCO1B1,-,-,Professional guideline,CPIC,Increased Function,Increased Function,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,Use desired starting dose and adjust doses based on disease-specific guidelines.,-,-,-
Pravastatin,Actionable,CARDIOVASCULAR,Level 1A(No Recommendation),SLCO1B1,Yes,SLCO1B1,-,-,Professional guideline,CPIC,Indeterminate,Indeterminate,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,n/a,No recommendation,-,-,No recommendation,-,-,-
Pravastatin,Actionable,CARDIOVASCULAR,Level 1A(Strong),SLCO1B1,Yes,SLCO1B1,-,-,Professional guideline,CPIC,Normal Function,Normal Function,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,Prescribe desired starting dose and adjust doses based on disease-specific guidelines.,-,-,-
Pravastatin,Actionable,CARDIOVASCULAR,Level 1A(Moderate),SLCO1B1,Yes,SLCO1B1,-,-,Professional guideline,CPIC,Poor Function,Poor Function,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure; Increased Risk of ADR (risk of myopathy),Increased Caution/Avoid,Toxicity,üõë,"Prescribe ‚â§40mg as a starting dose and adjust doses based on disease-specific guidelines. If 40mg is tolerated but higher potency is needed, a higher dose (>40mg) or an alternative statin or combination therapy could be considered.",-,-,-
Pravastatin,Actionable,CARDIOVASCULAR,Level 1A(Moderate),SLCO1B1,Yes,SLCO1B1,-,-,Professional guideline,CPIC,Possible Decreased Function,Possible Decreased Function,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure; Increased Risk of ADR (risk of myopathy),Use with Caution,-,‚ö†Ô∏è,Prescribe desired starting dose and adjust doses based on disease-specific guidelines.,-,-,-
Propafenone,Actionable,CARDIOVASCULAR,Level 1A,CYP2D6,Yes,CYP2D6,-,-,FDA evidence,DPWG,Ultrarapid Metabolizer (>2),Ultrarapid Metabolizer,-,>2,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure;  Minimal Evidence for Clinical impact,Increased Caution/Avoid,Toxicity,üõë,"It is not possible to offer adequately substantiated recommendations for dose adjustment based on the literature.
1. Either monitor plasma concentrations, perform an ECG and be alert to reduced efficacy of the therapy.
2. Or choose an alternative. Antiarrhythmic drugs that are hardly if at all metabolised by CYP2D6 include, for example, sotalol, disopyramide, quinidine and amiodarone.",-,-,-
Propafenone,Actionable,CARDIOVASCULAR,Level 1A,CYP2D6,Yes,CYP2D6,-,-,FDA evidence,DPWG,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Propafenone,Actionable,CARDIOVASCULAR,Level 1A,CYP2D6,Yes,CYP2D6,-,-,FDA evidence,DPWG,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure;  Minimal Evidence for Clinical impact,Increased Caution/Avoid,Toxicity,üõë,"It is not possible to offer adequately substantiated recommendations for dose adjustment based on the literature.
1. Either guide the dose by therapeutic drug monitoring, perform an ECG and be alert to side effects
2. Or choose an alternative. Antiarrhythmic drugs that are hardly if at all metabolised by CYP2D6 include, for example, sotalol, disopyramide, quinidine and amiodarone.",-,-,-
Propafenone,Actionable,CARDIOVASCULAR,Level 1A,CYP2D6,Yes,CYP2D6,-,-,FDA evidence,DPWG,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure;  Minimal Evidence for Clinical impact,Increased Caution/Avoid,Toxicity,üõë,Reduce the dose to 30% of the standard dose [DPWG_],-,-,-
Propranolol,Actionable,CARDIOVASCULAR,Level 2A,CYP2D6,Yes,CYP2D6,-,-,FDA evidence,-,Ultrarapid Metabolizer (>2),Ultrarapid Metabolizer,-,>2,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure,Use with Caution,-,‚ö†Ô∏è,-,-,-,"The FDA-approved drug label for propranolol (INNOPRAN XL) states that no difference in clearance of the drug was observed between CYP2D6 extensive and poor metabolizers. But FDA Table of Pharmacogenetic Associations states that there may be PK changes, so to reflect the genotype change, which may translate to PK Change, ""Caution"" is given when variant is present."
Propranolol,Actionable,CARDIOVASCULAR,Level 2A,CYP2D6,Yes,CYP2D6,-,-,FDA evidence,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,"The FDA-approved drug label for propranolol (INNOPRAN XL) states that no difference in clearance of the drug was observed between CYP2D6 extensive and poor metabolizers. But FDA Table of Pharmacogenetic Associations states that there may be PK changes, so to reflect the genotype change, which may translate to PK Change, ""Caution"" is given when variant is present."
Propranolol,Actionable,CARDIOVASCULAR,Level 2A,CYP2D6,Yes,CYP2D6,-,-,FDA evidence,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,-,‚ö†Ô∏è,-,-,-,"The FDA-approved drug label for propranolol (INNOPRAN XL) states that no difference in clearance of the drug was observed between CYP2D6 extensive and poor metabolizers. But FDA Table of Pharmacogenetic Associations states that there may be PK changes, so to reflect the genotype change, which may translate to PK Change, ""Caution"" is given when variant is present."
Propranolol,Actionable,CARDIOVASCULAR,Level 2A,CYP2D6,Yes,CYP2D6,-,-,FDA evidence,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,-,‚ö†Ô∏è,-,-,-,"The FDA-approved drug label for propranolol (INNOPRAN XL) states that no difference in clearance of the drug was observed between CYP2D6 extensive and poor metabolizers. But FDA Table of Pharmacogenetic Associations states that there may be PK changes, so to reflect the genotype change, which may translate to PK Change, ""Caution"" is given when variant is present."
Quinidine,Actionable,CARDIOVASCULAR,Level 2B,CYP3A4,Yes,CYP3A4,-,-,FDA evidence (Its a CYP2D6 inhibitor),DPWG (No recommendation),Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Quinidine,Actionable,CARDIOVASCULAR,Level 2B,CYP3A4,Yes,CYP3A4,-,-,FDA evidence (Its a CYP2D6 inhibitor),DPWG (No recommendation),Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK or Clinical Effects,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Quinidine,Actionable,CARDIOVASCULAR,Level 2B,CYP3A4,Yes,CYP3A4,-,-,FDA evidence (Its a CYP2D6 inhibitor),DPWG (No recommendation),Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK or Clinical Effects,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Simvastatin,Actionable,CARDIOVASCULAR,Level 2A,SLCO1B1,Yes,SLCO1B1,-,-,Professional guideline,"CPIC, DPWG",Decreased Function,Decreased Function,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure; Increased Risk of ADR (risk of myopathy),Increased Caution/Avoid,Toxicity,üõë,"Use alternative statin; If simvastatin therapy is warranted, limit dose to <20mg/day.",-,-,-
Simvastatin,Actionable,CARDIOVASCULAR,Level 2A,SLCO1B1,Yes,SLCO1B1,-,-,Professional guideline,"CPIC, DPWG",Increased Function,Increased Function,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,Use desired starting dose and adjust doses based on disease-specific guidelines.,-,-,-
Simvastatin,Actionable,CARDIOVASCULAR,Level 2A,SLCO1B1,Yes,SLCO1B1,-,-,Professional guideline,"CPIC, DPWG",Indeterminate,Indeterminate,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,n/a,No recommendation,-,-,No recommendation,-,-,-
Simvastatin,Actionable,CARDIOVASCULAR,Level 2A,SLCO1B1,Yes,SLCO1B1,-,-,Professional guideline,"CPIC, DPWG",Normal Function,Normal Function,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,Use desired starting dose and adjust doses based on disease-specific guidelines.,-,-,-
Simvastatin,Actionable,CARDIOVASCULAR,Level 2A,SLCO1B1,Yes,SLCO1B1,-,-,Professional guideline,"CPIC, DPWG",Poor Function,Poor Function,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure; Increased Risk of ADR (risk of myopathy),Increased Caution/Avoid,Toxicity,üõë,Increased Risk of ADR (risk of myopathy); Use alternative statin,-,-,-
Simvastatin,Actionable,CARDIOVASCULAR,Level 2A,SLCO1B1,Yes,SLCO1B1,-,-,Professional guideline,"CPIC, DPWG",Possible Decreased Function,Possible Decreased Function,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure; Increased Risk of ADR (risk of myopathy),Increased Caution/Avoid,Toxicity,üõë,"Use an alternative statin depending on the desired potency. If simvastatin therapy is warranted, limit dose to <20mg/day.",-,-,-
Simvastatin / Fenofibrate,Actionable,CARDIOVASCULAR,Level 2A,SLCO1B1,Yes,SLCO1B1,-,-,-,-,Decreased Function,Decreased Function,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure; Increased Risk of ADR (risk of myopathy),Use with Caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Simvastatin / Fenofibrate,Actionable,CARDIOVASCULAR,Level 2A,SLCO1B1,Yes,SLCO1B1,-,-,-,-,Increased Function,Increased Function,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Simvastatin / Fenofibrate,Actionable,CARDIOVASCULAR,Level 2A,SLCO1B1,Yes,SLCO1B1,-,-,-,-,Indeterminate,Indeterminate,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,n/a,No recommendation,-,-,-,-,-,-
Simvastatin / Fenofibrate,Actionable,CARDIOVASCULAR,Level 2A,SLCO1B1,Yes,SLCO1B1,-,-,-,-,Normal Function,Normal Function,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Simvastatin / Fenofibrate,Actionable,CARDIOVASCULAR,Level 2A,SLCO1B1,Yes,SLCO1B1,-,-,-,-,Poor Function,Poor Function,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure; Increased Risk of ADR (risk of myopathy),Use with Caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Simvastatin / Fenofibrate,Actionable,CARDIOVASCULAR,Level 2A,SLCO1B1,Yes,SLCO1B1,-,-,-,-,Possible Decreased Function,Possible Decreased Function,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure; Increased Risk of ADR (risk of myopathy),Use with Caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Verapamil,Actionable,CARDIOVASCULAR,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Verapamil,Actionable,CARDIOVASCULAR,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for Clinical Effects,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Verapamil,Actionable,CARDIOVASCULAR,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for Clinical Effects,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Flecainide,Actionable,CARDIOVASCULAR,Level 1A,CYP2D6,Yes,CYP2D6,-,-,Professional guideline,DPWG,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased risk of ADR,Increased Caution/Avoid,Toxicity,üõë,Reduce the dose to 50% of the standard dose ,-,-,-
Flecainide,Actionable,CARDIOVASCULAR,Level 1A,CYP2D6,Yes,CYP2D6,-,-,Professional guideline,DPWG,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased risk of ADR,Increased Caution/Avoid,Toxicity,üõë,Reduce the dose to 75% of the standard dose ,-,-,-
Flecainide,Actionable,CARDIOVASCULAR,Level 1A,CYP2D6,Yes,CYP2D6,-,-,Professional guideline,DPWG,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Flecainide,Actionable,CARDIOVASCULAR,Level 1A,CYP2D6,Yes,CYP2D6,-,-,Professional guideline,DPWG,Ultrarapid Metabolizer (>2),Ultrarapid Metabolizer,-,>2,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure,Increased Caution/Avoid,Efficacy,üõë,"Select an alternative; Choices include sotalol, disopyramide, quinidine and amiodarone.",-,-,-
Flecainide,Actionable,CARDIOVASCULAR,Level 1A,CYP2D6,Yes,CYP2D6,-,-,Professional guideline,DPWG,Indeterminate,Indeterminate,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,No recommendation,-,-,-
Labetalol,Actionable,CARDIOVASCULAR,Level 2C,CYP2C19,Yes,CYP2C19,-,-,-,-,Indeterminate,Indeterminate,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,n/a,-,PK,-,-,-,-,-
Labetalol,Actionable,CARDIOVASCULAR,Level 2C,CYP2C19,Yes,CYP2C19,-,-,-,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure; Minimal evidence for clinical impact,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Labetalol,Actionable,CARDIOVASCULAR,Level 2C,CYP2C19,Yes,CYP2C19,-,-,-,-,Likely Intermediate Metabolizer,Likely Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure; Minimal evidence for clinical impact,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Labetalol,Actionable,CARDIOVASCULAR,Level 2C,CYP2C19,Yes,CYP2C19,-,-,-,-,Likely Poor Metabolizer,Likely Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure; Minimal evidence for clinical impact,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Labetalol,Actionable,CARDIOVASCULAR,Level 2C,CYP2C19,Yes,CYP2C19,-,-,-,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Labetalol,Actionable,CARDIOVASCULAR,Level 2C,CYP2C19,Yes,CYP2C19,-,-,-,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure; Minimal evidence for clinical impact,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Labetalol,Actionable,CARDIOVASCULAR,Level 2C,CYP2C19,Yes,CYP2C19,-,-,-,-,Rapid Metabolizer,Rapid Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure; Minimal eviidence for clinical impact,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Labetalol,Actionable,CARDIOVASCULAR,Level 2C,CYP2C19,Yes,CYP2C19,-,-,-,-,Ultrarapid Metabolizer,Ultrarapid Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure; Minimal eviidence for clinical impact,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Ranolazine,Actionable,CARDIOVASCULAR,Level 1B,CYP2D6,Yes,CYP2D6,-,-,-,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Ranolazine,Actionable,CARDIOVASCULAR,Level 1BB,CYP2D6,Yes,CYP2D6,-,-,-,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Ranolazine,Actionable,CARDIOVASCULAR,Level 1BB,CYP2D6,Yes,CYP2D6,-,-,-,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Ranolazine,Actionable,CARDIOVASCULAR,Level 1BB,CYP2D6,Yes,CYP2D6,-,-,-,-,Ultrarapid Metabolizer (>2),Ultrarapid Metabolizer,-,>2,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Ranolazine,Actionable,CARDIOVASCULAR,Level 1BB,CYP2D6,Yes,CYP2D6,-,-,-,-,Indeterminate,Indeterminate,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,-,No recommendation,-,-,-
Rosuvastatin,Actionable,CARDIOVASCULAR,Level 1A(Strong),ABCG2,Yes,ABCG2,-,-,Professional Guidelines; FDA evidence,CPIC,Normal function,Normal function,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines.,-,-,-
Rosuvastatin,Actionable,CARDIOVASCULAR,Level 1A(Moderate),ABCG2,Yes,ABCG2,-,-,Professional Guidelines; FDA evidence,CPIC,Decreased function,Decreased function,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with caution,Toxicity,‚ö†Ô∏è,Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific guidelines and specific population guidelines.,-,-,-
Rosuvastatin,Actionable,CARDIOVASCULAR,Level 1A(Moderate),ABCG2,Yes,ABCG2,-,-,Professional Guidelines; FDA evidence,CPIC,Poor function,Poor function,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Prescribe ‚â§20mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., rosuvastatin plus non-statin guideline directed medical therapy).",-,-,-
Rosuvastatin,Actionable,CARDIOVASCULAR,Level 1A(Strong),SLCO1B1,Yes,SLCO1B1,-,-,Professional Guidelines; FDA evidence,CPIC,Normal function,Normal function,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,Prescribe desired starting dose and adjust doses based on disease-specific guidelines.,-,-,-
Rosuvastatin,Actionable,CARDIOVASCULAR,Level 1A(Strong),SLCO1B1,Yes,SLCO1B1,-,-,Professional Guidelines; FDA evidence,CPIC,Increased function,Increased function,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,Prescribe desired starting dose and adjust doses based on disease-specific guidelines.,-,-,-
Rosuvastatin,Actionable,CARDIOVASCULAR,Level 1A(Strong),SLCO1B1,Yes,SLCO1B1,-,-,Professional Guidelines; FDA evidence,CPIC,Decreased function,Decreased function,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with caution,Toxicity,‚ö†Ô∏è,Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >20mg.,-,-,-
Rosuvastatin,Actionable,CARDIOVASCULAR,Level 1A(Strong),SLCO1B1,Yes,SLCO1B1,-,-,Professional Guidelines; FDA evidence,CPIC,Possible decreased function,Possible decreased function,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with caution,Toxicity,‚ö†Ô∏è,Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >20mg.,-,-,-
Rosuvastatin,Actionable,CARDIOVASCULAR,Level 1A(Moderate),SLCO1B1,Yes,SLCO1B1,-,-,Professional Guidelines; FDA evidence,CPIC,Poor function,Poor function,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Prescribe ‚â§20mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines If dose >20mg needed for desired efficacy, consider combination therapy (i.e. rosuvastatin plus non-statin guideline directed medical therapy).",-,-,-
Rosuvastatin,Actionable,CARDIOVASCULAR,Level 1A(Strong),ABCG2 + SLCO1B1,No,ABCG2,SLCO1B1,-,Professional Guidelines; FDA evidence,CPIC,SLCO1B1 normal function + ABCG2 normal function,Normal function,-,-,-,-,-,-,-,-,-,-,-,-,Normal function,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Rosuvastatin,Actionable,CARDIOVASCULAR,Level 1A(Moderate),ABCG2 + SLCO1B1,No,ABCG2,SLCO1B1,-,Professional Guidelines; FDA evidence,CPIC,SLCO1B1 normal function + ABCG2 decreased function,Decreased function,-,-,-,-,-,-,-,-,-,-,-,-,Normal function,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Rosuvastatin,Actionable,CARDIOVASCULAR,Level 1A(Optional),ABCG2 + SLCO1B1,No,ABCG2,SLCO1B1,-,Professional Guidelines; FDA evidence,CPIC,SLCO1B1 normal function + ABCG2 poor function,Poor function,-,-,-,-,-,-,-,-,-,-,-,-,Normal function,-,-,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Prescribe ‚â§20mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., rosuvastatin plus non-statin guideline directed medical therapy). ",-,-,-
Rosuvastatin,Actionable,CARDIOVASCULAR,Level 1A(Strong),ABCG2 + SLCO1B1,No,ABCG2,SLCO1B1,-,Professional Guidelines; FDA evidence,CPIC,SLCO1B1 increased function + ABCG2 normal function,Normal function,-,-,-,-,-,-,-,-,-,-,-,-,Increased function,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Rosuvastatin,Actionable,CARDIOVASCULAR,Level 1A(Moderate),ABCG2 + SLCO1B1,No,ABCG2,SLCO1B1,-,Professional Guidelines; FDA evidence,CPIC,SLCO1B1 increased function + ABCG2 decreased function,Decreased function,-,-,-,-,-,-,-,-,-,-,-,-,Increased function,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Rosuvastatin,Actionable,CARDIOVASCULAR,Level 1A(Optional),ABCG2 + SLCO1B1,No,ABCG2,SLCO1B1,-,Professional Guidelines; FDA evidence,CPIC,SLCO1B1 increased function + ABCG2 poor function,Poor function,-,-,-,-,-,-,-,-,-,-,-,-,Increased function,-,-,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Prescribe ‚â§20mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., rosuvastatin plus non-statin guideline directed medical therapy). OPTIONAL",-,-,-
Rosuvastatin,Actionable,CARDIOVASCULAR,Level 1A(Strong),ABCG2 + SLCO1B1,No,ABCG2,SLCO1B1,-,Professional Guidelines; FDA evidence,CPIC,SLCO1B1 decreased function + ABCG2 normal function,Normal function,-,-,-,-,-,-,-,-,-,-,-,-,Decreased function,-,-,-,-,-,Increased Exposure,Use with caution,-,‚ö†Ô∏è,-,-,-,-
Rosuvastatin,Actionable,CARDIOVASCULAR,Level 1A(Moderate),ABCG2 + SLCO1B1,No,ABCG2,SLCO1B1,-,Professional Guidelines; FDA evidence,CPIC,SLCO1B1 decreased function + ABCG2 decreased function,Decreased function,-,-,-,-,-,-,-,-,-,-,-,-,Decreased function,-,-,-,-,-,Increased Exposure,Use with caution,-,‚ö†Ô∏è,-,-,-,-
Rosuvastatin,Actionable,CARDIOVASCULAR,Level 1A(Optional),ABCG2 + SLCO1B1,No,ABCG2,SLCO1B1,-,Professional Guidelines; FDA evidence,CPIC,SLCO1B1 decreased function + ABCG2 poor function,Poor function,-,-,-,-,-,-,-,-,-,-,-,-,Decreased function,-,-,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Prescribe ‚â§10mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If dose >10mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., rosuvastatin plus non-statin guideline directed medical therapy). ",-,-,-
Rosuvastatin,Actionable,CARDIOVASCULAR,Level 1A(Strong),ABCG2 + SLCO1B1,No,ABCG2,SLCO1B1,-,Professional Guidelines; FDA evidence,CPIC,SLCO1B1 possible decreased function + ABCG2 normal function,Normal function,-,-,-,-,-,-,-,-,-,-,-,-,Possible decreased function,-,-,-,-,-,Increased Exposure,Use with caution,-,‚ö†Ô∏è,-,-,-,-
Rosuvastatin,Actionable,CARDIOVASCULAR,Level 1A(Moderate),ABCG2 + SLCO1B1,No,ABCG2,SLCO1B1,-,Professional Guidelines; FDA evidence,CPIC,SLCO1B1 possible decreased function + ABCG2 decreased function,Decreased function,-,-,-,-,-,-,-,-,-,-,-,-,Possible decreased function,-,-,-,-,-,Increased Exposure,Use with caution,-,‚ö†Ô∏è,-,-,-,-
Rosuvastatin,Actionable,CARDIOVASCULAR,Level 1A(Optional),ABCG2 + SLCO1B1,No,ABCG2,SLCO1B1,-,Professional Guidelines; FDA evidence,CPIC,SLCO1B1 possible decreased function + ABCG2 poor function,Poor function,-,-,-,-,-,-,-,-,-,-,-,-,Possible decreased function,-,-,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Prescribe ‚â§10mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If dose >10mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., rosuvastatin plus non-statin guideline directed medical therapy).",-,-,-
Rosuvastatin,Actionable,CARDIOVASCULAR,Level 1A(Moderate),ABCG2 + SLCO1B1,No,ABCG2,SLCO1B1,-,Professional Guidelines; FDA evidence,CPIC,SLCO1B1 poor function + ABCG2 normal function,Normal function,-,-,-,-,-,-,-,-,-,-,-,-,Poor function,-,-,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Prescribe ‚â§20mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If dose > 20mg needed for desired efficacy, consider combination therapy (i.e., rosuvastatin plus non-statin guideline directed medical therapy).",-,-,-
Rosuvastatin,Actionable,CARDIOVASCULAR,Level 1A(Moderate),ABCG2 + SLCO1B1,No,ABCG2,SLCO1B1,-,Professional Guidelines; FDA evidence,CPIC,SLCO1B1 poor function + ABCG2 decreased function,Decreased function,-,-,-,-,-,-,-,-,-,-,-,-,Poor function,-,-,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Prescribe ‚â§20mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If dose >20mg needed for desired efficacy, consider combination therapy (i.e., rosuvastatin plus non-statin guideline directed medical therapy). ",-,-,-
Rosuvastatin,Actionable,CARDIOVASCULAR,Level 1A(Optional),ABCG2 + SLCO1B1,No,ABCG2,SLCO1B1,-,Professional Guidelines; FDA evidence,CPIC,SLCO1B1 poor function + ABCG2 poor function,Poor function,-,-,-,-,-,-,-,-,-,-,-,-,Poor function,-,-,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Prescribe ‚â§10mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If dose >10mg needed for desired efficacy, consider combination therapy (i.e., rosuvastatin plus non-statin guideline directed medical therapy). ",-,-,-
Timolol,Actionable,CARDIOVASCULAR,Level 2C,CYP2D6,Yes,CYP2D6,-,-,-,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure; Minimal evidence for clinical effect,Use with caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Timolol,Actionable,CARDIOVASCULAR,Level 2C,CYP2D6,Yes,CYP2D6,-,-,-,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure; Minimal evidence for clinical effect,Use with caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Timolol,Actionable,CARDIOVASCULAR,Level 2C,CYP2D6,Yes,CYP2D6,-,-,-,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Timolol,Actionable,CARDIOVASCULAR,Level 2C,CYP2D6,Yes,CYP2D6,-,-,-,-,Ultrarapid Metabolizer (>2),Ultrarapid Metabolizer,-,>2,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure; ; Minimal evidence for clinical effect,Use with caution,Efficacy,‚ö†Ô∏è,-,-,-,-
Timolol,Actionable,CARDIOVASCULAR,Level 2C,CYP2D6,Yes,CYP2D6,-,-,-,-,Indeterminate,Indeterminate,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,No recommendation,-,-,-
Caffeine,Actionable,DIETARY,Level 2C,CYP1A2,Yes,CYP1A2,-,-,-,-,"rs762551,AA; Fast Metabolizer",Fast Metabolizer,"rs762551,AA",-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure,Use with caution,Toxicity,‚ö†Ô∏è,Decreased Exposure,-,-,-
Caffeine,Actionable,DIETARY,Level 2C,CYP1A2,Yes,CYP1A2,-,-,-,-,"rs762551,AC; Fast Metabolizer",Fast Metabolizer,"rs762551,AC",-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure,Use with caution,Toxicity,‚ö†Ô∏è,Decreased Exposure,-,-,-
Caffeine,Actionable,DIETARY,Level 2C,CYP1A2,Yes,CYP1A2,-,-,-,-,"rs762551,CC; Slow Metabolizer",Slow Metabolizer,"rs762551,CC",-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Chlorpropamide,Actionable,ENDOCRINOLOGY,Level 1BB,G6PD,Yes,G6PD,-,-,FDA evidence; Additional testing ,CPIC (No recommendation),Normal,Normal,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Risk of ADR (acute hemolytic anemia),Use as Directed,-,‚úÖ,-,-,-,-
Chlorpropamide,Actionable,ENDOCRINOLOGY,Level 1B,G6PD,Yes,G6PD,-,-,FDA evidence; Additional testing ,CPIC (No recommendation),Deficient,Deficient,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Risk of ADR (acute hemolytic anemia),Use with Caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Chlorpropamide,Actionable,ENDOCRINOLOGY,Level 1B,G6PD,Yes,G6PD,-,-,FDA evidence; Additional testing ,CPIC (No recommendation),Deficient with CNSHA,Deficient with CNSHA,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Risk of ADR (acute hemolytic anemia),Use with Caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Chlorpropamide,Actionable,ENDOCRINOLOGY,Level 1BB,G6PD,Yes,G6PD,-,-,FDA evidence; Additional testing ,CPIC (No recommendation),Variable,Variable,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Risk of ADR (acute hemolytic anemia),Use as Directed,-,‚úÖ,-,-,-,-
Chlorpropamide,Actionable,ENDOCRINOLOGY,Level 1BB,G6PD,Yes,G6PD,-,-,FDA evidence; Additional testing ,CPIC (No recommendation),Indeterminate,Indeterminate,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Unknown Risk of ADR (acute hemolytic anemia),-,-,-,-,-,-,-
Glipizide,Actionable,ENDOCRINOLOGY,Level 1BB,G6PD,Yes,G6PD,-,-,FDA evidence; Additional testing ,CPIC (No recommendation),Normal,Normal,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Risk of ADR (acute hemolytic anemia),Use as Directed,-,‚úÖ,-,-,-,-
Glipizide,Actionable,ENDOCRINOLOGY,Level 1B,G6PD,Yes,G6PD,-,-,FDA evidence; Additional testing ,CPIC (No recommendation),Deficient,Deficient,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Risk of ADR (acute hemolytic anemia),Use with Caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Glipizide,Actionable,ENDOCRINOLOGY,Level 1B,G6PD,Yes,G6PD,-,-,FDA evidence; Additional testing ,CPIC (No recommendation),Deficient with CNSHA,Deficient with CNSHA,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Risk of ADR (acute hemolytic anemia),Use with Caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Glipizide,Actionable,ENDOCRINOLOGY,Level 1BB,G6PD,Yes,G6PD,-,-,FDA evidence; Additional testing ,CPIC (No recommendation),Variable,Variable,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Risk of ADR (acute hemolytic anemia),Use as Directed,-,‚úÖ,-,-,-,-
Glipizide,Actionable,ENDOCRINOLOGY,Level 1BB,G6PD,Yes,G6PD,-,-,FDA evidence; Additional testing ,CPIC (No recommendation),Indeterminate,Indeterminate,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Unknown Risk of ADR (acute hemolytic anemia),-,-,-,-,-,-,-
Glyburide,Actionable,ENDOCRINOLOGY,Level 1BB,G6PD,Yes,G6PD,-,-,FDA evidence; Additional testing ,CPIC (No recommendation); DPWG (No recommendation),Normal,Normal,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Risk of ADR (acute hemolytic anemia),Use as Directed,-,‚úÖ,-,-,-,-
Glyburide,Actionable,ENDOCRINOLOGY,Level 1B,G6PD,Yes,G6PD,-,-,FDA evidence; Additional testing ,CPIC (No recommendation); DPWG (No recommendation),Deficient,Deficient,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Risk of ADR (acute hemolytic anemia),Use with Caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Glyburide,Actionable,ENDOCRINOLOGY,Level 1B,G6PD,Yes,G6PD,-,-,FDA evidence; Additional testing ,CPIC (No recommendation); DPWG (No recommendation),Deficient with CNSHA,Deficient with CNSHA,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Risk of ADR (acute hemolytic anemia),Use with Caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Glyburide,Actionable,ENDOCRINOLOGY,Level 1BB,G6PD,Yes,G6PD,-,-,FDA evidence; Additional testing ,CPIC (No recommendation); DPWG (No recommendation),Variable,Variable,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Risk of ADR (acute hemolytic anemia),Use as Directed,-,‚úÖ,-,-,-,-
Glyburide,Actionable,ENDOCRINOLOGY,Level 1BB,G6PD,Yes,G6PD,-,-,FDA evidence; Additional testing ,CPIC (No recommendation); DPWG (No recommendation),Indeterminate,Indeterminate,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Unknown Risk of ADR (acute hemolytic anemia),-,-,-,-,-,-,-
Nateglinide,Actionable,ENDOCRINOLOGY,Level 1AA,CYP2C9,Yes,CYP2C9,-,-,FDA evidence,-,Normal Metabolizer(2.0),Normal Metabolizer,-,2,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Nateglinide,Actionable,ENDOCRINOLOGY,Level 1AA,CYP2C9,Yes,CYP2C9,-,-,FDA evidence,-,Intermediate Metabolizer(1.5),Intermediate Metabolizer,-,1.5,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Nateglinide,Actionable,ENDOCRINOLOGY,Level 1AA,CYP2C9,Yes,CYP2C9,-,-,FDA evidence,-,Intermediate Metabolizer (1.0),Intermediate Metabolizer,-,1,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Nateglinide,Actionable,ENDOCRINOLOGY,Level 1A,CYP2C9,Yes,CYP2C9,-,-,FDA evidence,-,"Poor Metabolizer (0.0, 0.5)",Poor Metabolizer,-,0,0.5,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure; Increased Risk of ADR (hypoglycemia),Increased Caution/Avoid,PK,üõë,Dosage reduction is recommended [FDA].,-,-,-
Nateglinide,Actionable,ENDOCRINOLOGY,Level 1AA,CYP2C9,Yes,CYP2C9,-,-,FDA evidence,-,Indeterminate(n/a),Indeterminate,-,n/a,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,No Recommendation,-,-,-,-,-,-
Tolbutamide,Actionable,ENDOCRINOLOGY,Level 1BB,G6PD,Yes,G6PD,-,-,FDA evidence,CPIC (No recommendation); DPWG (No recommendation),Normal,Normal,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Risk of ADR (acute hemolytic anemia),Use as Directed,-,‚úÖ,-,-,-,-
Tolbutamide,Actionable,ENDOCRINOLOGY,Level 1B,G6PD,Yes,G6PD,-,-,FDA evidence,CPIC (No recommendation); DPWG (No recommendation),Deficient,Deficient,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Risk of ADR (acute hemolytic anemia),Use with Caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Tolbutamide,Actionable,ENDOCRINOLOGY,Level 1B,G6PD,Yes,G6PD,-,-,FDA evidence,CPIC (No recommendation); DPWG (No recommendation),Deficient with CNSHA,Deficient with CNSHA,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Risk of ADR (acute hemolytic anemia),Use with Caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Tolbutamide,Actionable,ENDOCRINOLOGY,Level 1BB,G6PD,Yes,G6PD,-,-,FDA evidence,CPIC (No recommendation); DPWG (No recommendation),Variable,Variable,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Risk of ADR (acute hemolytic anemia),Use as Directed,-,‚úÖ,-,-,-,-
Tolbutamide,Actionable,ENDOCRINOLOGY,Level 1BB,G6PD,Yes,G6PD,-,-,FDA evidence,CPIC (No recommendation); DPWG (No recommendation),Indeterminate,Indeterminate,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Unknown Risk of ADR (acute hemolytic anemia),-,-,-,-,-,-,-
Aprepitant,Actionable,GASTROENTEROLOGY,Level 2B,CYP3A4,Yes,CYP3A4,-,-,-,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Aprepitant,Actionable,GASTROENTEROLOGY,Level 2B,CYP3A4,Yes,CYP3A4,-,-,-,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK and Clinical impact,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Aprepitant,Actionable,GASTROENTEROLOGY,Level 2B,CYP3A4,Yes,CYP3A4,-,-,-,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK and Clinical impact,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Dexlansoprazole,Actionable,GASTROENTEROLOGY,n/a,CYP2C19,Yes,CYP2C19,-,-,Professional Guidelines; FDA evidence,CPIC,Indeterminate,Indeterminate,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,n/a,-,n/a,-,No recommendation,-,-,-
Dexlansoprazole,Actionable,GASTROENTEROLOGY,Level 1A(Optional),CYP2C19,Yes,CYP2C19,-,-,Professional Guidelines; FDA evidence,CPIC,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,Toxicity,‚ö†Ô∏è,"Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.",-,-,-
Dexlansoprazole,Actionable,GASTROENTEROLOGY,Level 1A(Optional),CYP2C19,Yes,CYP2C19,-,-,Professional Guidelines; FDA evidence,CPIC,Likely Intermediate Metabolizer,Likely Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,Toxicity,‚ö†Ô∏è,"Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.",-,-,-
Dexlansoprazole,Actionable,GASTROENTEROLOGY,Level 1A(Optional),CYP2C19,Yes,CYP2C19,-,-,Professional Guidelines; FDA evidence,CPIC,Likely Poor Metabolizer,Likely Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,Toxicity,‚ö†Ô∏è,"Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.",-,-,-
Dexlansoprazole,Actionable,GASTROENTEROLOGY,Level 1A(Optional),CYP2C19,Yes,CYP2C19,-,-,Professional Guidelines; FDA evidence,CPIC,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,"Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses.
Monitor for efficacy.",-,-,-
Dexlansoprazole,Actionable,GASTROENTEROLOGY,Level 1A(Optional),CYP2C19,Yes,CYP2C19,-,-,Professional Guidelines; FDA evidence,CPIC,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,Toxicity,‚ö†Ô∏è,"Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.",-,-,-
Dexlansoprazole,Actionable,GASTROENTEROLOGY,Level 1A(Optional),CYP2C19,Yes,CYP2C19,-,-,Professional Guidelines; FDA evidence,CPIC,Rapid Metabolizer,Rapid Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure; Minimal eviidence for clinical impact,Use with Caution,PK,‚ö†Ô∏è,Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. ,-,-,-
Dexlansoprazole,Actionable,GASTROENTEROLOGY,Level 1A(Optional),CYP2C19,Yes,CYP2C19,-,-,Professional Guidelines; FDA evidence,CPIC,Ultrarapid Metabolizer,Ultrarapid Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure,Increased Caution/Avoid,Efficacy,üõë,Increase starting daily dose by 100%. ,-,-,-
Dolasetron,Actionable,GASTROENTEROLOGY,Level 2C,CYP2D6,Yes,CYP2D6,-,-,-,-,Ultrarapid Metabolizer (>2),Ultrarapid Metabolizer,-,>2,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure,Use with Caution,Efficacy,‚ö†Ô∏è,-,-,-,-
Dolasetron,Actionable,GASTROENTEROLOGY,Level 2C,CYP2D6,Yes,CYP2D6,-,-,-,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Dolasetron,Actionable,GASTROENTEROLOGY,Level 2C,CYP2D6,Yes,CYP2D6,-,-,-,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Dolasetron,Actionable,GASTROENTEROLOGY,Level 2C,CYP2D6,Yes,CYP2D6,-,-,-,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Dronabinol,Actionable,GASTROENTEROLOGY,Level 1BB,CYP2C9,Yes,CYP2C9,-,-,FDA evidence,-,Normal Metabolizer(2.0),Normal Metabolizer,-,2,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Dronabinol,Actionable,GASTROENTEROLOGY,Level 1BB,CYP2C9,Yes,CYP2C9,-,-,FDA evidence,-,Intermediate Metabolizer(1.5),Intermediate Metabolizer,-,1.5,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,"The action of Intermediate Metabolizer 1.5 is inferred based on phenytoin, which also utilizes CYP2C9 as its primary metabolizer. It appears that there will be a slight reduction in metabolism, but this may not have a significant clinical effect."
Dronabinol,Actionable,GASTROENTEROLOGY,Level 1B,CYP2C9,Yes,CYP2C9,-,-,FDA evidence,-,Intermediate Metabolizer (1.0),Intermediate Metabolizer,-,1,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Dronabinol,Actionable,GASTROENTEROLOGY,Level 1B,CYP2C9,Yes,CYP2C9,-,-,FDA evidence,-,"Poor Metabolizer (0.0, 0.5)",Poor Metabolizer,-,0,0.5,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Dronabinol,Actionable,GASTROENTEROLOGY,Level 1BB,CYP2C9,Yes,CYP2C9,-,-,FDA evidence,-,Indeterminate(n/a),Indeterminate,-,n/a,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Use as Directed,-,‚úÖ,-,-,-,-
Esomeprazole,Actionable,GASTROENTEROLOGY,Level 1BB,CYP2C19,Yes,CYP2C19,-,-,FDA evidence,CPIC (No recommendation); DPWG (No recommendation),Ultrarapid Metabolizer,Ultrarapid Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure; Minimal Evidence for Clinical Impact,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Esomeprazole,Actionable,GASTROENTEROLOGY,Level 1BB,CYP2C19,Yes,CYP2C19,-,-,FDA evidence,CPIC (No recommendation); DPWG (No recommendation),Rapid Metabolizer,Rapid Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure; Minimal eviidence for clinical impact,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Esomeprazole,Actionable,GASTROENTEROLOGY,Level 1BB,CYP2C19,Yes,CYP2C19,-,-,FDA evidence,CPIC (No recommendation); DPWG (No recommendation),Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Esomeprazole,Actionable,GASTROENTEROLOGY,Level 1BB,CYP2C19,Yes,CYP2C19,-,-,FDA evidence,CPIC (No recommendation); DPWG (No recommendation),Likely Intermediate Metabolizer,Likely Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Esomeprazole,Actionable,GASTROENTEROLOGY,Level 1BB,CYP2C19,Yes,CYP2C19,-,-,FDA evidence,CPIC (No recommendation); DPWG (No recommendation),Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Esomeprazole,Actionable,GASTROENTEROLOGY,Level 1BB,CYP2C19,Yes,CYP2C19,-,-,FDA evidence,CPIC (No recommendation); DPWG (No recommendation),Likely Poor Metabolizer,Likely Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure; Minimal Evidence for Clinical Impact,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Esomeprazole,Actionable,GASTROENTEROLOGY,Level 1B,CYP2C19,Yes,CYP2C19,-,-,FDA evidence,CPIC (No recommendation); DPWG (No recommendation),Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure; Minimal Evidence for Clinical Impact; ,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Esomeprazole,Actionable,GASTROENTEROLOGY,N/A,CYP2C19,Yes,CYP2C19,-,-,FDA evidence,CPIC (No recommendation); DPWG (No recommendation),Indeterminate,Indeterminate,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,n/a,-,n/a,‚úÖ,-,-,-,-
Fosaprepitant,Actionable,GASTROENTEROLOGY,Level 2B,CYP3A4,Yes,CYP3A4,-,-,-,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Fosaprepitant,Actionable,GASTROENTEROLOGY,Level 2B,CYP3A4,Yes,CYP3A4,-,-,-,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK or Clinical Effects,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Fosaprepitant,Actionable,GASTROENTEROLOGY,Level 2B,CYP3A4,Yes,CYP3A4,-,-,-,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK or Clinical Effects,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Glimepiride,Actionable,ENDOCRINOLOGY,Level 1BB,G6PD,Yes,G6PD,-,-,FDA evidence; Additional testing,CPIC (No recommendation); DPWG (No recommendation),Normal,Normal,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Risk of ADR (acute hemolytic anemia),Use as Directed,-,‚úÖ,-,-,-,-
Glimepiride,Actionable,ENDOCRINOLOGY,Level 1B,G6PD,Yes,G6PD,-,-,FDA evidence; Additional testing,CPIC (No recommendation); DPWG (No recommendation),Deficient,Deficient,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Risk of ADR (acute hemolytic anemia),Use with Caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Glimepiride,Actionable,ENDOCRINOLOGY,Level 1B,G6PD,Yes,G6PD,-,-,FDA evidence; Additional testing,CPIC (No recommendation); DPWG (No recommendation),Deficient with CNSHA,Deficient with CNSHA,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Risk of ADR (acute hemolytic anemia),Use with Caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Glimepiride,Actionable,ENDOCRINOLOGY,Level 1BB,G6PD,Yes,G6PD,-,-,FDA evidence; Additional testing,CPIC (No recommendation); DPWG (No recommendation),Variable,Variable,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Risk of ADR (acute hemolytic anemia),Use as Directed,-,‚úÖ,-,-,-,-
Glimepiride,Actionable,ENDOCRINOLOGY,Level 1BB,G6PD,Yes,G6PD,-,-,FDA evidence; Additional testing,CPIC (No recommendation); DPWG (No recommendation),Indeterminate,Indeterminate,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Unknown Risk of ADR (acute hemolytic anemia),-,-,-,-,-,-,-
Granisetron,Actionable,GASTROENTEROLOGY,Level 2B,CYP1A1 + CYP3A5,No,CYP1A1,CYP3A5,-,-,-,CYP1A1*1 + CYP3A5: Poor Metabolizer,-,*1,-,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Granisetron,Actionable,GASTROENTEROLOGY,Level 2B,CYP1A1 + CYP3A5,No,CYP1A1,CYP3A5,-,-,-,CYP1A1*1 + CYP3A5: Intermediate Metabolizer,-,*1,-,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,-,-,-,-,Decreased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Granisetron,Actionable,GASTROENTEROLOGY,Level 2B,CYP1A1 + CYP3A5,No,CYP1A1,CYP3A5,-,-,-,CYP1A1*1 + CYP3A5: Normal Metabolizer,-,*1,-,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,-,-,-,-,Decreased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Granisetron,Actionable,GASTROENTEROLOGY,Level 2B,CYP1A1 + CYP3A5,No,CYP1A1,CYP3A5,-,-,-,CYP1A1*2A + CYP3A5: Poor Metabolizer,-,*2A,-,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,-,-,-,-,Decreased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Granisetron,Actionable,GASTROENTEROLOGY,Level 2B,CYP1A1 + CYP3A5,No,CYP1A1,CYP3A5,-,-,-,CYP1A1*2A + CYP3A5: Intermediate Metabolizer,-,*2A,-,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,-,-,-,-,Decreased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Granisetron,Actionable,GASTROENTEROLOGY,Level 2B,CYP1A1 + CYP3A5,No,CYP1A1,CYP3A5,-,-,-,CYP1A1*2A + CYP3A5: Normal Metabolizer,-,*2A,-,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,-,-,-,-,Decreased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Lansoprazole,Actionable,GASTROENTEROLOGY,n/a,CYP2C19,Yes,CYP2C19,-,-,Professional guideline; FDA evidence,CPIC; DPWG,Indeterminate,Indeterminate,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,n/a,-,n/a,‚úÖ,No recommendation,-,-,-
Lansoprazole,Actionable,GASTROENTEROLOGY,Level 1A(Optional),CYP2C19,Yes,CYP2C19,-,-,Professional guideline; FDA evidence,CPIC; DPWG,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,Toxicity,‚ö†Ô∏è,"Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.",-,-,-
Lansoprazole,Actionable,GASTROENTEROLOGY,Level 1A(Optional),CYP2C19,Yes,CYP2C19,-,-,Professional guideline; FDA evidence,CPIC; DPWG,Likely Intermediate Metabolizer,Likely Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,Toxicity,‚ö†Ô∏è,"Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.",-,-,-
Lansoprazole,Actionable,GASTROENTEROLOGY,Level 1A(Moderate),CYP2C19,Yes,CYP2C19,-,-,Professional guideline; FDA evidence,CPIC; DPWG,Likely Poor Metabolizer,Likely Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,Toxicity,‚ö†Ô∏è,"Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.",-,-,-
Lansoprazole,Actionable,GASTROENTEROLOGY,Level 1A(Moderate),CYP2C19,Yes,CYP2C19,-,-,Professional guideline; FDA evidence,CPIC; DPWG,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,"Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses.
Monitor for efficacy.",-,-,-
Lansoprazole,Actionable,GASTROENTEROLOGY,Level 1A(Moderate),CYP2C19,Yes,CYP2C19,-,-,Professional guideline; FDA evidence,CPIC; DPWG,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,Toxicity,‚ö†Ô∏è,"Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.",-,-,-
Lansoprazole,Actionable,GASTROENTEROLOGY,Level 1A(Moderate),CYP2C19,Yes,CYP2C19,-,-,Professional guideline; FDA evidence,CPIC; DPWG,Rapid Metabolizer,Rapid Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure; Minimal eviidence for clinical impact,Use with Caution,PK,‚ö†Ô∏è,"Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses.
Monitor for efficacy.",-,-,-
Lansoprazole,Actionable,GASTROENTEROLOGY,Level 1A(Optional),CYP2C19,Yes,CYP2C19,-,-,Professional guideline; FDA evidence,CPIC; DPWG,Ultrarapid Metabolizer,Ultrarapid Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure,Increased Caution/Avoid,Efficacy,üõë,Increase starting daily dose by 100%. ,-,-,-
Metoclopramide,Actionable,GASTROENTEROLOGY,,CYP2D6 + G6PD,No,CYP2D6,G6PD,-,FDA evidence,-,CYP2D6: Ultrarapid Metabolizer (>2) + G6PD: Deficient,Ultrarapid Metabolizer,-,>2,-,-,-,-,-,-,-,-,-,-,Deficient,-,-,-,-,-,Decreased Exposure;  Minimal Evidence for Clinical impact,Use with Caution,Efficacy,‚ö†Ô∏è,-,-,-,-
Metoclopramide,Actionable,GASTROENTEROLOGY,,CYP2D6 + G6PD,No,CYP2D6,G6PD,-,FDA evidence,-,CYP2D6: Normal Metabolizer + G6PD: Deficient,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,Deficient,-,-,-,-,-,Higher adverse reaction risk,Use with Caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Metoclopramide,Actionable,GASTROENTEROLOGY,,CYP2D6 + G6PD,No,CYP2D6,G6PD,-,FDA evidence,-,CYP2D6: Intermediate Metabolizer + G6PD: Deficient,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,Deficient,-,-,-,-,-,Increased Exposure;  Minimal Evidence for Clinical impact,Use with Caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Metoclopramide,Actionable,GASTROENTEROLOGY,,CYP2D6 + G6PD,No,CYP2D6,G6PD,-,FDA evidence,-,CYP2D6: Poor Metabolizer + G6PD: Deficient,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,Deficient,-,-,-,-,-,Increased Risk of ADR,Increased Caution/Avoid,Toxicity,üõë,The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations [FDA],-,-,-
Metoclopramide,Actionable,GASTROENTEROLOGY,,CYP2D6 + G6PD,No,CYP2D6,G6PD,-,FDA evidence,-,CYP2D6: Ultrarapid Metabolizer (>2) + G6PD: Normal,Ultrarapid Metabolizer,-,>2,-,-,-,-,-,-,-,-,-,-,Normal,-,-,-,-,-,Decreased Exposure;  Minimal Evidence for Clinical impact,Use with Caution,Efficacy,‚ö†Ô∏è,-,-,-,-
Metoclopramide,Actionable,GASTROENTEROLOGY,,CYP2D6 + G6PD,No,CYP2D6,G6PD,-,FDA evidence,-,CYP2D6: Normal Metabolizer + G6PD: Normal,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,Normal,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Metoclopramide,Actionable,GASTROENTEROLOGY,,CYP2D6 + G6PD,No,CYP2D6,G6PD,-,FDA evidence,-,CYP2D6: Intermediate Metabolizer + G6PD: Normal,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,Normal,-,-,-,-,-,Increased Exposure;  Minimal Evidence for Clinical impact,Use with Caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Metoclopramide,Actionable,GASTROENTEROLOGY,,CYP2D6 + G6PD,No,CYP2D6,G6PD,-,FDA evidence,-,CYP2D6: Poor Metabolizer + G6PD: Normal,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,Normal,-,-,-,-,-,Increased Risk of ADR,Increased Caution/Avoid,Toxicity,üõë,The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations [FDA],-,-,-
Metoclopramide,Actionable,GASTROENTEROLOGY,Level 1BB,CYP2D6,Yes,CYP2D6,-,-,FDA evidence,-,Ultrarapid Metabolizer (>2),Ultrarapid Metabolizer,-,>2,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure;  Minimal Evidence for Clinical impact,Use with Caution,Efficacy,‚ö†Ô∏è,-,-,-,-
Metoclopramide,Actionable,GASTROENTEROLOGY,Level 1BB,CYP2D6,Yes,CYP2D6,-,-,FDA evidence,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Metoclopramide,Actionable,GASTROENTEROLOGY,Level 1BB,CYP2D6,Yes,CYP2D6,-,-,FDA evidence,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure;  Minimal Evidence for Clinical impact,Use with Caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Metoclopramide,Actionable,GASTROENTEROLOGY,Level 1B,CYP2D6,Yes,CYP2D6,-,-,FDA evidence,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Risk of ADR,Increased Caution/Avoid,Toxicity,üõë,The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations [FDA],-,-,-
Metoclopramide,Actionable,GASTROENTEROLOGY,Level 1B,G6PD,Yes,G6PD,-,-,FDA evidence,-,Normal,Normal,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Risk of ADR (acute hemolytic anemia),Use as Directed,-,‚úÖ,-,-,-,-
Metoclopramide,Actionable,GASTROENTEROLOGY,Level 1B,G6PD,Yes,G6PD,-,-,FDA evidence,-,Deficient,Deficient,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Risk of ADR (acute hemolytic anemia),Use with Caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Metoclopramide,Actionable,GASTROENTEROLOGY,Level 1B,G6PD,Yes,G6PD,-,-,FDA evidence,-,Deficient with CNSHA,Deficient with CNSHA,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Risk of ADR (acute hemolytic anemia),Use with Caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Metoclopramide,Actionable,GASTROENTEROLOGY,Level 1B,G6PD,Yes,G6PD,-,-,FDA evidence,-,Variable,Variable,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Risk of ADR (acute hemolytic anemia),Use as Directed,-,‚úÖ,-,-,-,-
Metoclopramide,Actionable,GASTROENTEROLOGY,Level 1B,G6PD,Yes,G6PD,-,-,FDA evidence,-,Indeterminate,Indeterminate,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Unknown Risk of ADR (acute hemolytic anemia),-,-,-,-,-,-,-
Omeprazole,Actionable,GASTROENTEROLOGY,n/a,CYP2C19,Yes,CYP2C19,-,-,Professional guideline; FDA evidence,CPIC; DPWG,Indeterminate,Indeterminate,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,n/a,-,n/a,-,No recommendation,-,-,-
Omeprazole,Actionable,GASTROENTEROLOGY,Level 1A(Optional),CYP2C19,Yes,CYP2C19,-,-,Professional guideline; FDA evidence,CPIC; DPWG,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,Toxicity,‚ö†Ô∏è,"Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.",-,-,-
Omeprazole,Actionable,GASTROENTEROLOGY,Level 1A(Optional),CYP2C19,Yes,CYP2C19,-,-,Professional guideline; FDA evidence,CPIC; DPWG,Likely Intermediate Metabolizer,Likely Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,Toxicity,‚ö†Ô∏è,"Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.",-,-,-
Omeprazole,Actionable,GASTROENTEROLOGY,Level 1A(Moderate),CYP2C19,Yes,CYP2C19,-,-,Professional guideline; FDA evidence,CPIC; DPWG,Likely Poor Metabolizer,Likely Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,Toxicity,‚ö†Ô∏è,"Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.",-,-,-
Omeprazole,Actionable,GASTROENTEROLOGY,Level 1A(Moderate),CYP2C19,Yes,CYP2C19,-,-,Professional guideline; FDA evidence,CPIC; DPWG,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,"Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses.
Monitor for efficacy.",-,-,-
Omeprazole,Actionable,GASTROENTEROLOGY,Level 1A(Moderate),CYP2C19,Yes,CYP2C19,-,-,Professional guideline; FDA evidence,CPIC; DPWG,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,Toxicity,‚ö†Ô∏è,"Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.",-,-,-
Omeprazole,Actionable,GASTROENTEROLOGY,Level 1A(Moderate),CYP2C19,Yes,CYP2C19,-,-,Professional guideline; FDA evidence,CPIC; DPWG,Rapid Metabolizer,Rapid Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure; Minimal eviidence for clinical impact,Use with Caution,PK,‚ö†Ô∏è,"Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses.
Monitor for efficacy.",-,-,-
Omeprazole,Actionable,GASTROENTEROLOGY,Level 1A(Optional),CYP2C19,Yes,CYP2C19,-,-,Professional guideline; FDA evidence,CPIC; DPWG,Ultrarapid Metabolizer,Ultrarapid Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure,Increased Caution/Avoid,Efficacy,üõë,Increase starting daily dose by 100%.,-,-,-
Ondansetron,Actionable,GASTROENTEROLOGY,Level 1A(No Recommendation),CYP2D6,Yes,CYP2D6,-,-,Professional guideline; FDA evidence,CPIC,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,n/a,Use with Caution,-,‚ö†Ô∏è,Initiate therapy with recommended starting dose.,-,-,-
Ondansetron,Actionable,GASTROENTEROLOGY,Level 1A(No Recommendation),CYP2D6,Yes,CYP2D6,-,-,Professional guideline; FDA evidence,CPIC,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,n/a,Use with Caution,-,‚ö†Ô∏è,Initiate therapy with recommended starting dose.,-,-,-
Ondansetron,Actionable,GASTROENTEROLOGY,Level 1A(Strong),CYP2D6,Yes,CYP2D6,-,-,Professional guideline; FDA evidence,CPIC,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Response,Use as Directed,-,‚úÖ,Initiate therapy with recommended starting dose.,-,-,-
Ondansetron,Actionable,GASTROENTEROLOGY,Level 1A(Moderate),CYP2D6,Yes,CYP2D6,-,-,Professional guideline; FDA evidence,CPIC,Ultrarapid Metabolizer (>2),Ultrarapid Metabolizer,-,>2,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure; Reduced Response,Increased Caution/Avoid,Efficacy,üõë,"Choose an alternative medication, such as granisetron, that is not primarily metabolized by CYP2D6.",-,-,-
Ondansetron,Actionable,GASTROENTEROLOGY,Level 1A(No Recommendation),CYP2D6,Yes,CYP2D6,-,-,Professional guideline; FDA evidence,CPIC,Indeterminate,Indeterminate,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,n/a,No recommendation,-,-,No recommendation,-,-,-
Palonosetron,Actionable,GASTROENTEROLOGY,Level 1B,CYP2D6,Yes,CYP2D6,-,-,FDA evidence,-,Ultrarapid Metabolizer (>2),Ultrarapid Metabolizer,-,>2,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Palonosetron,Actionable,GASTROENTEROLOGY,Level 1B,CYP2D6,Yes,CYP2D6,-,-,FDA evidence,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Palonosetron,Actionable,GASTROENTEROLOGY,Level 1B,CYP2D6,Yes,CYP2D6,-,-,FDA evidence,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Palonosetron,Actionable,GASTROENTEROLOGY,Level 1B,CYP2D6,Yes,CYP2D6,-,-,FDA evidence,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Pantoprazole,Actionable,GASTROENTEROLOGY,n/a,CYP2C19,Yes,CYP2C19,-,-,Professional guideline; FDA evidence,CPIC; DPWG,Indeterminate,Indeterminate,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,n/a,-,n/a,‚úÖ,No recommendation,-,-,-
Pantoprazole,Actionable,GASTROENTEROLOGY,Level 1A(Optional),CYP2C19,Yes,CYP2C19,-,-,Professional guideline; FDA evidence,CPIC; DPWG,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,Toxicity,‚ö†Ô∏è,"Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.",-,-,-
Pantoprazole,Actionable,GASTROENTEROLOGY,Level 1A(Optional),CYP2C19,Yes,CYP2C19,-,-,Professional guideline; FDA evidence,CPIC; DPWG,Likely Intermediate Metabolizer,Likely Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,Toxicity,‚ö†Ô∏è,"Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.",-,-,-
Pantoprazole,Actionable,GASTROENTEROLOGY,Level 1A(Moderate),CYP2C19,Yes,CYP2C19,-,-,Professional guideline; FDA evidence,CPIC; DPWG,Likely Poor Metabolizer,Likely Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,Toxicity,‚ö†Ô∏è,"Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.",-,-,-
Pantoprazole,Actionable,GASTROENTEROLOGY,Level 1A(Moderate),CYP2C19,Yes,CYP2C19,-,-,Professional guideline; FDA evidence,CPIC; DPWG,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,"Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses.
Monitor for efficacy.",-,-,-
Pantoprazole,Actionable,GASTROENTEROLOGY,Level 1A(Moderate),CYP2C19,Yes,CYP2C19,-,-,Professional guideline; FDA evidence,CPIC; DPWG,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,Toxicity,‚ö†Ô∏è,"Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.",-,-,-
Pantoprazole,Actionable,GASTROENTEROLOGY,Level 1A(Moderate),CYP2C19,Yes,CYP2C19,-,-,Professional guideline; FDA evidence,CPIC; DPWG,Rapid Metabolizer,Rapid Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure; Minimal eviidence for clinical impact,Use with Caution,PK,‚ö†Ô∏è,"Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses.
Monitor for efficacy.",-,-,-
Pantoprazole,Actionable,GASTROENTEROLOGY,Level 1A(Optional),CYP2C19,Yes,CYP2C19,-,-,Professional guideline; FDA evidence,CPIC; DPWG,Ultrarapid Metabolizer,Ultrarapid Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure; Reduced Response (increased risk of therapeutic failure),Increased Caution/Avoid,Efficacy,üõë,Increase starting daily dose by 100%.,-,-,-
Rabeprazole,Actionable,GASTROENTEROLOGY,Level 1BB,CYP2C19,Yes,CYP2C19,-,-,FDA evidence,CPIC (No recommendation); DPWG (No recommendation),Ultrarapid Metabolizer,Ultrarapid Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure,Use with Caution,Efficacy,‚ö†Ô∏è,-,-,-,-
Rabeprazole,Actionable,GASTROENTEROLOGY,Level 1BB,CYP2C19,Yes,CYP2C19,-,-,FDA evidence,CPIC (No recommendation); DPWG (No recommendation),Rapid Metabolizer,Rapid Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure; Minimal eviidence for clinical impact,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Rabeprazole,Actionable,GASTROENTEROLOGY,Level 1BB,CYP2C19,Yes,CYP2C19,-,-,FDA evidence,CPIC (No recommendation); DPWG (No recommendation),Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Rabeprazole,Actionable,GASTROENTEROLOGY,Level 1BB,CYP2C19,Yes,CYP2C19,-,-,FDA evidence,CPIC (No recommendation); DPWG (No recommendation),Likely Intermediate Metabolizer,Likely Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Rabeprazole,Actionable,GASTROENTEROLOGY,Level 1BB,CYP2C19,Yes,CYP2C19,-,-,FDA evidence,CPIC (No recommendation); DPWG (No recommendation),Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Rabeprazole,Actionable,GASTROENTEROLOGY,Level 1BB,CYP2C19,Yes,CYP2C19,-,-,FDA evidence,CPIC (No recommendation); DPWG (No recommendation),Likely Poor Metabolizer,Likely Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure; Minimal Evidence for Clinical Impact,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Rabeprazole,Actionable,GASTROENTEROLOGY,Level 1B,CYP2C19,Yes,CYP2C19,-,-,FDA evidence,CPIC (No recommendation); DPWG (No recommendation),Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure; Minimal Evidence for Clinical Impact; ,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Rabeprazole,Actionable,GASTROENTEROLOGY,N/A,CYP2C19,Yes,CYP2C19,-,-,FDA evidence,CPIC (No recommendation); DPWG (No recommendation),Indeterminate,Indeterminate,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,n/a,-,n/a,‚úÖ,-,-,-,-
Eliglustat,Actionable,GENETIC DISEASE,Level 1A,CYP2D6,Yes,CYP2D6,-,-,Professional guideline; FDA evidence; additional testing,DPWG,Ultrarapid Metabolizer (>2),Ultrarapid Metabolizer,-,>2,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure,Increased Caution/Avoid,PK,üõë,Eliglustat is contra-indicated. Choose an alternative if possible [DPWG]; Use 84 mg twice daily [FDA],-,-,-
Eliglustat,Actionable,GENETIC DISEASE,Level 1A,CYP2D6,Yes,CYP2D6,-,-,Professional guideline; FDA evidence; additional testing,DPWG,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Eliglustat,Actionable,GENETIC DISEASE,Level 1A,CYP2D6,Yes,CYP2D6,-,-,Professional guideline; FDA evidence; additional testing,DPWG,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure;  Minimal Evidence for Clinical impact,Using with Caution,PK,‚ö†Ô∏è,Use 84 mg orally once daily [FDA],-,-,-
Eliglustat,Actionable,GENETIC DISEASE,Level 1A,CYP2D6,Yes,CYP2D6,-,-,Professional guideline; FDA evidence; additional testing,DPWG,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Risk of ADR (QT interval elongation).,Increased Caution/Avoid,PK,üõë,Choose an alternative [DPWG]; Use 84 mg orally once daily [FDA],-,-,-
Ivacaftor,Actionable,GENETIC DISEASE,Level 2A,CYP3A4,Yes,CYP3A4,-,-,Additional testing,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Ivacaftor,Actionable,GENETIC DISEASE,Level 2A,CYP3A4,Yes,CYP3A4,-,-,Additional testing,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for Clinical Effects,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Ivacaftor,Actionable,GENETIC DISEASE,Level 2A,CYP3A4,Yes,CYP3A4,-,-,Additional testing,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for Clinical Effects,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Ivacaftor / Lumacaftor,Actionable,GENETIC DISEASE,Level 2A,CYP3A4,Yes,CYP3A4,-,-,Additional testing,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Ivacaftor / Lumacaftor,Actionable,GENETIC DISEASE,Level 2A,CYP3A4,Yes,CYP3A4,-,-,Additional testing,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for Clinical Effects,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Ivacaftor / Lumacaftor,Actionable,GENETIC DISEASE,Level 2A,CYP3A4,Yes,CYP3A4,-,-,Additional testing,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for Clinical Effects,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Azathioprine,Actionable,IMMUNOSUPPRESSION,Level 1A(Strong),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: Indeterminate (n/a) | NUDT15: Indeterminate (n/a),Indeterminate,-,n/a,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,No recommendation,No recommendation,-,-,"Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.",-,-,-
Azathioprine,Actionable,IMMUNOSUPPRESSION,Level 1A(Strong),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: Indeterminate (n/a) | NUDT15: Intermediate Metabolizer (n/a),Indeterminate,-,n/a,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,"Increased risk of ADR (thiopurine-related leukopenia, neutropenia, myelosuppression)",Increased Caution/Avoid,Toxicity,üõë,"Based on NUDT15 status, reduce initial dose to 30%-80% of normal dose, eg., if normal dose is 2-3 mg/kg/day reduce it to 0.6-2.4 mg/kg/day and adjust doses based on degree of myelosuppression and disease-specific guidelines. After each dose adjustment, allow 2-4 weeks to reach steady-state. Consider evaluating erythrocyte TPMT activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.",-,-,-
Azathioprine,Actionable,IMMUNOSUPPRESSION,Level 1A(Strong),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: Indeterminate (n/a) | NUDT15: No Result (n/a),Indeterminate,-,n/a,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,No recommendation,No recommendation,-,-,"Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.",-,-,-
Azathioprine,Actionable,IMMUNOSUPPRESSION,Level 1A(Strong),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: Indeterminate (n/a) | NUDT15: Normal Metabolizer (n/a),Indeterminate,-,n/a,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,"Normal risk of ADR (thiopurine-related leukopenia, neutropenia, myelosuppression)",Use with Caution,-,‚ö†Ô∏è,"Based on NUDT15 status, use recommended starting dose, e.g., 2-3 mg/kg/day and adjust doses based on disease-specific guidelines. After each dose adjustment, allow 2 weeks to reach steady-state. Consider evaluating erythrocyte TPMT activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.",-,-,-
Azathioprine,Actionable,IMMUNOSUPPRESSION,Level 1A(Strong),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: Indeterminate (n/a) | NUDT15: Poor Metabolizer (n/a),Indeterminate,-,n/a,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,"Increased risk of ADR (thiopurine-related leukopenia, neutropenia, myelosuppression)",Increased Caution/Avoid,Toxicity,üõë,"Based on NUDT15 status, for non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignant conditions, reduce daily dose by 10-fold and adjust doses based on degree of myelosuppression and disease-specific guidelines. After each dose adjustment, allow 4-6 weeks to reach steady-state. Consider evaluating erythrocyte TPMT activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.",-,-,-
Azathioprine,Actionable,IMMUNOSUPPRESSION,Level 1A(Strong),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: Indeterminate (n/a) | NUDT15: Possible Intermediate Metabolizer (n/a),Indeterminate,-,n/a,-,-,-,-,-,-,-,-,-,-,Possible Intermediate Metabolizer,-,n/a,-,-,-,"Increased risk of ADR (thiopurine-related leukopenia, neutropenia, myelosuppression)",Increased Caution/Avoid,Toxicity,üõë,"Based on NUDT15 status, reduce initial dose to 30%-80% of normal dose, eg., if normal dose is 2-3 mg/kg/day reduce it to 0.6-2.4 mg/kg/day and adjust doses based on degree of myelosuppression and disease-specific guidelines. After each dose adjustment, allow 2-4 weeks to reach steady-state. Consider evaluating erythrocyte TPMT activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.",-,-,-
Azathioprine,Actionable,IMMUNOSUPPRESSION,Level 1A(Strong),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: Intermediate Metabolizer (n/a) | NUDT15: Indeterminate (n/a),Intermediate Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,"Increased risk of ADR (thiopurine-related leukopenia, neutropenia, myelosuppression)",Increased Caution/Avoid,Toxicity,üõë,"Based on TPMT status, reduce initial dose to 30%-80% of normal dose, eg., if normal dose is 2-3 mg/kg/day reduce it to 0.6-2.4 mg/kg/day and adjust doses based on degree of myelosuppression and disease-specific guidelines. After each dose adjustment, allow 2-4 weeks to reach steady-state. If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity.",-,-,-
Azathioprine,Actionable,IMMUNOSUPPRESSION,Level 1A(Strong),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: Intermediate Metabolizer (n/a) | NUDT15: Intermediate Metabolizer (n/a),Intermediate Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,"Increased risk of ADR (thiopurine-related leukopenia, neutropenia, myelosuppression)",Increased Caution/Avoid,Toxicity,üõë,"Reduce initial dose to 30%-80% of normal dose, eg., if normal dose is 2-3 mg/kg/day reduce it to 0.6-2.4 mg/kg/day and adjust doses based on degree of myelosuppression and disease-specific guidelines. After each dose adjustment, allow 2-4 weeks to reach steady-state.",-,-,-
Azathioprine,Actionable,IMMUNOSUPPRESSION,Level 1A(Strong),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: Intermediate Metabolizer (n/a) | NUDT15: No Result (n/a),Intermediate Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,"Increased risk of ADR (thiopurine-related leukopenia, neutropenia, myelosuppression)",Increased Caution/Avoid,Toxicity,üõë,"Based on TPMT status, reduce initial dose to 30%-80% of normal dose, eg., if normal dose is 2-3 mg/kg/day reduce it to 0.6-2.4 mg/kg/day and adjust doses based on degree of myelosuppression and disease-specific guidelines. After each dose adjustment, allow 2-4 weeks to reach steady-state. If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity.",-,-,-
Azathioprine,Actionable,IMMUNOSUPPRESSION,Level 1A(Strong),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: Intermediate Metabolizer (n/a) | NUDT15: Normal Metabolizer (n/a),Intermediate Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Reduce initial dose to 30%-80% of normal dose, eg., if normal dose is 2-3 mg/kg/day reduce it to 0.6-2.4 mg/kg/day and adjust doses based on degree of myelosuppression and disease-specific guidelines. After each dose adjustment, allow 2-4 weeks to reach steady-state.",-,-,-
Azathioprine,Actionable,IMMUNOSUPPRESSION,Level 1A(Strong),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: Intermediate Metabolizer (n/a) | NUDT15: Poor Metabolizer (n/a),Intermediate Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,"Increased risk of ADR (thiopurine-related leukopenia, neutropenia, myelosuppression)",Increased Caution/Avoid,Toxicity,üõë,"For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignant conditions, reduce daily dose by 10-fold and adjust doses based on degree of myelosuppression and disease-specific guidelines. After each dose adjustment, allow 4-6 weeks to reach steady-state.",-,-,-
Azathioprine,Actionable,IMMUNOSUPPRESSION,Level 1A(Strong),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: Intermediate Metabolizer (n/a) | NUDT15: Possible Intermediate Metabolizer (n/a),Intermediate Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Possible Intermediate Metabolizer,-,n/a,-,-,-,"Increased risk of ADR (thiopurine-related leukopenia, neutropenia, myelosuppression)",Increased Caution/Avoid,Toxicity,üõë,"Reduce initial dose to 30%-80% of normal dose, eg., if normal dose is 2-3 mg/kg/day reduce it to 0.6-2.4 mg/kg/day and adjust doses based on degree of myelosuppression and disease-specific guidelines. After each dose adjustment, allow 2-4 weeks to reach steady-state.",-,-,-
Azathioprine,Actionable,IMMUNOSUPPRESSION,Level 1A(Strong),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: No Result (n/a) | NUDT15: Indeterminate (n/a),No Result,-,n/a,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,No recommendation,No recommendation,Toxicity,-,"Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.",-,-,-
Azathioprine,Actionable,IMMUNOSUPPRESSION,Level 1A(Strong),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: No Result (n/a) | NUDT15: Intermediate Metabolizer (n/a),No Result,-,n/a,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,"Increased risk of ADR (thiopurine-related leukopenia, neutropenia, myelosuppression)",Increased Caution/Avoid,Toxicity,üõë,"Based on NUDT15 status, reduce initial dose to 30%-80% of normal dose, eg., if normal dose is 2-3 mg/kg/day reduce it to 0.6-2.4 mg/kg/day and adjust doses based on degree of myelosuppression and disease-specific guidelines. After each dose adjustment, allow 2-4 weeks to reach steady-state. Consider evaluating erythrocyte TPMT activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.",-,-,-
Azathioprine,Actionable,IMMUNOSUPPRESSION,Level 1A(Strong),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: No Result (n/a) | NUDT15: Normal Metabolizer (n/a),No Result,-,n/a,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,"Normal risk of ADR (thiopurine-related leukopenia, neutropenia, myelosuppression)",Use with Caution,-,‚ö†Ô∏è,"Based on NUDT15 status, use recommended starting dose, e.g., 2-3 mg/kg/day and adjust doses based on disease-specific guidelines. After each dose adjustment, allow 2 weeks to reach steady-state. Consider evaluating erythrocyte TPMT activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.",-,-,-
Azathioprine,Actionable,IMMUNOSUPPRESSION,Level 1A(Strong),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: No Result (n/a) | NUDT15: Poor Metabolizer (n/a),No Result,-,n/a,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,"Increased risk of ADR (thiopurine-related leukopenia, neutropenia, myelosuppression)",Increased Caution/Avoid,Toxicity,üõë,"Based on NUDT15 status, for non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignant conditions, reduce daily dose by 10-fold and adjust doses based on degree of myelosuppression and disease-specific guidelines. After each dose adjustment, allow 4-6 weeks to reach steady-state. Consider evaluating erythrocyte TPMT activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.",-,-,-
Azathioprine,Actionable,IMMUNOSUPPRESSION,Level 1A(Strong),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: No Result (n/a) | NUDT15: Possible Intermediate Metabolizer (n/a),No Result,-,n/a,-,-,-,-,-,-,-,-,-,-,Possible Intermediate Metabolizer,-,n/a,-,-,-,"Increased risk of ADR (thiopurine-related leukopenia, neutropenia, myelosuppression)",Increased Caution/Avoid,Toxicity,üõë,"Based on NUDT15 status, reduce initial dose to 30%-80% of normal dose, eg., if normal dose is 2-3 mg/kg/day reduce it to 0.6-2.4 mg/kg/day and adjust doses based on degree of myelosuppression and disease-specific guidelines. After each dose adjustment, allow 2-4 weeks to reach steady-state. Consider evaluating erythrocyte TPMT activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.",-,-,-
Azathioprine,Actionable,IMMUNOSUPPRESSION,Level 1A(Strong),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: Normal Metabolizer (n/a) | NUDT15: Indeterminate (n/a),Normal Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,"Normal risk of ADR (thiopurine-related leukopenia, neutropenia, myelosuppression)",Use with Caution,-,‚ö†Ô∏è,"Based on TPMT status, use recommended starting dose, e.g., 2-3 mg/kg/day and adjust doses based on disease-specific guidelines. After each dose adjustment, allow 2 weeks to reach steady-state. If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity.",-,-,-
Azathioprine,Actionable,IMMUNOSUPPRESSION,Level 1A(Strong),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: Normal Metabolizer (n/a) | NUDT15: Intermediate Metabolizer (n/a),Normal Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Reduce initial dose to 30%-80% of normal dose, eg., if normal dose is 2-3 mg/kg/day reduce it to 0.6-2.4 mg/kg/day and adjust doses based on degree of myelosuppression and disease-specific guidelines. After each dose adjustment, allow 2-4 weeks to reach steady-state.",-,-,-
Azathioprine,Actionable,IMMUNOSUPPRESSION,Level 1A(Strong),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: Normal Metabolizer (n/a) | NUDT15: No Result (n/a),Normal Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,"Normal risk of ADR (thiopurine-related leukopenia, neutropenia, myelosuppression)",Use with Caution,-,‚ö†Ô∏è,"Based on TPMT status, use recommended starting dose, e.g., 2-3 mg/kg/day and adjust doses based on disease-specific guidelines. After each dose adjustment, allow 2 weeks to reach steady-state. If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity.",-,-,-
Azathioprine,Actionable,IMMUNOSUPPRESSION,Level 1A(Strong),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: Normal Metabolizer (n/a) | NUDT15: Normal Metabolizer (n/a),Normal Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,"Normal risk of ADR (thiopurine-related leukopenia, neutropenia, myelosuppression)",Use as Directed,-,‚úÖ,"Use recommended starting dose, e.g., 2-3 mg/kg/day and adjust doses based on disease-specific guidelines. After each dose adjustment, allow 2 weeks to reach steady-state.",-,-,-
Azathioprine,Actionable,IMMUNOSUPPRESSION,Level 1A(Strong),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: Normal Metabolizer (n/a) | NUDT15: Poor Metabolizer (n/a),Normal Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,"For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignant conditions, reduce daily dose by 10-fold and adjust doses based on degree of myelosuppression and disease-specific guidelines. After each dose adjustment, allow 4-6 weeks to reach steady-state.",-,-,-
Azathioprine,Actionable,IMMUNOSUPPRESSION,Level 1A(Strong),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: Normal Metabolizer (n/a) | NUDT15: Possible Intermediate Metabolizer (n/a),Normal Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Possible Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Reduce initial dose to 30%-80% of normal dose, eg., if normal dose is 2-3 mg/kg/day reduce it to 0.6-2.4 mg/kg/day and adjust doses based on degree of myelosuppression and disease-specific guidelines. After each dose adjustment, allow 2-4 weeks to reach steady-state.",-,-,-
Azathioprine,Actionable,IMMUNOSUPPRESSION,Level 1A(Strong),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: Poor Metabolizer (n/a) | NUDT15: Indeterminate (n/a),Poor Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,"Increased risk of ADR (thiopurine-related leukopenia, neutropenia, myelosuppression)",Increased Caution/Avoid,Toxicity,üõë,"Based on TPMT status, for non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignant conditions, reduce daily dose by 10-fold and dose thrice weekly instead of daily. Adjust doses based on degree of myelosuppression and disease-specific guidelines. After each dose adjustment, allow 4-6 weeks to reach steady-state. If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity.",-,-,-
Azathioprine,Actionable,IMMUNOSUPPRESSION,Level 1A(Strong),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: Poor Metabolizer (n/a) | NUDT15: Intermediate Metabolizer (n/a),Poor Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,"Increased risk of ADR (thiopurine-related leukopenia, neutropenia, myelosuppression)",Increased Caution/Avoid,Toxicity,üõë,"For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignant conditions, reduce daily dose by 10-fold and dose thrice weekly instead of daily. Adjust doses based on degree of myelosuppression and disease-specific guidelines. After each dose adjustment, allow 4-6 weeks to reach steady-state.",-,-,-
Azathioprine,Actionable,IMMUNOSUPPRESSION,Level 1A(Strong),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: Poor Metabolizer (n/a) | NUDT15: No Result (n/a),Poor Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,"Increased risk of ADR (thiopurine-related leukopenia, neutropenia, myelosuppression)",Increased Caution/Avoid,Toxicity,üõë,"Based on TPMT status, for non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignant conditions, reduce daily dose by 10-fold and dose thrice weekly instead of daily. Adjust doses based on degree of myelosuppression and disease-specific guidelines. After each dose adjustment, allow 4-6 weeks to reach steady-state. If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity.",-,-,-
Azathioprine,Actionable,IMMUNOSUPPRESSION,Level 1A(Strong),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: Poor Metabolizer (n/a) | NUDT15: Normal Metabolizer (n/a),Poor Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,"Increased risk of ADR (thiopurine-related leukopenia, neutropenia, myelosuppression)",Increased Caution/Avoid,Toxicity,üõë,"For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignant conditions, reduce daily dose by 10-fold and dose thrice weekly instead of daily. Adjust doses based on degree of myelosuppression and disease-specific guidelines. After each dose adjustment, allow 4-6 weeks to reach steady-state.",-,-,-
Azathioprine,Actionable,IMMUNOSUPPRESSION,Level 1A(Strong),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: Poor Metabolizer (n/a) | NUDT15: Poor Metabolizer (n/a),Poor Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,"Increased risk of ADR (thiopurine-related leukopenia, neutropenia, myelosuppression)",Increased Caution/Avoid,Toxicity,üõë,"For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignant conditions, reduce daily dose by 10-fold and dose thrice weekly instead of daily. Adjust doses based on degree of myelosuppression and disease-specific guidelines. After each dose adjustment, allow 4-6 weeks to reach steady-state.",-,-,-
Azathioprine,Actionable,IMMUNOSUPPRESSION,Level 1A(Strong),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: Poor Metabolizer (n/a) | NUDT15: Possible Intermediate Metabolizer (n/a),Poor Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Possible Intermediate Metabolizer,-,n/a,-,-,-,"Increased risk of ADR (thiopurine-related leukopenia, neutropenia, myelosuppression)",Increased Caution/Avoid,Toxicity,üõë,"For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignant conditions, reduce daily dose by 10-fold and dose thrice weekly instead of daily. Adjust doses based on degree of myelosuppression and disease-specific guidelines. After each dose adjustment, allow 4-6 weeks to reach steady-state.",-,-,-
Azathioprine,Actionable,IMMUNOSUPPRESSION,Level 1A(Strong),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: Possible Intermediate Metabolizer (n/a) | NUDT15: Indeterminate (n/a),Possible Intermediate Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,"Increased risk of ADR (thiopurine-related leukopenia, neutropenia, myelosuppression)",Increased Caution/Avoid,Toxicity,üõë,"Based on TPMT status, reduce initial dose to 30%-80% of normal dose, eg., if normal dose is 2-3 mg/kg/day reduce it to 0.6-2.4 mg/kg/day and adjust doses based on degree of myelosuppression and disease-specific guidelines. After each dose adjustment, allow 2-4 weeks to reach steady-state. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.",-,-,-
Azathioprine,Actionable,IMMUNOSUPPRESSION,Level 1A(Strong),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: Possible Intermediate Metabolizer (n/a) | NUDT15: Intermediate Metabolizer (n/a),Possible Intermediate Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,"Increased risk of ADR (thiopurine-related leukopenia, neutropenia, myelosuppression)",Increased Caution/Avoid,Toxicity,üõë,"Reduce initial dose to 30%-80% of normal dose, eg., if normal dose is 2-3 mg/kg/day reduce it to 0.6-2.4 mg/kg/day and adjust doses based on degree of myelosuppression and disease-specific guidelines. After each dose adjustment, allow 2-4 weeks to reach steady-state.",-,-,-
Azathioprine,Actionable,IMMUNOSUPPRESSION,Level 1A(Strong),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: Possible Intermediate Metabolizer (n/a) | NUDT15: No Result (n/a),Possible Intermediate Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,"Increased risk of ADR (thiopurine-related leukopenia, neutropenia, myelosuppression)",Increased Caution/Avoid,Toxicity,üõë,"Based on TPMT status, reduce initial dose to 30%-80% of normal dose, eg., if normal dose is 2-3 mg/kg/day reduce it to 0.6-2.4 mg/kg/day and adjust doses based on degree of myelosuppression and disease-specific guidelines. After each dose adjustment, allow 2-4 weeks to reach steady-state. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.",-,-,-
Azathioprine,Actionable,IMMUNOSUPPRESSION,Level 1A(Strong),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: Possible Intermediate Metabolizer (n/a) | NUDT15: Normal Metabolizer (n/a),Possible Intermediate Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Reduce initial dose to 30%-80% of normal dose, eg., if normal dose is 2-3 mg/kg/day reduce it to 0.6-2.4 mg/kg/day and adjust doses based on degree of myelosuppression and disease-specific guidelines. After each dose adjustment, allow 2-4 weeks to reach steady-state.",-,-,-
Azathioprine,Actionable,IMMUNOSUPPRESSION,Level 1A(Strong),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: Possible Intermediate Metabolizer (n/a) | NUDT15: Poor Metabolizer (n/a),Possible Intermediate Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,"Increased risk of ADR (thiopurine-related leukopenia, neutropenia, myelosuppression)",Increased Caution/Avoid,Toxicity,üõë,"For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignant conditions, reduce daily dose by 10-fold and adjust doses based on degree of myelosuppression and disease-specific guidelines. After each dose adjustment, allow 4-6 weeks to reach steady-state.",-,-,-
Azathioprine,Actionable,IMMUNOSUPPRESSION,Level 1A(Strong),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: Possible Intermediate Metabolizer (n/a) | NUDT15: Possible Intermediate Metabolizer (n/a),Possible Intermediate Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Possible Intermediate Metabolizer,-,n/a,-,-,-,"Increased risk of ADR (thiopurine-related leukopenia, neutropenia, myelosuppression)",Increased Caution/Avoid,Toxicity,üõë,"Reduce initial dose to 30%-80% of normal dose, eg., if normal dose is 2-3 mg/kg/day reduce it to 0.6-2.4 mg/kg/day and adjust doses based on degree of myelosuppression and disease-specific guidelines. After each dose adjustment, allow 2-4 weeks to reach steady-state.",-,-,-
Cyclosporine,Actionable,IMMUNOSUPPRESSION,Level 2B,CYP3A4,Yes,CYP3A4,-,-,-,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Cyclosporine,Actionable,IMMUNOSUPPRESSION,Level 2B,CYP3A4,Yes,CYP3A4,-,-,-,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased risk of ADR(graft rejection or kidney function),Use with Caution,Toxicity/Efficacy,‚ö†Ô∏è,-,-,-,-
Cyclosporine,Actionable,IMMUNOSUPPRESSION,Level 2B,CYP3A4,Yes,CYP3A4,-,-,-,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased risk of ADR(graft rejection or kidney function),Use with Caution,Toxicity/Efficacy,‚ö†Ô∏è,-,-,-,-
Everolimus,Actionable,IMMUNOSUPPRESSION,Level 2A,CYP3A4,Yes,CYP3A4,-,-,Additional testing,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Everolimus,Actionable,IMMUNOSUPPRESSION,Level 2A,CYP3A4,Yes,CYP3A4,-,-,Additional testing,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,Toxicity/Efficacy,‚ö†Ô∏è,-,-,-,-
Everolimus,Actionable,IMMUNOSUPPRESSION,Level 2A,CYP3A4,Yes,CYP3A4,-,-,Additional testing,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,Toxicity/Efficacy,‚ö†Ô∏è,-,-,-,-
Sirolimus,Actionable,IMMUNOSUPPRESSION,Level 2A,CYP3A4,Yes,CYP3A4,-,-,Additional testing,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Sirolimus,Actionable,IMMUNOSUPPRESSION,Level 2A,CYP3A4,Yes,CYP3A4,-,-,Additional testing,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Sirolimus,Actionable,IMMUNOSUPPRESSION,Level 2A,CYP3A4,Yes,CYP3A4,-,-,Additional testing,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Tacrolimus,Actionable,IMMUNOSUPPRESSION,n/a,CYP3A5,Yes,CYP3A5,-,-,Professional guideline,CPIC; DPWG,Indeterminate,Indeterminate,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,n/a,No recommendation,-,-,No recommendation,-,-,-
Tacrolimus,Actionable,IMMUNOSUPPRESSION,Level 1A(Strong),CYP3A5,Yes,CYP3A5,-,-,Professional guideline,CPIC; DPWG,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure,Increased Caution/Avoid,PK,üõë,"Titrate initial dose up to 1.5-2 times recommended, not exceeding 0.3 mg/kg/day, and monitor with therapeutic drug levels for dose adjustments.",-,-,-
Tacrolimus,Actionable,IMMUNOSUPPRESSION,Level 1A(Strong),CYP3A5,Yes,CYP3A5,-,-,Professional guideline,CPIC; DPWG,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure,Increased Caution/Avoid,PK,üõë,"Titrate initial dose up to 1.5-2 times recommended, not exceeding 0.3 mg/kg/day, and monitor with therapeutic drug levels for dose adjustments.",-,-,-
Tacrolimus,Actionable,IMMUNOSUPPRESSION,Level 1A(Strong),CYP3A5,Yes,CYP3A5,-,-,Professional guideline,CPIC; DPWG,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,Initiate therapy with standard recommended dose. ,-,-,-
Tacrolimus,Actionable,IMMUNOSUPPRESSION,Level 1A(Strong),CYP3A5,Yes,CYP3A5,-,-,Professional guideline,CPIC; DPWG,Possible Intermediate Metabolizer,Possible Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure,Increased Caution/Avoid,PK,üõë,"Titrate initial dose up to 1.5-2 times recommended, not exceeding 0.3 mg/kg/day, and monitor with therapeutic drug levels for dose adjustments.",-,-,-
Atazanavir,Actionable,INFECTIOUS DISEASE,n/a,UGT1A1,Yes,UGT1A1,-,-,Professional guideline,CPIC,Indeterminate,Indeterminate,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,n/a,No recommendation,Toxicity,‚úÖ,No recommendation,-,-,-
Atazanavir,Actionable,INFECTIOUS DISEASE,Level 1A(Strong),UGT1A1,Yes,UGT1A1,-,-,Professional guideline,CPIC,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Risk of ADR (low likelihood of bilirubin-related discontinuation of atazanavir),Use as Directed,-,‚úÖ,Use label specified dosing,-,-,-
Atazanavir,Actionable,INFECTIOUS DISEASE,Level 1A(Strong),UGT1A1,Yes,UGT1A1,-,-,Professional guideline,CPIC,Extensive Metabolizer,Extensive Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Risk of ADR (low likelihood of bilirubin-related discontinuation of atazanavir),Use as Directed,-,‚úÖ,-,-,-,-
Atazanavir,Actionable,INFECTIOUS DISEASE,Level 1A(Strong),UGT1A1,Yes,UGT1A1,-,-,Professional guideline,CPIC,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Risk of ADR (High likelihood of bilirubin-related discontinuation of atazanavir),Increased Caution/Avoid,Toxicity,üõë,Increased Risk of ADR (High likelihood of bilirubin-related discontinuation of atazanavir). Avoid Atazanavir,-,-,-
Clarithromycin,Actionable,INFECTIOUS DISEASE,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Clarithromycin,Actionable,INFECTIOUS DISEASE,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK and clinical Effect,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Clarithromycin,Actionable,INFECTIOUS DISEASE,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK and clinical Effect,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Dapsone,Actionable,INFECTIOUS DISEASE,Level 1A(Strong),G6PD,Yes,G6PD,-,-,Professional guideline; FDA evidence,CPIC,Deficient,Deficient,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Risk of ADR (acute hemolytic anemia),Increased Caution/Avoid,Toxicity,üõë,Avoid use,-,-,-
Dapsone,Actionable,INFECTIOUS DISEASE,Level 1A(Strong),G6PD,Yes,G6PD,-,-,Professional guideline; FDA evidence,CPIC,Deficient with CNSHA,Deficient with CNSHA,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Risk of ADR (acute eacerbation of chronic hemolysis),Increased Caution/Avoid,Toxicity,üõë,Avoid use,-,-,-
Dapsone,Actionable,INFECTIOUS DISEASE,Level 1A(Moderate),G6PD,Yes,G6PD,-,-,Professional guideline; FDA evidence,CPIC,Indeterminate,Indeterminate,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Unknown risk of ADR (acute hemolytic anemia),-,-,-,NO RECOMMENDATION,-,-,-
Dapsone,Actionable,INFECTIOUS DISEASE,Level 1A(Strong),G6PD,Yes,G6PD,-,-,Professional guideline; FDA evidence,CPIC,Normal,Normal,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Risk of ADR (acute hemolytic anemia),Use as Directed,-,‚úÖ,na,-,-,-
Dapsone,Actionable,INFECTIOUS DISEASE,Level 1A(Moderate),G6PD,Yes,G6PD,-,-,Professional guideline; FDA evidence,CPIC,Variable,Variable,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Variable Risk of ADR (acute hemolytic anemia),Use as Directed,-,‚úÖ,NO RECOMMENDATION,-,-,-
Darunavir,Actionable,INFECTIOUS DISEASE,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Darunavir,Actionable,INFECTIOUS DISEASE,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK and Clinical impact,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Darunavir,Actionable,INFECTIOUS DISEASE,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK and Clinical impact,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Delavirdine,Actionable,INFECTIOUS DISEASE,Level 2B,CYP3A4,Yes,CYP3A4,-,-,-,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Delavirdine,Actionable,INFECTIOUS DISEASE,Level 2B,CYP3A4,Yes,CYP3A4,-,-,-,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK and Clinical impact,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Delavirdine,Actionable,INFECTIOUS DISEASE,Level 2B,CYP3A4,Yes,CYP3A4,-,-,-,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK and Clinical impact,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Efavirenz,Actionable,INFECTIOUS DISEASE,n/a,CYP2B6,Yes,CYP2B6,-,-,Professional guideline; FDA evidence,CPIC; DPWG,Indeterminate,Indeterminate,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,n/a,Use as Directed,-,-,No recommendation,-,-,-
Efavirenz,Actionable,INFECTIOUS DISEASE,Level 1A(Moderate),CYP2B6,Yes,CYP2B6,-,-,Professional guideline; FDA evidence,CPIC; DPWG,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure; Increased Risk of ADR (CNS),Increased Caution/Avoid,Toxicity,üõë,Use decreased dose of 400 mg/day,-,-,-
Efavirenz,Actionable,INFECTIOUS DISEASE,Level 1A(Strong),CYP2B6,Yes,CYP2B6,-,-,Professional guideline; FDA evidence,CPIC; DPWG,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,Use standard dosing (600 mg/day),-,-,-
Efavirenz,Actionable,INFECTIOUS DISEASE,Level 1A(Moderate),CYP2B6,Yes,CYP2B6,-,-,Professional guideline; FDA evidence,CPIC; DPWG,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,Use decreased dose of 400 or 200 mg/day,-,-,-
Efavirenz,Actionable,INFECTIOUS DISEASE,Level 1A(Strong),CYP2B6,Yes,CYP2B6,-,-,Professional guideline; FDA evidence,CPIC; DPWG,Rapid Metabolizer,Rapid Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure,Use as Directed,-,‚úÖ,Use standard dosing (600 mg/day),-,-,-
Efavirenz,Actionable,INFECTIOUS DISEASE,Level 1A(Strong),CYP2B6,Yes,CYP2B6,-,-,Professional guideline; FDA evidence,CPIC; DPWG,Ultrarapid Metabolizer,Ultrarapid Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure,Use as Directed,-,‚úÖ,Use standard dosing (600 mg/day),-,-,-
Erythromycin,Actionable,INFECTIOUS DISEASE,Level 2C,CYP3A4,Yes,CYP3A4,-,-,-,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Erythromycin,Actionable,INFECTIOUS DISEASE,Level 2C,CYP3A4,Yes,CYP3A4,-,-,-,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure; Minimal Evidence for Clinical Impact,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Erythromycin,Actionable,INFECTIOUS DISEASE,Level 2C,CYP3A4,Yes,CYP3A4,-,-,-,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure; Minimal Evidence for Clinical Impact,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Isavuconazole,Actionable,INFECTIOUS DISEASE,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Isavuconazole,Actionable,INFECTIOUS DISEASE,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK or Clinical Impact,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Isavuconazole,Actionable,INFECTIOUS DISEASE,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK or Clinical Impact,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Ivermectin,Actionable,INFECTIOUS DISEASE,Level 2C,CYP3A4,Yes,CYP3A4,-,-,-,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Ivermectin,Actionable,INFECTIOUS DISEASE,Level 2C,CYP3A4,Yes,CYP3A4,-,-,-,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK or Clinical Impact,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Ivermectin,Actionable,INFECTIOUS DISEASE,Level 2C,CYP3A4,Yes,CYP3A4,-,-,-,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK or Clinical Impact,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Ketoconazole,Actionable,INFECTIOUS DISEASE,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Ketoconazole,Actionable,INFECTIOUS DISEASE,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK or Clinical Impact,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Ketoconazole,Actionable,INFECTIOUS DISEASE,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK or Clinical Impact,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Mefloquine,Actionable,INFECTIOUS DISEASE,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Mefloquine,Actionable,INFECTIOUS DISEASE,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK or Clinical Impact,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Mefloquine,Actionable,INFECTIOUS DISEASE,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK or Clinical Impact,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Nelfinavir,Actionable,INFECTIOUS DISEASE,Level 2A,CYP2C19,Yes,CYP2C19,-,-,-,-,Ultrarapid Metabolizer,Ultrarapid Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure,Use with Caution,Drug-Drug Interaction,‚ö†Ô∏è,-,-,-,-
Nelfinavir,Actionable,INFECTIOUS DISEASE,Level 2A,CYP2C19,Yes,CYP2C19,-,-,-,-,Rapid Metabolizer,Rapid Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure; Minimal eviidence for clinical impact,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Nelfinavir,Actionable,INFECTIOUS DISEASE,Level 2AA,CYP2C19,Yes,CYP2C19,-,-,-,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Nelfinavir,Actionable,INFECTIOUS DISEASE,Level 2AA,CYP2C19,Yes,CYP2C19,-,-,-,-,Likely Intermediate Metabolizer,Likely Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Nelfinavir,Actionable,INFECTIOUS DISEASE,Level 2A,CYP2C19,Yes,CYP2C19,-,-,-,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use with Caution,Drug-Drug Interaction,‚ö†Ô∏è,-,-,-,-
Nelfinavir,Actionable,INFECTIOUS DISEASE,Level 2A,CYP2C19,Yes,CYP2C19,-,-,-,-,Likely Poor Metabolizer,Likely Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,Drug-Drug Interaction,‚ö†Ô∏è,-,-,-,-
Nelfinavir,Actionable,INFECTIOUS DISEASE,Level 2A,CYP2C19,Yes,CYP2C19,-,-,-,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,Drug-Drug Interaction,‚ö†Ô∏è,-,-,-,-
Nelfinavir,Actionable,INFECTIOUS DISEASE,n/a,CYP2C19,Yes,CYP2C19,-,-,-,-,Indeterminate,Indeterminate,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,n/a,Use as Directed,-,-,-,-,-,-
Nitrofurantoin,Actionable,INFECTIOUS DISEASE,Level 1A(Optional),G6PD,Yes,G6PD,-,-,Professional guideline; FDA evidence,CPIC,Deficient,Deficient,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Medium Risk of ADR (acute hemolytic anemia),Use as with Caution,Toxicity,‚ö†Ô∏è,Use standard dose,-,-,-
Nitrofurantoin,Actionable,INFECTIOUS DISEASE,Level 1A(Moderate),G6PD,Yes,G6PD,-,-,Professional guideline; FDA evidence,CPIC,Deficient with CNSHA,Deficient with CNSHA,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Risk of of ADR (acute of acute exacerbation of chronic hemolysis),Increased Caution/Avoid,Toxicity,üõë,Avoid Use,-,-,-
Nitrofurantoin,Actionable,INFECTIOUS DISEASE,Level 1A(Moderate),G6PD,Yes,G6PD,-,-,Professional guideline; FDA evidence,CPIC,Indeterminate,Indeterminate,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Unknown risk of ADR (acute hemolytic anemia),-,-,-,"To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.",-,-,-
Nitrofurantoin,Actionable,INFECTIOUS DISEASE,Level 1A(Strong),G6PD,Yes,G6PD,-,-,Professional guideline; FDA evidence,CPIC,Normal,Normal,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Risk of ADR (acute hemolytic anemia),Use as Directed,-,‚úÖ,Use standard dose,-,-,-
Nitrofurantoin,Actionable,INFECTIOUS DISEASE,Level 1A(Moderate),G6PD,Yes,G6PD,-,-,Professional guideline; FDA evidence,CPIC,Variable,Variable,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Variable risk of ADR (acute hemolytic anemia),Use as Directed,-,‚úÖ,"If deemed necessary to ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.",-,-,-
Peginterferon alfa-2a,Actionable,INFECTIOUS DISEASE,Level 1B,IFNL3,Yes,IFNL3,-,-,Professional guideline,CPIC,Favorable response genotype,-,Favorable response genotype,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Favorable Response,Use as Directed,-,‚úÖ,-,-,-,-
Peginterferon alfa-2a,Actionable,INFECTIOUS DISEASE,Level 1B,IFNL3,Yes,IFNL3,-,-,Professional guideline,CPIC,Unfavorable response genotype,-,Unfavorable response genotype,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Reduced Response,Use with Caution,Efficacy,‚ö†Ô∏è,-,-,-,-
Peginterferon alfa-2a,Actionable,INFECTIOUS DISEASE,Level 1B,IFNL3,Yes,IFNL3,-,-,Professional guideline,CPIC,Unfavorable response genotype,-,Unfavorable response genotype,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Reduced Response,Use with Caution,Efficacy,‚ö†Ô∏è,-,-,-,-
Peginterferon alfa-2b,Actionable,INFECTIOUS DISEASE,Level 1B,IFNL3,Yes,IFNL3,-,-,FDA evidence; Professional guideline,CPIC,Favorable response genotype,-,Favorable response genotype,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Favorable Response,Use as Directed,-,‚úÖ,-,-,-,-
Peginterferon alfa-2b,Actionable,INFECTIOUS DISEASE,Level 1B,IFNL3,Yes,IFNL3,-,-,FDA evidence; Professional guideline,CPIC,Unfavorable response genotype,-,Unfavorable response genotype,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Reduced Response,Use with Caution,Efficacy,‚ö†Ô∏è,-,-,-,-
Peginterferon alfa-2b,Actionable,INFECTIOUS DISEASE,Level 1B,IFNL3,Yes,IFNL3,-,-,FDA evidence; Professional guideline,CPIC,Unfavorable response genotype,-,Unfavorable response genotype,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Reduced Response,Use with Caution,Efficacy,‚ö†Ô∏è,-,-,-,-
Quinine,Actionable,Infectious disease,Level 2A,G6PD,Yes,G6PD,-,-,FDA evidence,-,Normal,Normal,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Risk of ADR (acute hemolytic anemia),Use as Directed,-,‚úÖ,-,-,-,-
Quinine,Actionable,Infectious disease,Level 2A,G6PD,Yes,G6PD,-,-,FDA evidence,-,Deficient,Deficient,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Risk of ADR (acute hemolytic anemia),Use with Caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Quinine,Actionable,Infectious disease,Level 2A,G6PD,Yes,G6PD,-,-,FDA evidence,-,Deficient with CNSHA,Deficient with CNSHA,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Risk of ADR (acute hemolytic anemia),Use with Caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Quinine,Actionable,Infectious disease,Level 2A,G6PD,Yes,G6PD,-,-,FDA evidence,-,Variable,Variable,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Risk of ADR (acute hemolytic anemia),Use as Directed,-,‚úÖ,-,-,-,-
Quinine,Actionable,Infectious disease,Level 2A,G6PD,Yes,G6PD,-,-,FDA evidence,-,Indeterminate,Indeterminate,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-
Ribavirin,Actionable,INFECTIOUS DISEASE,Level 1B,IFNL3,Yes,IFNL3,-,-,Professional guideline,CPIC; DPWG,Favorable response genotype,-,Favorable response genotype,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Favorable Response,Use as Directed,-,‚úÖ,-,-,-,-
Ribavirin,Actionable,INFECTIOUS DISEASE,Level 1B,IFNL3,Yes,IFNL3,-,-,Professional guideline,CPIC; DPWG,Unfavorable response genotype,-,Unfavorable response genotype,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Reduced Response,Use with Caution,Efficacy,‚ö†Ô∏è,-,-,-,-
Ribavirin,Actionable,INFECTIOUS DISEASE,Level 1B,IFNL3,Yes,IFNL3,-,-,Professional guideline,CPIC; DPWG,Unfavorable response genotype,-,Unfavorable response genotype,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Reduced Response,Use with Caution,Efficacy,‚ö†Ô∏è,-,-,-,-
Ritonavir,Actionable,INFECTIOUS DISEASE,Level 2C,CYP3A4,Yes,CYP3A4,-,-,-,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Ritonavir,Actionable,INFECTIOUS DISEASE,Level 2C,CYP3A4,Yes,CYP3A4,-,-,-,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK and Clinical Effects,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Ritonavir,Actionable,INFECTIOUS DISEASE,Level 2C,CYP3A4,Yes,CYP3A4,-,-,-,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK and Clinical Effects,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Saquinavir,Actionable,INFECTIOUS DISEASE,Level 2B,CYP3A4,Yes,CYP3A4,-,-,-,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Saquinavir,Actionable,INFECTIOUS DISEASE,Level 2B,CYP3A4,Yes,CYP3A4,-,-,-,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK or Clinical Impact,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Saquinavir,Actionable,INFECTIOUS DISEASE,Level 2B,CYP3A4,Yes,CYP3A4,-,-,-,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK or Clinical Impact,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Simeprevir,Actionable,INFECTIOUS DISEASE,Level 2A*(Doubtful),IFNL3,Yes,IFNL3,-,-,FDA evidence,-,Favorable response genotype,-,Favorable response genotype,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Favorable Response,Use as Directed,-,‚úÖ,-,-,-,-
Simeprevir,Actionable,INFECTIOUS DISEASE,Level 2A*(Doubtful),IFNL3,Yes,IFNL3,-,-,FDA evidence,-,Unfavorable response genotype,-,Unfavorable response genotype,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Reduced Response,Use with Caution,Efficacy,‚ö†Ô∏è,-,-,-,-
Simeprevir,Actionable,INFECTIOUS DISEASE,Level 2A*(Doubtful),IFNL3,Yes,IFNL3,-,-,FDA evidence,-,Unfavorable response genotype,-,Unfavorable response genotype,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Reduced Response,Use with Caution,Efficacy,‚ö†Ô∏è,-,-,-,-
Sulfamethoxazole,Actionable,INFECTIOUS DISEASE,Level 1B,G6PD,Yes,G6PD,-,-,-,CPIC (No recommendation),Normal,Normal,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Risk of ADR (acute hemolytic anemia),Use as Directed,-,‚úÖ,-,-,-,-
Sulfamethoxazole,Actionable,INFECTIOUS DISEASE,Level 1B,G6PD,Yes,G6PD,-,-,-,CPIC (No recommendation),Deficient,Deficient,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Risk of ADR (acute hemolytic anemia),Use with Caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Sulfamethoxazole,Actionable,INFECTIOUS DISEASE,Level 1B,G6PD,Yes,G6PD,-,-,-,CPIC (No recommendation),Deficient with CNSHA,Deficient with CNSHA,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Risk of ADR (acute hemolytic anemia),Use with Caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Sulfamethoxazole,Actionable,INFECTIOUS DISEASE,Level 1B,G6PD,Yes,G6PD,-,-,-,CPIC (No recommendation),Variable,Variable,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Risk of ADR (acute hemolytic anemia),Use as Directed,-,‚úÖ,-,-,-,-
Sulfamethoxazole,Actionable,INFECTIOUS DISEASE,Level 1B,G6PD,Yes,G6PD,-,-,-,CPIC (No recommendation),Indeterminate,Indeterminate,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Unknown Risk of ADR (acute hemolytic anemia),-,-,-,-,-,-,-
Telithromycin*,Actionable,INFECTIOUS DISEASE,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Telithromycin*,Actionable,INFECTIOUS DISEASE,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK or Clinical Impact,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Telithromycin*,Actionable,INFECTIOUS DISEASE,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK or Clinical Impact,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Tipranavir,Actionable,INFECTIOUS DISEASE,Level 2B,CYP3A4,Yes,CYP3A4,-,-,-,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Tipranavir,Actionable,INFECTIOUS DISEASE,Level 2B,CYP3A4,Yes,CYP3A4,-,-,-,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK or Clinical Impact,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Tipranavir,Actionable,INFECTIOUS DISEASE,Level 2B,CYP3A4,Yes,CYP3A4,-,-,-,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK or Clinical Impact,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Voriconazole,Actionable,INFECTIOUS DISEASE,Level 1A,CYP2C19,Yes,CYP2C19,-,-,Professional guideline; FDA evidence,CPIC; DPWG,Indeterminate,Indeterminate,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,n/a,-,n/a,-,No recommendation,-,-,-
Voriconazole,Actionable,INFECTIOUS DISEASE,Level 1A(Moderate),CYP2C19,Yes,CYP2C19,-,-,Professional guideline; FDA evidence,CPIC; DPWG,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure; Minimal evidence for clinical impact,Use with Caution,-,‚ö†Ô∏è,Initiate therapy with recommended standard of care dosing,-,-,-
Voriconazole,Actionable,INFECTIOUS DISEASE,Level 1A(Moderate),CYP2C19,Yes,CYP2C19,-,-,Professional guideline; FDA evidence,CPIC; DPWG,Likely Intermediate Metabolizer,Likely Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure; Minimal evidence for clinical impact,Use with Caution,-,‚ö†Ô∏è,Initiate therapy with recommended standard of care dosing,-,-,-
Voriconazole,Actionable,INFECTIOUS DISEASE,Level 1A(Moderate),CYP2C19,Yes,CYP2C19,-,-,Professional guideline; FDA evidence,CPIC; DPWG,Likely Poor Metabolizer,Likely Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy in lieu of voriconazole. Such agents include isavuconazole, liposomal amphotericin B, and posaconazole. In the event that voriconazole is considered to be the most appropriate agent, based on clinical advice, for a patient with poor metabolizer genotype, voriconazole should be administered at a preferably lower than standard dosage with careful therapeutic drug monitoring.",-,-,-
Voriconazole,Actionable,INFECTIOUS DISEASE,Level 1A(Strong),CYP2C19,Yes,CYP2C19,-,-,Professional guideline; FDA evidence,CPIC; DPWG,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,Initiate therapy with recommended standard of care dosing,-,-,-
Voriconazole,Actionable,INFECTIOUS DISEASE,Level 1A(Moderate),CYP2C19,Yes,CYP2C19,-,-,Professional guideline; FDA evidence,CPIC; DPWG,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy in lieu of voriconazole. Such agents include isavuconazole, liposomal amphotericin B, and posaconazole. In the event that voriconazole is considered to be the most appropriate agent, based on clinical advice, for a patient with poor metabolizer genotype, voriconazole should be administered at a preferably lower than standard dosage with careful therapeutic drug monitoring.",-,-,-
Voriconazole,Actionable,INFECTIOUS DISEASE,Level 1A(Moderate),CYP2C19,Yes,CYP2C19,-,-,Professional guideline; FDA evidence,CPIC; DPWG,Rapid Metabolizer,Rapid Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure,Increased Caution/Avoid,Efficacy,üõë,"Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy in lieu of voriconazole. Such agents include isavuconazole, liposomal amphotericin B, and posaconazole.",-,-,-
Voriconazole,Actionable,INFECTIOUS DISEASE,Level 1A(Moderate),CYP2C19,Yes,CYP2C19,-,-,Professional guideline; FDA evidence,CPIC; DPWG,Ultrarapid Metabolizer,Ultrarapid Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure,Increased Caution/Avoid,Efficacy,üõë,"Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy in lieu of voriconazole. Such agents include isavuconazole, liposomal amphotericin B, and posaconazole.",-,-,-
Atovaquone/ Proguanil,Actionable,INFECTIOUS DISEASE,Level 2C,CYP2C19,Yes,CYP2C19,-,-,-,-,Indeterminate,Indeterminate,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,n/a,-,n/a,‚úÖ,-,-,-,-
Atovaquone/ Proguanil,Actionable,INFECTIOUS DISEASE,Level 2C,CYP2C19,Yes,CYP2C19,-,-,-,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure; Minimal evidence for clinical impact,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Atovaquone/ Proguanil,Actionable,INFECTIOUS DISEASE,Level 2C,CYP2C19,Yes,CYP2C19,-,-,-,-,Likely Intermediate Metabolizer,Likely Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure; Minimal evidence for clinical impact,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Atovaquone/ Proguanil,Actionable,INFECTIOUS DISEASE,Level 2C,CYP2C19,Yes,CYP2C19,-,-,-,-,Likely Poor Metabolizer,Likely Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure; Minimal evidence for clinical impact,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Atovaquone/ Proguanil,Actionable,INFECTIOUS DISEASE,Level 2C,CYP2C19,Yes,CYP2C19,-,-,-,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Atovaquone/ Proguanil,Actionable,INFECTIOUS DISEASE,Level 2C,CYP2C19,Yes,CYP2C19,-,-,-,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure; Minimal evidence for clinical impact,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Atovaquone/ Proguanil,Actionable,INFECTIOUS DISEASE,Level 2C,CYP2C19,Yes,CYP2C19,-,-,-,-,Rapid Metabolizer,Rapid Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased exposure; Minimal evidence for clinical impact,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Atovaquone/ Proguanil,Actionable,INFECTIOUS DISEASE,Level 2C,CYP2C19,Yes,CYP2C19,-,-,-,-,Ultrarapid Metabolizer,Ultrarapid Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure; Minimal evidence for clinical impact,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Fosamprenavir,Actionable,INFECTIOUS DISEASE,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Fosamprenavir,Actionable,INFECTIOUS DISEASE,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK or Clinical Impact,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Fosamprenavir,Actionable,INFECTIOUS DISEASE,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK or Clinical Impact,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Amphetamine,Actionable,NEUROLOGY,Level 1BB,CYP2D6,Yes,CYP2D6,-,-,FDA evidence,-,Ultrarapid Metabolizer (>2),Ultrarapid Metabolizer,-,>2,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK and Clinical impact,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Amphetamine,Actionable,NEUROLOGY,Level 1BB,CYP2D6,Yes,CYP2D6,-,-,FDA evidence,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Amphetamine,Actionable,NEUROLOGY,Level 1BB,CYP2D6,Yes,CYP2D6,-,-,FDA evidence,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure; Increased Risk of ADR,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Amphetamine,Actionable,NEUROLOGY,Level 1B,CYP2D6,Yes,CYP2D6,-,-,FDA evidence,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure; Increased Risk of ADR,Increased Caution/Avoid,Toxicity,üõë,Consider lower starting dosage or use alternative agent [FDA],-,-,-
Brivaracetam,Actionable,NEUROLOGY,Level 1BB,CYP2C19,Yes,CYP2C19,-,-,FDA evidence,-,Ultrarapid Metabolizer,Ultrarapid Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Brivaracetam,Actionable,NEUROLOGY,Level 1BB,CYP2C19,Yes,CYP2C19,-,-,FDA evidence,-,Rapid Metabolizer,Rapid Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Brivaracetam,Actionable,NEUROLOGY,Level 1BB,CYP2C19,Yes,CYP2C19,-,-,FDA evidence,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Brivaracetam,Actionable,NEUROLOGY,Level 1B,CYP2C19,Yes,CYP2C19,-,-,FDA evidence,-,Likely Intermediate Metabolizer,Likely Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Brivaracetam,Actionable,NEUROLOGY,Level 1B,CYP2C19,Yes,CYP2C19,-,-,FDA evidence,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Brivaracetam,Actionable,NEUROLOGY,Level 1B,CYP2C19,Yes,CYP2C19,-,-,FDA evidence,-,Likely Poor Metabolizer,Likely Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Brivaracetam,Actionable,NEUROLOGY,Level 1B,CYP2C19,Yes,CYP2C19,-,-,FDA evidence,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Increased Caution/Avoid,PK,üõë,Dosage Reductions Recommended [FDA],-,-,-
Brivaracetam,Actionable,NEUROLOGY,n/a,CYP2C19,Yes,CYP2C19,-,-,FDA evidence,-,Indeterminate,Indeterminate,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,n/a,-,n/a,-,-,-,-,-
Clobazam,Actionable,NEUROLOGY,n/a,CYP2C19,Yes,CYP2C19,-,-,FDA evidence,-,Indeterminate,Indeterminate,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,n/a,-,n/a,-,-,-,-,-
Clobazam,Actionable,NEUROLOGY,Level 1B,CYP2C19,Yes,CYP2C19,-,-,FDA evidence,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Clobazam,Actionable,NEUROLOGY,Level 1B,CYP2C19,Yes,CYP2C19,-,-,FDA evidence,-,Likely Intermediate Metabolizer,Likely Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Clobazam,Actionable,NEUROLOGY,Level 1B,CYP2C19,Yes,CYP2C19,-,-,FDA evidence,-,Likely Poor Metabolizer,Likely Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Clobazam,Actionable,NEUROLOGY,Level 1BB,CYP2C19,Yes,CYP2C19,-,-,FDA evidence,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Clobazam,Actionable,NEUROLOGY,Level 1B,CYP2C19,Yes,CYP2C19,-,-,FDA evidence,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Initial dose of clobazam should be 5 mg/day, and that dose titration should be proceed slowly according to weight [FDA]",-,-,-
Clobazam,Actionable,NEUROLOGY,Level 1BB,CYP2C19,Yes,CYP2C19,-,-,FDA evidence,-,Rapid Metabolizer,Rapid Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure,Use with Caution,Efficacy,‚ö†Ô∏è,-,-,-,-
Clobazam,Actionable,NEUROLOGY,Level 1BB,CYP2C19,Yes,CYP2C19,-,-,FDA evidence,-,Ultrarapid Metabolizer,Ultrarapid Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure,Use with Caution,Efficacy,‚ö†Ô∏è,-,-,-,-
Dextromethorphan / quinidine,Actionable,NEUROLOGY,Level 1B,CYP2D6,Yes,CYP2D6,-,-,FDA evidence,-,Ultrarapid Metabolizer (>2),Ultrarapid Metabolizer,-,>2,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure; Minimal Evidence for clinical Impact,Use with Caution,Efficacy,‚ö†Ô∏è,-,-,-,-
Dextromethorphan / quinidine,Actionable,NEUROLOGY,Level 1B,CYP2D6,Yes,CYP2D6,-,-,FDA evidence,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Dextromethorphan / quinidine,Actionable,NEUROLOGY,Level 1B,CYP2D6,Yes,CYP2D6,-,-,FDA evidence,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure;  Minimal Evidence for Clinical impact,Use with Caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Dextromethorphan / quinidine,Actionable,NEUROLOGY,Level 1B,CYP2D6,Yes,CYP2D6,-,-,FDA evidence,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure;  Minimal Evidence for Clinical impact,Use with Caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Donepezil,Actionable,NEUROLOGY,Level 1B,CYP2D6,Yes,CYP2D6,-,-,FDA evidence,-,Ultrarapid Metabolizer (>2),Ultrarapid Metabolizer,-,>2,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure; Minimal Evidence for clinical Impact,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Donepezil,Actionable,NEUROLOGY,Level 1B,CYP2D6,Yes,CYP2D6,-,-,FDA evidence,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Donepezil,Actionable,NEUROLOGY,Level 1B,CYP2D6,Yes,CYP2D6,-,-,FDA evidence,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Donepezil,Actionable,NEUROLOGY,Level 1B,CYP2D6,Yes,CYP2D6,-,-,FDA evidence,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure;  Minimal Evidence for Clinical impact,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Eletriptan,Actionable,NEUROLOGY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Eletriptan,Actionable,NEUROLOGY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK or Clinical Impact,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Eletriptan,Actionable,NEUROLOGY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK or Clinical Impact,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Ethosuximide,Actionable,NEUROLOGY,Level 2C,CYP3A4,Yes,CYP3A4,-,-,-,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Ethosuximide,Actionable,NEUROLOGY,Level 2C,CYP3A4,Yes,CYP3A4,-,-,-,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK or Clinical Impact,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Ethosuximide,Actionable,NEUROLOGY,Level 2C,CYP3A4,Yes,CYP3A4,-,-,-,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK or Clinical Impact,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Fosphenytoin,Actionable,NEUROLOGY,Level 1A(Strong),HLA-B,Yes,HLA-B,-,-,Professional guideline; FDA evidence,CPIC,Normal Risk,Normal Risk,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Risk,Use as Directed,-,‚úÖ,-,-,-,-
Fosphenytoin,Actionable,NEUROLOGY,Level 1A(Strong),HLA-B,Yes,HLA-B,-,-,Professional guideline; FDA evidence,CPIC,Increased Risk,Increased Risk,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased risk of phenytoin-induced SJS/TEN,Increased Caution/Avoid,-,üõë,"If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.
Optional recommendation: If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.",-,-,-
Fosphenytoin,Actionable,NEUROLOGY,Level 1A(Strong),CYP2C9,Yes,CYP2C9,-,-,Professional guideline; FDA evidence,CPIC,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Using with Caution,PK,‚ö†Ô∏è,"For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects.",-,-,-
Fosphenytoin,Actionable,NEUROLOGY,Level 1A(Moderate),CYP2C9,Yes,CYP2C9,-,-,Professional guideline; FDA evidence,CPIC,Intermediate Metabolizer (1),Intermediate Metabolizer,-,1,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Using with Caution,PK,‚ö†Ô∏è,"For first dose, use typical initial or loading dose. For subsequent doses, use approximately 25% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects.",-,-,-
Fosphenytoin,Actionable,NEUROLOGY,Level 1A(Moderate),CYP2C9,Yes,CYP2C9,-,-,Professional guideline; FDA evidence,CPIC,Intermediate Metabolizer (1.5),Intermediate Metabolizer,-,1.5,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,"No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects.",-,-,-
Fosphenytoin,Actionable,NEUROLOGY,Level 1A(Strong),CYP2C9,Yes,CYP2C9,-,-,Professional guideline; FDA evidence,CPIC,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,"No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects.",-,-,-
Fosphenytoin,Actionable,NEUROLOGY,-,CYP2C9,Yes,CYP2C9,-,-,Professional guideline; FDA evidence,CPIC,Indeterminate,Indeterminate,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-
Fosphenytoin,Actionable,NEUROLOGY,Level 1A(Strong),HLA-B + CYP2C9,No,HLA-B,CYP2C9,-,Professional guideline; FDA evidence,CPIC,HLA-B: Normal Risk + CYP2C9: Poor Metabolizer (0.0),Normal Risk,-,-,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,0,-,-,-,Increased Exposure,Using with Caution,PK,‚ö†Ô∏è,"For first dose, consider typical initial or loading dose. For subsequent doses use ~50% less than typical maintenance dose and adjust dose based on therapeutic drug monitoring, response, and side effects.",-,-,-
Fosphenytoin,Actionable,NEUROLOGY,Level 1A(Strong),HLA-B + CYP2C9,No,HLA-B,CYP2C9,-,Professional guideline; FDA evidence,CPIC,HLA-B: Normal Risk + CYP2C9: Poor Metabolizer (0.5),Normal Risk,-,-,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,0.5,-,-,-,Increased Exposure,Using with Caution,PK,‚ö†Ô∏è,"For first dose, consider typical initial or loading dose. For subsequent doses use ~50% less than typical maintenance dose and adjust dose based on therapeutic drug monitoring, response, and side effects.",-,-,-
Fosphenytoin,Actionable,NEUROLOGY,Level 1A(Moderate),HLA-B + CYP2C9,No,HLA-B,CYP2C9,-,Professional guideline; FDA evidence,CPIC,HLA-B: Normal Risk + CYP2C9: Intermediate Metabolizer (1.0),Normal Risk,-,-,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,1,-,-,-,Increased Exposure,Using with Caution,PK,‚ö†Ô∏è,"For first dose, use typical initial or loading dose. For subsequent doses, use approximately 25% less than typical maintenance dose and adjust according to therapeutic drug monitoring, response and side effects.",-,-,-
Fosphenytoin,Actionable,NEUROLOGY,Level 1A(Moderate),HLA-B + CYP2C9,No,HLA-B,CYP2C9,-,Professional guideline; FDA evidence,CPIC,HLA-B: Normal Risk + CYP2C9: Intermediate Metabolizer (1.5),Normal Risk,-,-,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,1.5,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,No adjustments needed from typical dosing strategies.,-,-,-
Fosphenytoin,Actionable,NEUROLOGY,Level 1A(Strong),HLA-B + CYP2C9,No,HLA-B,CYP2C9,-,Professional guideline; FDA evidence,CPIC,HLA-B: Normal Risk + CYP2C9: Normal Metabolizer (2.0),Normal Risk,-,-,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,2,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,No adjustments needed from typical dosing strategies. ,-,-,-
Fosphenytoin,Actionable,NEUROLOGY,-,HLA-B + CYP2C9,No,HLA-B,CYP2C9,-,Professional guideline; FDA evidence,CPIC,HLA-B: Normal Risk + CYP2C9: Indeterminate (n/a),Normal Risk,-,-,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,No recommendation,No recommendation,-,-,No recommendation,-,-,-
Fosphenytoin,Actionable,NEUROLOGY,-,HLA-B + CYP2C9,No,HLA-B,CYP2C9,-,Professional guideline; FDA evidence,CPIC,HLA-B: Normal Risk + CYP2C9: No Result (No Result),Normal Risk,-,-,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,No recommendation,No recommendation,-,-,"Use recommended dosing strategies. Adjust subsequent doses based on therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.",-,-,-
Fosphenytoin,Actionable,NEUROLOGY,Level 1A(Strong),HLA-B + CYP2C9,No,HLA-B,CYP2C9,-,Professional guideline; FDA evidence,CPIC,HLA-B: Increased Risk + CYP2C9: Poor Metabolizer (0.0),Increased Risk,-,-,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,0,-,-,-,Increased risk of ADR (phenytoin-induced SJS/TEN),Increased Caution/Avoid,-,üõë,"Increased risk of ADR (phenytoin-induced SJS/TEN). If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine. Optional recommendation: If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future.",-,-,-
Fosphenytoin,Actionable,NEUROLOGY,Level 1A(Strong),HLA-B + CYP2C9,No,HLA-B,CYP2C9,-,Professional guideline; FDA evidence,CPIC,HLA-B: Increased Risk + CYP2C9: Poor Metabolizer (0.5),Increased Risk,-,-,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,0.5,-,-,-,Increased risk of ADR (phenytoin-induced SJS/TEN),Increased Caution/Avoid,-,üõë,"Increased risk of ADR (phenytoin-induced SJS/TEN). If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine. Optional recommendation: If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future.",-,-,-
Fosphenytoin,Actionable,NEUROLOGY,Level 1A(Strong),HLA-B + CYP2C9,No,HLA-B,CYP2C9,-,Professional guideline; FDA evidence,CPIC,HLA-B: Increased Risk + CYP2C9: Intermediate Metabolizer (1.0),Increased Risk,-,-,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,1,-,-,-,Increased risk of ADR (phenytoin-induced SJS/TEN),Increased Caution/Avoid,-,üõë,"Increased risk of ADR (phenytoin-induced SJS/TEN). If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine. Optional recommendation: If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future.",-,-,-
Fosphenytoin,Actionable,NEUROLOGY,Level 1A(Strong),HLA-B + CYP2C9,No,HLA-B,CYP2C9,-,Professional guideline; FDA evidence,CPIC,HLA-B: Increased Risk + CYP2C9: Intermediate Metabolizer (1.5),Increased Risk,-,-,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,1.5,-,-,-,Increased risk of ADR (phenytoin-induced SJS/TEN),Increased Caution/Avoid,-,üõë,"Increased risk of ADR (phenytoin-induced SJS/TEN). If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine. Optional recommendation: If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future.",-,-,-
Fosphenytoin,Actionable,NEUROLOGY,Level 1A(Strong),HLA-B + CYP2C9,No,HLA-B,CYP2C9,-,Professional guideline; FDA evidence,CPIC,HLA-B: Increased Risk + CYP2C9: Normal Metabolizer (2.0),Increased Risk,-,-,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,2,-,-,-,Increased risk of ADR (phenytoin-induced SJS/TEN),Increased Caution/Avoid,-,üõë,"Increased risk of ADR (phenytoin-induced SJS/TEN). If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine. Optional recommendation: If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future.",-,-,-
Fosphenytoin,Actionable,NEUROLOGY,Level 1A(Strong),HLA-B + CYP2C9,No,HLA-B,CYP2C9,-,Professional guideline; FDA evidence,CPIC,HLA-B: Increased Risk + CYP2C9: Indeterminate (n/a),Increased Risk,-,-,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Increased risk of ADR (phenytoin-induced SJS/TEN),Increased Caution/Avoid,-,üõë,"Increased risk of ADR (phenytoin-induced SJS/TEN). If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine. Optional recommendation: If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future.",-,-,-
Fosphenytoin,Actionable,NEUROLOGY,Level 1A(Strong),HLA-B + CYP2C9,No,HLA-B,CYP2C9,-,Professional guideline; FDA evidence,CPIC,HLA-B: Increased Risk + CYP2C9: No Result (No Result),Increased Risk,-,-,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Increased risk of ADR (phenytoin-induced SJS/TEN),Increased Caution/Avoid,-,üõë,"Increased risk of ADR (phenytoin-induced SJS/TEN). If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine. Optional recommendation: If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future.",-,-,-
Frovatriptan,Actionable,NEUROLOGY,Level 2C,CYP1A2,Yes,CYP1A2,-,-,-,-,Extensive Metabolizer,Extensive Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Frovatriptan,Actionable,NEUROLOGY,Level 2C,CYP1A2,Yes,CYP1A2,-,-,-,-,High Inducibility,High Inducibility,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure,Use with caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Frovatriptan,Actionable,NEUROLOGY,Level 2C,CYP1A2,Yes,CYP1A2,-,-,-,-,Slow metabolizers; *1C heterozygous,Slow metabolizers,*1C Heterozygous,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Frovatriptan,Actionable,NEUROLOGY,Level 2C,CYP1A2,Yes,CYP1A2,-,-,-,-,Intermediate metabolizer,Intermediate metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Frovatriptan,Actionable,NEUROLOGY,Level 2C,CYP1A2,Yes,CYP1A2,-,-,-,-,Slow metabolizers; *1C Homozygous,Slow metabolizers,*1C Homozygous,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Frovatriptan,Actionable,NEUROLOGY,Level 2C,CYP1A2,Yes,CYP1A2,-,-,-,-,Poor metabolizer,Poor metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Phenytoin,Actionable,NEUROLOGY,Level 1A(Strong),HLA-B,Yes,HLA-B,-,-,Professional guideline; FDA evidence,-,Normal Risk,Normal Risk,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Risk,Use as Directed,-,‚úÖ,-,-,-,-
Phenytoin,Actionable,NEUROLOGY,Level 1A(Strong),HLA-B,Yes,HLA-B,-,-,Professional guideline; FDA evidence,-,Increased Risk,Increased Risk,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased risk of phenytoin-induced SJS/TEN,Increased Caution/Avoid,-,üõë,"If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.
Optional recommendation: If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.",-,-,-
Phenytoin,Actionable,NEUROLOGY,Level 1A(Strong),CYP2C9,Yes,CYP2C9,-,-,Professional guideline; FDA evidence,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Using with Caution,PK,‚ö†Ô∏è,"For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to standard practice.",-,-,-
Phenytoin,Actionable,NEUROLOGY,Level 1A(Moderate),CYP2C9,Yes,CYP2C9,-,-,Professional guideline; FDA evidence,-,Intermediate Metabolizer (1),Intermediate Metabolizer,-,1,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Using with Caution,PK,‚ö†Ô∏è,"For first dose, use typical initial or loading dose. For subsequent doses, use approximately 25% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to standard practice.",-,-,-
Phenytoin,Actionable,NEUROLOGY,Level 1A(Moderate),CYP2C9,Yes,CYP2C9,-,-,Professional guideline; FDA evidence,-,Intermediate Metabolizer (1.5),Intermediate Metabolizer,-,1.5,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,"No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to standard practice.",-,-,-
Phenytoin,Actionable,NEUROLOGY,Level 1A(Strong),CYP2C9,Yes,CYP2C9,-,-,Professional guideline; FDA evidence,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Phenytoin,Actionable,NEUROLOGY,-,CYP2C9,Yes,CYP2C9,-,-,Professional guideline; FDA evidence,-,Indeterminate,Indeterminate,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-
Phenytoin,Actionable,NEUROLOGY,Level 1A(Strong),HLA-B + CYP2C9,No,HLA-B,CYP2C9,-,Professional guideline; FDA evidence,CPIC; DPWG,HLA-B: Normal Risk + CYP2C9: Poor Metabolizer (0.0),Normal Risk,-,-,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,0,-,-,-,Increased Exposure,Using with Caution,PK,‚ö†Ô∏è,"For first dose, consider typical initial or loading dose. For subsequent doses use ~50% less than typical maintenance dose and adjust dose based on therapeutic drug monitoring, response, and side effects.",-,-,-
Phenytoin,Actionable,NEUROLOGY,Level 1A(Strong),HLA-B + CYP2C9,No,HLA-B,CYP2C9,-,Professional guideline; FDA evidence,CPIC; DPWG,HLA-B: Normal Risk + CYP2C9: Poor Metabolizer (0.5),Normal Risk,-,-,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,0.5,-,-,-,Increased Exposure,Using with Caution,PK,‚ö†Ô∏è,"For first dose, consider typical initial or loading dose. For subsequent doses use ~50% less than typical maintenance dose and adjust dose based on therapeutic drug monitoring, response, and side effects.",-,-,-
Phenytoin,Actionable,NEUROLOGY,Level 1A(Moderate),HLA-B + CYP2C9,No,HLA-B,CYP2C9,-,Professional guideline; FDA evidence,CPIC; DPWG,HLA-B: Normal Risk + CYP2C9: Intermediate Metabolizer (1.0),Normal Risk,-,-,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,1,-,-,-,Increased Exposure,Using with Caution,PK,‚ö†Ô∏è,"For first dose, use typical initial or loading dose. For subsequent doses, use approximately 25% less than typical maintenance dose and adjust according to therapeutic drug monitoring, response and side effects.",-,-,-
Phenytoin,Actionable,NEUROLOGY,Level 1A(Moderate),HLA-B + CYP2C9,No,HLA-B,CYP2C9,-,Professional guideline; FDA evidence,CPIC; DPWG,HLA-B: Normal Risk + CYP2C9: Intermediate Metabolizer (1.5),Normal Risk,-,-,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,1.5,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,No adjustments needed from typical dosing strategies.,-,-,-
Phenytoin,Actionable,NEUROLOGY,Level 1A(Strong),HLA-B + CYP2C9,No,HLA-B,CYP2C9,-,Professional guideline; FDA evidence,CPIC; DPWG,HLA-B: Normal Risk + CYP2C9: Normal Metabolizer (2.0),Normal Risk,-,-,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,2,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,No adjustments needed from typical dosing strategies. ,-,-,-
Phenytoin,Actionable,NEUROLOGY,-,HLA-B + CYP2C9,No,HLA-B,CYP2C9,-,Professional guideline; FDA evidence,CPIC; DPWG,HLA-B: Normal Risk + CYP2C9: Indeterminate (n/a),Normal Risk,-,-,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,No recommendation,No recommendation,-,-,No recommendation,-,-,-
Phenytoin,Actionable,NEUROLOGY,Level 1A(Strong),HLA-B + CYP2C9,No,HLA-B,CYP2C9,-,Professional guideline; FDA evidence,CPIC; DPWG,HLA-B: Normal Risk + CYP2C9: No Result (No Result),Normal Risk,-,-,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,No recommendation,No recommendation,-,-,"Use recommended dosing strategies. Adjust subsequent doses based on therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.",-,-,-
Phenytoin,Actionable,NEUROLOGY,Level 1A(Strong),HLA-B + CYP2C9,No,HLA-B,CYP2C9,-,Professional guideline; FDA evidence,CPIC; DPWG,HLA-B: Increased Risk + CYP2C9: Poor Metabolizer (0.0),Increased Risk,-,-,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,0,-,-,-,Increased risk of ADR (phenytoin-induced SJS/TEN),Increased Caution/Avoid,-,üõë,"Increased risk of ADR (phenytoin-induced SJS/TEN). If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.
Optional recommendation: If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. ",-,-,-
Phenytoin,Actionable,NEUROLOGY,Level 1A(Strong),HLA-B + CYP2C9,No,HLA-B,CYP2C9,-,Professional guideline; FDA evidence,CPIC; DPWG,HLA-B: Increased Risk + CYP2C9: Poor Metabolizer (0.5),Increased Risk,-,-,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,0.5,-,-,-,Increased risk of ADR (phenytoin-induced SJS/TEN),Increased Caution/Avoid,-,üõë,"Increased risk of ADR (phenytoin-induced SJS/TEN). If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.
Optional recommendation: If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. ",-,-,-
Phenytoin,Actionable,NEUROLOGY,Level 1A(Strong),HLA-B + CYP2C9,No,HLA-B,CYP2C9,-,Professional guideline; FDA evidence,CPIC; DPWG,HLA-B: Increased Risk + CYP2C9: Intermediate Metabolizer (1.0),Increased Risk,-,-,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,1,-,-,-,Increased risk of ADR (phenytoin-induced SJS/TEN),Increased Caution/Avoid,-,üõë,"Increased risk of ADR (phenytoin-induced SJS/TEN). If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.
Optional recommendation: If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. ",-,-,-
Phenytoin,Actionable,NEUROLOGY,Level 1A(Strong),HLA-B + CYP2C9,No,HLA-B,CYP2C9,-,Professional guideline; FDA evidence,CPIC; DPWG,HLA-B: Increased Risk + CYP2C9: Intermediate Metabolizer (1.5),Increased Risk,-,-,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,1.5,-,-,-,Increased risk of ADR (phenytoin-induced SJS/TEN),Increased Caution/Avoid,-,üõë,"Increased risk of ADR (phenytoin-induced SJS/TEN). If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.
Optional recommendation: If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. ",-,-,-
Phenytoin,Actionable,NEUROLOGY,Level 1A(Strong),HLA-B + CYP2C9,No,HLA-B,CYP2C9,-,Professional guideline; FDA evidence,CPIC; DPWG,HLA-B: Increased Risk + CYP2C9: Normal Metabolizer (2.0),Increased Risk,-,-,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,2,-,-,-,Increased risk of ADR (phenytoin-induced SJS/TEN),Increased Caution/Avoid,-,üõë,"Increased risk of ADR (phenytoin-induced SJS/TEN). If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.
Optional recommendation: If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. ",-,-,-
Phenytoin,Actionable,NEUROLOGY,Level 1A(Strong),HLA-B + CYP2C9,No,HLA-B,CYP2C9,-,Professional guideline; FDA evidence,CPIC; DPWG,HLA-B: Increased Risk + CYP2C9: Indeterminate (n/a),Increased Risk,-,-,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Increased risk of ADR (phenytoin-induced SJS/TEN),Increased Caution/Avoid,-,üõë,"Increased risk of ADR (phenytoin-induced SJS/TEN). If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.
Optional recommendation: If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. ",-,-,-
Phenytoin,Actionable,NEUROLOGY,Level 1A(Strong),HLA-B + CYP2C9,No,HLA-B,CYP2C9,-,Professional guideline; FDA evidence,CPIC; DPWG,HLA-B: Increased Risk + CYP2C9: No Result (No Result),Increased Risk,-,-,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Increased risk of ADR (phenytoin-induced SJS/TEN),Increased Caution/Avoid,-,üõë,"Increased risk of ADR (phenytoin-induced SJS/TEN). If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.
Optional recommendation: If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. ",-,-,-
Rasagiline,Actionable,NEUROLOGY,Level 2A,CYP1A2,Yes,CYP1A2,-,-,-,-,Extensive Metabolizer,Extensive Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Rasagiline,Actionable,NEUROLOGY,Level 2A,CYP1A2,Yes,CYP1A2,-,-,-,-,High Inducibility,High Inducibility,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure,Use with caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Rasagiline,Actionable,NEUROLOGY,Level 2A,CYP1A2,Yes,CYP1A2,-,-,-,-,Slow metabolizers; *1C heterozygous,Slow metabolizers,*1C Heterozygous,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Rasagiline,Actionable,NEUROLOGY,Level 2A,CYP1A2,Yes,CYP1A2,-,-,-,-,Intermediate metabolizer,Intermediate metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Rasagiline,Actionable,NEUROLOGY,Level 2A,CYP1A2,Yes,CYP1A2,-,-,-,-,Slow metabolizers; *1C Homozygous,Slow metabolizers,*1C Homozygous,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Rasagiline,Actionable,NEUROLOGY,Level 2A,CYP1A2,Yes,CYP1A2,-,-,-,-,Poor metabolizer,Poor metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Selegiline,Actionable,NEUROLOGY,Level 2B,CYP2B6,Yes,CYP2B6,-,-,-,-,Indeterminate,Indeterminate,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,na,-,-,-,-,-,-,-
Selegiline,Actionable,NEUROLOGY,Level 2B,CYP2B6,Yes,CYP2B6,-,-,-,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Selegiline,Actionable,NEUROLOGY,Level 2B,CYP2B6,Yes,CYP2B6,-,-,-,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Selegiline,Actionable,NEUROLOGY,Level 2B,CYP2B6,Yes,CYP2B6,-,-,-,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Selegiline,Actionable,NEUROLOGY,Level 2B,CYP2B6,Yes,CYP2B6,-,-,-,-,Rapid Metabolizer,Rapid Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Selegiline,Actionable,NEUROLOGY,Level 2B,CYP2B6,Yes,CYP2B6,-,-,-,-,Ultrarapid Metabolizer,Ultrarapid Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Tetrabenazine,Actionable,NEUROLOGY,Level 1B,CYP2D6,Yes,CYP2D6,-,-,FDA evidence,-,Ultrarapid Metabolizer (>2),Ultrarapid Metabolizer,-,>2,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure,Use with Caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Tetrabenazine,Actionable,NEUROLOGY,Level 1B,CYP2D6,Yes,CYP2D6,-,-,FDA evidence,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,The maximum daily dose in EMs 100 mg with a maximum single dose of 37.5 mg.,-,-,-
Tetrabenazine,Actionable,NEUROLOGY,Level 1B,CYP2D6,Yes,CYP2D6,-,-,FDA evidence,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure ,Use with Caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Tetrabenazine,Actionable,NEUROLOGY,Level 1B,CYP2D6,Yes,CYP2D6,-,-,FDA evidence,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,The maximum recommended single dose is 25 mg and should not exceed 50 mg/day [FDA].,-,-,-
Zonisamide,Actionable,NEUROLOGY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Zonisamide,Actionable,NEUROLOGY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK or Clinical Impact,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Zonisamide,Actionable,NEUROLOGY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK or Clinical Impact,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Axitinib,Actionable,ONCOLOGY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Axitinib,Actionable,ONCOLOGY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK and Clinical impact,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Axitinib,Actionable,ONCOLOGY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK and Clinical impact,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Belinostat,Actionable,ONCOLOGY,Level 1AA,UGT1A1,Yes,UGT1A1,-,-,FDA evidence,-,Extensive Metabolizer,Extensive Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Risk of ADR,Use as Directed,-,‚úÖ,-,-,-,-
Belinostat,Actionable,ONCOLOGY,Level 1AA,UGT1A1,Yes,UGT1A1,-,-,FDA evidence,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure; Increased Risk of ADR,Use with Caution,Toxicity,‚ö†Ô∏è,Increased Risk of ADR/multiple toxicities,-,-,-
Belinostat,Actionable,ONCOLOGY,Level 1A,UGT1A1,Yes,UGT1A1,-,-,FDA evidence,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure; Increased Risk of ADR,Increased Caution/Avoid,Toxicity,üõë,Increased Risk of ADR/multiple toxicities; Reduce the starting dose to 750 mg/m2 [FDA],-,-,-
Binimetinib,Actionable,ONCOLOGY,Level 1A,UGT1A1,Yes,UGT1A1,-,-,FDA evidence; Additional testing,-,Extensive Metabolizer,Extensive Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Risk of ADR,Use as Directed,-,‚úÖ,-,-,-,-
Binimetinib,Actionable,ONCOLOGY,Level 1A,UGT1A1,Yes,UGT1A1,-,-,FDA evidence; Additional testing,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Risk of ADR,Use as Directed,-,‚úÖ,-,-,-,-
Binimetinib,Actionable,ONCOLOGY,Level 1A,UGT1A1,Yes,UGT1A1,-,-,FDA evidence; Additional testing,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Risk of ADR,Use as Directed,-,‚úÖ,-,-,-,-
Bortezomib,Actionable,ONCOLOGY,Level 2B,CYP3A4,Yes,CYP3A4,-,-,-,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Bortezomib,Actionable,ONCOLOGY,Level 2B,CYP3A4,Yes,CYP3A4,-,-,-,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence of PK and clinical effect,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Bortezomib,Actionable,ONCOLOGY,Level 2B,CYP3A4,Yes,CYP3A4,-,-,-,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence of PK and clinical effect,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Bosutinib,Actionable,ONCOLOGY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,Additional testing,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Bosutinib,Actionable,ONCOLOGY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,Additional testing,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK and Clinical impact,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Bosutinib,Actionable,ONCOLOGY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,Additional testing,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK and Clinical impact,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Brentuximab vedotin,Actionable,ONCOLOGY,Level 2B,CYP3A4,Yes,CYP3A4,-,-,Additional testing,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Brentuximab vedotin,Actionable,ONCOLOGY,Level 2B,CYP3A4,Yes,CYP3A4,-,-,Additional testing,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence of PK and clinical effect,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Brentuximab vedotin,Actionable,ONCOLOGY,Level 2B,CYP3A4,Yes,CYP3A4,-,-,Additional testing,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence of PK and clinical effect,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Cabazitaxel,Actionable,ONCOLOGY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Cabazitaxel,Actionable,ONCOLOGY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal evidence for PK and Clinical effect,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Cabazitaxel,Actionable,ONCOLOGY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal evidence for PK and Clinical effect,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Capecitabine,Actionable,ONCOLOGY,Level 1A(Strong),DPYD,Yes,DPYD,-,-,Professional guideline; FDA evidence; Additional testing,CPIC; DPWG,Poor Metabolizer (0),Poor Metabolizer,-,0,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Risk of ADR (severe or even fatal drug toxicity),Increased Caution/Avoid,Toxicity,üõë,Avoid use of 5-fluorouracil or 5-fluorouracil prodrug-based regimens.,-,-,-
Capecitabine,Actionable,ONCOLOGY,Level 1A(Strong),DPYD,Yes,DPYD,-,-,Professional guideline; FDA evidence; Additional testing,CPIC; DPWG,Poor Metabolizer (0.5),Poor Metabolizer,-,0.5,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Risk of ADR (severe or even fatal drug toxicity),Increased Caution/Avoid,Toxicity,üõë,"Avoid use. If 5-fluorouracil is warrented, use at a strongly reduced dose (<25%).",-,-,-
Capecitabine,Actionable,ONCOLOGY,Level 1A(Strong),DPYD,Yes,DPYD,-,-,Professional guideline; FDA evidence; Additional testing,CPIC; DPWG,Intermediate Metabolizer (1),Intermediate Metabolizer,-,1,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Risk of ADR (severe or even fatal drug toxicity),Increased Caution/Avoid,Toxicity,üõë,Increased Risk of ADR (severe or even fatal drug toxicity); Reduce starting dose by 50% followed by titration upwards. Patients with the c.2846A>T/c.2846A>T genotype may require >50% reduction in starting dose.,-,-,-
Capecitabine,Actionable,ONCOLOGY,Level 1A(Moderate),DPYD,Yes,DPYD,-,-,Professional guideline; FDA evidence; Additional testing,CPIC; DPWG,Intermediate Metabolizer (1.5),Intermediate Metabolizer,-,1.5,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Risk of ADR (severe or even fatal drug toxicity),Increased Caution/Avoid,Toxicity,üõë,Increased Risk of ADR (severe or even fatal drug toxicity); Reduce starting dose by 50% followed by titration upwards.,-,-,-
Capecitabine,Actionable,ONCOLOGY,Level 1A(Strong),DPYD,Yes,DPYD,-,-,Professional guideline; FDA evidence; Additional testing,CPIC; DPWG,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Risk of ADR,Use as Directed,-,‚úÖ,Use label-recommended dosage,-,-,-
Cisplatin,Actionable,ONCOLOGY,Level 2A,TPMT,Yes,TPMT,-,-,FDA evidence,-,Normal Risk,Normal Risk,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Risk of ADR (ototoxicity),Use as Directed,-,‚úÖ,-,-,-,-
Cisplatin,Actionable,ONCOLOGY,Level 2A,TPMT,Yes,TPMT,-,-,FDA evidence,-,Normal Risk,Normal Risk,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Risk of ADR (ototoxicity),Use as Directed,-,‚úÖ,-,-,-,-
Cisplatin,Actionable,ONCOLOGY,Level 2A,TPMT,Yes,TPMT,-,-,FDA evidence,-,Increased Risk,Increased Risk,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Risk of ADR (ototoxicity),Use with Caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Crizotinib,Actionable,ONCOLOGY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,Additional testing,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Crizotinib,Actionable,ONCOLOGY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,Additional testing,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK and Clinical impact,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Crizotinib,Actionable,ONCOLOGY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,Additional testing,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK and Clinical impact,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Cyclophosphamide,Actionable,ONCOLOGY,Level 2C,CYP2B6,Yes,CYP2B6,-,-,-,-,Indeterminate,Indeterminate,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,na,-,-,-,-,-,-,-
Cyclophosphamide,Actionable,ONCOLOGY,Level 2C,CYP2B6,Yes,CYP2B6,-,-,-,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Cyclophosphamide,Actionable,ONCOLOGY,Level 2C,CYP2B6,Yes,CYP2B6,-,-,-,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Cyclophosphamide,Actionable,ONCOLOGY,Level 2C,CYP2B6,Yes,CYP2B6,-,-,-,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Cyclophosphamide,Actionable,ONCOLOGY,Level 2C,CYP2B6,Yes,CYP2B6,-,-,-,-,Rapid Metabolizer,Rapid Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Cyclophosphamide,Actionable,ONCOLOGY,Level 2C,CYP2B6,Yes,CYP2B6,-,-,-,-,Ultrarapid Metabolizer,Ultrarapid Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Dabrafenib,Actionable,ONCOLOGY,Level 1B,G6PD,Yes,G6PD,-,-,FDA evidence; Additional testing,CPIC (No Recommendation),Normal,Normal,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Risk of ADR (acute hemolytic anemia),Use as Directed,-,‚úÖ,-,-,-,-
Dabrafenib,Actionable,ONCOLOGY,Level 1B,G6PD,Yes,G6PD,-,-,FDA evidence; Additional testing,CPIC (No Recommendation),Deficient,Deficient,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Risk of ADR (acute hemolytic anemia),Use with Caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Dabrafenib,Actionable,ONCOLOGY,Level 1B,G6PD,Yes,G6PD,-,-,FDA evidence; Additional testing,CPIC (No Recommendation),Deficient with CNSHA,Deficient with CNSHA,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Risk of ADR (acute hemolytic anemia),Use with Caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Dabrafenib,Actionable,ONCOLOGY,Level 1B,G6PD,Yes,G6PD,-,-,FDA evidence; Additional testing,CPIC (No Recommendation),Variable,Variable,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Risk of ADR (acute hemolytic anemia),Use as Directed,-,‚úÖ,-,-,-,-
Dabrafenib,Actionable,ONCOLOGY,Level 1B,G6PD,Yes,G6PD,-,-,FDA evidence; Additional testing,CPIC (No Recommendation),Indeterminate,Indeterminate,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Unknown Risk of ADR (acute hemolytic anemia),-,-,-,-,-,-,-
Dexamethasone,Actionable,ONCOLOGY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Dexamethasone,Actionable,ONCOLOGY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK and Clinical impact,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Dexamethasone,Actionable,ONCOLOGY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK and Clinical impact,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Docetaxel,Actionable,ONCOLOGY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,"Studies shows role of rs2740574 in predicting risk of infusion-related reaction for Docetaxel in Turkish and europian but studies in Central/South Asian population shows no such significance. So, not added in this report but can be added based on ethinicity."
Docetaxel,Actionable,ONCOLOGY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,Toxicity,‚ö†Ô∏è,-,-,-,"Studies shows role of rs2740574 in predicting risk of infusion-related reaction for Docetaxel in Turkish and europian but studies in Central/South Asian population shows no such significance. So, not added in this report but can be added based on ethinicity."
Docetaxel,Actionable,ONCOLOGY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,Toxicity,‚ö†Ô∏è,-,-,-,"Studies shows role of rs2740574 in predicting risk of infusion-related reaction for Docetaxel in Turkish and europian but studies in Central/South Asian population shows no such significance. So, not added in this report but can be added based on ethinicity."
Enzalutamide,Actionable,ONCOLOGY,Level 2B,CYP3A4,Yes,CYP3A4,-,-,-,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Enzalutamide,Actionable,ONCOLOGY,Level 2B,CYP3A4,Yes,CYP3A4,-,-,-,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure; Minimal evidence for clinical impact,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Enzalutamide,Actionable,ONCOLOGY,Level 2B,CYP3A4,Yes,CYP3A4,-,-,-,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure; Minimal evidence for clinical impact,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Erdafitinib,Actionable,ONCOLOGY,Level 1BB,CYP2C9,Yes,CYP2C9,-,-,FDA evidence; additional testing,-,Normal Metabolizer(2.0),Normal Metabolizer,-,2,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Erdafitinib,Actionable,ONCOLOGY,Level 1BB,CYP2C9,Yes,CYP2C9,-,-,FDA evidence; additional testing,-,Intermediate Metabolizer(1.5),Intermediate Metabolizer,-,1.5,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,"The action of Intermediate Metabolizer 1.5 is inferred based on phenytoin, which also utilizes CYP2C9 as its primary metabolizer. It appears that there will be a slight reduction in metabolism, but this may not have a significant clinical effect."
Erdafitinib,Actionable,ONCOLOGY,Level 1BB,CYP2C9,Yes,CYP2C9,-,-,FDA evidence; additional testing,-,Intermediate Metabolizer (1.0),Intermediate Metabolizer,-,1,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Erdafitinib,Actionable,ONCOLOGY,Level 1B,CYP2C9,Yes,CYP2C9,-,-,FDA evidence; additional testing,-,"Poor Metabolizer (0.0, 0.5)",Poor Metabolizer,-,0,0.5,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Erdafitinib,Actionable,ONCOLOGY,Level 1BB,CYP2C9,Yes,CYP2C9,-,-,FDA evidence; additional testing,-,Indeterminate(n/a),Indeterminate,-,n/a,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,No Recommendation,-,-,-,-,-,-
Erlotinib,Actionable,ONCOLOGY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,Additional testing,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Erlotinib,Actionable,ONCOLOGY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,Additional testing,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure; Minimal Evidence for Clinical Impact,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Erlotinib,Actionable,ONCOLOGY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,Additional testing,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure; Minimal Evidence for Clinical Impact,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Etoposide,Actionable,ONCOLOGY,Level 2C,CYP3A4,Yes,CYP3A4,-,-,-,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,In Chilean patients there is data to showing increased risk of developing alopecia based on rs2740574. But for this report its not included but can be included based on ethnicity.
Etoposide,Actionable,ONCOLOGY,Level 2C,CYP3A4,Yes,CYP3A4,-,-,-,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,Toxicity,‚ö†Ô∏è,-,-,-,In Chilean patients there is data to showing increased risk of developing alopecia based on rs2740574. But for this report its not included but can be included based on ethnicity.
Etoposide,Actionable,ONCOLOGY,Level 2C,CYP3A4,Yes,CYP3A4,-,-,-,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,Toxicity,‚ö†Ô∏è,-,-,-,In Chilean patients there is data to showing increased risk of developing alopecia based on rs2740574. But for this report its not included but can be included based on ethnicity.
Exemestane,Actionable,ONCOLOGY,Level 2A(talks about inducer but not about inhibitors),CYP3A4,Yes,CYP3A4,-,-,additional testing,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Exemestane,Actionable,ONCOLOGY,Level 2A(talks about inducer but not about inhibitors),CYP3A4,Yes,CYP3A4,-,-,additional testing,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK and Clinical Effects,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Exemestane,Actionable,ONCOLOGY,Level 2A(talks about inducer but not about inhibitors),CYP3A4,Yes,CYP3A4,-,-,additional testing,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK and Clinical Effects,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Fluorouracil,Actionable,ONCOLOGY,Level 1A(Strong),DPYD,Yes,DPYD,-,-,Professional guideline; FDA evidence,CPIC; DPWG,Poor Metabolizer (0),Poor Metabolizer,-,0,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Risk of ADR (severe or even fatal drug toxicity),Increased Caution/Avoid,Toxicity,üõë,Avoid use of 5-fluorouracil or 5-fluorouracil prodrug-based regimens.,-,-,-
Fluorouracil,Actionable,ONCOLOGY,Level 1A(Strong),DPYD,Yes,DPYD,-,-,Professional guideline; FDA evidence,CPIC; DPWG,Poor Metabolizer (0.5),Poor Metabolizer,-,0.5,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Risk of ADR (severe or even fatal drug toxicity),Increased Caution/Avoid,Toxicity,üõë,"Avoid use. If 5-fluorouracil is warrented, use at a strongly reduced dose (<25%).",-,-,-
Fluorouracil,Actionable,ONCOLOGY,Level 1A(Strong),DPYD,Yes,DPYD,-,-,Professional guideline; FDA evidence,CPIC; DPWG,Intermediate Metabolizer (1),Intermediate Metabolizer,-,1,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Risk of ADR (severe or even fatal drug toxicity),Increased Caution/Avoid,Toxicity,üõë,Increased Risk of ADR (severe or even fatal drug toxicity); Reduce starting dose by 50% followed by titration upwards. Patients with the c.2846A>T/c.2846A>T genotype may require >50% reduction in starting dose.,-,-,-
Fluorouracil,Actionable,ONCOLOGY,Level 1A(Moderate),DPYD,Yes,DPYD,-,-,Professional guideline; FDA evidence,CPIC; DPWG,Intermediate Metabolizer (1.5),Intermediate Metabolizer,-,1.5,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Risk of ADR (severe or even fatal drug toxicity),Increased Caution/Avoid,Toxicity,üõë,Increased Risk of ADR (severe or even fatal drug toxicity); Reduce starting dose by 50% followed by titration upwards.,-,-,-
Fluorouracil,Actionable,ONCOLOGY,Level 1A(Strong),DPYD,Yes,DPYD,-,-,Professional guideline; FDA evidence,CPIC; DPWG,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Risk of ADR,Use as Directed,-,‚úÖ,Use label-recommended dosage,-,-,-
Flutamide,Actionable,ONCOLOGY,Level 1B,G6PD,Yes,G6PD,-,-,FDA evidence,-,Normal,Normal,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Risk of ADR (acute hemolytic anemia),Use as Directed,-,‚úÖ,-,-,-,-
Flutamide,Actionable,ONCOLOGY,Level 1B,G6PD,Yes,G6PD,-,-,FDA evidence,-,Deficient,Deficient,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Risk of ADR (acute hemolytic anemia),Use with Caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Flutamide,Actionable,ONCOLOGY,Level 1B,G6PD,Yes,G6PD,-,-,FDA evidence,-,Deficient with CNSHA,Deficient with CNSHA,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Risk of ADR (acute hemolytic anemia),Use with Caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Flutamide,Actionable,ONCOLOGY,Level 1B,G6PD,Yes,G6PD,-,-,FDA evidence,-,Variable,Variable,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Risk of ADR (acute hemolytic anemia),Use as Directed,-,‚úÖ,-,-,-,-
Flutamide,Actionable,ONCOLOGY,Level 1B,G6PD,Yes,G6PD,-,-,FDA evidence,-,Indeterminate,Indeterminate,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Unknown Risk of ADR (acute hemolytic anemia),-,-,-,-,-,-,-
Gefitinib,Actionable,ONCOLOGY,Level 1B,CYP2D6,Yes,CYP2D6,-,-,FDA evidence; additional testing,DPWG (No Recommendation),Ultrarapid Metabolizer (>2),Ultrarapid Metabolizer,-,>2,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure; Minimal Evidence for Clinical impact,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Gefitinib,Actionable,ONCOLOGY,Level 1B,CYP2D6,Yes,CYP2D6,-,-,FDA evidence; additional testing,DPWG (No Recommendation),Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Gefitinib,Actionable,ONCOLOGY,Level 1B,CYP2D6,Yes,CYP2D6,-,-,FDA evidence; additional testing,DPWG (No Recommendation),Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Risk of ADR,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Gefitinib,Actionable,ONCOLOGY,Level 1B,CYP2D6,Yes,CYP2D6,-,-,FDA evidence; additional testing,DPWG (No Recommendation),Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Risk of ADR,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Ifosfamide,Actionable,ONCOLOGY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Ifosfamide,Actionable,ONCOLOGY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK and Clinical Effects,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Ifosfamide,Actionable,ONCOLOGY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK and Clinical Effects,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Imatinib,Actionable,ONCOLOGY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,additional testing,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,PK,‚úÖ,-,-,-,-
Imatinib,Actionable,ONCOLOGY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,additional testing,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure; Minimal Exvidence for Clinical Impact,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Imatinib,Actionable,ONCOLOGY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,additional testing,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure; Minimal Exvidence for Clinical Impact,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Irinotecan,Actionable,ONCOLOGY,Level 1AA,UGT1A1,Yes,UGT1A1,-,-,Professional guideline; FDA evidence,DPWG,Extensive Metabolizer,Extensive Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Risk of ADR,Use as Directed,-,‚úÖ,-,-,-,-
Irinotecan,Actionable,ONCOLOGY,Level 1A,UGT1A1,Yes,UGT1A1,-,-,Professional guideline; FDA evidence,DPWG,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,"Increased Risk of ADR (Diarrhea, Neutropenia).",Use with Caution,Toxicity,‚ö†Ô∏è,"Increased Risk of ADR (Diarrhea, Neutropenia).",-,-,-
Irinotecan,Actionable,ONCOLOGY,Level 1A,UGT1A1,Yes,UGT1A1,-,-,Professional guideline; FDA evidence,DPWG,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,"Increased Risk of ADR (Diarrhea, Neutropenia).",Increased Caution/Avoid,Toxicity,üõë,"Increased Risk of ADR (Diarrhea, Neutropenia).The recommended starting dose is 50 mg/m2 administered by intravenous infusion over 90 minutes and can be Increased to 70 mg/m2 as tolerated in subsequent cycles [FDA].",-,-,-
Ixabepilone,Actionable,ONCOLOGY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Ixabepilone,Actionable,ONCOLOGY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK and Clinical Effects,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Ixabepilone,Actionable,ONCOLOGY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK and Clinical Effects,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Mercaptopurine,Actionable,ONCOLOGY,Level 1A(Strong),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: Indeterminate (n/a) | NUDT15: Indeterminate (n/a),Indeterminate,-,n/a,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,No recommendation,No recommendation,-,-,"Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.",-,-,-
Mercaptopurine,Actionable,ONCOLOGY,Level 1A(Strong),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: Indeterminate (n/a) | NUDT15: Intermediate Metabolizer (n/a),Indeterminate,-,n/a,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,"Increased risk of ADR (thiopurine-related leukopenia, neutropenia, myelosuppression)",Increased Caution/Avoid,Toxicity,üõë,"Based NUDT15 status, reduce initial dose to 30%-80% of normal dose, eg., if normal dose is ‚â•75 mg/m2/day or ‚â• 1.5 mg/kg/day, reduce it to 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day and adjust doses based on degree of myelosuppression and disease-specific guidelines. After each dose adjustment, allow 2-4 weeks to reach steady-state. If myelosuppression occurs, and depending on other therapy, reduce mercaptopurine over other agents. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.

If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended. 
",-,-,-
Mercaptopurine,Actionable,ONCOLOGY,Level 1A(Strong),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: Indeterminate (n/a) | NUDT15: No Result (n/a),Indeterminate,-,n/a,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,No recommendation,No recommendation,-,-,"Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.",-,-,-
Mercaptopurine,Actionable,ONCOLOGY,Level 1A(Strong),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: Indeterminate (n/a) | NUDT15: Normal Metabolizer (n/a),Indeterminate,-,n/a,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,-,-,-,-,"Based on NUDT15 status, use recommended starting dose, e.g., 75 mg/m2/day or 1.5 mg/kg/day and adjust doses (and of any other myelosuppressive therapy) without any special emphasis on mercaptopurine compared to other agents. After each dose adjustment, allow at least 2 weeks to reach steady-state. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.",-,-,-
Mercaptopurine,Actionable,ONCOLOGY,Level 1A(Strong),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: Indeterminate (n/a) | NUDT15: Poor Metabolizer (n/a),Indeterminate,-,n/a,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,"Increased risk of ADR (thiopurine-related leukopenia, neutropenia, myelosuppression)",Increased Caution/Avoid,Toxicity,üõë,"Based on NUDT15 status, for malignant conditions, initiate dose at 10 mg/m2/day and adjust doses based on myelosuppression and disease-specific guidelines. After each dose adjustment, allow 4-6 weeks to reach steady-state. If myelosuppression occurs, reduce mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.",-,-,-
Mercaptopurine,Actionable,ONCOLOGY,Level 1A(Strong),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: Indeterminate (n/a) | NUDT15: Possible Intermediate Metabolizer (n/a),Indeterminate,-,n/a,-,-,-,-,-,-,-,-,-,-,Possible Intermediate Metabolizer,-,n/a,-,-,-,"Increased risk of ADR (thiopurine-related leukopenia, neutropenia, myelosuppression)",Increased Caution/Avoid,Toxicity,üõë,"Based NUDT15 status, reduce initial dose to 30%-80% of normal dose, eg., if normal dose is ‚â•75 mg/m2/day or ‚â• 1.5 mg/kg/day, reduce it to 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day and adjust doses based on degree of myelosuppression and disease-specific guidelines. After each dose adjustment, allow 2-4 weeks to reach steady-state. If myelosuppression occurs, and depending on other therapy, reduce mercaptopurine over other agents. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.

If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended. 
",-,-,-
Mercaptopurine,Actionable,ONCOLOGY,Level 1A(Strong),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: Intermediate Metabolizer (n/a) | NUDT15: Indeterminate (n/a),Intermediate Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,"Increased risk of ADR (thiopurine-related leukopenia, neutropenia, myelosuppression)",Increased Caution/Avoid,Toxicity,üõë,"Based on TPMT status, reduce initial dose to 30%-80% of normal dose, eg., if normal dose is ‚â•75 mg/m2/day or ‚â• 1.5 mg/kg/day, reduce it to 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day and adjust doses based on degree of myelosuppression and disease-specific guidelines. After each dose adjustment, allow 2-4 weeks to reach steady-state. If myelosuppression occurs, and depending on other therapy, reduce mercaptopurine over other agents. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.

If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended.",-,-,-
Mercaptopurine,Actionable,ONCOLOGY,Level 1A(Strong),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: Intermediate Metabolizer (n/a) | NUDT15: Intermediate Metabolizer (n/a),Intermediate Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,"Increased risk of ADR (thiopurine-related leukopenia, neutropenia, myelosuppression)",Increased Caution/Avoid,Toxicity,üõë,"Reduce initial dose to 30%-80% of normal dose, eg., if normal dose is ‚â•75 mg/m2/day or ‚â• 1.5 mg/kg/day, reduce it to 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day and adjust doses based on degree of myelosuppression and disease-specific guidelines. After each dose adjustment, allow 2-4 weeks to reach steady-state. If myelosuppression occurs, and depending on other therapy, reduce mercaptopurine over other agents.
If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended.",-,-,-
Mercaptopurine,Actionable,ONCOLOGY,Level 1A(Strong),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: Intermediate Metabolizer (n/a) | NUDT15: No Result (n/a),Intermediate Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,"Increased risk of ADR (thiopurine-related leukopenia, neutropenia, myelosuppression)",Increased Caution/Avoid,Toxicity,üõë,"Based on TPMT status, reduce initial dose to 30%-80% of normal dose, eg., if normal dose is ‚â•75 mg/m2/day or ‚â• 1.5 mg/kg/day, reduce it to 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day and adjust doses based on degree of myelosuppression and disease-specific guidelines. After each dose adjustment, allow 2-4 weeks to reach steady-state. If myelosuppression occurs, and depending on other therapy, reduce mercaptopurine over other agents. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.

If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended. 
",-,-,-
Mercaptopurine,Actionable,ONCOLOGY,Level 1A(Strong),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: Intermediate Metabolizer (n/a) | NUDT15: Normal Metabolizer (n/a),Intermediate Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Reduce initial dose to 30%-80% of normal dose, eg., if normal dose is ‚â•75 mg/m2/day or ‚â• 1.5 mg/kg/day, reduce it to 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day and adjust doses based on degree of myelosuppression and disease-specific guidelines. After each dose adjustment, allow 2-4 weeks to reach steady-state. If myelosuppression occurs, and depending on other therapy, reduce mercaptopurine over other agents.
If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended.",-,-,-
Mercaptopurine,Actionable,ONCOLOGY,Level 1A(Strong),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: Intermediate Metabolizer (n/a) | NUDT15: Poor Metabolizer (n/a),Intermediate Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,"Increased risk of ADR (thiopurine-related leukopenia, neutropenia, myelosuppression)",Increased Caution/Avoid,Toxicity,üõë,"For malignant conditions, initiate dose at 10 mg/m2/day and adjust dose based on myelosuppression and disease-specific guidelines. After each dose adjustment, allow 4-6 weeks to reach steady-state. If myelosuppression occurs, reduce mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy.",-,-,-
Mercaptopurine,Actionable,ONCOLOGY,Level 1A(Strong),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: Intermediate Metabolizer (n/a) | NUDT15: Possible Intermediate Metabolizer (n/a),Intermediate Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Possible Intermediate Metabolizer,-,n/a,-,-,-,"Increased risk of ADR (thiopurine-related leukopenia, neutropenia, myelosuppression)",Increased Caution/Avoid,Toxicity,üõë,"Reduce initial dose to 30%-80% of normal dose, eg., if normal dose is ‚â•75 mg/m2/day or ‚â• 1.5 mg/kg/day, reduce it to 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day and adjust doses based on degree of myelosuppression and disease-specific guidelines. After each dose adjustment, allow 2-4 weeks to reach steady-state. If myelosuppression occurs, and depending on other therapy, reduce mercaptopurine over other agents.
If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended.",-,-,-
Mercaptopurine,Actionable,ONCOLOGY,Level 1A(Strong),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: No Result (n/a) | NUDT15: Indeterminate (n/a),No Result,-,n/a,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,No recommendation,No recommendation,-,-,"Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.",-,-,-
Mercaptopurine,Actionable,ONCOLOGY,Level 1A(Strong),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: No Result (n/a) | NUDT15: Intermediate Metabolizer (n/a),No Result,-,n/a,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,"Increased risk of ADR (thiopurine-related leukopenia, neutropenia, myelosuppression)",Increased Caution/Avoid,Toxicity,üõë,"Based NUDT15 status, reduce initial dose to 30%-80% of normal dose, eg., if normal dose is ‚â•75 mg/m2/day or ‚â• 1.5 mg/kg/day, reduce it to 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day and adjust doses based on degree of myelosuppression and disease-specific guidelines. After each dose adjustment, allow 2-4 weeks to reach steady-state. If myelosuppression occurs, and depending on other therapy, reduce mercaptopurine over other agents. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.

If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended. 
",-,-,-
Mercaptopurine,Actionable,ONCOLOGY,Level 1A(Strong),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: No Result (n/a) | NUDT15: Normal Metabolizer (n/a),No Result,-,n/a,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,"Normal risk of ADR (thiopurine-related leukopenia, neutropenia, myelosuppression)",Use with Caution,-,‚ö†Ô∏è,"Based on NUDT15 status, use recommended starting dose, e.g., 75 mg/m2/day or 1.5 mg/kg/day and adjust doses (and of any other myelosuppressive therapy) without any special emphasis on mercaptopurine compared to other agents. After each dose adjustment, allow at least 2 weeks to reach steady-state. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.",-,-,-
Mercaptopurine,Actionable,ONCOLOGY,Level 1A(Strong),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: No Result (n/a) | NUDT15: Poor Metabolizer (n/a),No Result,-,n/a,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,"Increased risk of ADR (thiopurine-related leukopenia, neutropenia, myelosuppression)",Increased Caution/Avoid,Toxicity,üõë,"Based NUDT15 status, for malignant conditions, initiate dose at 10 mg/m2/day and adjust doses based on myelosuppression and disease-specific guidelines. After each dose adjustment, allow 4-6 weeks to reach steady-state. If myelosuppression occurs, reduce mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.",-,-,-
Mercaptopurine,Actionable,ONCOLOGY,Level 1A(Strong),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: No Result (n/a) | NUDT15: Possible Intermediate Metabolizer (n/a),No Result,-,n/a,-,-,-,-,-,-,-,-,-,-,Possible Intermediate Metabolizer,-,n/a,-,-,-,"Increased risk of ADR (thiopurine-related leukopenia, neutropenia, myelosuppression)",Increased Caution/Avoid,Toxicity,üõë,"Based NUDT15 status, reduce initial dose to 30%-80% of normal dose, eg., if normal dose is ‚â•75 mg/m2/day or ‚â• 1.5 mg/kg/day, reduce it to 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day and adjust doses based on degree of myelosuppression and disease-specific guidelines. After each dose adjustment, allow 2-4 weeks to reach steady-state. If myelosuppression occurs, and depending on other therapy, reduce mercaptopurine over other agents. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.

If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended. 
",-,-,-
Mercaptopurine,Actionable,ONCOLOGY,Level 1A(Strong),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: Normal Metabolizer (n/a) | NUDT15: Indeterminate (n/a),Normal Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,"Normal risk of ADR (thiopurine-related leukopenia, neutropenia, myelosuppression)",Use with Caution,-,‚ö†Ô∏è,"Based on TPMT status, use recommended starting dose, e.g., 75 mg/m2/day or 1.5 mg/kg/day and adjust doses (and of any other myelosuppressive therapy) without any special emphasis on mercaptopurine compared to other agents. After each dose adjustment, allow at least 2 weeks to reach steady-state. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.",-,-,-
Mercaptopurine,Actionable,ONCOLOGY,Level 1A(Strong),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: Normal Metabolizer (n/a) | NUDT15: Intermediate Metabolizer (n/a),Normal Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Reduce initial dose to 30%-80% of normal dose, eg., if normal dose is ‚â•75 mg/m2/day or ‚â• 1.5 mg/kg/day, reduce it to 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day and adjust doses based on degree of myelosuppression and disease-specific guidelines. After each dose adjustment, allow 2-4 weeks to reach steady-state. If myelosuppression occurs, and depending on other therapy, reduce mercaptopurine over other agents.
If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended.",-,-,-
Mercaptopurine,Actionable,ONCOLOGY,Level 1A(Strong),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: Normal Metabolizer (n/a) | NUDT15: No Result (n/a),Normal Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,"Normal risk of ADR (thiopurine-related leukopenia, neutropenia, myelosuppression)",Use with Caution,-,‚ö†Ô∏è,"Based on TPMT status, use recommended starting dose, e.g., 75 mg/m2/day or 1.5 mg/kg/day and adjust doses (and of any other myelosuppressive therapy) without any special emphasis on mercaptopurine compared to other agents. After each dose adjustment, allow at least 2 weeks to reach steady-state. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.",-,-,-
Mercaptopurine,Actionable,ONCOLOGY,Level 1A(Strong),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: Normal Metabolizer (n/a) | NUDT15: Normal Metabolizer (n/a),Normal Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,"Normal risk of ADR (thiopurine-related leukopenia, neutropenia, myelosuppression)",Use as Directed,-,‚úÖ,"Use recommended starting dose, e.g., 75 mg/m2/day or 1.5 mg/kg/day and adjust doses (and of any other myelosuppressive therapy) without any special emphasis on mercaptopurine compared to other agents. After each dose adjustment, allow at least 2 weeks to reach steady-state.",-,-,-
Mercaptopurine,Actionable,ONCOLOGY,Level 1A(Strong),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: Normal Metabolizer (n/a) | NUDT15: Poor Metabolizer (n/a),Normal Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,"For malignant conditions, initiate dose at 10 mg/m2/day and adjust dose based on myelosuppression and disease-specific guidelines. After each dose adjustment, allow 4-6 weeks to reach steady state. If myelosuppression occurs, reduce mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy.",-,-,-
Mercaptopurine,Actionable,ONCOLOGY,Level 1A(Strong),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: Normal Metabolizer (n/a) | NUDT15: Possible Intermediate Metabolizer (n/a),Normal Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Possible Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Reduce initial dose to 30%-80% of normal dose, eg., if normal dose is ‚â•75 mg/m2/day or ‚â• 1.5 mg/kg/day, reduce it to 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day and adjust doses based on degree of myelosuppression and disease-specific guidelines. After each dose adjustment, allow 2-4 weeks to reach steady-state. If myelosuppression occurs, and depending on other therapy, reduce mercaptopurine over other agents.
If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended.",-,-,-
Mercaptopurine,Actionable,ONCOLOGY,Level 1A(Strong),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: Poor Metabolizer (n/a) | NUDT15: Indeterminate (n/a),Poor Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,"Increased risk of ADR (thiopurine-related leukopenia, neutropenia, myelosuppression)",Increased Caution/Avoid,Toxicity,üõë,"Based on TPMT status, for malignant conditions, reduce daily dose by 10-fold and reduce frequency to thrice weekly instead of daily, e.g., 10 mg/m2/day given just 3 days/week. Adjust doses based on degree of myelosuppression and disease-specific guidelines. After each dose adjustment, allow 4-6 weeks to reach steady-state. If myelosuppression occurs, reduce mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.",-,-,-
Mercaptopurine,Actionable,ONCOLOGY,Level 1A(Strong),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: Poor Metabolizer (n/a) | NUDT15: Intermediate Metabolizer (n/a),Poor Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,"Increased risk of ADR (thiopurine-related leukopenia, neutropenia, myelosuppression)",Increased Caution/Avoid,Toxicity,üõë,"For malignant conditions, reduce daily dose by 10-fold and reduce frequency to thrice weekly instead of daily, e.g., 10 mg/m2/day given just 3 days/week. Adjust doses based on degree of myelosuppression and disease-specific guidelines. After each dose adjustment, allow 4-6 weeks to reach steady-state. If myelosuppression occurs, reduce mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy.",-,-,-
Mercaptopurine,Actionable,ONCOLOGY,Level 1A(Strong),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: Poor Metabolizer (n/a) | NUDT15: No Result (n/a),Poor Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,"Increased risk of ADR (thiopurine-related leukopenia, neutropenia, myelosuppression)",Increased Caution/Avoid,Toxicity,üõë,"Based on TPMT status, for malignant conditions, reduce daily dose by 10-fold and reduce frequency to thrice weekly instead of daily, e.g., 10 mg/m2/day given just 3 days/week. Adjust doses based on degree of myelosuppression and disease-specific guidelines. After each dose adjustment, allow 4-6 weeks to reach steady-state. If myelosuppression occurs, reduce mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.",-,-,-
Mercaptopurine,Actionable,ONCOLOGY,Level 1A(Strong),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: Poor Metabolizer (n/a) | NUDT15: Normal Metabolizer (n/a),Poor Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,"For malignant conditions, reduce daily dose by 10-fold and reduce frequency to thrice weekly instead of daily, e.g., 10 mg/m2/day given just 3 days/week. Adjust doses based on degree of myelosuppression and disease-specific guidelines. After each dose adjustment, allow 4-6 weeks to reach steady-state. If myelosuppression occurs, reduce mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy.",-,-,-
Mercaptopurine,Actionable,ONCOLOGY,Level 1A(Strong),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: Poor Metabolizer (n/a) | NUDT15: Poor Metabolizer (n/a),Poor Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,"Increased risk of ADR (thiopurine-related leukopenia, neutropenia, myelosuppression)",Increased Caution/Avoid,Toxicity,üõë,"For malignant conditions, reduce daily dose by 10-fold and reduce frequency to thrice weekly instead of daily, e.g., 10 mg/m2/day given just 3 days/week. Adjust doses based on degree of myelosuppression and disease-specific guidelines. After each dose adjustment, allow 4-6 weeks to reach steady-state. If myelosuppression occurs, reduce mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy.",-,-,-
Mercaptopurine,Actionable,ONCOLOGY,Level 1A(Strong),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: Poor Metabolizer (n/a) | NUDT15: Possible Intermediate Metabolizer (n/a),Poor Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Possible Intermediate Metabolizer,-,n/a,-,-,-,"Increased risk of ADR (thiopurine-related leukopenia, neutropenia, myelosuppression)",Increased Caution/Avoid,Toxicity,üõë,"For malignant conditions, reduce daily dose by 10-fold and reduce frequency to thrice weekly instead of daily, e.g., 10 mg/m2/day given just 3 days/week. Adjust doses based on degree of myelosuppression and disease-specific guidelines. After each dose adjustment, allow 4-6 weeks to reach steady-state. If myelosuppression occurs, reduce mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy.",-,-,-
Mercaptopurine,Actionable,ONCOLOGY,Level 1A(Strong),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: Possible Intermediate Metabolizer (n/a) | NUDT15: Indeterminate (n/a),Possible Intermediate Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,"Increased risk of ADR (thiopurine-related leukopenia, neutropenia, myelosuppression)",Increased Caution/Avoid,Toxicity,üõë,"Based on TPMT status, reduce initial dose to 30%-80% of normal dose, eg., if normal dose is ‚â•75 mg/m2/day or ‚â• 1.5 mg/kg/day, reduce it to 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day and adjust doses based on degree of myelosuppression and disease-specific guidelines. After each dose adjustment, allow 2-4 weeks to reach steady-state. If myelosuppression occurs, and depending on other therapy, reduce mercaptopurine over other agents. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.

If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended.",-,-,-
Mercaptopurine,Actionable,ONCOLOGY,Level 1A(Strong),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: Possible Intermediate Metabolizer (n/a) | NUDT15: Intermediate Metabolizer (n/a),Possible Intermediate Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,"Increased risk of ADR (thiopurine-related leukopenia, neutropenia, myelosuppression)",Increased Caution/Avoid,Toxicity,üõë,"Reduce initial dose to 30%-80% of normal dose, eg., if normal dose is ‚â•75 mg/m2/day or ‚â• 1.5 mg/kg/day, reduce it to 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day and adjust doses based on degree of myelosuppression and disease-specific guidelines. After each dose adjustment, allow 2-4 weeks to reach steady-state. If myelosuppression occurs, and depending on other therapy, reduce mercaptopurine over other agents.
If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended.",-,-,-
Mercaptopurine,Actionable,ONCOLOGY,Level 1A(Strong),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: Possible Intermediate Metabolizer (n/a) | NUDT15: No Result (n/a),Possible Intermediate Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,"Increased risk of ADR (thiopurine-related leukopenia, neutropenia, myelosuppression)",Increased Caution/Avoid,Toxicity,üõë,"Based on TPMT status, reduce initial dose to 30%-80% of normal dose, eg., if normal dose is ‚â•75 mg/m2/day or ‚â• 1.5 mg/kg/day, reduce it to 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day and adjust doses based on degree of myelosuppression and disease-specific guidelines. After each dose adjustment, allow 2-4 weeks to reach steady-state. If myelosuppression occurs, and depending on other therapy, reduce mercaptopurine over other agents. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.

If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended. 
",-,-,-
Mercaptopurine,Actionable,ONCOLOGY,Level 1A(Strong),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: Possible Intermediate Metabolizer (n/a) | NUDT15: Normal Metabolizer (n/a),Possible Intermediate Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Reduce initial dose to 30%-80% of normal dose, eg., if normal dose is ‚â•75 mg/m2/day or ‚â• 1.5 mg/kg/day, reduce it to 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day and adjust doses based on degree of myelosuppression and disease-specific guidelines. After each dose adjustment, allow 2-4 weeks to reach steady-state. If myelosuppression occurs, and depending on other therapy, reduce mercaptopurine over other agents.
If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended.",-,-,-
Mercaptopurine,Actionable,ONCOLOGY,Level 1A(Strong),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: Possible Intermediate Metabolizer (n/a) | NUDT15: Poor Metabolizer (n/a),Possible Intermediate Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,"Increased risk of ADR (thiopurine-related leukopenia, neutropenia, myelosuppression)",Increased Caution/Avoid,Toxicity,üõë,"For malignant conditions, initiate dose at 10 mg/m2/day and adjust dose based on myelosuppression and disease-specific guidelines. After each dose adjustment, allow 4-6 weeks to reach steady-state. If myelosuppression occurs, reduce mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy.",-,-,-
Mercaptopurine,Actionable,ONCOLOGY,Level 1A(Strong),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: Possible Intermediate Metabolizer (n/a) | NUDT15: Possible Intermediate Metabolizer (n/a),Possible Intermediate Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Possible Intermediate Metabolizer,-,n/a,-,-,-,"Increased risk of ADR (thiopurine-related leukopenia, neutropenia, myelosuppression)",Increased Caution/Avoid,Toxicity,üõë,"Reduce initial dose to 30%-80% of normal dose, eg., if normal dose is ‚â•75 mg/m2/day or ‚â• 1.5 mg/kg/day, reduce it to 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day and adjust doses based on degree of myelosuppression and disease-specific guidelines. After each dose adjustment, allow 2-4 weeks to reach steady-state. If myelosuppression occurs, and depending on other therapy, reduce mercaptopurine over other agents.
If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended.",-,-,-
Nilotinib,Actionable,ONCOLOGY,Level 1AA,UGT1A1,Yes,UGT1A1,-,-,FDA evidence; additional testing,-,Extensive Metabolizer,Extensive Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Risk of ADR,Use as Directed,-,‚úÖ,-,-,-,-
Nilotinib,Actionable,ONCOLOGY,Level 1AA,UGT1A1,Yes,UGT1A1,-,-,FDA evidence; additional testing,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Nilotinib,Actionable,ONCOLOGY,Level 1A,UGT1A1,Yes,UGT1A1,-,-,FDA evidence; additional testing,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Risk of ADR (hyperbilirubinemia).,Increased Caution/Avoid,Toxicity,üõë,Increased Risk of ADR (hyperbilirubinemia),-,-,-
Paclitaxel,Actionable,ONCOLOGY,Level 2B,CYP3A4 ,Yes,CYP3A4,-,-,-,DPWG (No Recommendation),Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Paclitaxel,Actionable,ONCOLOGY,Level 2B,CYP3A4,Yes,CYP3A4,-,-,-,DPWG (No Recommendation),Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK and Clinical Effects,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Paclitaxel,Actionable,ONCOLOGY,Level 2B,CYP3A4,Yes,CYP3A4,-,-,-,DPWG (No Recommendation),Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK and Clinical Effects,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Pazopanib,Actionable,ONCOLOGY,Level 1A,UGT1A1,Yes,UGT1A1,-,-,FDA evidence,-,Extensive Metabolizer,Extensive Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,"Normal Risk of ADR (hyperbilirubinemia, liver enzyme elevations)",Use as Directed,-,‚úÖ,-,-,-,-
Pazopanib,Actionable,ONCOLOGY,Level 1A,UGT1A1,Yes,UGT1A1,-,-,FDA evidence,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Risk of ADR (liver enzyme elevations),Use with Caution,Toxicity,‚ö†Ô∏è,Increased Risk of ADR (hyperbilirubinemia),-,-,-
Pazopanib,Actionable,ONCOLOGY,Level 1A,UGT1A1,Yes,UGT1A1,-,-,FDA evidence,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Risk of ADR (hyperbilirubinemia),Increased Caution/Avoid,Toxicity,üõë,Increased Risk of ADR (hyperbilirubinemia),-,-,-
Pazopanib,Actionable,ONCOLOGY,Level 1A,HLA-B + UGT1A1,No,HLA-B,UGT1A1,-,FDA evidence,-,UGT1A1: Extensive Metabolizer/ HLA-B*57:01: Positive,Positive,*57:01,-,-,-,-,-,-,-,-,-,-,-,Extensive Metabolizer,-,-,-,-,-,Increased Risk of ADR (liver enzyme elevations),Use with Caution,Toxicity,‚ö†Ô∏è,Increased Risk of ADR (liver enzyme elevations),-,-,-
Pazopanib,Actionable,ONCOLOGY,Level 1A,HLA-B + UGT1A1,No,HLA-B,UGT1A1,-,FDA evidence,-,UGT1A1: Extensive Metabolizer/ HLA-B*57:01: Negative,Negative,*57:01,-,-,-,-,-,-,-,-,-,-,-,Extensive Metabolizer,-,-,-,-,-,"Normal Risk of ADR (hyperbilirubinemia, liver enzyme elevations)",Use as Directed,-,‚úÖ,-,-,-,-
Pazopanib,Actionable,ONCOLOGY,Level 1A,HLA-B + UGT1A1,No,HLA-B,UGT1A1,-,FDA evidence,-,UGT1A1: Intermediate Metabolizer/ HLA-B*57:01: Positive,Positive,*57:01,-,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,-,-,-,-,Increased Risk of ADR (liver enzyme elevations),Use with Caution,Toxicity,‚ö†Ô∏è,Increased Risk of ADR (liver enzyme elevations),-,-,-
Pazopanib,Actionable,ONCOLOGY,Level 1A,HLA-B + UGT1A1,No,HLA-B,UGT1A1,-,FDA evidence,-,UGT1A1: Intermediate Metabolizer/ HLA-B*57:01: Negative,Negative,*57:01,-,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,-,-,-,-,Increased Risk of ADR (liver enzyme elevations),Use with Caution,Toxicity,‚ö†Ô∏è,Increased Risk of ADR (liver enzyme elevations),-,-,-
Pazopanib,Actionable,ONCOLOGY,Level 1A,HLA-B + UGT1A1,No,HLA-B,UGT1A1,-,FDA evidence,-,UGT1A1: Poor Metabolizer/ HLA-B*57:01: Positive,Positive,*57:01,-,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,-,-,-,-,"Increased Risk of ADR (hyperbilirubinemia, liver enzyme elevations)",Increased Caution/Avoid,Toxicity,üõë,"Increased Risk of ADR (hyperbilirubinemia, liver enzyme elevations)",-,-,-
Pazopanib,Actionable,ONCOLOGY,Level 1A,HLA-B + UGT1A1,No,HLA-B,UGT1A1,-,FDA evidence,-,UGT1A1: Poor Metabolizer/ HLA-B*57:01: Negative,Negative,*57:01,-,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,-,-,-,-,Increased Risk of ADR (hyperbilirubinemia),Increased Caution/Avoid,Toxicity,üõë,Increased Risk of ADR (hyperbilirubinemia),-,-,-
Rasburicase,Actionable,ONCOLOGY,Level 1A(Strong),G6PD,Yes,G6PD,-,-,Professional guideline; FDA evidence,CPIC,Deficient,Deficient,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Risk of ADR (acute hemolytic anemia),Increased Caution/Avoid,Toxicity,üõë,Increased Risk of ADR (acute hemolytic anemia); Avoid use,-,-,-
Rasburicase,Actionable,ONCOLOGY,Level 1A(Strong),G6PD,Yes,G6PD,-,-,Professional guideline; FDA evidence,CPIC,Deficient with CNSHA,Deficient with CNSHA,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Risk of ADR (acute exacerbation of chronic hemolysis),Increased Caution/Avoid,Toxicity,üõë,Increased Risk of ADR (acute exacerbation of chronic hemolysis); Avoid use,-,-,-
Rasburicase,Actionable,ONCOLOGY,Level 1A(Moderate),G6PD,Yes,G6PD,-,-,Professional guideline; FDA evidence,CPIC,Indeterminate,Indeterminate,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,n/a,-,-,-,NO RECOMMENDATION,-,-,-
Rasburicase,Actionable,ONCOLOGY,Level 1A(Strong),G6PD,Yes,G6PD,-,-,Professional guideline; FDA evidence,CPIC,Normal,Normal,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Risk of ADR (acute hemolytic anemia),Use as Directed,-,‚úÖ,na,-,-,-
Rasburicase,Actionable,ONCOLOGY,Level 1A(Moderate),G6PD,Yes,G6PD,-,-,Professional guideline; FDA evidence,CPIC,Variable,Variable,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,n/a,NO RECOMMENDATION,Toxicity,‚úÖ,NO RECOMMENDATION,-,-,-
Regorafenib,Actionable,ONCOLOGY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Regorafenib,Actionable,ONCOLOGY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK and Clinical Effects,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Regorafenib,Actionable,ONCOLOGY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK and Clinical Effects,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Ruxolitinib,Actionable,ONCOLOGY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Ruxolitinib,Actionable,ONCOLOGY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK and Clinical Effects,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Ruxolitinib,Actionable,ONCOLOGY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK and Clinical Effects,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Sorafenib,Actionable,ONCOLOGY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Sorafenib,Actionable,ONCOLOGY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Sorafenib,Actionable,ONCOLOGY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure; Minimal Evidence about Clinical Impact,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Sorafenib,Actionable,ONCOLOGY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Sorafenib,Actionable,ONCOLOGY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Sorafenib,Actionable,ONCOLOGY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Sunitinib,Actionable,ONCOLOGY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Sunitinib,Actionable,ONCOLOGY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure; Minimal Information about Clinical Impact,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Sunitinib,Actionable,ONCOLOGY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure; Minimal Information about Clinical Impact,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Temsirolimus,Actionable,ONCOLOGY,Level 2B,CYP3A4,Yes,CYP3A4,-,-,-,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Temsirolimus,Actionable,ONCOLOGY,Level 2B,CYP3A4,Yes,CYP3A4,-,-,-,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK and Clinical Effects,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Temsirolimus,Actionable,ONCOLOGY,Level 2B,CYP3A4,Yes,CYP3A4,-,-,-,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK and Clinical Effects,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Teniposide,Actionable,ONCOLOGY,Level 2C,CYP3A4,Yes,CYP3A4,-,-,-,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Teniposide,Actionable,ONCOLOGY,Level 2C,CYP3A4,Yes,CYP3A4,-,-,-,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK and Clinical Effects,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Teniposide,Actionable,ONCOLOGY,Level 2C,CYP3A4,Yes,CYP3A4,-,-,-,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK and Clinical Effects,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Thioguanine,Actionable,ONCOLOGY,Level 1A(Strong),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: Indeterminate (n/a) | NUDT15: Indeterminate (n/a),Indeterminate,-,n/a,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,No recommendation,-,-,-,"Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.",-,-,-
Thioguanine,Actionable,ONCOLOGY,Level 1A(Moderate),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: Indeterminate (n/a) | NUDT15: Intermediate Metabolizer (n/a),Indeterminate,-,n/a,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,"Increased risk of ADR (thiopurine-related leukopenia, neutropenia, myelosuppression)",Increased Caution/Avoid,Toxicity,üõë,"Based on NUDT15 status, reduce initial dose to 50%-80% of normal dose, eg., if normal dose is ‚â• 40-60 mg/m2/day, reduce it to 20-48 mg/m2/day and adjust doses based on degree of myelosuppression and disease-specific guidelines. After each dose adjustment, allow 2-4 weeks to reach steady-state. If myelosuppression occurs, reduce thioguanine over other agents. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.",-,-,-
Thioguanine,Actionable,ONCOLOGY,Level 1A(Strong),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: Indeterminate (n/a) | NUDT15: No Result (n/a),Indeterminate,-,n/a,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,No recommendation,-,-,-,"Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.",-,-,-
Thioguanine,Actionable,ONCOLOGY,Level 1A(Strong),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: Indeterminate (n/a) | NUDT15: Normal Metabolizer (n/a),Indeterminate,-,n/a,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,"Normal risk of ADR (thiopurine-related leukopenia, neutropenia, myelosuppression)",-,-,-,"Based on NUDT15 status, use recommended starting dose e.g., 40-60 mg/m2/day and adjust doses of thioguanine and of other myelosuppressive therapy without any special emphasis on thioguanine. After each dose adjustment, allow 2 weeks to reach steady-state. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.",-,-,-
Thioguanine,Actionable,ONCOLOGY,Level 1A(Strong),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: Indeterminate (n/a) | NUDT15: Poor Metabolizer (n/a),Indeterminate,-,n/a,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,"Increased risk of ADR (thiopurine-related leukopenia, neutropenia, myelosuppression)",Increased Caution/Avoid,Toxicity,üõë,"Based on NUDT15 status, for malignant conditions, reduce initial dose to 25% of normal dose and adjust doses based on degree of myelosuppression and disease-specific guidelines. After each dose adjustment, allow 4-6 weeks to reach steady-state. If myelosuppression occurs, reduce thioguanine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.",-,-,-
Thioguanine,Actionable,ONCOLOGY,Level 1A(Moderate),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: Indeterminate (n/a) | NUDT15: Possible Intermediate Metabolizer (n/a),Indeterminate,-,n/a,-,-,-,-,-,-,-,-,-,-,Possible Intermediate Metabolizer,-,n/a,-,-,-,"Increased risk of ADR (thiopurine-related leukopenia, neutropenia, myelosuppression)",Increased Caution/Avoid,Toxicity,üõë,"Based on NUDT15 status, reduce initial dose to 50%-80% of normal dose, eg., if normal dose is ‚â• 40-60 mg/m2/day, reduce it to 20-48 mg/m2/day and adjust doses based on degree of myelosuppression and disease-specific guidelines. After each dose adjustment, allow 2-4 weeks to reach steady-state. If myelosuppression occurs, reduce thioguanine over other agents. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.",-,-,-
Thioguanine,Actionable,ONCOLOGY,Level 1A(Moderate),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: Intermediate Metabolizer (n/a) | NUDT15: Indeterminate (n/a),Intermediate Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,"Increased risk of ADR (thiopurine-related leukopenia, neutropenia, myelosuppression)",Increased Caution/Avoid,Toxicity,üõë,"Based on TPMT status, reduce initial dose to 50%-80% of normal dose, eg., if normal dose is ‚â• 40-60 mg/m2/day, reduce it to 20-48 mg/m2/day and adjust doses based on degree of myelosuppression and disease-specific guidelines. After each dose adjustment, allow 2-4 weeks to reach steady-state. If myelosuppression occurs, and depending on other therapy, reduce thioguanine over other agents. If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity.
",-,-,-
Thioguanine,Actionable,ONCOLOGY,Level 1A(Moderate),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: Intermediate Metabolizer (n/a) | NUDT15: Intermediate Metabolizer (n/a),Intermediate Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,"Increased risk of ADR (thiopurine-related leukopenia, neutropenia, myelosuppression)",Increased Caution/Avoid,Toxicity,üõë,"Reduce initial dose to 50%-80% of normal dose, eg., if normal dose is ‚â• 40-60 mg/m2/day, reduce it to 20-48 mg/m2/day and adjust doses based on degree of myelosuppression and disease-specific guidelines. After each dose adjustment, allow 2-4 weeks to reach steady-state. If myelosuppression occurs, and depending on other therapy, reduce thioguanine over other agents.",-,-,-
Thioguanine,Actionable,ONCOLOGY,Level 1A(Moderate),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: Intermediate Metabolizer (n/a) | NUDT15: No Result (n/a),Intermediate Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,"Increased risk of ADR (thiopurine-related leukopenia, neutropenia, myelosuppression)",Increased Caution/Avoid,Toxicity,üõë,"Based on TPMT status, reduce initial dose to 50%-80% of normal dose, eg., if normal dose is ‚â• 40-60 mg/m2/day, reduce it to 20-48 mg/m2/day and adjust doses based on degree of myelosuppression and disease-specific guidelines. After each dose adjustment, allow 2-4 weeks to reach steady-state. If myelosuppression occurs, and depending on other therapy, reduce thioguanine over other agents. If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity.",-,-,-
Thioguanine,Actionable,ONCOLOGY,Level 1A(Moderate),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: Intermediate Metabolizer (n/a) | NUDT15: Normal Metabolizer (n/a),Intermediate Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Reduce initial dose to 50%-80% of normal dose, eg., if normal dose is ‚â• 40-60 mg/m2/day, reduce it to 20-48 mg/m2/day and adjust doses based on degree of myelosuppression and disease-specific guidelines. After each dose adjustment, allow 2-4 weeks to reach steady-state. If myelosuppression occurs, and depending on other therapy, reduce thioguanine over other agents.",-,-,-
Thioguanine,Actionable,ONCOLOGY,Level 1A(Strong),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: Intermediate Metabolizer (n/a) | NUDT15: Poor Metabolizer (n/a),Intermediate Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,"Increased risk of ADR (thiopurine-related leukopenia, neutropenia, myelosuppression)",Increased Caution/Avoid,Toxicity,üõë,"For malignant conditions, reduce initial dose to 25% of normal dose and adjust doses based on degree of myelosuppression and disease-specific guidelines. After each dose adjustment, allow 4-6 weeks to reach steady-state. If myelosuppression occurs, reduce thioguanine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy.",-,-,-
Thioguanine,Actionable,ONCOLOGY,Level 1A(Moderate),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: Intermediate Metabolizer (n/a) | NUDT15: Possible Intermediate Metabolizer (n/a),Intermediate Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Possible Intermediate Metabolizer,-,n/a,-,-,-,"Increased risk of ADR (thiopurine-related leukopenia, neutropenia, myelosuppression)",Increased Caution/Avoid,Toxicity,üõë,"Reduce initial dose to 50%-80% of normal dose, eg., if normal dose is ‚â• 40-60 mg/m2/day, reduce it to 20-48 mg/m2/day and adjust doses based on degree of myelosuppression and disease-specific guidelines. After each dose adjustment, allow 2-4 weeks to reach steady-state. If myelosuppression occurs, and depending on other therapy, reduce thioguanine over other agents.",-,-,-
Thioguanine,Actionable,ONCOLOGY,Level 1A(Strong),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: No Result (n/a) | NUDT15: Indeterminate (n/a),No Result,-,n/a,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,No recommendation,-,-,-,"Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.",-,-,-
Thioguanine,Actionable,ONCOLOGY,Level 1A(Moderate),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: No Result (n/a) | NUDT15: Intermediate Metabolizer (n/a),No Result,-,n/a,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,"Increased risk of ADR (thiopurine-related leukopenia, neutropenia, myelosuppression)",Increased Caution/Avoid,Toxicity,üõë,"Based on NUDT15 status, reduce initial dose to 50%-80% of normal dose, eg., if normal dose is ‚â• 40-60 mg/m2/day, reduce it to 20-48 mg/m2/day and adjust doses based on degree of myelosuppression and disease-specific guidelines. After each dose adjustment, allow 2-4 weeks to reach steady-state. If myelosuppression occurs, reduce thioguanine over other agents. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.",-,-,-
Thioguanine,Actionable,ONCOLOGY,Level 1A(Strong),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: No Result (n/a) | NUDT15: Normal Metabolizer (n/a),No Result,-,n/a,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,"Normal risk of ADR (thiopurine-related leukopenia, neutropenia, myelosuppression)",-,-,-,"Based on NUDT15 status, use recommended starting dose e.g., 40-60 mg/m2/day and adjust doses of thioguanine and of other myelosuppressive therapy without any special emphasis on thioguanine. After each dose adjustment, allow 2 weeks to reach steady-state. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.",-,-,-
Thioguanine,Actionable,ONCOLOGY,Level 1A(Strong),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: No Result (n/a) | NUDT15: Poor Metabolizer (n/a),No Result,-,n/a,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,"Increased risk of ADR (thiopurine-related leukopenia, neutropenia, myelosuppression)",Increased Caution/Avoid,Toxicity,üõë,"Based on NUDT15 status, for malignant conditions, reduce initial dose to 25% of normal dose and adjust doses based on degree of myelosuppression and disease-specific guidelines. After each dose adjustment, allow 4-6 weeks to reach steady-state. If myelosuppression occurs, reduce thioguanine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.",-,-,-
Thioguanine,Actionable,ONCOLOGY,Level 1A(Moderate),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: No Result (n/a) | NUDT15: Possible Intermediate Metabolizer (n/a),No Result,-,n/a,-,-,-,-,-,-,-,-,-,-,Possible Intermediate Metabolizer,-,n/a,-,-,-,"Increased risk of ADR (thiopurine-related leukopenia, neutropenia, myelosuppression)",Increased Caution/Avoid,Toxicity,üõë,"Based on NUDT15 status, reduce initial dose to 50%-80% of normal dose, eg., if normal dose is ‚â• 40-60 mg/m2/day, reduce it to 20-48 mg/m2/day and adjust doses based on degree of myelosuppression and disease-specific guidelines. After each dose adjustment, allow 2-4 weeks to reach steady-state. If myelosuppression occurs, reduce thioguanine over other agents. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.",-,-,-
Thioguanine,Actionable,ONCOLOGY,Level 1A(Strong),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: Normal Metabolizer (n/a) | NUDT15: Indeterminate (n/a),Normal Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,"Normal risk of ADR (thiopurine-related leukopenia, neutropenia, myelosuppression)",-,-,-,"Based on TPMT status, use recommended starting dose, e.g., 40-60 mg/m2/day and adjust doses of thioguanine and of other myelosuppressive therapy without any special emphasis on thioguanine. After each dose adjustment, allow 2 weeks to reach steady-state. If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity.",-,-,-
Thioguanine,Actionable,ONCOLOGY,Level 1A(Moderate),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: Normal Metabolizer (n/a) | NUDT15: Intermediate Metabolizer (n/a),Normal Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Reduce initial dose to 50%-80% of normal dose, eg., if normal dose is ‚â• 40-60 mg/m2/day, reduce it to 20-48 mg/m2/day and adjust doses based on degree of myelosuppression and disease-specific guidelines. After each dose adjustment, allow 2-4 weeks to reach steady-state. If myelosuppression occurs, and depending on other therapy, reduce thioguanine over other agents.",-,-,-
Thioguanine,Actionable,ONCOLOGY,Level 1A(Strong),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: Normal Metabolizer (n/a) | NUDT15: No Result (n/a),Normal Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,"Normal risk of ADR (thiopurine-related leukopenia, neutropenia, myelosuppression)",-,-,-,"Based on TPMT status, use recommended starting dose, e.g., 40-60 mg/m2/day and adjust doses of thioguanine and of other myelosuppressive therapy without any special emphasis on thioguanine. After each dose adjustment, allow 2 weeks to reach steady-state. If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity.",-,-,-
Thioguanine,Actionable,ONCOLOGY,Level 1A(Strong),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: Normal Metabolizer (n/a) | NUDT15: Normal Metabolizer (n/a),Normal Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,"Normal risk of ADR (thiopurine-related leukopenia, neutropenia, myelosuppression)",Use as Directed,Toxicity,‚úÖ,"Use recommended starting dose, e.g., 40-60 mg/m2/day and adjust doses of thioguanine and of other myelosuppressive therapy without any special emphasis on thioguanine. After each dose adjustment, allow 2 weeks to reach steady-state.",-,-,-
Thioguanine,Actionable,ONCOLOGY,Level 1A(Strong),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: Normal Metabolizer (n/a) | NUDT15: Poor Metabolizer (n/a),Normal Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,"For malignant conditions, reduce initial dose to 25% of normal dose and adjust doses based on degree of myelosuppression and disease-specific guidelines. After each dose adjustment, allow 4-6 weeks to reach steady-state. 
If myelosuppression occurs, reduce thioguanine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy.",-,-,-
Thioguanine,Actionable,ONCOLOGY,Level 1A(Moderate),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: Normal Metabolizer (n/a) | NUDT15: Possible Intermediate Metabolizer (n/a),Normal Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Possible Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Reduce initial dose to 50%-80% of normal dose, eg., if normal dose is ‚â• 40-60 mg/m2/day, reduce it to 20-48 mg/m2/day and adjust doses based on degree of myelosuppression and disease-specific guidelines. After each dose adjustment, allow 2-4 weeks to reach steady-state. If myelosuppression occurs, and depending on other therapy, reduce thioguanine over other agents.",-,-,-
Thioguanine,Actionable,ONCOLOGY,Level 1A(Strong),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: Poor Metabolizer (n/a) | NUDT15: Indeterminate (n/a),Poor Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,"Increased risk of ADR (thiopurine-related leukopenia, neutropenia, myelosuppression)",Increased Caution/Avoid,Toxicity,üõë,"Based on TPMT status, for malignant conditions, reduce daily dose by 10-fold and dose thrice weekly instead of daily. Adjust doses based on degree of myelosuppression and disease-specific guidelines. After each dose adjustment, allow 4-6 weeks to reach steady-state. If myelosuppression occurs, reduce thioguanine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.
",-,-,-
Thioguanine,Actionable,ONCOLOGY,Level 1A(Strong),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: Poor Metabolizer (n/a) | NUDT15: Intermediate Metabolizer (n/a),Poor Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,"Increased risk of ADR (thiopurine-related leukopenia, neutropenia, myelosuppression)",Increased Caution/Avoid,Toxicity,üõë,"For malignant conditions, reduce daily dose by 10-fold and dose thrice weekly instead of daily. Adjust doses based on degree of myelosuppression and disease-specific guidelines. After each dose adjustment, allow 4-6 weeks to reach steady-state. If myelosuppression occurs, reduce thioguanine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy.",-,-,-
Thioguanine,Actionable,ONCOLOGY,Level 1A(Strong),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: Poor Metabolizer (n/a) | NUDT15: No Result (n/a),Poor Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,"Increased risk of ADR (thiopurine-related leukopenia, neutropenia, myelosuppression)",Increased Caution/Avoid,Toxicity,üõë,"Based on TPMT status, for malignant conditions, reduce daily dose by 10-fold and dose thrice weekly instead of daily. Adjust doses based on degree of myelosuppression and disease-specific guidelines. After each dose adjustment, allow 4-6 weeks to reach steady-state. If myelosuppression occurs, reduce thioguanine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.
",-,-,-
Thioguanine,Actionable,ONCOLOGY,Level 1A(Strong),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: Poor Metabolizer (n/a) | NUDT15: Normal Metabolizer (n/a),Poor Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,"For malignant conditions, reduce daily dose by 10-fold and dose thrice weekly instead of daily. Adjust doses based on degree of myelosuppression and disease-specific guidelines. After each dose adjustment, allow 4-6 weeks to reach steady-state. If myelosuppression occurs, reduce thioguanine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy.",-,-,-
Thioguanine,Actionable,ONCOLOGY,Level 1A(Strong),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: Poor Metabolizer (n/a) | NUDT15: Poor Metabolizer (n/a),Poor Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,"Increased risk of ADR (thiopurine-related leukopenia, neutropenia, myelosuppression)",Increased Caution/Avoid,Toxicity,üõë,"For malignant conditions, reduce daily dose by 10-fold and dose thrice weekly instead of daily. Adjust doses based on degree of myelosuppression and disease-specific guidelines. After each dose adjustment, allow 4-6 weeks to reach steady-state. If myelosuppression occurs, reduce thioguanine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy.",-,-,-
Thioguanine,Actionable,ONCOLOGY,Level 1A(Strong),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: Poor Metabolizer (n/a) | NUDT15: Possible Intermediate Metabolizer (n/a),Poor Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Possible Intermediate Metabolizer,-,n/a,-,-,-,"Increased risk of ADR (thiopurine-related leukopenia, neutropenia, myelosuppression)",Increased Caution/Avoid,Toxicity,üõë,"For malignant conditions, reduce daily dose by 10-fold and dose thrice weekly instead of daily. Adjust doses based on degree of myelosuppression and disease-specific guidelines. After each dose adjustment, allow 4-6 weeks to reach steady-state. If myelosuppression occurs, reduce thioguanine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy.",-,-,-
Thioguanine,Actionable,ONCOLOGY,Level 1A(Moderate),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: Possible Intermediate Metabolizer (n/a) | NUDT15: Indeterminate (n/a),Possible Intermediate Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,"Increased risk of ADR (thiopurine-related leukopenia, neutropenia, myelosuppression)",Increased Caution/Avoid,Toxicity,üõë,"Based on TPMT status, reduce initial dose to 50%-80% of normal dose, eg., if normal dose is ‚â• 40-60 mg/m2/day, reduce it to 20-48 mg/m2/day and adjust doses based on degree of myelosuppression and disease-specific guidelines. After each dose adjustment, allow 2-4 weeks to reach steady-state. If myelosuppression occurs, and depending on other therapy, reduce thioguanine over other agents. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.",-,-,-
Thioguanine,Actionable,ONCOLOGY,Level 1A(Moderate),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: Possible Intermediate Metabolizer (n/a) | NUDT15: Intermediate Metabolizer (n/a),Possible Intermediate Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,"Increased risk of ADR (thiopurine-related leukopenia, neutropenia, myelosuppression)",Increased Caution/Avoid,Toxicity,üõë,"Reduce initial dose to 50%-80% of normal dose, eg., if normal dose is ‚â• 40-60 mg/m2/day, reduce it to 20-48 mg/m2/day and adjust doses based on degree of myelosuppression and disease-specific guidelines. After each dose adjustment, allow 2-4 weeks to reach steady-state. If myelosuppression occurs, and depending on other therapy, reduce thioguanine over other agents.",-,-,-
Thioguanine,Actionable,ONCOLOGY,Level 1A(Moderate),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: Possible Intermediate Metabolizer (n/a) | NUDT15: No Result (n/a),Possible Intermediate Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,"Increased risk of ADR (thiopurine-related leukopenia, neutropenia, myelosuppression)",Increased Caution/Avoid,Toxicity,üõë,"Based on TPMT status, reduce initial dose to 50%-80% of normal dose, eg., if normal dose is ‚â• 40-60 mg/m2/day, reduce it to 20-48 mg/m2/day and adjust doses based on degree of myelosuppression and disease-specific guidelines. After each dose adjustment, allow 2-4 weeks to reach steady-state. If myelosuppression occurs, and depending on other therapy, reduce thioguanine over other agents. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.",-,-,-
Thioguanine,Actionable,ONCOLOGY,Level 1A(Moderate),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: Possible Intermediate Metabolizer (n/a) | NUDT15: Normal Metabolizer (n/a),Possible Intermediate Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Reduce initial dose to 50%-80% of normal dose, eg., if normal dose is ‚â• 40-60 mg/m2/day, reduce it to 20-48 mg/m2/day and adjust doses based on degree of myelosuppression and disease-specific guidelines. After each dose adjustment, allow 2-4 weeks to reach steady-state. If myelosuppression occurs, and depending on other therapy, reduce thioguanine over other agents.",-,-,-
Thioguanine,Actionable,ONCOLOGY,Level 1A(Strong),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: Possible Intermediate Metabolizer (n/a) | NUDT15: Poor Metabolizer (n/a),Possible Intermediate Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,"Increased risk of ADR (thiopurine-related leukopenia, neutropenia, myelosuppression)",Increased Caution/Avoid,Toxicity,üõë,"For malignant conditions, reduce initial dose to 25% of normal dose and adjust doses based on degree of myelosuppression and disease-specific guidelines. After each dose adjustment, allow 4-6 weeks to reach steady-state. If myelosuppression occurs, reduce thioguanine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy.",-,-,-
Thioguanine,Actionable,ONCOLOGY,Level 1A(Moderate),TPMT + NUDT15,No,TPMT,NUDT15,-,Professional guideline; FDA evidence,CPIC; DPWG,TPMT: Possible Intermediate Metabolizer (n/a) | NUDT15: Possible Intermediate Metabolizer (n/a),Possible Intermediate Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Possible Intermediate Metabolizer,-,n/a,-,-,-,"Increased risk of ADR (thiopurine-related leukopenia, neutropenia, myelosuppression)",Increased Caution/Avoid,Toxicity,üõë,"Reduce initial dose to 50%-80% of normal dose, eg., if normal dose is ‚â• 40-60 mg/m2/day, reduce it to 20-48 mg/m2/day and adjust doses based on degree of myelosuppression and disease-specific guidelines. After each dose adjustment, allow 2-4 weeks to reach steady-state. If myelosuppression occurs, and depending on other therapy, reduce thioguanine over other agents.",-,-,-
Trabectedin,Actionable,ONCOLOGY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Trabectedin,Actionable,ONCOLOGY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK and Clinical Effects,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Trabectedin,Actionable,ONCOLOGY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK and Clinical Effects,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Trametinib,Actionable,ONCOLOGY,-,G6PD,Yes,G6PD,-,-,FDA evidence; additional testing,CPIC (No Recommendation),Normal,Normal,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Risk of ADR (acute hemolytic anemia),Use as Directed,-,‚úÖ,-,-,-,-
Trametinib,Actionable,ONCOLOGY,-,G6PD,Yes,G6PD,-,-,FDA evidence; additional testing,CPIC (No Recommendation),Deficient,Deficient,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Risk of ADR (acute hemolytic anemia),Use with Caution,Toxicity,‚ö†Ô∏è,Increased Risk of ADR (acute hemolytic anemia),-,-,-
Trametinib,Actionable,ONCOLOGY,-,G6PD,Yes,G6PD,-,-,FDA evidence; additional testing,CPIC (No Recommendation),Deficient with CNSHA,Deficient with CNSHA,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Risk of ADR (acute hemolytic anemia),Use with Caution,Toxicity,‚ö†Ô∏è,Increased Risk of ADR (acute hemolytic anemia),-,-,-
Trametinib,Actionable,ONCOLOGY,-,G6PD,Yes,G6PD,-,-,FDA evidence; additional testing,CPIC (No Recommendation),Variable,Variable,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Risk of ADR (acute hemolytic anemia),Use as Directed,Toxicity,‚úÖ,-,-,-,-
Trametinib,Actionable,ONCOLOGY,-,G6PD,Yes,G6PD,-,-,FDA evidence; additional testing,CPIC (No Recommendation),Indeterminate,Indeterminate,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Unknown Risk of ADR (acute hemolytic anemia),-,-,-,-,-,-,-
Vincristine,Actionable,ONCOLOGY,Level 2A,CYP3A5,Yes,CYP3A5,-,-,additional testing,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure,Use with Caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Vincristine,Actionable,ONCOLOGY,Level 2A,CYP3A5,Yes,CYP3A5,-,-,additional testing,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure,Use with Caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Vincristine,Actionable,ONCOLOGY,Level 2A,CYP3A5,Yes,CYP3A5,-,-,additional testing,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Vinorelbine,Actionable,ONCOLOGY,Level 2B,CYP3A4,Yes,CYP3A4,-,-,-,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Vinorelbine,Actionable,ONCOLOGY,Level 2B,CYP3A4,Yes,CYP3A4,-,-,-,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK and Clinical Effects,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Vinorelbine,Actionable,ONCOLOGY,Level 2B,CYP3A4,Yes,CYP3A4,-,-,-,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK and Clinical Effects,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Methotrexate,Actionable,ONCOLOGY,Level 2A,MTHFR,Yes,MTHFR,-,-,-,DPWG (No Recommendation),AA Genotype,-,AA Genotype,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Risk of ADR/Toxicity,Use with Caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Methotrexate,Actionable,ONCOLOGY,Level 2A,MTHFR,Yes,MTHFR,-,-,-,DPWG (No Recommendation),AG Genotype,-,AG Genotype,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Risk of ADR/Toxicity,Use with Caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Methotrexate,Actionable,ONCOLOGY,Level 2A,MTHFR,Yes,MTHFR,-,-,-,DPWG (No Recommendation),GG Genotype,-,GG Genotype,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Risk of ADR/Toxicity,Use as Directed,-,‚úÖ,-,-,-,-
Drospirenone / ethinyl estradiol,Actionable,ORAL CONTRACEPTIVES,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Drospirenone / ethinyl estradiol,Actionable,ORAL CONTRACEPTIVES,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK and Clinical impact,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Drospirenone / ethinyl estradiol,Actionable,ORAL CONTRACEPTIVES,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK and Clinical impact,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Poor Metabolizer (0.0) | CYP2C19: Indeterminate (n/a),Poor Metabolizer,-,0,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tricyclic use. Consider alternative drug. If TCA is warranted, reduce initial dose to 50% and adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Poor Metabolizer (0.0) | CYP2C19: Intermediate Metabolizer (n/a),Poor Metabolizer,-,0,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitripyline is warranted, consider 50% reduction of recommended starting dose and adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Poor Metabolizer (0.0) | CYP2C19: Likely Intermediate Metabolizer (n/a),Poor Metabolizer,-,0,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitripyline is warranted, consider 50% reduction of recommended starting dose and adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Poor Metabolizer (0.0) | CYP2C19: Likely Poor Metabolizer (n/a),Poor Metabolizer,-,0,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitriptyline is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Poor Metabolizer (0.0) | CYP2C19: No Result (n/a),Poor Metabolizer,-,0,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tricyclic use. Consider alternative agent. If TCA is warranted, reduce initial dose to 50% and adjust dosage based on therapeutic drug monitoring. ",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Poor Metabolizer (0.0) | CYP2C19: Normal Metabolizer (n/a),Poor Metabolizer,-,0,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitripyline is warranted, consider 50% reduction of recommended starting dose and adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Poor Metabolizer (0.0) | CYP2C19: Poor Metabolizer (n/a),Poor Metabolizer,-,0,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitriptyline is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Poor Metabolizer (0.0) | CYP2C19: Rapid Metabolizer (n/a),Poor Metabolizer,-,0,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitriptyline is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Poor Metabolizer (0.0) | CYP2C19: Ultrarapid Metabolizer (n/a),Poor Metabolizer,-,0,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitriptyline is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Moderate),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.25) | CYP2C19: Indeterminate (n/a),Intermediate Metabolizer,-,0.25,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,Reduce initial dose to 25% and adjust dosage based on therapeutic drug monitoring. ,-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.25) | CYP2C19: Intermediate Metabolizer (n/a),Intermediate Metabolizer,-,0.25,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,Reduce initial dose to 25% and adjust dosage based on therapeutic drug monitoring.,-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.25) | CYP2C19: Likely Intermediate Metabolizer (n/a),Intermediate Metabolizer,-,0.25,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,Reduce initial dose to 25% and adjust dosage based on therapeutic drug monitoring.,-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.25) | CYP2C19: Likely Poor Metabolizer (n/a),Intermediate Metabolizer,-,0.25,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitriptyline is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Moderate),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.25) | CYP2C19: No Result (n/a),Intermediate Metabolizer,-,0.25,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,Reduce initial dose to 25% and adjust dosage based on therapeutic drug monitoring.,-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Moderate),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.25) | CYP2C19: Normal Metabolizer (n/a),Intermediate Metabolizer,-,0.25,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,Reduce initial dose to 25% and adjust dosage based on therapeutic drug monitoring.,-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.25) | CYP2C19: Poor Metabolizer (n/a),Intermediate Metabolizer,-,0.25,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitriptyline is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.25) | CYP2C19: Rapid Metabolizer (n/a),Intermediate Metabolizer,-,0.25,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Consider alternative agent. If amitriptyline is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.25) | CYP2C19: Ultrarapid Metabolizer (n/a),Intermediate Metabolizer,-,0.25,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Consider alternative agent. If amitriptyline is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Moderate),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.5) | CYP2C19: Indeterminate (n/a),Intermediate Metabolizer,-,0.5,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,Reduce initial dose to 25% and adjust dosage based on therapeutic drug monitoring. ,-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.5) | CYP2C19: Intermediate Metabolizer (n/a),Intermediate Metabolizer,-,0.5,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,Reduce initial dose to 25% and adjust dosage based on therapeutic drug monitoring.,-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.5) | CYP2C19: Likely Intermediate Metabolizer (n/a),Intermediate Metabolizer,-,0.5,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,Reduce initial dose to 25% and adjust dosage based on therapeutic drug monitoring.,-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.5) | CYP2C19: Likely Poor Metabolizer (n/a),Intermediate Metabolizer,-,0.5,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitriptyline is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Moderate),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.5) | CYP2C19: No Result (n/a),Intermediate Metabolizer,-,0.5,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,Reduce initial dose to 25%. Adjust dosage based on therapeutic drug monitoring. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.,-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Moderate),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.5) | CYP2C19: Normal Metabolizer (n/a),Intermediate Metabolizer,-,0.5,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,Reduce initial dose to 25%. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.5) | CYP2C19: Poor Metabolizer (n/a),Intermediate Metabolizer,-,0.5,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitriptyline is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.5) | CYP2C19: Rapid Metabolizer (n/a),Intermediate Metabolizer,-,0.5,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Consider using an alternative agent. If amitriptyline is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.5) | CYP2C19: Ultrarapid Metabolizer (n/a),Intermediate Metabolizer,-,0.5,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Consider using an alternative agent. If amitriptyline is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Moderate),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.75) | CYP2C19: Indeterminate (n/a),Intermediate Metabolizer,-,0.75,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,Reduce initial dose to 25%. Adjust dosage based on therapeutic drug monitoring. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.,-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.75) | CYP2C19: Intermediate Metabolizer (n/a),Intermediate Metabolizer,-,0.75,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,Reduce initial dose to 25%. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.75) | CYP2C19: Likely Intermediate Metabolizer (n/a),Intermediate Metabolizer,-,0.75,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,Reduce initial dose to 25%. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.75) | CYP2C19: Likely Poor Metabolizer (n/a),Intermediate Metabolizer,-,0.75,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitriptyline is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Moderate),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.75) | CYP2C19: No Result (n/a),Intermediate Metabolizer,-,0.75,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,Reduce initial dose to 25%. Adjust dosage based on therapeutic drug monitoring. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.,-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Moderate),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.75) | CYP2C19: Normal Metabolizer (n/a),Intermediate Metabolizer,-,0.75,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,Reduce initial dose to 25%. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.75) | CYP2C19: Poor Metabolizer (n/a),Intermediate Metabolizer,-,0.75,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitriptyline is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.75) | CYP2C19: Rapid Metabolizer (n/a),Intermediate Metabolizer,-,0.75,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Consider using an alternative agent. If amitriptyline is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.75) | CYP2C19: Ultrarapid Metabolizer (n/a),Intermediate Metabolizer,-,0.75,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Consider using an alternative agent. If amitriptyline is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Moderate),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (1.0) | CYP2C19: Indeterminate (n/a),Intermediate Metabolizer,-,1,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,Reduce initial dose to 25%. Adjust dosage based on therapeutic drug monitoring. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.,-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (1.0) | CYP2C19: Intermediate Metabolizer (n/a),Intermediate Metabolizer,-,1,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,Reduce initial dose to 25%. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (1.0) | CYP2C19: Likely Intermediate Metabolizer (n/a),Intermediate Metabolizer,-,1,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,Reduce initial dose to 25%. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (1.0) | CYP2C19: Likely Poor Metabolizer (n/a),Intermediate Metabolizer,-,1,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitriptyline is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Moderate),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (1.0) | CYP2C19: No Result (n/a),Intermediate Metabolizer,-,1,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,Reduce initial dose to 25%. Adjust dosage based on therapeutic drug monitoring. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.,-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Moderate),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (1.0) | CYP2C19: Normal Metabolizer (n/a),Intermediate Metabolizer,-,1,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,Reduce initial dose to 25%. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (1.0) | CYP2C19: Poor Metabolizer (n/a),Intermediate Metabolizer,-,1,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitriptyline is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (1.0) | CYP2C19: Rapid Metabolizer (n/a),Intermediate Metabolizer,-,1,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Consider using an alternative agent. If amitriptyline is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (1.0) | CYP2C19: Ultrarapid Metabolizer (n/a),Intermediate Metabolizer,-,1,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Consider using an alternative agent. If amitriptyline is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,n/a,CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.25) | CYP2C19: Indeterminate (n/a),Normal Metabolizer,-,1.25,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Normal Exposure,No recommendation,-,-,No recommendation,-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.25) | CYP2C19: Intermediate Metabolizer (n/a),Normal Metabolizer,-,1.25,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Use with Caution,-,‚ö†Ô∏è,Use recommended starting dose.,-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.25) | CYP2C19: Likely Intermediate Metabolizer (n/a),Normal Metabolizer,-,1.25,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Use with Caution,-,‚ö†Ô∏è,Use recommended starting dose.,-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Moderate),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.25) | CYP2C19: Likely Poor Metabolizer (n/a),Normal Metabolizer,-,1.25,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitripyline is warranted, consider 50% reduction of recommended starting dose. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.25) | CYP2C19: No Result (n/a),Normal Metabolizer,-,1.25,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,Use recommended starting dose,-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.25) | CYP2C19: Normal Metabolizer (n/a),Normal Metabolizer,-,1.25,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,Use recommended starting dose,-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Moderate),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.25) | CYP2C19: Poor Metabolizer (n/a),Normal Metabolizer,-,1.25,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitripyline is warranted, consider 50% reduction of recommended starting dose. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.25) | CYP2C19: Rapid Metabolizer (n/a),Normal Metabolizer,-,1.25,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,Consider using an alternative agent. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.25) | CYP2C19: Ultrarapid Metabolizer (n/a),Normal Metabolizer,-,1.25,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,Consider using an alternative agent. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Amitriptyline,Actionable,PSYCHIATRY,n/a,CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.5) | CYP2C19: Indeterminate (n/a),Normal Metabolizer,-,1.5,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Normal Exposure,No recommendation,-,-,No recommendation,-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.5) | CYP2C19: Intermediate Metabolizer (n/a),Normal Metabolizer,-,1.5,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Use with Caution,-,‚ö†Ô∏è,Use recommended starting dose.,-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.5) | CYP2C19: Likely Intermediate Metabolizer (n/a),Normal Metabolizer,-,1.5,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Use with Caution,-,‚ö†Ô∏è,Use recommended starting dose.,-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Moderate),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.5) | CYP2C19: Likely Poor Metabolizer (n/a),Normal Metabolizer,-,1.5,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitripyline is warranted, consider 50% reduction of recommended starting dose. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.5) | CYP2C19: No Result (n/a),Normal Metabolizer,-,1.5,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,Use recommended starting dose,-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.5) | CYP2C19: Normal Metabolizer (n/a),Normal Metabolizer,-,1.5,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,Use recommended starting dose,-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Moderate),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.5) | CYP2C19: Poor Metabolizer (n/a),Normal Metabolizer,-,1.5,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitripyline is warranted, consider 50% reduction of recommended starting dose. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.5) | CYP2C19: Rapid Metabolizer (n/a),Normal Metabolizer,-,1.5,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,Consider using an alternative agent. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.5) | CYP2C19: Ultrarapid Metabolizer (n/a),Normal Metabolizer,-,1.5,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,Consider using an alternative agent. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Amitriptyline,Actionable,PSYCHIATRY,n/a,CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.75) | CYP2C19: Indeterminate (n/a),Normal Metabolizer,-,1.75,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Normal Exposure,No recommendation,-,-,No recommendation,-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.75) | CYP2C19: Intermediate Metabolizer (n/a),Normal Metabolizer,-,1.75,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Use with Caution,-,‚ö†Ô∏è,Use recommended starting dose.,-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.75) | CYP2C19: Likely Intermediate Metabolizer (n/a),Normal Metabolizer,-,1.75,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Use with Caution,-,‚ö†Ô∏è,Use recommended starting dose.,-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Moderate),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.75) | CYP2C19: Likely Poor Metabolizer (n/a),Normal Metabolizer,-,1.75,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitripyline is warranted, consider 50% reduction of recommended starting dose. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.75) | CYP2C19: No Result (n/a),Normal Metabolizer,-,1.75,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,Use recommended starting dose,-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.75) | CYP2C19: Normal Metabolizer (n/a),Normal Metabolizer,-,1.75,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,Use recommended starting dose,-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Moderate),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.75) | CYP2C19: Poor Metabolizer (n/a),Normal Metabolizer,-,1.75,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitripyline is warranted, consider 50% reduction of recommended starting dose. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.75) | CYP2C19: Rapid Metabolizer (n/a),Normal Metabolizer,-,1.75,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,Consider using an alternative agent. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.75) | CYP2C19: Ultrarapid Metabolizer (n/a),Normal Metabolizer,-,1.75,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,Consider using an alternative agent. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Amitriptyline,Actionable,PSYCHIATRY,n/a,CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (2.0) | CYP2C19: Indeterminate (n/a),Normal Metabolizer,-,2,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Normal Exposure,No recommendation,-,-,No recommendation,-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (2.0) | CYP2C19: Intermediate Metabolizer (n/a),Normal Metabolizer,-,2,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Use with Caution,-,‚ö†Ô∏è,Use recommended starting dose.,-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (2.0) | CYP2C19: Likely Intermediate Metabolizer (n/a),Normal Metabolizer,-,2,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Use with Caution,-,‚ö†Ô∏è,Use recommended starting dose.,-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Moderate),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (2.0) | CYP2C19: Likely Poor Metabolizer (n/a),Normal Metabolizer,-,2,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitripyline is warranted, consider 50% reduction of recommended starting dose. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (2.0) | CYP2C19: No Result (n/a),Normal Metabolizer,-,2,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,Use recommended starting dose,-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (2.0) | CYP2C19: Normal Metabolizer (n/a),Normal Metabolizer,-,2,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,Use recommended starting dose,-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Moderate),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (2.0) | CYP2C19: Poor Metabolizer (n/a),Normal Metabolizer,-,2,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitripyline is warranted, consider 50% reduction of recommended starting dose. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (2.0) | CYP2C19: Rapid Metabolizer (n/a),Normal Metabolizer,-,2,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,Consider using an alternative agent. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (2.0) | CYP2C19: Ultrarapid Metabolizer (n/a),Normal Metabolizer,-,2,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,Consider using an alternative agent. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Amitriptyline,Actionable,PSYCHIATRY,n/a,CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (2.25) | CYP2C19: Indeterminate (n/a),Normal Metabolizer,-,2.25,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Normal Exposure,No recommendation,-,-,No recommendation,-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (2.25) | CYP2C19: Intermediate Metabolizer (n/a),Normal Metabolizer,-,2.25,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Use with Caution,-,‚ö†Ô∏è,Use recommended starting dose.,-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (2.25) | CYP2C19: Likely Intermediate Metabolizer (n/a),Normal Metabolizer,-,2.25,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Use with Caution,-,‚ö†Ô∏è,Use recommended starting dose.,-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Moderate),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (2.25) | CYP2C19: Likely Poor Metabolizer (n/a),Normal Metabolizer,-,2.25,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitripyline is warranted, consider 50% reduction of recommended starting dose. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (2.25) | CYP2C19: No Result (n/a),Normal Metabolizer,-,2.25,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,Use recommended starting dose,-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (2.25) | CYP2C19: Normal Metabolizer (n/a),Normal Metabolizer,-,2.25,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,Use recommended starting dose,-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Moderate),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (2.25) | CYP2C19: Poor Metabolizer (n/a),Normal Metabolizer,-,2.25,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitripyline is warranted, consider 50% reduction of recommended starting dose. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (2.25) | CYP2C19: Rapid Metabolizer (n/a),Normal Metabolizer,-,2.25,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,Consider using an alternative agent. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (2.25) | CYP2C19: Ultrarapid Metabolizer (n/a),Normal Metabolizer,-,2.25,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,Consider using an alternative agent. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (2.5) | CYP2C19: Indeterminate (n/a),Ultrarapid Metabolizer,-,2.5,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (2.5) | CYP2C19: Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,2.5,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitriptyline is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (2.5) | CYP2C19: Likely Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,2.5,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitriptyline is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (2.5) | CYP2C19: Likely Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,2.5,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitriptyline is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (2.5) | CYP2C19: No Result (n/a),Ultrarapid Metabolizer,-,2.5,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (2.5) | CYP2C19: Normal Metabolizer (n/a),Ultrarapid Metabolizer,-,2.5,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitriptyline is warranted, titrate to a higher target dose. Adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (2.5) | CYP2C19: Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,2.5,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitriptyline is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (2.5) | CYP2C19: Rapid Metabolizer (n/a),Ultrarapid Metabolizer,-,2.5,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitriptyline is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (2.5) | CYP2C19: Ultrarapid Metabolizer (n/a),Ultrarapid Metabolizer,-,2.5,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitriptyline is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.0) | CYP2C19: Indeterminate (n/a),Ultrarapid Metabolizer,-,‚â•3.0,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.0) | CYP2C19: Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.0,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitriptyline is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.0) | CYP2C19: Likely Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.0,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitriptyline is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.0) | CYP2C19: Likely Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.0,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitriptyline is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.0) | CYP2C19: No Result (n/a),Ultrarapid Metabolizer,-,‚â•3.0,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.0) | CYP2C19: Normal Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.0,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitriptyline is warranted, titrate to a higher target dose. Adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.0) | CYP2C19: Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.0,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitriptyline is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.0) | CYP2C19: Rapid Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.0,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitriptyline is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.0) | CYP2C19: Ultrarapid Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.0,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitriptyline is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (3.0) | CYP2C19: Indeterminate (n/a),Ultrarapid Metabolizer,-,3,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (3.0) | CYP2C19: Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,3,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitriptyline is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (3.0) | CYP2C19: Likely Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,3,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitriptyline is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (3.0) | CYP2C19: Likely Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,3,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitriptyline is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (3.0) | CYP2C19: No Result (n/a),Ultrarapid Metabolizer,-,3,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (3.0) | CYP2C19: Normal Metabolizer (n/a),Ultrarapid Metabolizer,-,3,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitriptyline is warranted, titrate to a higher target dose. Adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (3.0) | CYP2C19: Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,3,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitriptyline is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (3.0) | CYP2C19: Rapid Metabolizer (n/a),Ultrarapid Metabolizer,-,3,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitriptyline is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (3.0) | CYP2C19: Ultrarapid Metabolizer (n/a),Ultrarapid Metabolizer,-,3,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitriptyline is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.25) | CYP2C19: Indeterminate (n/a),Ultrarapid Metabolizer,-,‚â•3.25,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.25) | CYP2C19: Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.25,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitriptyline is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.25) | CYP2C19: Likely Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.25,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitriptyline is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.25) | CYP2C19: Likely Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.25,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitriptyline is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.25) | CYP2C19: No Result (n/a),Ultrarapid Metabolizer,-,‚â•3.25,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.25) | CYP2C19: Normal Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.25,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitriptyline is warranted, titrate to a higher target dose. Adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.25) | CYP2C19: Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.25,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitriptyline is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.25) | CYP2C19: Rapid Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.25,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitriptyline is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.25) | CYP2C19: Ultrarapid Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.25,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitriptyline is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.5) | CYP2C19: Indeterminate (n/a),Ultrarapid Metabolizer,-,‚â•3.5,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.5) | CYP2C19: Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.5,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitriptyline is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.5) | CYP2C19: Likely Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.5,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitriptyline is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.5) | CYP2C19: Likely Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.5,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitriptyline is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.5) | CYP2C19: No Result (n/a),Ultrarapid Metabolizer,-,‚â•3.5,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.5) | CYP2C19: Normal Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.5,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitriptyline is warranted, titrate to a higher target dose. Adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.5) | CYP2C19: Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.5,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitriptyline is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.5) | CYP2C19: Rapid Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.5,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitriptyline is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.5) | CYP2C19: Ultrarapid Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.5,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitriptyline is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (3.5) | CYP2C19: Indeterminate (n/a),Ultrarapid Metabolizer,-,3.5,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (3.5) | CYP2C19: Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,3.5,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitriptyline is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (3.5) | CYP2C19: Likely Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,3.5,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitriptyline is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (3.5) | CYP2C19: Likely Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,3.5,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitriptyline is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (3.5) | CYP2C19: No Result (n/a),Ultrarapid Metabolizer,-,3.5,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (3.5) | CYP2C19: Normal Metabolizer (n/a),Ultrarapid Metabolizer,-,3.5,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitriptyline is warranted, titrate to a higher target dose. Adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (3.5) | CYP2C19: Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,3.5,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitriptyline is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (3.5) | CYP2C19: Rapid Metabolizer (n/a),Ultrarapid Metabolizer,-,3.5,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitriptyline is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (3.5) | CYP2C19: Ultrarapid Metabolizer (n/a),Ultrarapid Metabolizer,-,3.5,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitriptyline is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•4.0) | CYP2C19: Indeterminate (n/a),Ultrarapid Metabolizer,-,‚â•4.0,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•4.0) | CYP2C19: Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•4.0,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitriptyline is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•4.0) | CYP2C19: Likely Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•4.0,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitriptyline is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•4.0) | CYP2C19: Likely Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•4.0,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitriptyline is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•4.0) | CYP2C19: No Result (n/a),Ultrarapid Metabolizer,-,‚â•4.0,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•4.0) | CYP2C19: Normal Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•4.0,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitriptyline is warranted, titrate to a higher target dose. Adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•4.0) | CYP2C19: Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•4.0,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitriptyline is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•4.0) | CYP2C19: Rapid Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•4.0,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitriptyline is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•4.0) | CYP2C19: Ultrarapid Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•4.0,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitriptyline is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (4.0) | CYP2C19: Indeterminate (n/a),Ultrarapid Metabolizer,-,4,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (4.0) | CYP2C19: Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,4,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitriptyline is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (4.0) | CYP2C19: Likely Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,4,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitriptyline is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (4.0) | CYP2C19: Likely Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,4,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitriptyline is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (4.0) | CYP2C19: No Result (n/a),Ultrarapid Metabolizer,-,4,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (4.0) | CYP2C19: Normal Metabolizer (n/a),Ultrarapid Metabolizer,-,4,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitriptyline is warranted, titrate to a higher target dose. Adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (4.0) | CYP2C19: Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,4,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitriptyline is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (4.0) | CYP2C19: Rapid Metabolizer (n/a),Ultrarapid Metabolizer,-,4,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitriptyline is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (4.0) | CYP2C19: Ultrarapid Metabolizer (n/a),Ultrarapid Metabolizer,-,4,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitriptyline is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•4.5) | CYP2C19: Indeterminate (n/a),Ultrarapid Metabolizer,-,‚â•4.5,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•4.5) | CYP2C19: Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•4.5,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitriptyline is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•4.5) | CYP2C19: Likely Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•4.5,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitriptyline is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•4.5) | CYP2C19: Likely Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•4.5,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitriptyline is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•4.5) | CYP2C19: No Result (n/a),Ultrarapid Metabolizer,-,‚â•4.5,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•4.5) | CYP2C19: Normal Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•4.5,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitriptyline is warranted, titrate to a higher target dose. Adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•4.5) | CYP2C19: Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•4.5,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitriptyline is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•4.5) | CYP2C19: Rapid Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•4.5,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitriptyline is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•4.5) | CYP2C19: Ultrarapid Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•4.5,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitriptyline is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•5.0) | CYP2C19: Indeterminate (n/a),Ultrarapid Metabolizer,-,‚â•5.0,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•5.0) | CYP2C19: Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•5.0,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitriptyline is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•5.0) | CYP2C19: Likely Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•5.0,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitriptyline is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•5.0) | CYP2C19: Likely Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•5.0,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitriptyline is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•5.0) | CYP2C19: No Result (n/a),Ultrarapid Metabolizer,-,‚â•5.0,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•5.0) | CYP2C19: Normal Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•5.0,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitriptyline is warranted, titrate to a higher target dose. Adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•5.0) | CYP2C19: Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•5.0,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitriptyline is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•5.0) | CYP2C19: Rapid Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•5.0,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitriptyline is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•5.0) | CYP2C19: Ultrarapid Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•5.0,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitriptyline is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•6.0) | CYP2C19: Indeterminate (n/a),Ultrarapid Metabolizer,-,‚â•6.0,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•6.0) | CYP2C19: Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•6.0,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitriptyline is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•6.0) | CYP2C19: Likely Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•6.0,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitriptyline is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•6.0) | CYP2C19: Likely Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•6.0,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitriptyline is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•6.0) | CYP2C19: No Result (n/a),Ultrarapid Metabolizer,-,‚â•6.0,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•6.0) | CYP2C19: Normal Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•6.0,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitriptyline is warranted, titrate to a higher target dose. Adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•6.0) | CYP2C19: Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•6.0,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitriptyline is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•6.0) | CYP2C19: Rapid Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•6.0,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitriptyline is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•6.0) | CYP2C19: Ultrarapid Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•6.0,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid amitriptyline use. If amitriptyline is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,n/a,CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Indeterminate (n/a) | CYP2C19: Indeterminate (n/a),Indeterminate,-,n/a,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,No recommendation,No recommendation,-,-,No recommendation,-,-,-
Amitriptyline,Actionable,PSYCHIATRY,n/a,CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Indeterminate (n/a) | CYP2C19: Intermediate Metabolizer (n/a),Indeterminate,-,n/a,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,No recommendation,-,-,No recommendation,-,-,-
Amitriptyline,Actionable,PSYCHIATRY,n/a,CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Indeterminate (n/a) | CYP2C19: Likely Intermediate Metabolizer (n/a),Indeterminate,-,n/a,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,No recommendation,-,-,No recommendation,-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Moderate),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Indeterminate (n/a) | CYP2C19: Likely Poor Metabolizer (n/a),Indeterminate,-,n/a,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tertiary amine use. Consider alternative agents: Secondary amines nortriptyline and desipramine. If tertiary amine is warranted, reduce initial dose to 50%. Adjust dosage based on therapeutic drug monitoting. ",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,n/a,CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Indeterminate (n/a) | CYP2C19: No Result (n/a),Indeterminate,-,n/a,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,No recommendation,No recommendation,-,-,No recommendation,-,-,-
Amitriptyline,Actionable,PSYCHIATRY,n/a,CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Indeterminate (n/a) | CYP2C19: Normal Metabolizer (n/a),Indeterminate,-,n/a,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Normal Exposure,No recommendation,-,-,No recommendation,-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Moderate),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Indeterminate (n/a) | CYP2C19: Poor Metabolizer (n/a),Indeterminate,-,n/a,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tertiary amine use. Consider alternative agents: Secondary amines nortriptyline and desipramine. If tertiary amine is warranted, reduce initial dose to 50%. Adjust dosage based on therapeutic drug monitoting.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Indeterminate (n/a) | CYP2C19: Rapid Metabolizer (n/a),Indeterminate,-,n/a,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tertiary amine use. Consider alternative agents: Secondary amines nortriptyline and desipramine. If tertiary amine is warranted, adjust dosage based on therapeutic drug monitoting.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Indeterminate (n/a) | CYP2C19: Ultrarapid Metabolizer (n/a),Indeterminate,-,n/a,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tertiary amine use. Consider alternative agents: Secondary amines nortriptyline and desipramine. If tertiary amine is warranted, adjust dosage based on therapeutic drug monitoting.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,n/a,CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: No Result | CYP2C19: Indeterminate (n/a),No Result,-,n/a,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,No recommendation,No recommendation,-,-,No recommendation,-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: No Result | CYP2C19: Intermediate Metabolizer (n/a),No Result,-,n/a,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Use with Caution,-,‚ö†Ô∏è,Use recommended starting dose.,-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: No Result | CYP2C19: Likely Intermediate Metabolizer (n/a),No Result,-,n/a,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Use with Caution,-,‚ö†Ô∏è,Use recommended starting dose.,-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Moderate),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: No Result | CYP2C19: Likely Poor Metabolizer (n/a),No Result,-,n/a,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tertiary amine use. Consider alternative agents: Secondary amines nortriptyline and desipramine. If tertiary amine is warranted, reduce initial dose to 50%. Adjust dosage based on therapeutic drug monitoting.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: No Result | CYP2C19: Normal Metabolizer (n/a),No Result,-,n/a,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Normal Exposure,Use with Caution,-,‚ö†Ô∏è,Use recommended starting dose,-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Moderate),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: No Result | CYP2C19: Poor Metabolizer (n/a),No Result,-,n/a,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tertiary amine use. Consider alternative agents: Secondary amines nortriptyline and desipramine. If tertiary amine is warranted, reduce initial dose to 50%. Adjust dosage based on therapeutic drug monitoting. ",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: No Result | CYP2C19: Rapid Metabolizer (n/a),No Result,-,n/a,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tertiary amine use. Consider alternative agents: Secondary amines nortriptyline and desipramine. If tertiary amine is warranted, adjust dosage based on therapeutic drug monitoting.",-,-,-
Amitriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: No Result | CYP2C19: Ultrarapid Metabolizer (n/a),No Result,-,n/a,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tertiary amine use. Consider alternative agents: Secondary amines nortriptyline and desipramine. If tertiary amine is warranted, adjust dosage based on therapeutic drug monitoting.",-,-,-
Asenapine,Actionable,PSYCHIATRY,Level 2A,CYP1A2,Yes,CYP1A2,-,-,-,-,Extensive Metabolizer,Extensive Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Asenapine,Actionable,PSYCHIATRY,Level 2A,CYP1A2,Yes,CYP1A2,-,-,-,-,High Inducibility,High Inducibility,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure,Use with caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Asenapine,Actionable,PSYCHIATRY,Level 2A,CYP1A2,Yes,CYP1A2,-,-,-,-,Slow metabolizers; *1C heterozygous,Slow metabolizers,*1C Heterozygous,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Asenapine,Actionable,PSYCHIATRY,Level 2A,CYP1A2,Yes,CYP1A2,-,-,-,-,Intermediate metabolizer,Intermediate metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Asenapine,Actionable,PSYCHIATRY,Level 2A,CYP1A2,Yes,CYP1A2,-,-,-,-,Slow metabolizers; *1C Homozygous,Slow metabolizers,*1C Homozygous,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Asenapine,Actionable,PSYCHIATRY,Level 2A,CYP1A2,Yes,CYP1A2,-,-,-,-,Poor metabolizer,Poor metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Atomoxetine,Actionable,PSYCHIATRY,Level 1A(Moderate),CYP2D6,Yes,CYP2D6,-,-,Professional guideline; FDA evidence,CPIC; DPWG,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure; Increased Risk of ADR,Increased Caution/Avoid,Toxicity/Efficacy,üõë,"Start with a dose of 40 mg/day and if no clinical response and in the absence of adverse events after 2 weeks increase dose to 80 mg/day. If response is inadequate after 2 weeks, consider obtaining a plasma concentration 2 to 4 hours after dosing. If concentration is <200 ng/mL, consider a proportional dose increase to achieve a concentration to approach 400 ng/mL. If unacceptable side effects are present at any time, consider a reduction in dose.",-,-,-
Atomoxetine,Actionable,PSYCHIATRY,Level 1A(Moderate),CYP2D6,Yes,CYP2D6,-,-,Professional guideline; FDA evidence,CPIC; DPWG,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure; Increased Risk of ADR,Increased Caution/Avoid,Toxicity/Efficacy,üõë,"Start at 40 mg/day and if no response or adverse events after 2 weeks, increase to 80 mg/day; if inadequate response after 2 weeks, assess plasma concentration at 2-4 hours post-dose and if <200 ng/mL, consider proportional dose increase to approach 400 ng/mL; adjust dose if unacceptable side effects occur.",-,-,-
Atomoxetine,Actionable,PSYCHIATRY,Level 1A(Moderate),CYP2D6,Yes,CYP2D6,-,-,Professional guideline; FDA evidence,CPIC; DPWG,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure; Increased Risk of ADR,Increased Caution/Avoid,Toxicity/Efficacy,üõë,"Start at 40 mg/day and if no response or adverse events after 2 weeks, increase to 80 mg/day; if inadequate response after 2 weeks, assess plasma concentration at 2-4 hours post-dose and if <200 ng/mL, consider proportional dose increase to approach 400 ng/mL; adjust dose if unacceptable side effects occur.",-,-,-
Atomoxetine,Actionable,PSYCHIATRY,Level 1A(Moderate),CYP2D6,Yes,CYP2D6,-,-,Professional guideline; FDA evidence,CPIC; DPWG,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure; Increased Risk of ADR,Increased Caution/Avoid,Toxicity/Efficacy,üõë,"Start at 40 mg/day and if no response or adverse events after 2 weeks, increase to 80 mg/day; if inadequate response after 2 weeks, assess plasma concentration at 2-4 hours post-dose and if <200 ng/mL, consider proportional dose increase to approach 400 ng/mL; adjust dose if unacceptable side effects occur.",-,-,-
Atomoxetine,Actionable,PSYCHIATRY,Level 1A(Moderate),CYP2D6,Yes,CYP2D6,-,-,Professional guideline; FDA evidence,CPIC; DPWG,Intermediate Metabolizer (1) (no *10 allele present),Intermediate Metabolizer,-,1,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure; Increased Risk of ADR,Use with Caution,Efficacy,‚ö†Ô∏è,"Start with a daily dose of 40 mg, increase to 80 mg after 3 days, and if there's no response or adverse events after 2 weeks, consider increasing to 100 mg; if no response after 2 weeks, assess peak plasma concentration and consider a proportional dose increase to achieve a target concentration of 400 ng/mL if below 200 ng/mL, as doses higher than 100 mg/day may be necessary.",-,-,-
Atomoxetine,Actionable,PSYCHIATRY,Level 1A(Moderate),CYP2D6,Yes,CYP2D6,-,-,Professional guideline; FDA evidence,CPIC; DPWG,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,"Start with a daily dose of 40 mg, increase to 80 mg after 3 days, and if there's no response or adverse events after 2 weeks, consider increasing to 100 mg; if no response after 2 weeks, assess peak plasma concentration and consider a proportional dose increase to achieve a target concentration of 400 ng/mL if below 200 ng/mL, as doses higher than 100 mg/day may be necessary.",-,-,-
Atomoxetine,Actionable,PSYCHIATRY,Level 1A(Moderate),CYP2D6,Yes,CYP2D6,-,-,Professional guideline; FDA evidence,CPIC; DPWG,Ultrarapid Metabolizer (>2),Ultrarapid Metabolizer,-,>2,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure,Use with Caution,Efficacy,‚ö†Ô∏è,"Start with a daily dose of 40 mg, increase to 80 mg after 3 days, and if there's no response or adverse events after 2 weeks, consider increasing to 100 mg; if no response after 2 weeks, assess peak plasma concentration and consider a proportional dose increase to achieve a target concentration of 400 ng/mL if below 200 ng/mL, as doses higher than 100 mg/day may be necessary.",-,-,-
Atomoxetine,Actionable,PSYCHIATRY,n/a,CYP2D6,Yes,CYP2D6,-,-,Professional guideline; FDA evidence,CPIC; DPWG,Indeterminate,Indeterminate,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,n/a,No recommendation,-,-,No recommendation,-,-,-
Brexpiprazole,Actionable,PSYCHIATRY,Level 1A,CYP2D6,Yes,CYP2D6,-,-,Professional guideline; FDA evidence,DPWG,Ultrarapid Metabolizer (>2),Ultrarapid Metabolizer,-,>2,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure;  Minimal Evidence for Clinical impact,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Brexpiprazole,Actionable,PSYCHIATRY,Level 1A,CYP2D6,Yes,CYP2D6,-,-,Professional guideline; FDA evidence,DPWG,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Brexpiprazole,Actionable,PSYCHIATRY,Level 1A,CYP2D6,Yes,CYP2D6,-,-,Professional guideline; FDA evidence,DPWG,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure;  Minimal Evidence for Clinical impact,Use with Caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Brexpiprazole,Actionable,PSYCHIATRY,Level 1A,CYP2D6,Yes,CYP2D6,-,-,Professional guideline; FDA evidence,DPWG,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Risk of ADR,Increased Caution/Avoid,Toxicity,üõë,Use half of the normal dose [DPWG],-,-,-
Bupropion,Actionable,PSYCHIATRY,Level 2B,CYP2B6,Yes,CYP2B6,-,-,FDA evidence,-,Indeterminate,Indeterminate,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,na,-,-,-,-,-,-,-
Bupropion,Actionable,PSYCHIATRY,Level 2B,CYP2B6,Yes,CYP2B6,-,-,FDA evidence,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Bupropion,Actionable,PSYCHIATRY,Level 2B,CYP2B6,Yes,CYP2B6,-,-,FDA evidence,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Bupropion,Actionable,PSYCHIATRY,Level 2B,CYP2B6,Yes,CYP2B6,-,-,FDA evidence,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Bupropion,Actionable,PSYCHIATRY,Level 2B,CYP2B6,Yes,CYP2B6,-,-,FDA evidence,-,Rapid Metabolizer,Rapid Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Bupropion,Actionable,PSYCHIATRY,Level 2B,CYP2B6,Yes,CYP2B6,-,-,FDA evidence,-,Ultrarapid Metabolizer,Ultrarapid Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Buspirone,Actionable,PSYCHIATRY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Buspirone,Actionable,PSYCHIATRY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal evidence for PK and Clinical effect,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Buspirone,Actionable,PSYCHIATRY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal evidence for PK and Clinical effect,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Cariprazine,Actionable,PSYCHIATRY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,FDA evidence,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,"Cariprazine is primarily metabolised by CYP3A4. FDA label notes that CYP2D6 poor metabolizer status does not have a clinically relevant effect on cariprazine pharmacokinetics. So, CYP2D6 hasn't been used for recommendation purposes."
Cariprazine,Actionable,PSYCHIATRY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,FDA evidence,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,-,‚ö†Ô∏è,-,-,-,"Cariprazine is primarily metabolised by CYP3A4. FDA label notes that CYP2D6 poor metabolizer status does not have a clinically relevant effect on cariprazine pharmacokinetics. So, CYP2D6 hasn't been used for recommendation purposes."
Cariprazine,Actionable,PSYCHIATRY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,FDA evidence,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,-,‚ö†Ô∏è,-,-,-,"Cariprazine is primarily metabolised by CYP3A4. FDA label notes that CYP2D6 poor metabolizer status does not have a clinically relevant effect on cariprazine pharmacokinetics. So, CYP2D6 hasn't been used for recommendation purposes."
Chlorpromazine,Actionable,PSYCHIATRY,Level 2A,CYP1A2,Yes,CYP1A2,-,-,-,-,Extensive Metabolizer,Extensive Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Chlorpromazine,Actionable,PSYCHIATRY,Level 2A,CYP1A2,Yes,CYP1A2,-,-,-,-,High Inducibility,High Inducibility,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Chlorpromazine,Actionable,PSYCHIATRY,Level 2A,CYP1A2,Yes,CYP1A2,-,-,-,-,Slow metabolizers; *1C heterozygous,Slow metabolizers,*1C Heterozygous,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Chlorpromazine,Actionable,PSYCHIATRY,Level 2A,CYP1A2,Yes,CYP1A2,-,-,-,-,Intermediate metabolizer,Intermediate metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Chlorpromazine,Actionable,PSYCHIATRY,Level 2A,CYP1A2,Yes,CYP1A2,-,-,-,-,Slow metabolizers; *1C Homozygous,Slow metabolizers,*1C Homozygous,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Citalopram,Actionable,PSYCHIATRY,-,CYP2C19 + HTR2A,No,CYP2C19,HTR2A,-,Professional guideline; FDA evidence,CPIC; DPWG,"CYP2C19: Indeterminate + rs7997012, AA",Indeterminate,-,-,-,-,-,-,-,-,-,-,-,-,-,"rs7997012, AA",-,-,-,-,n/a,-,n/a,-,No recommendation,-,-,-
Citalopram,Actionable,PSYCHIATRY,Level 1A(Moderate)+ Level 3,CYP2C19 + HTR2A,No,CYP2C19,HTR2A,-,Professional guideline; FDA evidence,CPIC; DPWG,"CYP2C19: Intermediate Metabolizer + rs7997012, AA",Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,"rs7997012, AA",-,-,-,-,Increased Exposure; Minimal evidence for clinical impact,Use with Caution,Efficacy,‚ö†Ô∏è,Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose than normal metabolizers.,-,-,-
Citalopram,Actionable,PSYCHIATRY,Level 1A(Moderate)+ Level 3,CYP2C19 + HTR2A,No,CYP2C19,HTR2A,-,Professional guideline; FDA evidence,CPIC; DPWG,"CYP2C19: Likely Intermediate Metabolizer + rs7997012, AA",Likely Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,"rs7997012, AA",-,-,-,-,Increased Exposure; Minimal evidence for clinical impact,Use with Caution,Efficacy,‚ö†Ô∏è,Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose than normal metabolizers.,-,-,-
Citalopram,Actionable,PSYCHIATRY,Level 1A(Strong)+ Level 3,CYP2C19 + HTR2A,No,CYP2C19,HTR2A,-,Professional guideline; FDA evidence,CPIC; DPWG,"CYP2C19: Likely Poor Metabolizer + rs7997012, AA",Likely Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,"rs7997012, AA",-,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Consider a clinically appropriate antidepressant not predominantly metabolized by CYP2C19. If citalopram or escitalopram are clinically appropriate, consider a lower starting dose, slower titration schedule and 50% reduction of the standard maintenance dose as compared to normal metabolizers.",-,-,-
Citalopram,Actionable,PSYCHIATRY,Level 1A(Strong)+ Level 3,CYP2C19 + HTR2A,No,CYP2C19,HTR2A,-,Professional guideline; FDA evidence,CPIC; DPWG,"CYP2C19: Normal Metabolizer + rs7997012, AA",Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,"rs7997012, AA",-,-,-,-,Normal Exposure,Use as Directed,PK/Toxicity/Efficacy,‚úÖ,Initiate therapy with recommended starting dose,-,-,-
Citalopram,Actionable,PSYCHIATRY,Level 1A(Strong)+ Level 3,CYP2C19 + HTR2A,No,CYP2C19,HTR2A,-,Professional guideline; FDA evidence,CPIC; DPWG,"CYP2C19: Poor Metabolizer + rs7997012, AA",Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,"rs7997012, AA",-,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Consider a clinically appropriate antidepressant not predominantly metabolized by CYP2C19. If citalopram or escitalopram are clinically appropriate, consider a lower starting dose, slower titration schedule and 50% reduction of the standard maintenance dose as compared to normal metabolizers.",-,-,-
Citalopram,Actionable,PSYCHIATRY,Level 1A(Optional)+ Level 3,CYP2C19 + HTR2A,No,CYP2C19,HTR2A,-,Professional guideline; FDA evidence,CPIC; DPWG,"CYP2C19: Rapid Metabolizer + rs7997012, AA",Rapid Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,"rs7997012, AA",-,-,-,-,Decreased Exposure,Use with Caution,Efficacy,‚ö†Ô∏è,"Initiate therapy with recommended starting dose. If patient does not adequately respond to recommended maintenance dosing, consider titrating to a higher maintenance dose or switching to a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.",-,-,-
Citalopram,Actionable,PSYCHIATRY,Level 1A(Strong)+ Level 3,CYP2C19 + HTR2A,No,CYP2C19,HTR2A,-,Professional guideline; FDA evidence,CPIC; DPWG,"CYP2C19: Ultrarapid Metabolizer + rs7997012, AA",Ultrarapid Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,"rs7997012, AA",-,-,-,-,Decreased Exposure,Increased Caution/Avoid,Efficacy,üõë,"Consider a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19. If citalopram or escitalopram are clinically appropriate, and adequate efficacy is not achieved at standard maintenance dosing, consider titrating to a higher maintenance dose.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Poor Metabolizer (0.0) | CYP2C19: Indeterminate (n/a),Poor Metabolizer,-,0,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, reduce initial dose to 50%. Adjust dosage based on therapeutic drug monitoring. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Poor Metabolizer (0.0) | CYP2C19: Intermediate Metabolizer (n/a),Poor Metabolizer,-,0,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, consider 50% reduction of recommended starting dose. Adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Poor Metabolizer (0.0) | CYP2C19: Likely Intermediate Metabolizer (n/a),Poor Metabolizer,-,0,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, consider 50% reduction of recommended starting dose. Adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Poor Metabolizer (0.0) | CYP2C19: Likely Poor Metabolizer (n/a),Poor Metabolizer,-,0,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Poor Metabolizer (0.0) | CYP2C19: No Result (n/a),Poor Metabolizer,-,0,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, reduce initial dose to 50%. Adjust dosage based on therapeutic drug monitoring. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Poor Metabolizer (0.0) | CYP2C19: Normal Metabolizer (n/a),Poor Metabolizer,-,0,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, reduce initial dose to 50%. Adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Poor Metabolizer (0.0) | CYP2C19: Poor Metabolizer (n/a),Poor Metabolizer,-,0,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Poor Metabolizer (0.0) | CYP2C19: Rapid Metabolizer (n/a),Poor Metabolizer,-,0,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Poor Metabolizer (0.0) | CYP2C19: Ultrarapid Metabolizer (n/a),Poor Metabolizer,-,0,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.25) | CYP2C19: Indeterminate (n/a),Intermediate Metabolizer,-,0.25,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,Reduce initial dose to 25%. Adjust dosage based on therapeutic drug monitoring. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.,-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.25) | CYP2C19: Intermediate Metabolizer (n/a),Intermediate Metabolizer,-,0.25,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,Reduce initial dose to 25%. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.25) | CYP2C19: Likely Intermediate Metabolizer (n/a),Intermediate Metabolizer,-,0.25,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,Reduce initial dose to 25%. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.25) | CYP2C19: Likely Poor Metabolizer (n/a),Intermediate Metabolizer,-,0.25,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.25) | CYP2C19: No Result (n/a),Intermediate Metabolizer,-,0.25,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,Reduce initial dose to 25%. Adjust dosage based on therapeutic drug monitoring. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.,-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.25) | CYP2C19: Normal Metabolizer (n/a),Intermediate Metabolizer,-,0.25,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,Reduce initial dose to 25%. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.25) | CYP2C19: Poor Metabolizer (n/a),Intermediate Metabolizer,-,0.25,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.25) | CYP2C19: Rapid Metabolizer (n/a),Intermediate Metabolizer,-,0.25,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Consider using an alternative agent. If clomipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.25) | CYP2C19: Ultrarapid Metabolizer (n/a),Intermediate Metabolizer,-,0.25,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Consider using an alternative agent. If clomipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.5) | CYP2C19: Indeterminate (n/a),Intermediate Metabolizer,-,0.5,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,Reduce initial dose to 25%. Adjust dosage based on therapeutic drug monitoring. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.,-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.5) | CYP2C19: Intermediate Metabolizer (n/a),Intermediate Metabolizer,-,0.5,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,Reduce initial dose to 25%. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.5) | CYP2C19: Likely Intermediate Metabolizer (n/a),Intermediate Metabolizer,-,0.5,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,Reduce initial dose to 25%. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.5) | CYP2C19: Likely Poor Metabolizer (n/a),Intermediate Metabolizer,-,0.5,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.5) | CYP2C19: No Result (n/a),Intermediate Metabolizer,-,0.5,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,Reduce initial dose to 25%. Adjust dosage based on therapeutic drug monitoring. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.,-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.5) | CYP2C19: Normal Metabolizer (n/a),Intermediate Metabolizer,-,0.5,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,Reduce initial dose to 25%. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.5) | CYP2C19: Poor Metabolizer (n/a),Intermediate Metabolizer,-,0.5,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.5) | CYP2C19: Rapid Metabolizer (n/a),Intermediate Metabolizer,-,0.5,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Consider using an alternative agent. If clomipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.5) | CYP2C19: Ultrarapid Metabolizer (n/a),Intermediate Metabolizer,-,0.5,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Consider using an alternative agent. If clomipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.75) | CYP2C19: Indeterminate (n/a),Intermediate Metabolizer,-,0.75,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,Reduce initial dose to 25%. Adjust dosage based on therapeutic drug monitoring. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.,-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.75) | CYP2C19: Intermediate Metabolizer (n/a),Intermediate Metabolizer,-,0.75,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,Reduce initial dose to 25%. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.75) | CYP2C19: Likely Intermediate Metabolizer (n/a),Intermediate Metabolizer,-,0.75,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,Reduce initial dose to 25%. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.75) | CYP2C19: Likely Poor Metabolizer (n/a),Intermediate Metabolizer,-,0.75,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.75) | CYP2C19: No Result (n/a),Intermediate Metabolizer,-,0.75,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,Reduce initial dose to 25%. Adjust dosage based on therapeutic drug monitoring. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.,-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.75) | CYP2C19: Normal Metabolizer (n/a),Intermediate Metabolizer,-,0.75,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,Reduce initial dose to 25%. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.75) | CYP2C19: Poor Metabolizer (n/a),Intermediate Metabolizer,-,0.75,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.75) | CYP2C19: Rapid Metabolizer (n/a),Intermediate Metabolizer,-,0.75,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Consider using an alternative agent. If clomipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.75) | CYP2C19: Ultrarapid Metabolizer (n/a),Intermediate Metabolizer,-,0.75,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Consider using an alternative agent. If clomipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (1.0) | CYP2C19: Indeterminate (n/a),Intermediate Metabolizer,-,1,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,Reduce initial dose to 25%. Adjust dosage based on therapeutic drug monitoring. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.,-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (1.0) | CYP2C19: Intermediate Metabolizer (n/a),Intermediate Metabolizer,-,1,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,Reduce initial dose to 25%. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (1.0) | CYP2C19: Likely Intermediate Metabolizer (n/a),Intermediate Metabolizer,-,1,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,Reduce initial dose to 25%. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (1.0) | CYP2C19: Likely Poor Metabolizer (n/a),Intermediate Metabolizer,-,1,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (1.0) | CYP2C19: No Result (n/a),Intermediate Metabolizer,-,1,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,Reduce initial dose to 25%. Adjust dosage based on therapeutic drug monitoring. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.,-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (1.0) | CYP2C19: Normal Metabolizer (n/a),Intermediate Metabolizer,-,1,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,Reduce initial dose to 25%. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (1.0) | CYP2C19: Poor Metabolizer (n/a),Intermediate Metabolizer,-,1,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (1.0) | CYP2C19: Rapid Metabolizer (n/a),Intermediate Metabolizer,-,1,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Consider using an alternative agent. If clomipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (1.0) | CYP2C19: Ultrarapid Metabolizer (n/a),Intermediate Metabolizer,-,1,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Consider using an alternative agent. If clomipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.25) | CYP2C19: Indeterminate (n/a),Normal Metabolizer,-,1.25,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Normal Exposure,No recommendation,-,-,No recommendation,-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.25) | CYP2C19: Intermediate Metabolizer (n/a),Normal Metabolizer,-,1.25,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Use with Caution,-,‚ö†Ô∏è,Use recommended starting dose.,-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.25) | CYP2C19: Likely Intermediate Metabolizer (n/a),Normal Metabolizer,-,1.25,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Use with Caution,-,‚ö†Ô∏è,Use recommended starting dose.,-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.25) | CYP2C19: Likely Poor Metabolizer (n/a),Normal Metabolizer,-,1.25,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, reduce initial dose to 50%. Adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.25) | CYP2C19: No Result (n/a),Normal Metabolizer,-,1.25,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Normal Exposure,-,-,-,Use recommended starting dose,-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.25) | CYP2C19: Normal Metabolizer (n/a),Normal Metabolizer,-,1.25,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,Use recommended starting dose,-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.25) | CYP2C19: Poor Metabolizer (n/a),Normal Metabolizer,-,1.25,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, reduce initial dose to 50%. Adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.25) | CYP2C19: Rapid Metabolizer (n/a),Normal Metabolizer,-,1.25,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,Consider using an alternative agent. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.25) | CYP2C19: Ultrarapid Metabolizer (n/a),Normal Metabolizer,-,1.25,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,Consider using an alternative agent. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.5) | CYP2C19: Indeterminate (n/a),Normal Metabolizer,-,1.5,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Normal Exposure,No recommendation,-,-,No recommendation,-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.5) | CYP2C19: Intermediate Metabolizer (n/a),Normal Metabolizer,-,1.5,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Use with Caution,-,‚ö†Ô∏è,Use recommended starting dose.,-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.5) | CYP2C19: Likely Intermediate Metabolizer (n/a),Normal Metabolizer,-,1.5,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Use with Caution,-,‚ö†Ô∏è,Use recommended starting dose.,-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.5) | CYP2C19: Likely Poor Metabolizer (n/a),Normal Metabolizer,-,1.5,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, reduce initial dose to 50%. Adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.5) | CYP2C19: No Result (n/a),Normal Metabolizer,-,1.5,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Normal Exposure,-,-,-,Use recommended starting dose,-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.5) | CYP2C19: Normal Metabolizer (n/a),Normal Metabolizer,-,1.5,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,Use recommended starting dose,-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.5) | CYP2C19: Poor Metabolizer (n/a),Normal Metabolizer,-,1.5,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, reduce initial dose to 50%. Adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.5) | CYP2C19: Rapid Metabolizer (n/a),Normal Metabolizer,-,1.5,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,Consider using an alternative agent. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.5) | CYP2C19: Ultrarapid Metabolizer (n/a),Normal Metabolizer,-,1.5,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,Consider using an alternative agent. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.75) | CYP2C19: Indeterminate (n/a),Normal Metabolizer,-,1.75,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Normal Exposure,No recommendation,-,-,No recommendation,-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.75) | CYP2C19: Intermediate Metabolizer (n/a),Normal Metabolizer,-,1.75,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Use with Caution,-,‚ö†Ô∏è,Use recommended starting dose.,-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.75) | CYP2C19: Likely Intermediate Metabolizer (n/a),Normal Metabolizer,-,1.75,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Use with Caution,-,‚ö†Ô∏è,Use recommended starting dose.,-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.75) | CYP2C19: Likely Poor Metabolizer (n/a),Normal Metabolizer,-,1.75,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, reduce initial dose to 50%. Adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.75) | CYP2C19: No Result (n/a),Normal Metabolizer,-,1.75,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Normal Exposure,-,-,-,Use recommended starting dose,-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.75) | CYP2C19: Normal Metabolizer (n/a),Normal Metabolizer,-,1.75,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,Use recommended starting dose,-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.75) | CYP2C19: Poor Metabolizer (n/a),Normal Metabolizer,-,1.75,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, reduce initial dose to 50%. Adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.75) | CYP2C19: Rapid Metabolizer (n/a),Normal Metabolizer,-,1.75,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,Consider using an alternative agent. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.75) | CYP2C19: Ultrarapid Metabolizer (n/a),Normal Metabolizer,-,1.75,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,Consider using an alternative agent. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (2.0) | CYP2C19: Indeterminate (n/a),Normal Metabolizer,-,2,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Normal Exposure,No recommendation,-,-,No recommendation,-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (2.0) | CYP2C19: Intermediate Metabolizer (n/a),Normal Metabolizer,-,2,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Use with Caution,-,‚ö†Ô∏è,Use recommended starting dose.,-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (2.0) | CYP2C19: Likely Intermediate Metabolizer (n/a),Normal Metabolizer,-,2,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Use with Caution,-,‚ö†Ô∏è,Use recommended starting dose.,-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (2.0) | CYP2C19: Likely Poor Metabolizer (n/a),Normal Metabolizer,-,2,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, reduce initial dose to 50%. Adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (2.0) | CYP2C19: No Result (n/a),Normal Metabolizer,-,2,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Normal Exposure,-,-,-,Use recommended starting dose,-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (2.0) | CYP2C19: Normal Metabolizer (n/a),Normal Metabolizer,-,2,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,Use recommended starting dose,-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (2.0) | CYP2C19: Poor Metabolizer (n/a),Normal Metabolizer,-,2,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, reduce initial dose to 50%. Adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (2.0) | CYP2C19: Rapid Metabolizer (n/a),Normal Metabolizer,-,2,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,Consider using an alternative agent. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (2.0) | CYP2C19: Ultrarapid Metabolizer (n/a),Normal Metabolizer,-,2,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,Consider using an alternative agent. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (2.25) | CYP2C19: Indeterminate (n/a),Normal Metabolizer,-,2.25,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Normal Exposure,No recommendation,-,-,No recommendation,-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (2.25) | CYP2C19: Intermediate Metabolizer (n/a),Normal Metabolizer,-,2.25,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Use with Caution,-,‚ö†Ô∏è,Use recommended starting dose.,-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (2.25) | CYP2C19: Likely Intermediate Metabolizer (n/a),Normal Metabolizer,-,2.25,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Use with Caution,-,‚ö†Ô∏è,Use recommended starting dose.,-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (2.25) | CYP2C19: Likely Poor Metabolizer (n/a),Normal Metabolizer,-,2.25,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, reduce initial dose to 50%. Adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (2.25) | CYP2C19: No Result (n/a),Normal Metabolizer,-,2.25,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Normal Exposure,-,-,-,Use recommended starting dose,-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (2.25) | CYP2C19: Normal Metabolizer (n/a),Normal Metabolizer,-,2.25,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,Use recommended starting dose,-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (2.25) | CYP2C19: Poor Metabolizer (n/a),Normal Metabolizer,-,2.25,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, reduce initial dose to 50%. Adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (2.25) | CYP2C19: Rapid Metabolizer (n/a),Normal Metabolizer,-,2.25,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,Consider using an alternative agent. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (2.25) | CYP2C19: Ultrarapid Metabolizer (n/a),Normal Metabolizer,-,2.25,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,Consider using an alternative agent. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (2.5) | CYP2C19: Indeterminate (n/a),Ultrarapid Metabolizer,-,2.5,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (2.5) | CYP2C19: Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,2.5,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (2.5) | CYP2C19: Likely Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,2.5,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (2.5) | CYP2C19: Likely Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,2.5,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (2.5) | CYP2C19: No Result (n/a),Ultrarapid Metabolizer,-,2.5,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (2.5) | CYP2C19: Normal Metabolizer (n/a),Ultrarapid Metabolizer,-,2.5,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, titrate to a higher target dose. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (2.5) | CYP2C19: Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,2.5,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (2.5) | CYP2C19: Rapid Metabolizer (n/a),Ultrarapid Metabolizer,-,2.5,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (2.5) | CYP2C19: Ultrarapid Metabolizer (n/a),Ultrarapid Metabolizer,-,2.5,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.0) | CYP2C19: Indeterminate (n/a),Ultrarapid Metabolizer,-,‚â•3.0,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.0) | CYP2C19: Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.0,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.0) | CYP2C19: Likely Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.0,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.0) | CYP2C19: Likely Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.0,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.0) | CYP2C19: No Result (n/a),Ultrarapid Metabolizer,-,‚â•3.0,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.0) | CYP2C19: Normal Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.0,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, titrate to a higher target dose. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.0) | CYP2C19: Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.0,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.0) | CYP2C19: Rapid Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.0,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.0) | CYP2C19: Ultrarapid Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.0,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (3.0) | CYP2C19: Indeterminate (n/a),Ultrarapid Metabolizer,-,3,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (3.0) | CYP2C19: Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,3,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (3.0) | CYP2C19: Likely Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,3,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (3.0) | CYP2C19: Likely Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,3,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (3.0) | CYP2C19: No Result (n/a),Ultrarapid Metabolizer,-,3,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (3.0) | CYP2C19: Normal Metabolizer (n/a),Ultrarapid Metabolizer,-,3,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, titrate to a higher target dose. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (3.0) | CYP2C19: Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,3,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (3.0) | CYP2C19: Rapid Metabolizer (n/a),Ultrarapid Metabolizer,-,3,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (3.0) | CYP2C19: Ultrarapid Metabolizer (n/a),Ultrarapid Metabolizer,-,3,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.25) | CYP2C19: Indeterminate (n/a),Ultrarapid Metabolizer,-,‚â•3.25,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.25) | CYP2C19: Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.25,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.25) | CYP2C19: Likely Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.25,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.25) | CYP2C19: Likely Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.25,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.25) | CYP2C19: No Result (n/a),Ultrarapid Metabolizer,-,‚â•3.25,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.25) | CYP2C19: Normal Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.25,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, titrate to a higher target dose. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.25) | CYP2C19: Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.25,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.25) | CYP2C19: Rapid Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.25,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.25) | CYP2C19: Ultrarapid Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.25,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.5) | CYP2C19: Indeterminate (n/a),Ultrarapid Metabolizer,-,‚â•3.5,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.5) | CYP2C19: Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.5,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.5) | CYP2C19: Likely Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.5,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.5) | CYP2C19: Likely Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.5,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.5) | CYP2C19: No Result (n/a),Ultrarapid Metabolizer,-,‚â•3.5,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.5) | CYP2C19: Normal Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.5,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, titrate to a higher target dose. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.5) | CYP2C19: Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.5,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.5) | CYP2C19: Rapid Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.5,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.5) | CYP2C19: Ultrarapid Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.5,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (3.5) | CYP2C19: Indeterminate (n/a),Ultrarapid Metabolizer,-,3.5,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (3.5) | CYP2C19: Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,3.5,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (3.5) | CYP2C19: Likely Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,3.5,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (3.5) | CYP2C19: Likely Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,3.5,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (3.5) | CYP2C19: No Result (n/a),Ultrarapid Metabolizer,-,3.5,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (3.5) | CYP2C19: Normal Metabolizer (n/a),Ultrarapid Metabolizer,-,3.5,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, titrate to a higher target dose. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (3.5) | CYP2C19: Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,3.5,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (3.5) | CYP2C19: Rapid Metabolizer (n/a),Ultrarapid Metabolizer,-,3.5,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (3.5) | CYP2C19: Ultrarapid Metabolizer (n/a),Ultrarapid Metabolizer,-,3.5,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•4.0) | CYP2C19: Indeterminate (n/a),Ultrarapid Metabolizer,-,‚â•4.0,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•4.0) | CYP2C19: Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•4.0,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•4.0) | CYP2C19: Likely Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•4.0,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•4.0) | CYP2C19: Likely Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•4.0,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•4.0) | CYP2C19: No Result (n/a),Ultrarapid Metabolizer,-,‚â•4.0,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•4.0) | CYP2C19: Normal Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•4.0,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, titrate to a higher target dose. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•4.0) | CYP2C19: Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•4.0,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•4.0) | CYP2C19: Rapid Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•4.0,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•4.0) | CYP2C19: Ultrarapid Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•4.0,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (4.0) | CYP2C19: Indeterminate (n/a),Ultrarapid Metabolizer,-,4,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (4.0) | CYP2C19: Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,4,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (4.0) | CYP2C19: Likely Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,4,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (4.0) | CYP2C19: Likely Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,4,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (4.0) | CYP2C19: No Result (n/a),Ultrarapid Metabolizer,-,4,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (4.0) | CYP2C19: Normal Metabolizer (n/a),Ultrarapid Metabolizer,-,4,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, titrate to a higher target dose. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (4.0) | CYP2C19: Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,4,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (4.0) | CYP2C19: Rapid Metabolizer (n/a),Ultrarapid Metabolizer,-,4,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (4.0) | CYP2C19: Ultrarapid Metabolizer (n/a),Ultrarapid Metabolizer,-,4,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•4.5) | CYP2C19: Indeterminate (n/a),Ultrarapid Metabolizer,-,‚â•4.5,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•4.5) | CYP2C19: Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•4.5,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•4.5) | CYP2C19: Likely Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•4.5,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•4.5) | CYP2C19: Likely Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•4.5,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•4.5) | CYP2C19: No Result (n/a),Ultrarapid Metabolizer,-,‚â•4.5,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•4.5) | CYP2C19: Normal Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•4.5,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, titrate to a higher target dose. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•4.5) | CYP2C19: Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•4.5,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•4.5) | CYP2C19: Rapid Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•4.5,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•4.5) | CYP2C19: Ultrarapid Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•4.5,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•5.0) | CYP2C19: Indeterminate (n/a),Ultrarapid Metabolizer,-,‚â•5.0,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•5.0) | CYP2C19: Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•5.0,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•5.0) | CYP2C19: Likely Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•5.0,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•5.0) | CYP2C19: Likely Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•5.0,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•5.0) | CYP2C19: No Result (n/a),Ultrarapid Metabolizer,-,‚â•5.0,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•5.0) | CYP2C19: Normal Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•5.0,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, titrate to a higher target dose. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•5.0) | CYP2C19: Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•5.0,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•5.0) | CYP2C19: Rapid Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•5.0,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•5.0) | CYP2C19: Ultrarapid Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•5.0,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•6.0) | CYP2C19: Indeterminate (n/a),Ultrarapid Metabolizer,-,‚â•6.0,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•6.0) | CYP2C19: Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•6.0,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•6.0) | CYP2C19: Likely Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•6.0,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•6.0) | CYP2C19: Likely Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•6.0,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•6.0) | CYP2C19: No Result (n/a),Ultrarapid Metabolizer,-,‚â•6.0,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•6.0) | CYP2C19: Normal Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•6.0,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, titrate to a higher target dose. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•6.0) | CYP2C19: Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•6.0,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•6.0) | CYP2C19: Rapid Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•6.0,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•6.0) | CYP2C19: Ultrarapid Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•6.0,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid clomipramine use. If clomipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Indeterminate (n/a) | CYP2C19: Indeterminate (n/a),Indeterminate,-,n/a,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,No recommendation,No recommendation,-,-,No recommendation,-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Indeterminate (n/a) | CYP2C19: Intermediate Metabolizer (n/a),Indeterminate,-,n/a,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Use with Caution,-,‚ö†Ô∏è,No recommendation,-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Indeterminate (n/a) | CYP2C19: Likely Intermediate Metabolizer (n/a),Indeterminate,-,n/a,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Use with Caution,-,‚ö†Ô∏è,No recommendation,-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Indeterminate (n/a) | CYP2C19: Likely Poor Metabolizer (n/a),Indeterminate,-,n/a,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tertiary amine use. Consider alternative agents: Secondary amines nortriptyline and desipramine. If tertiary amine is warranted, reduce initial dose to 50%. Adjust dosage based on therapeutic drug monitoting. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Indeterminate (n/a) | CYP2C19: No Result (n/a),Indeterminate,-,n/a,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,No recommendation,No recommendation,-,-,No recommendation,-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Indeterminate (n/a) | CYP2C19: Normal Metabolizer (n/a),Indeterminate,-,n/a,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Normal Exposure,No recommendation,-,-,No recommendation,-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Indeterminate (n/a) | CYP2C19: Poor Metabolizer (n/a),Indeterminate,-,n/a,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tertiary amine use. Consider alternative agents: Secondary amines nortriptyline and desipramine. If tertiary amine is warranted, reduce initial dose to 50%. Adjust dosage based on therapeutic drug monitoting. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Indeterminate (n/a) | CYP2C19: Rapid Metabolizer (n/a),Indeterminate,-,n/a,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tertiary amine use. Consider alternative agents: Secondary amines nortriptyline and desipramine. If tertiary amine is warranted, adjust dosage based on therapeutic drug monitoting.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Indeterminate (n/a) | CYP2C19: Ultrarapid Metabolizer (n/a),Indeterminate,-,n/a,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tertiary amine use. Consider alternative agents: Secondary amines nortriptyline and desipramine. If tertiary amine is warranted, adjust dosage based on therapeutic drug monitoting.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: No Result (No Result) | CYP2C19: Indeterminate (n/a),No Result,-,n/a,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,No recommendation,No recommendation,-,-,No recommendation,-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: No Result (No Result) | CYP2C19: Intermediate Metabolizer (n/a),No Result,-,n/a,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Use with Caution,-,‚ö†Ô∏è,Use recommended starting dose.,-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: No Result (No Result) | CYP2C19: Likely Intermediate Metabolizer (n/a),No Result,-,n/a,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Use with Caution,-,‚ö†Ô∏è,Use recommended starting dose.,-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: No Result (No Result) | CYP2C19: Likely Poor Metabolizer (n/a),No Result,-,n/a,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tertiary amine use. Consider alternative agents: Secondary amines nortriptyline and desipramine. If tertiary amine is warranted, reduce initial dose to 50%. Adjust dosage based on therapeutic drug monitoting. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: No Result (No Result) | CYP2C19: Normal Metabolizer (n/a),No Result,-,n/a,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Normal Exposure,-,-,-,Use recommended starting dose,-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: No Result (No Result) | CYP2C19: Poor Metabolizer (n/a),No Result,-,n/a,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tertiary amine use. Consider alternative agents: Secondary amines nortriptyline and desipramine. If tertiary amine is warranted, reduce initial dose to 50%. Adjust dosage based on therapeutic drug monitoting. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: No Result (No Result) | CYP2C19: Rapid Metabolizer (n/a),No Result,-,n/a,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tertiary amine use. Consider alternative agents: Secondary amines nortriptyline and desipramine. If tertiary amine is warranted, adjust dosage based on therapeutic drug monitoting.",-,-,-
Clomipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: No Result (No Result) | CYP2C19: Ultrarapid Metabolizer (n/a),No Result,-,n/a,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tertiary amine use. Consider alternative agents: Secondary amines nortriptyline and desipramine. If tertiary amine is warranted, adjust dosage based on therapeutic drug monitoting.",-,-,-
Clozapine,Actionable,PSYCHIATRY,Level 1B,CYP2D6 + HTR2C,No,CYP2D6,HTR2C,-,FDA evidence,DPWG (No Recommendation),"CYP2D6: Ultrarapid Metabolizer (>2) + rs3813929,C",Ultrarapid Metabolizer,-,>2,-,-,-,-,-,-,-,-,-,-,-,"rs3813929,C",-,-,-,-,Decreased Exposure; Minimal Evidence for clinical Impact,Use with Caution,Toxicity,‚ö†Ô∏è,Increased risk of ADR(Weight Gain),-,-,-
Clozapine,Actionable,PSYCHIATRY,Level 1B,CYP2D6 + HTR2C,No,CYP2D6,HTR2C,-,FDA evidence,DPWG (No Recommendation),"CYP2D6: Normal metabolizer (1.5 and 2) + rs3813929,C",Normal metabolizer,-,1.5,2,-,-,-,-,-,-,-,-,-,-,"rs3813929,C",-,-,-,-,Normal Exposure,Use with Caution,Toxicity,‚ö†Ô∏è,Increased risk of ADR(Weight Gain),-,-,-
Clozapine,Actionable,PSYCHIATRY,Level 1B,CYP2D6 + HTR2C,No,CYP2D6,HTR2C,-,FDA evidence,DPWG (No Recommendation),"CYP2D6: Normal metabolizer or Intermediate metabolizer (1 (no *10 allele present)) + rs3813929,C",Normal metabolizer,-,1,-,-,-,-,-,-,-,-,-,-,-,"rs3813929,C",-,-,-,-,Normal Exposure,Use with Caution,Toxicity,‚ö†Ô∏è,Increased risk of ADR(Weight Gain),-,-,-
Clozapine,Actionable,PSYCHIATRY,Level 1B,CYP2D6 + HTR2C,No,CYP2D6,HTR2C,-,FDA evidence,DPWG (No Recommendation),"CYP2D6: Normal metabolizer or Intermediate metabolizer (1 (no *10 allele present)) + rs3813929,C",Intermediate metabolizer,-,1,-,-,-,-,-,-,-,-,-,-,-,"rs3813929,C",-,-,-,-,Normal Exposure,Use with Caution,Toxicity,‚ö†Ô∏è,Increased risk of ADR(Weight Gain),-,-,-
Clozapine,Actionable,PSYCHIATRY,Level 1B,CYP2D6 + HTR2C,No,CYP2D6,HTR2C,-,FDA evidence,DPWG (No Recommendation),"CYP2D6: Normal metabolizer or Intermediate metabolizer (1 (*10 allele present)) + rs3813929,C",Normal metabolizer,*10,1,-,-,-,-,-,-,-,-,-,-,-,"rs3813929,C",-,-,-,-,Normal Exposure,Use with Caution,Toxicity,‚ö†Ô∏è,Increased risk of ADR(Weight Gain),-,-,-
Clozapine,Actionable,PSYCHIATRY,Level 1B,CYP2D6 + HTR2C,No,CYP2D6,HTR2C,-,FDA evidence,DPWG (No Recommendation),"CYP2D6: Normal metabolizer or Intermediate metabolizer (1 (*10 allele present)) + rs3813929,C",Intermediate metabolizer,*10,1,-,-,-,-,-,-,-,-,-,-,-,"rs3813929,C",-,-,-,-,Normal Exposure,Use with Caution,Toxicity,‚ö†Ô∏è,Increased risk of ADR(Weight Gain),-,-,-
Clozapine,Actionable,PSYCHIATRY,Level 1B,CYP2D6 + HTR2C,No,CYP2D6,HTR2C,-,FDA evidence,DPWG (No Recommendation),"CYP2D6: Intermediate metabolizer (0.5) + rs3813929,C",Intermediate metabolizer,-,0.5,-,-,-,-,-,-,-,-,-,-,-,"rs3813929,C",-,-,-,-,Normal Exposure,Use with Caution,Toxicity,‚ö†Ô∏è,Increased risk of ADR(Weight Gain),-,-,-
Clozapine,Actionable,PSYCHIATRY,Level 1B,CYP2D6 + HTR2C,No,CYP2D6,HTR2C,-,FDA evidence,DPWG (No Recommendation),"CYP2D6: Poor metabolizer (0) + rs3813929,C",Poor metabolizer,-,0,-,-,-,-,-,-,-,-,-,-,-,"rs3813929,C",-,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,Increased risk of ADR(Weight Gain); Dosage reductions may be necessary.,-,-,-
Desipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6,Yes,CYP2D6,-,-,Professional guideline; FDA evidence,CPIC,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Avoid tricyclic use. Consider non-CYP2D6-metabolized drug. If a TCA is warranted, consider a 50% reduction of recommended starting dose. ",-,-,-
Desipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6,Yes,CYP2D6,-,-,Professional guideline; FDA evidence,CPIC,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,Use 25% reduction of recommended starting dose. ,-,-,-
Desipramine,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6,Yes,CYP2D6,-,-,Professional guideline; FDA evidence,CPIC,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,Initiate therapy with recommended starting dose,-,-,-
Desipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6,Yes,CYP2D6,-,-,Professional guideline; FDA evidence,CPIC,Ultrarapid Metabolizer (>2),Ultrarapid Metabolizer,-,>2,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure,Increased Caution/Avoid,Efficacy,üõë,"Avoid tricyclic use. Consider non-CYP2D6-metabolized drug. If a TCA is warranted, consider titrating to a higher target dose.",-,-,-
Desipramine,Actionable,PSYCHIATRY,-,CYP2D6,Yes,CYP2D6,-,-,Professional guideline; FDA evidence,CPIC,Indeterminate,Indeterminate,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,n/a,Use as Directed,-,-,No recommendation,-,-,-
Diazepam,Actionable,PSYCHIATRY,Level 1BB,CYP2C19,Yes,CYP2C19,-,-,FDA evidence,-,Ultrarapid Metabolizer,Ultrarapid Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure; Minimal Evidence for clinical Impact,Use with Caution,PK,‚ö†Ô∏è,-,-,-,"The active metabolites of diazepam are formed through N-demethylation, which is primarily mediated by CYP3A4 and CYP2C19 enzymes. Both of these genes are significant and appear to play primary roles. Although CYP2C19 seems to have a greater impact on clinical variations, we have considered it as the primary gene. However, it is advisable to exercise caution and also consider the status of CYP3A4 if it is an intermediate metabolizer (IM) or poor metabolizer (PM), and if CYP2C19 is a normal metabolizer (NM)."
Diazepam,Actionable,PSYCHIATRY,Level 1BB,CYP2C19,Yes,CYP2C19,-,-,FDA evidence,-,Rapid Metabolizer,Rapid Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure; Minimal Evidence for clinical Impact,Use with Caution,PK,‚ö†Ô∏è,-,-,-,"The active metabolites of diazepam are formed through N-demethylation, which is primarily mediated by CYP3A4 and CYP2C19 enzymes. Both of these genes are significant and appear to play primary roles. Although CYP2C19 seems to have a greater impact on clinical variations, we have considered it as the primary gene. However, it is advisable to exercise caution and also consider the status of CYP3A4 if it is an intermediate metabolizer (IM) or poor metabolizer (PM), and if CYP2C19 is a normal metabolizer (NM)."
Diazepam,Actionable,PSYCHIATRY,Level 1BB,CYP2C19,Yes,CYP2C19,-,-,FDA evidence,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,"The active metabolites of diazepam are formed through N-demethylation, which is primarily mediated by CYP3A4 and CYP2C19 enzymes. Both of these genes are significant and appear to play primary roles. Although CYP2C19 seems to have a greater impact on clinical variations, we have considered it as the primary gene. However, it is advisable to exercise caution and also consider the status of CYP3A4 if it is an intermediate metabolizer (IM) or poor metabolizer (PM), and if CYP2C19 is a normal metabolizer (NM)."
Diazepam,Actionable,PSYCHIATRY,Level 1BB,CYP2C19,Yes,CYP2C19,-,-,FDA evidence,-,Likely Intermediate Metabolizer,Likely Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure; Minimal eviidence for clinical impact,Use with Caution,PK,‚ö†Ô∏è,-,-,-,"The active metabolites of diazepam are formed through N-demethylation, which is primarily mediated by CYP3A4 and CYP2C19 enzymes. Both of these genes are significant and appear to play primary roles. Although CYP2C19 seems to have a greater impact on clinical variations, we have considered it as the primary gene. However, it is advisable to exercise caution and also consider the status of CYP3A4 if it is an intermediate metabolizer (IM) or poor metabolizer (PM), and if CYP2C19 is a normal metabolizer (NM)."
Diazepam,Actionable,PSYCHIATRY,Level 1BB,CYP2C19,Yes,CYP2C19,-,-,FDA evidence,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure; Minimal eviidence for clinical impact,Use with Caution,PK,‚ö†Ô∏è,-,-,-,"The active metabolites of diazepam are formed through N-demethylation, which is primarily mediated by CYP3A4 and CYP2C19 enzymes. Both of these genes are significant and appear to play primary roles. Although CYP2C19 seems to have a greater impact on clinical variations, we have considered it as the primary gene. However, it is advisable to exercise caution and also consider the status of CYP3A4 if it is an intermediate metabolizer (IM) or poor metabolizer (PM), and if CYP2C19 is a normal metabolizer (NM)."
Diazepam,Actionable,PSYCHIATRY,Level 1BB,CYP2C19,Yes,CYP2C19,-,-,FDA evidence,-,Likely Poor Metabolizer,Likely Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure; Minimal eviidence for clinical impact,Use with Caution,PK,‚ö†Ô∏è,-,-,-,"The active metabolites of diazepam are formed through N-demethylation, which is primarily mediated by CYP3A4 and CYP2C19 enzymes. Both of these genes are significant and appear to play primary roles. Although CYP2C19 seems to have a greater impact on clinical variations, we have considered it as the primary gene. However, it is advisable to exercise caution and also consider the status of CYP3A4 if it is an intermediate metabolizer (IM) or poor metabolizer (PM), and if CYP2C19 is a normal metabolizer (NM)."
Diazepam,Actionable,PSYCHIATRY,Level 1B,CYP2C19,Yes,CYP2C19,-,-,FDA evidence,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure; Minimal eviidence for clinical impact,Use with Caution,PK,‚ö†Ô∏è,-,-,-,"The active metabolites of diazepam are formed through N-demethylation, which is primarily mediated by CYP3A4 and CYP2C19 enzymes. Both of these genes are significant and appear to play primary roles. Although CYP2C19 seems to have a greater impact on clinical variations, we have considered it as the primary gene. However, it is advisable to exercise caution and also consider the status of CYP3A4 if it is an intermediate metabolizer (IM) or poor metabolizer (PM), and if CYP2C19 is a normal metabolizer (NM)."
Diazepam,Actionable,PSYCHIATRY,-,CYP2C19,Yes,CYP2C19,-,-,FDA evidence,-,Indeterminate,Indeterminate,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,n/a,-,n/a,-,-,-,-,"The active metabolites of diazepam are formed through N-demethylation, which is primarily mediated by CYP3A4 and CYP2C19 enzymes. Both of these genes are significant and appear to play primary roles. Although CYP2C19 seems to have a greater impact on clinical variations, we have considered it as the primary gene. However, it is advisable to exercise caution and also consider the status of CYP3A4 if it is an intermediate metabolizer (IM) or poor metabolizer (PM), and if CYP2C19 is a normal metabolizer (NM)."
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Poor Metabolizer (0.0) | CYP2C19: Indeterminate (n/a),Poor Metabolizer,-,0,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, reduce initial dose to 50%. Adjust dosage based on therapeutic drug monitoting. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Poor Metabolizer (0.0) | CYP2C19: Intermediate Metabolizer (n/a),Poor Metabolizer,-,0,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, consider 50% reduction of recommended starting dose. Adjust dosage based on therapeutic drug monitoring.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Poor Metabolizer (0.0) | CYP2C19: Likely Intermediate Metabolizer (n/a),Poor Metabolizer,-,0,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, consider 50% reduction of recommended starting dose. Adjust dosage based on therapeutic drug monitoring.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Poor Metabolizer (0.0) | CYP2C19: Likely Poor Metabolizer (n/a),Poor Metabolizer,-,0,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Poor Metabolizer (0.0) | CYP2C19: No Result (n/a),Poor Metabolizer,-,0,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, reduce initial dose to 50%. Adjust dosage based on therapeutic drug monitoting. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Poor Metabolizer (0.0) | CYP2C19: Normal Metabolizer (n/a),Poor Metabolizer,-,0,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, reduce initial dose to 50%. Adjust dosage based on therapeutic drug monitoring.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Poor Metabolizer (0.0) | CYP2C19: Poor Metabolizer (n/a),Poor Metabolizer,-,0,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Poor Metabolizer (0.0) | CYP2C19: Rapid Metabolizer (n/a),Poor Metabolizer,-,0,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Poor Metabolizer (0.0) | CYP2C19: Ultrarapid Metabolizer (n/a),Poor Metabolizer,-,0,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.25) | CYP2C19: Indeterminate (n/a),Intermediate Metabolizer,-,0.25,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,Reduce initial dose to 25%. Adjust dosage based on therapeutic drug monitoring. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.,-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.25) | CYP2C19: Intermediate Metabolizer (n/a),Intermediate Metabolizer,-,0.25,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,Reduce initial dose to 25%. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.25) | CYP2C19: Likely Intermediate Metabolizer (n/a),Intermediate Metabolizer,-,0.25,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,Reduce initial dose to 25%. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.25) | CYP2C19: Likely Poor Metabolizer (n/a),Intermediate Metabolizer,-,0.25,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.25) | CYP2C19: No Result (n/a),Intermediate Metabolizer,-,0.25,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,Reduce initial dose to 25%. Adjust dosage based on therapeutic drug monitoring. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.,-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.25) | CYP2C19: Normal Metabolizer (n/a),Intermediate Metabolizer,-,0.25,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,Reduce initial dose to 25%. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.25) | CYP2C19: Poor Metabolizer (n/a),Intermediate Metabolizer,-,0.25,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.25) | CYP2C19: Rapid Metabolizer (n/a),Intermediate Metabolizer,-,0.25,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Consider using an alternative agent. If doxepin is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.25) | CYP2C19: Ultrarapid Metabolizer (n/a),Intermediate Metabolizer,-,0.25,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Consider using an alternative agent. If doxepin is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.5) | CYP2C19: Indeterminate (n/a),Intermediate Metabolizer,-,0.5,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,Reduce initial dose to 25%. Adjust dosage based on therapeutic drug monitoring. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.,-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.5) | CYP2C19: Intermediate Metabolizer (n/a),Intermediate Metabolizer,-,0.5,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,Reduce initial dose to 25%. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.5) | CYP2C19: Likely Intermediate Metabolizer (n/a),Intermediate Metabolizer,-,0.5,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,Reduce initial dose to 25%. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.5) | CYP2C19: Likely Poor Metabolizer (n/a),Intermediate Metabolizer,-,0.5,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.5) | CYP2C19: No Result (n/a),Intermediate Metabolizer,-,0.5,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,Reduce initial dose to 25%. Adjust dosage based on therapeutic drug monitoring. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.,-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.5) | CYP2C19: Normal Metabolizer (n/a),Intermediate Metabolizer,-,0.5,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,Reduce initial dose to 25%. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.5) | CYP2C19: Poor Metabolizer (n/a),Intermediate Metabolizer,-,0.5,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.5) | CYP2C19: Rapid Metabolizer (n/a),Intermediate Metabolizer,-,0.5,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Consider using an alternative agent. If doxepin is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.5) | CYP2C19: Ultrarapid Metabolizer (n/a),Intermediate Metabolizer,-,0.5,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Consider using an alternative agent. If doxepin is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.75) | CYP2C19: Indeterminate (n/a),Intermediate Metabolizer,-,0.75,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,Reduce initial dose to 25%. Adjust dosage based on therapeutic drug monitoring. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.,-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.75) | CYP2C19: Intermediate Metabolizer (n/a),Intermediate Metabolizer,-,0.75,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,Reduce initial dose to 25%. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.75) | CYP2C19: Likely Intermediate Metabolizer (n/a),Intermediate Metabolizer,-,0.75,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,Reduce initial dose to 25%. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.75) | CYP2C19: Likely Poor Metabolizer (n/a),Intermediate Metabolizer,-,0.75,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.75) | CYP2C19: No Result (n/a),Intermediate Metabolizer,-,0.75,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,Reduce initial dose to 25%. Adjust dosage based on therapeutic drug monitoring. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.,-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.75) | CYP2C19: Normal Metabolizer (n/a),Intermediate Metabolizer,-,0.75,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,Reduce initial dose to 25%. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.75) | CYP2C19: Poor Metabolizer (n/a),Intermediate Metabolizer,-,0.75,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.75) | CYP2C19: Rapid Metabolizer (n/a),Intermediate Metabolizer,-,0.75,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Consider using an alternative agent. If doxepin is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.75) | CYP2C19: Ultrarapid Metabolizer (n/a),Intermediate Metabolizer,-,0.75,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Consider using an alternative agent. If doxepin is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (1.0) | CYP2C19: Indeterminate (n/a),Intermediate Metabolizer,-,1,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,Reduce initial dose to 25%. Adjust dosage based on therapeutic drug monitoring. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.,-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (1.0) | CYP2C19: Intermediate Metabolizer (n/a),Intermediate Metabolizer,-,1,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,Reduce initial dose to 25%. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (1.0) | CYP2C19: Likely Intermediate Metabolizer (n/a),Intermediate Metabolizer,-,1,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,Reduce initial dose to 25%. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (1.0) | CYP2C19: Likely Poor Metabolizer (n/a),Intermediate Metabolizer,-,1,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (1.0) | CYP2C19: No Result (n/a),Intermediate Metabolizer,-,1,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,Reduce initial dose to 25%. Adjust dosage based on therapeutic drug monitoring. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.,-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (1.0) | CYP2C19: Normal Metabolizer (n/a),Intermediate Metabolizer,-,1,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,Reduce initial dose to 25%. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (1.0) | CYP2C19: Poor Metabolizer (n/a),Intermediate Metabolizer,-,1,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (1.0) | CYP2C19: Rapid Metabolizer (n/a),Intermediate Metabolizer,-,1,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Consider using an alternative agent. If doxepin is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (1.0) | CYP2C19: Ultrarapid Metabolizer (n/a),Intermediate Metabolizer,-,1,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Consider using an alternative agent. If doxepin is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.25) | CYP2C19: Indeterminate (n/a),Normal Metabolizer,-,1.25,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Normal Exposure,No recommendation,-,-,No recommendation,-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.25) | CYP2C19: Intermediate Metabolizer (n/a),Normal Metabolizer,-,1.25,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Use as Directed,-,‚úÖ,Use recommended starting dose.,-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.25) | CYP2C19: Likely Intermediate Metabolizer (n/a),Normal Metabolizer,-,1.25,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Use as Directed,-,‚úÖ,Use recommended starting dose.,-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.25) | CYP2C19: Likely Poor Metabolizer (n/a),Normal Metabolizer,-,1.25,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, reduce initial dose to 50%. Adjust dosage based on therapeutic drug monitoring.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.25) | CYP2C19: No Result (n/a),Normal Metabolizer,-,1.25,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,Use recommended starting dose,-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.25) | CYP2C19: Normal Metabolizer (n/a),Normal Metabolizer,-,1.25,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,Use recommended starting dose,-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.25) | CYP2C19: Poor Metabolizer (n/a),Normal Metabolizer,-,1.25,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, reduce initial dose to 50%. Adjust dosage based on therapeutic drug monitoring.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.25) | CYP2C19: Rapid Metabolizer (n/a),Normal Metabolizer,-,1.25,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,Consider using an alternative agent. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.25) | CYP2C19: Ultrarapid Metabolizer (n/a),Normal Metabolizer,-,1.25,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,Consider using an alternative agent. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.5) | CYP2C19: Indeterminate (n/a),Normal Metabolizer,-,1.5,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,No recommendation,-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.5) | CYP2C19: Intermediate Metabolizer (n/a),Normal Metabolizer,-,1.5,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Use as Directed,-,‚úÖ,Use recommended starting dose.,-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.5) | CYP2C19: Likely Intermediate Metabolizer (n/a),Normal Metabolizer,-,1.5,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Use as Directed,-,‚úÖ,Use recommended starting dose.,-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.5) | CYP2C19: Likely Poor Metabolizer (n/a),Normal Metabolizer,-,1.5,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, reduce initial dose to 50%. Adjust dosage based on therapeutic drug monitoring.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.5) | CYP2C19: No Result (n/a),Normal Metabolizer,-,1.5,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,Use recommended starting dose,-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.5) | CYP2C19: Normal Metabolizer (n/a),Normal Metabolizer,-,1.5,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,Use recommended starting dose,-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.5) | CYP2C19: Poor Metabolizer (n/a),Normal Metabolizer,-,1.5,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, reduce initial dose to 50%. Adjust dosage based on therapeutic drug monitoring.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.5) | CYP2C19: Rapid Metabolizer (n/a),Normal Metabolizer,-,1.5,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,Consider using an alternative agent. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.5) | CYP2C19: Ultrarapid Metabolizer (n/a),Normal Metabolizer,-,1.5,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,Consider using an alternative agent. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.75) | CYP2C19: Indeterminate (n/a),Normal Metabolizer,-,1.75,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,No recommendation,-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.75) | CYP2C19: Intermediate Metabolizer (n/a),Normal Metabolizer,-,1.75,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Use as Directed,-,‚úÖ,Use recommended starting dose.,-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.75) | CYP2C19: Likely Intermediate Metabolizer (n/a),Normal Metabolizer,-,1.75,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Use as Directed,-,‚úÖ,Use recommended starting dose.,-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.75) | CYP2C19: Likely Poor Metabolizer (n/a),Normal Metabolizer,-,1.75,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, reduce initial dose to 50%. Adjust dosage based on therapeutic drug monitoring.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.75) | CYP2C19: No Result (n/a),Normal Metabolizer,-,1.75,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,Use recommended starting dose,-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.75) | CYP2C19: Normal Metabolizer (n/a),Normal Metabolizer,-,1.75,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,Use recommended starting dose,-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.75) | CYP2C19: Poor Metabolizer (n/a),Normal Metabolizer,-,1.75,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, reduce initial dose to 50%. Adjust dosage based on therapeutic drug monitoring.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.75) | CYP2C19: Rapid Metabolizer (n/a),Normal Metabolizer,-,1.75,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,Consider using an alternative agent. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.75) | CYP2C19: Ultrarapid Metabolizer (n/a),Normal Metabolizer,-,1.75,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,Consider using an alternative agent. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Normal Metabolizer (2.0) | CYP2C19: Indeterminate (n/a),Normal Metabolizer,-,2,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,No recommendation,-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Normal Metabolizer (2.0) | CYP2C19: Intermediate Metabolizer (n/a),Normal Metabolizer,-,2,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Use as Directed,-,‚úÖ,Use recommended starting dose.,-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Normal Metabolizer (2.0) | CYP2C19: Likely Intermediate Metabolizer (n/a),Normal Metabolizer,-,2,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Use as Directed,-,‚úÖ,Use recommended starting dose.,-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Normal Metabolizer (2.0) | CYP2C19: Likely Poor Metabolizer (n/a),Normal Metabolizer,-,2,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, reduce initial dose to 50%. Adjust dosage based on therapeutic drug monitoring.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Normal Metabolizer (2.0) | CYP2C19: No Result (n/a),Normal Metabolizer,-,2,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,Use recommended starting dose,-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Normal Metabolizer (2.0) | CYP2C19: Normal Metabolizer (n/a),Normal Metabolizer,-,2,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,Use recommended starting dose,-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Normal Metabolizer (2.0) | CYP2C19: Poor Metabolizer (n/a),Normal Metabolizer,-,2,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, reduce initial dose to 50%. Adjust dosage based on therapeutic drug monitoring.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Normal Metabolizer (2.0) | CYP2C19: Rapid Metabolizer (n/a),Normal Metabolizer,-,2,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,Consider using an alternative agent. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Normal Metabolizer (2.0) | CYP2C19: Ultrarapid Metabolizer (n/a),Normal Metabolizer,-,2,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,Consider using an alternative agent. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Normal Metabolizer (2.25) | CYP2C19: Indeterminate (n/a),Normal Metabolizer,-,2.25,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,No recommendation,-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Normal Metabolizer (2.25) | CYP2C19: Intermediate Metabolizer (n/a),Normal Metabolizer,-,2.25,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Use as Directed,-,‚úÖ,Use recommended starting dose.,-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Normal Metabolizer (2.25) | CYP2C19: Likely Intermediate Metabolizer (n/a),Normal Metabolizer,-,2.25,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Use as Directed,-,‚úÖ,Use recommended starting dose.,-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Normal Metabolizer (2.25) | CYP2C19: Likely Poor Metabolizer (n/a),Normal Metabolizer,-,2.25,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, reduce initial dose to 50%. Adjust dosage based on therapeutic drug monitoring.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Normal Metabolizer (2.25) | CYP2C19: No Result (n/a),Normal Metabolizer,-,2.25,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,Use recommended starting dose,-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Normal Metabolizer (2.25) | CYP2C19: Normal Metabolizer (n/a),Normal Metabolizer,-,2.25,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,Use recommended starting dose,-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Normal Metabolizer (2.25) | CYP2C19: Poor Metabolizer (n/a),Normal Metabolizer,-,2.25,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, reduce initial dose to 50%. Adjust dosage based on therapeutic drug monitoring.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Normal Metabolizer (2.25) | CYP2C19: Rapid Metabolizer (n/a),Normal Metabolizer,-,2.25,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,Consider using an alternative agent. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Normal Metabolizer (2.25) | CYP2C19: Ultrarapid Metabolizer (n/a),Normal Metabolizer,-,2.25,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,Consider using an alternative agent. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (2.5) | CYP2C19: Indeterminate (n/a),Ultrarapid Metabolizer,-,2.5,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (2.5) | CYP2C19: Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,2.5,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (2.5) | CYP2C19: Likely Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,2.5,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (2.5) | CYP2C19: Likely Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,2.5,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (2.5) | CYP2C19: No Result (n/a),Ultrarapid Metabolizer,-,2.5,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (2.5) | CYP2C19: Normal Metabolizer (n/a),Ultrarapid Metabolizer,-,2.5,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, titrate to a higher target dose. Adjust dosage based on therapeutic drug monitoring.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (2.5) | CYP2C19: Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,2.5,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (2.5) | CYP2C19: Rapid Metabolizer (n/a),Ultrarapid Metabolizer,-,2.5,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (2.5) | CYP2C19: Ultrarapid Metabolizer (n/a),Ultrarapid Metabolizer,-,2.5,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.0) | CYP2C19: Indeterminate (n/a),Ultrarapid Metabolizer,-,‚â•3.0,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.0) | CYP2C19: Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.0,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.0) | CYP2C19: Likely Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.0,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.0) | CYP2C19: Likely Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.0,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.0) | CYP2C19: No Result (n/a),Ultrarapid Metabolizer,-,‚â•3.0,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.0) | CYP2C19: Normal Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.0,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, titrate to a higher target dose. Adjust dosage based on therapeutic drug monitoring.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.0) | CYP2C19: Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.0,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.0) | CYP2C19: Rapid Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.0,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.0) | CYP2C19: Ultrarapid Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.0,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (3.0) | CYP2C19: Indeterminate (n/a),Ultrarapid Metabolizer,-,3,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (3.0) | CYP2C19: Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,3,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (3.0) | CYP2C19: Likely Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,3,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (3.0) | CYP2C19: Likely Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,3,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (3.0) | CYP2C19: No Result (n/a),Ultrarapid Metabolizer,-,3,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (3.0) | CYP2C19: Normal Metabolizer (n/a),Ultrarapid Metabolizer,-,3,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, titrate to a higher target dose. Adjust dosage based on therapeutic drug monitoring.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (3.0) | CYP2C19: Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,3,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (3.0) | CYP2C19: Rapid Metabolizer (n/a),Ultrarapid Metabolizer,-,3,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (3.0) | CYP2C19: Ultrarapid Metabolizer (n/a),Ultrarapid Metabolizer,-,3,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.25) | CYP2C19: Indeterminate (n/a),Ultrarapid Metabolizer,-,‚â•3.25,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.25) | CYP2C19: Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.25,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.25) | CYP2C19: Likely Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.25,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.25) | CYP2C19: Likely Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.25,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.25) | CYP2C19: No Result (n/a),Ultrarapid Metabolizer,-,‚â•3.25,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.25) | CYP2C19: Normal Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.25,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, titrate to a higher target dose. Adjust dosage based on therapeutic drug monitoring.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.25) | CYP2C19: Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.25,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.25) | CYP2C19: Rapid Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.25,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.25) | CYP2C19: Ultrarapid Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.25,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.5) | CYP2C19: Indeterminate (n/a),Ultrarapid Metabolizer,-,‚â•3.5,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.5) | CYP2C19: Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.5,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.5) | CYP2C19: Likely Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.5,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.5) | CYP2C19: Likely Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.5,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.5) | CYP2C19: No Result (n/a),Ultrarapid Metabolizer,-,‚â•3.5,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.5) | CYP2C19: Normal Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.5,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, titrate to a higher target dose. Adjust dosage based on therapeutic drug monitoring.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.5) | CYP2C19: Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.5,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.5) | CYP2C19: Rapid Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.5,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.5) | CYP2C19: Ultrarapid Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.5,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (3.5) | CYP2C19: Indeterminate (n/a),Ultrarapid Metabolizer,-,3.5,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (3.5) | CYP2C19: Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,3.5,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (3.5) | CYP2C19: Likely Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,3.5,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (3.5) | CYP2C19: Likely Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,3.5,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (3.5) | CYP2C19: No Result (n/a),Ultrarapid Metabolizer,-,3.5,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (3.5) | CYP2C19: Normal Metabolizer (n/a),Ultrarapid Metabolizer,-,3.5,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, titrate to a higher target dose. Adjust dosage based on therapeutic drug monitoring.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (3.5) | CYP2C19: Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,3.5,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (3.5) | CYP2C19: Rapid Metabolizer (n/a),Ultrarapid Metabolizer,-,3.5,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (3.5) | CYP2C19: Ultrarapid Metabolizer (n/a),Ultrarapid Metabolizer,-,3.5,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•4.0) | CYP2C19: Indeterminate (n/a),Ultrarapid Metabolizer,-,‚â•4.0,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•4.0) | CYP2C19: Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•4.0,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•4.0) | CYP2C19: Likely Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•4.0,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•4.0) | CYP2C19: Likely Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•4.0,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•4.0) | CYP2C19: No Result (n/a),Ultrarapid Metabolizer,-,‚â•4.0,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•4.0) | CYP2C19: Normal Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•4.0,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, titrate to a higher target dose. Adjust dosage based on therapeutic drug monitoring.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•4.0) | CYP2C19: Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•4.0,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•4.0) | CYP2C19: Rapid Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•4.0,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•4.0) | CYP2C19: Ultrarapid Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•4.0,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (4.0) | CYP2C19: Indeterminate (n/a),Ultrarapid Metabolizer,-,4,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (4.0) | CYP2C19: Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,4,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (4.0) | CYP2C19: Likely Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,4,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (4.0) | CYP2C19: Likely Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,4,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (4.0) | CYP2C19: No Result (n/a),Ultrarapid Metabolizer,-,4,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (4.0) | CYP2C19: Normal Metabolizer (n/a),Ultrarapid Metabolizer,-,4,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, titrate to a higher target dose. Adjust dosage based on therapeutic drug monitoring.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (4.0) | CYP2C19: Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,4,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (4.0) | CYP2C19: Rapid Metabolizer (n/a),Ultrarapid Metabolizer,-,4,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (4.0) | CYP2C19: Ultrarapid Metabolizer (n/a),Ultrarapid Metabolizer,-,4,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•4.5) | CYP2C19: Indeterminate (n/a),Ultrarapid Metabolizer,-,‚â•4.5,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•4.5) | CYP2C19: Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•4.5,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•4.5) | CYP2C19: Likely Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•4.5,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•4.5) | CYP2C19: Likely Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•4.5,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•4.5) | CYP2C19: No Result (n/a),Ultrarapid Metabolizer,-,‚â•4.5,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•4.5) | CYP2C19: Normal Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•4.5,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, titrate to a higher target dose. Adjust dosage based on therapeutic drug monitoring.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•4.5) | CYP2C19: Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•4.5,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•4.5) | CYP2C19: Rapid Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•4.5,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•4.5) | CYP2C19: Ultrarapid Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•4.5,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•5.0) | CYP2C19: Indeterminate (n/a),Ultrarapid Metabolizer,-,‚â•5.0,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•5.0) | CYP2C19: Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•5.0,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•5.0) | CYP2C19: Likely Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•5.0,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•5.0) | CYP2C19: Likely Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•5.0,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•5.0) | CYP2C19: No Result (n/a),Ultrarapid Metabolizer,-,‚â•5.0,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•5.0) | CYP2C19: Normal Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•5.0,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, titrate to a higher target dose. Adjust dosage based on therapeutic drug monitoring.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•5.0) | CYP2C19: Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•5.0,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•5.0) | CYP2C19: Rapid Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•5.0,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•5.0) | CYP2C19: Ultrarapid Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•5.0,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•6.0) | CYP2C19: Indeterminate (n/a),Ultrarapid Metabolizer,-,‚â•6.0,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•6.0) | CYP2C19: Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•6.0,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•6.0) | CYP2C19: Likely Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•6.0,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•6.0) | CYP2C19: Likely Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•6.0,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•6.0) | CYP2C19: No Result (n/a),Ultrarapid Metabolizer,-,‚â•6.0,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•6.0) | CYP2C19: Normal Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•6.0,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, titrate to a higher target dose. Adjust dosage based on therapeutic drug monitoring.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•6.0) | CYP2C19: Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•6.0,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•6.0) | CYP2C19: Rapid Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•6.0,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•6.0) | CYP2C19: Ultrarapid Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•6.0,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid doxepin use. If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Indeterminate (n/a) | CYP2C19: Indeterminate (n/a),Indeterminate,-,n/a,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,No recommendation,No recommendation,-,-,No recommendation,-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Indeterminate (n/a) | CYP2C19: Intermediate Metabolizer (n/a),Indeterminate,-,n/a,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,No recommendation,-,-,No recommendation,-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Indeterminate (n/a) | CYP2C19: Likely Intermediate Metabolizer (n/a),Indeterminate,-,n/a,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,No recommendation,-,-,No recommendation,-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Indeterminate (n/a) | CYP2C19: Likely Poor Metabolizer (n/a),Indeterminate,-,n/a,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tertiary amine use. Consider alternative agents: Secondary amines nortriptyline and desipramine. If tertiary amine is warranted, reduce initial dose to 50%. Adjust dosage based on therapeutic drug monitoting. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Indeterminate (n/a) | CYP2C19: No Result (n/a),Indeterminate,-,n/a,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,No recommendation,No recommendation,-,-,No recommendation,-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Indeterminate (n/a) | CYP2C19: Normal Metabolizer (n/a),Indeterminate,-,n/a,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Normal Exposure,No recommendation,-,-,No recommendation,-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Indeterminate (n/a) | CYP2C19: Poor Metabolizer (n/a),Indeterminate,-,n/a,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tertiary amine use. Consider alternative agents: Secondary amines nortriptyline and desipramine. If tertiary amine is warranted, reduce initial dose to 50%. Adjust dosage based on therapeutic drug monitoting. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Indeterminate (n/a) | CYP2C19: Rapid Metabolizer (n/a),Indeterminate,-,n/a,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tertiary amine use. Consider alternative agents: Secondary amines nortriptyline and desipramine. If tertiary amine is warranted, adjust dosage based on therapeutic drug monitoting.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: Indeterminate (n/a) | CYP2C19: Ultrarapid Metabolizer (n/a),Indeterminate,-,n/a,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tertiary amine use. Consider alternative agents: Secondary amines nortriptyline and desipramine. If tertiary amine is warranted, adjust dosage based on therapeutic drug monitoting.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: No Result (No Result) | CYP2C19: Indeterminate (n/a),No Result,-,n/a,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,No recommendation,No recommendation,-,-,No recommendation,-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: No Result (No Result) | CYP2C19: Intermediate Metabolizer (n/a),No Result,-,n/a,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Use as Directed,-,‚úÖ,Use recommended starting dose.,-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: No Result (No Result) | CYP2C19: Likely Intermediate Metabolizer (n/a),No Result,-,n/a,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Use as Directed,-,‚úÖ,Use recommended starting dose.,-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: No Result (No Result) | CYP2C19: Likely Poor Metabolizer (n/a),No Result,-,n/a,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tertiary amine use. Consider alternative agents: Secondary amines nortriptyline and desipramine. If tertiary amine is warranted, reduce initial dose to 50%. Adjust dosage based on therapeutic drug monitoting. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: No Result (No Result) | CYP2C19: Normal Metabolizer (n/a),No Result,-,n/a,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,Use recommended starting dose,-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: No Result (No Result) | CYP2C19: Poor Metabolizer (n/a),No Result,-,n/a,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tertiary amine use. Consider alternative agents: Secondary amines nortriptyline and desipramine. If tertiary amine is warranted, reduce initial dose to 50%. Adjust dosage based on therapeutic drug monitoting. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: No Result (No Result) | CYP2C19: Rapid Metabolizer (n/a),No Result,-,n/a,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tertiary amine use. Consider alternative agents: Secondary amines nortriptyline and desipramine. If tertiary amine is warranted, adjust dosage based on therapeutic drug monitoting.",-,-,-
Doxepin,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence ,CPIC; DPWG,CYP2D6: No Result (No Result) | CYP2C19: Ultrarapid Metabolizer (n/a),No Result,-,n/a,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tertiary amine use. Consider alternative agents: Secondary amines nortriptyline and desipramine. If tertiary amine is warranted, adjust dosage based on therapeutic drug monitoting.",-,-,-
Duloxetine,Actionable,PSYCHIATRY,Level 2A,CYP2D6,Yes,CYP2D6,-,-,FDA evidence,CPIC (No Recommendation); DPWG (No Recommendation),Ultrarapid Metabolizer (>2),Ultrarapid Metabolizer,-,>2,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure;  Minimal Evidence for Clinical impact,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Duloxetine,Actionable,PSYCHIATRY,Level 2A,CYP2D6,Yes,CYP2D6,-,-,FDA evidence,CPIC (No Recommendation); DPWG (No Recommendation),Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Duloxetine,Actionable,PSYCHIATRY,Level 2A,CYP2D6,Yes,CYP2D6,-,-,FDA evidence,CPIC (No Recommendation); DPWG (No Recommendation),Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,PK,‚úÖ,-,-,-,-
Duloxetine,Actionable,PSYCHIATRY,Level 2A,CYP2D6,Yes,CYP2D6,-,-,FDA evidence,CPIC (No Recommendation); DPWG (No Recommendation),Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure;  Minimal Evidence for Clinical impact,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Escitalopram,Actionable,PSYCHIATRY,n/a,CYP2C19,Yes,CYP2C19,-,-,Professional guideline; FDA evidence,CPIC; DPWG,Indeterminate,Indeterminate,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,n/a,-,n/a,-,No recommendation,-,-,"When it comes to the metabolism of escitalopram, it primarily occurs in the liver and is mainly mediated by CYP2C19 and CYP3A4 enzymes. While CYP3A4 usually remains normal, CYP2C19 exhibits more genetic variations and demonstrates alterations in clinical parameters, making it an important factor to consider for reporting. However, it is crucial to exercise caution when both CYP3A4 is IM or PM but CYP2C19 is NM."
Escitalopram,Actionable,PSYCHIATRY,Level 1A(Moderate),CYP2C19,Yes,CYP2C19,-,-,Professional guideline; FDA evidence,CPIC; DPWG,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure; Minimal evidence for clinical impact,Use with Caution,Efficacy,‚ö†Ô∏è,Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose than normal metabolizers.,-,-,"When it comes to the metabolism of escitalopram, it primarily occurs in the liver and is mainly mediated by CYP2C19 and CYP3A4 enzymes. While CYP3A4 usually remains normal, CYP2C19 exhibits more genetic variations and demonstrates alterations in clinical parameters, making it an important factor to consider for reporting. However, it is crucial to exercise caution when both CYP3A4 is IM or PM but CYP2C19 is NM."
Escitalopram,Actionable,PSYCHIATRY,Level 1A(Moderate),CYP2C19,Yes,CYP2C19,-,-,Professional guideline; FDA evidence,CPIC; DPWG,Likely Intermediate Metabolizer,Likely Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,Efficacy,‚ö†Ô∏è,Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose than normal metabolizers.,-,-,"When it comes to the metabolism of escitalopram, it primarily occurs in the liver and is mainly mediated by CYP2C19 and CYP3A4 enzymes. While CYP3A4 usually remains normal, CYP2C19 exhibits more genetic variations and demonstrates alterations in clinical parameters, making it an important factor to consider for reporting. However, it is crucial to exercise caution when both CYP3A4 is IM or PM but CYP2C19 is NM."
Escitalopram,Actionable,PSYCHIATRY,Level 1A(strong),CYP2C19,Yes,CYP2C19,-,-,Professional guideline; FDA evidence,CPIC; DPWG,Likely Poor Metabolizer,Likely Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Consider a clinically appropriate antidepressant not predominantly metabolized by CYP2C19. If citalopram or escitalopram are clinically appropriate, consider a lower starting dose, slower titration schedule and 50% reduction of the standard maintenance dose as compared to normal metabolizers.",-,"Antidepressants that are not metabolised or that are metabolised to a lesser extent by CYP2C19 are, for example, paroxetine or fluvoxamine.","When it comes to the metabolism of escitalopram, it primarily occurs in the liver and is mainly mediated by CYP2C19 and CYP3A4 enzymes. While CYP3A4 usually remains normal, CYP2C19 exhibits more genetic variations and demonstrates alterations in clinical parameters, making it an important factor to consider for reporting. However, it is crucial to exercise caution when both CYP3A4 is IM or PM but CYP2C19 is NM."
Escitalopram,Actionable,PSYCHIATRY,Level 1A(strong),CYP2C19,Yes,CYP2C19,-,-,Professional guideline; FDA evidence,CPIC; DPWG,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,Initiate therapy with recommended starting dose,-,-,"When it comes to the metabolism of escitalopram, it primarily occurs in the liver and is mainly mediated by CYP2C19 and CYP3A4 enzymes. While CYP3A4 usually remains normal, CYP2C19 exhibits more genetic variations and demonstrates alterations in clinical parameters, making it an important factor to consider for reporting. However, it is crucial to exercise caution when both CYP3A4 is IM or PM but CYP2C19 is NM."
Escitalopram,Actionable,PSYCHIATRY,Level 1A(strong),CYP2C19,Yes,CYP2C19,-,-,Professional guideline; FDA evidence,CPIC; DPWG,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Consider a clinically appropriate antidepressant not predominantly metabolized by CYP2C19. If citalopram or escitalopram are clinically appropriate, consider a lower starting dose, slower titration schedule and 50% reduction of the standard maintenance dose as compared to normal metabolizers.",-,"Antidepressants that are not metabolised or that are metabolised to a lesser extent by CYP2C19 are, for example, paroxetine or fluvoxamine.","When it comes to the metabolism of escitalopram, it primarily occurs in the liver and is mainly mediated by CYP2C19 and CYP3A4 enzymes. While CYP3A4 usually remains normal, CYP2C19 exhibits more genetic variations and demonstrates alterations in clinical parameters, making it an important factor to consider for reporting. However, it is crucial to exercise caution when both CYP3A4 is IM or PM but CYP2C19 is NM."
Escitalopram,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2C19,Yes,CYP2C19,-,-,Professional guideline; FDA evidence,CPIC; DPWG,Rapid Metabolizer,Rapid Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure,Use with Caution,Efficacy,‚ö†Ô∏è,"Initiate therapy with recommended starting dose. If patient does not adequately respond to recommended maintenance dosing, consider titrating to a higher maintenance dose or switching to a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.",-,-,"When it comes to the metabolism of escitalopram, it primarily occurs in the liver and is mainly mediated by CYP2C19 and CYP3A4 enzymes. While CYP3A4 usually remains normal, CYP2C19 exhibits more genetic variations and demonstrates alterations in clinical parameters, making it an important factor to consider for reporting. However, it is crucial to exercise caution when both CYP3A4 is IM or PM but CYP2C19 is NM."
Escitalopram,Actionable,PSYCHIATRY,Level 1A(strong),CYP2C19,Yes,CYP2C19,-,-,Professional guideline; FDA evidence,CPIC; DPWG,Ultrarapid Metabolizer,Ultrarapid Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure,Increased Caution/Avoid,Efficacy,üõë,"Consider a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19. If citalopram or escitalopram are clinically appropriate, and adequate efficacy is not achieved at standard maintenance dosing, consider titrating to a higher maintenance dose.",-,"Antidepressants that are not metabolised or that are metabolised to a lesser extent by CYP2C19 are, for example, paroxetine or fluvoxamine.","When it comes to the metabolism of escitalopram, it primarily occurs in the liver and is mainly mediated by CYP2C19 and CYP3A4 enzymes. While CYP3A4 usually remains normal, CYP2C19 exhibits more genetic variations and demonstrates alterations in clinical parameters, making it an important factor to consider for reporting. However, it is crucial to exercise caution when both CYP3A4 is IM or PM but CYP2C19 is NM."
Flibanserin,Actionable,PSYCHIATRY,Level 1BB,CYP2C19,Yes,CYP2C19,-,-,FDA evidence,-,Ultrarapid Metabolizer,Ultrarapid Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,"Flibanserin Metabolism is primarily via CYP3A4, slightly CYP2C19. But CYP2C19 variant has huge impact on PK Change, so its prudent to check both CYP3A4 and CYP2C19."
Flibanserin,Actionable,PSYCHIATRY,Level 1BB,CYP2C19,Yes,CYP2C19,-,-,FDA evidence,-,Rapid Metabolizer,Rapid Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,"Flibanserin Metabolism is primarily via CYP3A4, slightly CYP2C19. But CYP2C19 variant has huge impact on PK Change, so its prudent to check both CYP3A4 and CYP2C19."
Flibanserin,Actionable,PSYCHIATRY,Level 1BB,CYP2C19,Yes,CYP2C19,-,-,FDA evidence,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,"Flibanserin Metabolism is primarily via CYP3A4, slightly CYP2C19. But CYP2C19 variant has huge impact on PK Change, so its prudent to check both CYP3A4 and CYP2C19."
Flibanserin,Actionable,PSYCHIATRY,Level 1BB,CYP2C19,Yes,CYP2C19,-,-,FDA evidence,-,Likely Intermediate Metabolizer,Likely Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure; Increased Risk of ADR,Use with Caution,PK,‚ö†Ô∏è,-,-,-,"Flibanserin Metabolism is primarily via CYP3A4, slightly CYP2C19. But CYP2C19 variant has huge impact on PK Change, so its prudent to check both CYP3A4 and CYP2C19."
Flibanserin,Actionable,PSYCHIATRY,Level 1BB,CYP2C19,Yes,CYP2C19,-,-,FDA evidence,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure; Increased Risk of ADR,Use with Caution,PK,‚ö†Ô∏è,-,-,-,"Flibanserin Metabolism is primarily via CYP3A4, slightly CYP2C19. But CYP2C19 variant has huge impact on PK Change, so its prudent to check both CYP3A4 and CYP2C19."
Flibanserin,Actionable,PSYCHIATRY,Level 1B,CYP2C19,Yes,CYP2C19,-,-,FDA evidence,-,Likely Poor Metabolizer,Likely Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure; Increased Risk of ADR,Use with Caution,PK,‚ö†Ô∏è,-,-,-,"Flibanserin Metabolism is primarily via CYP3A4, slightly CYP2C19. But CYP2C19 variant has huge impact on PK Change, so its prudent to check both CYP3A4 and CYP2C19."
Flibanserin,Actionable,PSYCHIATRY,Level 1B,CYP2C19,Yes,CYP2C19,-,-,FDA evidence,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure; Increased Risk of ADR,Use with Caution,PK,‚ö†Ô∏è,-,-,-,"Flibanserin Metabolism is primarily via CYP3A4, slightly CYP2C19. But CYP2C19 variant has huge impact on PK Change, so its prudent to check both CYP3A4 and CYP2C19."
Flibanserin,Actionable,PSYCHIATRY,-,CYP2C19,Yes,CYP2C19,-,-,FDA evidence,-,Indeterminate,Indeterminate,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,n/a,-,n/a,-,-,-,-,"Flibanserin Metabolism is primarily via CYP3A4, slightly CYP2C19. But CYP2C19 variant has huge impact on PK Change, so its prudent to check both CYP3A4 and CYP2C19."
Fluoxetine,Actionable,PSYCHIATRY,Level 2A,CYP2D6,Yes,CYP2D6,-,-,FDA evidence,CPIC (No Recommendation); DPWG (No Recommendation),Ultrarapid Metabolizer (>2),Ultrarapid Metabolizer,-,>2,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure; Minimal Evidence for Clinical impact,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Fluoxetine,Actionable,PSYCHIATRY,Level 2A,CYP2D6,Yes,CYP2D6,-,-,FDA evidence,CPIC (No Recommendation); DPWG (No Recommendation),Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Fluoxetine,Actionable,PSYCHIATRY,Level 2A,CYP2D6,Yes,CYP2D6,-,-,FDA evidence,CPIC (No Recommendation); DPWG (No Recommendation),Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure; Minimal Evidence for Clinical impact,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Fluoxetine,Actionable,PSYCHIATRY,Level 2A,CYP2D6,Yes,CYP2D6,-,-,FDA evidence,CPIC (No Recommendation); DPWG (No Recommendation),Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure; Minimal Evidence for Clinical impact,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Fluvoxamine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6,Yes,CYP2D6,-,-,Professional guideline; FDA evidence,CPIC; DPWG,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,Consider a 25-50% lower starting dose and slower titration or consider alternative antidepressant not predominantly metabolized by CYP2D6,-,-,-
Fluvoxamine,Actionable,PSYCHIATRY,Level 1A(Moderate),CYP2D6,Yes,CYP2D6,-,-,Professional guideline; FDA evidence,CPIC; DPWG,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,-,‚ö†Ô∏è,Initiate therapy with recommended starting dose.,-,-,-
Fluvoxamine,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6,Yes,CYP2D6,-,-,Professional guideline; FDA evidence,CPIC; DPWG,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,Initiate therapy with recommended starting dose.,-,-,-
Fluvoxamine,Actionable,PSYCHIATRY,Level 1A(No Recommendation),CYP2D6,Yes,CYP2D6,-,-,Professional guideline; FDA evidence,CPIC; DPWG,Ultrarapid Metabolizer (>2),Ultrarapid Metabolizer,-,>2,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure,Use with Caution,-,‚ö†Ô∏è,No recommendation,-,-,-
Fluvoxamine,Actionable,PSYCHIATRY,Level 1A(No Recommendation),CYP2D6,Yes,CYP2D6,-,-,Professional guideline; FDA evidence,CPIC; DPWG,Indeterminate,Indeterminate,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,n/a,No recommendation,-,-,No recommendation,-,-,-
Guanfacine,Actionable,PSYCHIATRY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Guanfacine,Actionable,PSYCHIATRY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK and Clinical Effects,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Guanfacine,Actionable,PSYCHIATRY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK and Clinical Effects,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Haloperidol,Actionable,PSYCHIATRY,Level 1A,CYP2D6,Yes,CYP2D6,-,-,Professional guideline,DPWG,Ultrarapid Metabolizer (>2),Ultrarapid Metabolizer,-,>2,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure,Increased Caution/Avoid,Efficacy,üõë,"Use 1.5 times the normal dose or choose an alternative like flupentixol, penfluridol, quetiapine, olanzapine or clozapine",-,-,-
Haloperidol,Actionable,PSYCHIATRY,Level 1A,CYP2D6,Yes,CYP2D6,-,-,Professional guideline,DPWG,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Haloperidol,Actionable,PSYCHIATRY,Level 1A,CYP2D6,Yes,CYP2D6,-,-,Professional guideline,DPWG,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure; Minimal clinical effect,Use as Directed,-,‚úÖ,-,-,-,-
Haloperidol,Actionable,PSYCHIATRY,Level 1A,CYP2D6,Yes,CYP2D6,-,-,Professional guideline,DPWG,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure; Increased Risk of ADR,Increased Caution/Avoid,Toxicity,üõë,Use 60% of the normal dose.,-,-,-
Iloperidone,Actionable,PSYCHIATRY,Level 1BB,CYP2D6,Yes,CYP2D6,-,-,FDA evidence,-,Ultrarapid Metabolizer (>2),Ultrarapid Metabolizer,-,>2,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure; Minimal Evidence for clinical Impact,Use with Caution,Efficacy,‚ö†Ô∏è,-,-,-,-
Iloperidone,Actionable,PSYCHIATRY,Level 1BB,CYP2D6,Yes,CYP2D6,-,-,FDA evidence,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Iloperidone,Actionable,PSYCHIATRY,Level 1BB,CYP2D6,Yes,CYP2D6,-,-,FDA evidence,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure;  Minimal Evidence for Clinical impact,Use with Caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Iloperidone,Actionable,PSYCHIATRY,Level 1B,CYP2D6,Yes,CYP2D6,-,-,FDA evidence,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Risk of ADR (QT prolongation),Increased Caution/Avoid,Toxicity,üõë,Reduce dosage by 50%.,-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Poor Metabolizer (0.0) | CYP2C19: Indeterminate (n/a),Poor Metabolizer,-,0,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, reduce initial dose to 50%. Adjust dosage based on therapeutic drug monitoring. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Poor Metabolizer (0.0) | CYP2C19: Intermediate Metabolizer (n/a),Poor Metabolizer,-,0,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid imipramine use. If imipramine is warranted, consider 50% reduction of recommended starting dose. Adjust dosage based on therapeutic drug monitoring.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Poor Metabolizer (0.0) | CYP2C19: Likely Intermediate Metabolizer (n/a),Poor Metabolizer,-,0,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid imipramine use. If imipramine is warranted, consider 50% reduction of recommended starting dose. Adjust dosage based on therapeutic drug monitoring.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Poor Metabolizer (0.0) | CYP2C19: Likely Poor Metabolizer (n/a),Poor Metabolizer,-,0,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid imipramine use. If imipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Poor Metabolizer (0.0) | CYP2C19: No Result (n/a),Poor Metabolizer,-,0,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, reduce initial dose to 50%. Adjust dosage based on therapeutic drug monitoring. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.
",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Poor Metabolizer (0.0) | CYP2C19: Normal Metabolizer (n/a),Poor Metabolizer,-,0,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid imipramine use. If imipramine is warranted, reduce initial dose to 50%. Adjust dosage based on therapeutic drug monitoring.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Poor Metabolizer (0.0) | CYP2C19: Poor Metabolizer (n/a),Poor Metabolizer,-,0,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid imipramine use. If imipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Poor Metabolizer (0.0) | CYP2C19: Rapid Metabolizer (n/a),Poor Metabolizer,-,0,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid imipramine use. If imipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Poor Metabolizer (0.0) | CYP2C19: Ultrarapid Metabolizer (n/a),Poor Metabolizer,-,0,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid imipramine use. If imipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.25) | CYP2C19: Indeterminate (n/a),Intermediate Metabolizer,-,0.25,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,Reduce initial dose to 25%. Adjust dosage based on therapeutic drug monitoring. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.,-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.25) | CYP2C19: Intermediate Metabolizer (n/a),Intermediate Metabolizer,-,0.25,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,Reduce initial dose to 25%. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.25) | CYP2C19: Likely Intermediate Metabolizer (n/a),Intermediate Metabolizer,-,0.25,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,Reduce initial dose to 25%. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.25) | CYP2C19: Likely Poor Metabolizer (n/a),Intermediate Metabolizer,-,0.25,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid imipramine use. If imipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.25) | CYP2C19: No Result (n/a),Intermediate Metabolizer,-,0.25,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,Reduce initial dose to 25%. Adjust dosage based on therapeutic drug monitoring. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.,-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.25) | CYP2C19: Normal Metabolizer (n/a),Intermediate Metabolizer,-,0.25,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,Reduce initial dose to 25%. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.25) | CYP2C19: Poor Metabolizer (n/a),Intermediate Metabolizer,-,0.25,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid imipramine use. If imipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.25) | CYP2C19: Rapid Metabolizer (n/a),Intermediate Metabolizer,-,0.25,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Consider using an alternative agent. If imipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.25) | CYP2C19: Ultrarapid Metabolizer (n/a),Intermediate Metabolizer,-,0.25,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Consider using an alternative agent. If imipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.5) | CYP2C19: Indeterminate (n/a),Intermediate Metabolizer,-,0.5,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,Reduce initial dose to 25%. Adjust dosage based on therapeutic drug monitoring. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.,-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.5) | CYP2C19: Intermediate Metabolizer (n/a),Intermediate Metabolizer,-,0.5,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,Reduce initial dose to 25%. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.5) | CYP2C19: Likely Intermediate Metabolizer (n/a),Intermediate Metabolizer,-,0.5,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,Reduce initial dose to 25%. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.5) | CYP2C19: Likely Poor Metabolizer (n/a),Intermediate Metabolizer,-,0.5,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid imipramine use. If imipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.5) | CYP2C19: No Result (n/a),Intermediate Metabolizer,-,0.5,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,Reduce initial dose to 25%. Adjust dosage based on therapeutic drug monitoring. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.,-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.5) | CYP2C19: Normal Metabolizer (n/a),Intermediate Metabolizer,-,0.5,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,Reduce initial dose to 25%. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.5) | CYP2C19: Poor Metabolizer (n/a),Intermediate Metabolizer,-,0.5,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid imipramine use. If imipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.5) | CYP2C19: Rapid Metabolizer (n/a),Intermediate Metabolizer,-,0.5,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Consider using an alternative agent. If imipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.5) | CYP2C19: Ultrarapid Metabolizer (n/a),Intermediate Metabolizer,-,0.5,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Consider using an alternative agent. If imipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.75) | CYP2C19: Indeterminate (n/a),Intermediate Metabolizer,-,0.75,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,Reduce initial dose to 25%. Adjust dosage based on therapeutic drug monitoring. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.,-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.75) | CYP2C19: Intermediate Metabolizer (n/a),Intermediate Metabolizer,-,0.75,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,Reduce initial dose to 25%. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.75) | CYP2C19: Likely Intermediate Metabolizer (n/a),Intermediate Metabolizer,-,0.75,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,Reduce initial dose to 25%. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.75) | CYP2C19: Likely Poor Metabolizer (n/a),Intermediate Metabolizer,-,0.75,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid imipramine use. If imipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.75) | CYP2C19: No Result (n/a),Intermediate Metabolizer,-,0.75,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,Reduce initial dose to 25%. Adjust dosage based on therapeutic drug monitoring. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.,-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.75) | CYP2C19: Normal Metabolizer (n/a),Intermediate Metabolizer,-,0.75,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,Reduce initial dose to 25%. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.75) | CYP2C19: Poor Metabolizer (n/a),Intermediate Metabolizer,-,0.75,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid imipramine use. If imipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.75) | CYP2C19: Rapid Metabolizer (n/a),Intermediate Metabolizer,-,0.75,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Consider using an alternative agent. If imipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (0.75) | CYP2C19: Ultrarapid Metabolizer (n/a),Intermediate Metabolizer,-,0.75,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Consider using an alternative agent. If imipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (1.0) | CYP2C19: Indeterminate (n/a),Intermediate Metabolizer,-,1,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,Reduce initial dose to 25%. Adjust dosage based on therapeutic drug monitoring. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.,-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (1.0) | CYP2C19: Intermediate Metabolizer (n/a),Intermediate Metabolizer,-,1,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,Reduce initial dose to 25%. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (1.0) | CYP2C19: Likely Intermediate Metabolizer (n/a),Intermediate Metabolizer,-,1,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,Reduce initial dose to 25%. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (1.0) | CYP2C19: Likely Poor Metabolizer (n/a),Intermediate Metabolizer,-,1,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid imipramine use. If imipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (1.0) | CYP2C19: No Result (n/a),Intermediate Metabolizer,-,1,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,Reduce initial dose to 25%. Adjust dosage based on therapeutic drug monitoring. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.,-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (1.0) | CYP2C19: Normal Metabolizer (n/a),Intermediate Metabolizer,-,1,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,Reduce initial dose to 25%. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (1.0) | CYP2C19: Poor Metabolizer (n/a),Intermediate Metabolizer,-,1,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid imipramine use. If imipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (1.0) | CYP2C19: Rapid Metabolizer (n/a),Intermediate Metabolizer,-,1,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Consider using an alternative agent. If imipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Intermediate Metabolizer (1.0) | CYP2C19: Ultrarapid Metabolizer (n/a),Intermediate Metabolizer,-,1,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Consider using an alternative agent. If imipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.25) | CYP2C19: Indeterminate (n/a),Normal Metabolizer,-,1.25,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Normal Exposure,-,-,-,No recommendation,-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.25) | CYP2C19: Intermediate Metabolizer (n/a),Normal Metabolizer,-,1.25,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Use with Caution,-,‚ö†Ô∏è,Use recommended starting dose.,-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.25) | CYP2C19: Likely Intermediate Metabolizer (n/a),Normal Metabolizer,-,1.25,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Use with Caution,-,‚ö†Ô∏è,Use recommended starting dose.,-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.25) | CYP2C19: Likely Poor Metabolizer (n/a),Normal Metabolizer,-,1.25,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid imipramine amines. If imipramine is warranted, reduce initial dose to 50%. Adjust dosage based on therapeutic drug monitoting.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.25) | CYP2C19: No Result (n/a),Normal Metabolizer,-,1.25,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,Use recommended starting dose,-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.25) | CYP2C19: Normal Metabolizer (n/a),Normal Metabolizer,-,1.25,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,Use recommended starting dose,-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.25) | CYP2C19: Poor Metabolizer (n/a),Normal Metabolizer,-,1.25,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid imipramine amines. If imipramine is warranted, reduce initial dose to 50%. Adjust dosage based on therapeutic drug monitoting.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.25) | CYP2C19: Rapid Metabolizer (n/a),Normal Metabolizer,-,1.25,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,Consider using an alternative agent. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.25) | CYP2C19: Ultrarapid Metabolizer (n/a),Normal Metabolizer,-,1.25,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,Consider using an alternative agent. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.5) | CYP2C19: Indeterminate (n/a),Normal Metabolizer,-,1.5,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Normal Exposure,-,-,-,No recommendation,-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.5) | CYP2C19: Intermediate Metabolizer (n/a),Normal Metabolizer,-,1.5,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Use with Caution,-,‚ö†Ô∏è,Use recommended starting dose.,-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.5) | CYP2C19: Likely Intermediate Metabolizer (n/a),Normal Metabolizer,-,1.5,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Use with Caution,-,‚ö†Ô∏è,Use recommended starting dose.,-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.5) | CYP2C19: Likely Poor Metabolizer (n/a),Normal Metabolizer,-,1.5,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid imipramine amines. If imipramine is warranted, reduce initial dose to 50%. Adjust dosage based on therapeutic drug monitoting.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.5) | CYP2C19: No Result (n/a),Normal Metabolizer,-,1.5,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,Use recommended starting dose,-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.5) | CYP2C19: Normal Metabolizer (n/a),Normal Metabolizer,-,1.5,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,Use recommended starting dose,-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.5) | CYP2C19: Poor Metabolizer (n/a),Normal Metabolizer,-,1.5,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid imipramine amines. If imipramine is warranted, reduce initial dose to 50%. Adjust dosage based on therapeutic drug monitoting.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.5) | CYP2C19: Rapid Metabolizer (n/a),Normal Metabolizer,-,1.5,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,Consider using an alternative agent. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.5) | CYP2C19: Ultrarapid Metabolizer (n/a),Normal Metabolizer,-,1.5,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,Consider using an alternative agent. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.75) | CYP2C19: Indeterminate (n/a),Normal Metabolizer,-,1.75,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Normal Exposure,-,-,-,No recommendation,-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.75) | CYP2C19: Intermediate Metabolizer (n/a),Normal Metabolizer,-,1.75,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Use with Caution,-,‚ö†Ô∏è,Use recommended starting dose.,-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.75) | CYP2C19: Likely Intermediate Metabolizer (n/a),Normal Metabolizer,-,1.75,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Use with Caution,-,‚ö†Ô∏è,Use recommended starting dose.,-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.75) | CYP2C19: Likely Poor Metabolizer (n/a),Normal Metabolizer,-,1.75,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid imipramine amines. If imipramine is warranted, reduce initial dose to 50%. Adjust dosage based on therapeutic drug monitoting.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.75) | CYP2C19: No Result (n/a),Normal Metabolizer,-,1.75,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,Use recommended starting dose,-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.75) | CYP2C19: Normal Metabolizer (n/a),Normal Metabolizer,-,1.75,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,Use recommended starting dose,-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.75) | CYP2C19: Poor Metabolizer (n/a),Normal Metabolizer,-,1.75,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid imipramine amines. If imipramine is warranted, reduce initial dose to 50%. Adjust dosage based on therapeutic drug monitoting.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.75) | CYP2C19: Rapid Metabolizer (n/a),Normal Metabolizer,-,1.75,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,Consider using an alternative agent. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (1.75) | CYP2C19: Ultrarapid Metabolizer (n/a),Normal Metabolizer,-,1.75,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,Consider using an alternative agent. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (2.0) | CYP2C19: Indeterminate (n/a),Normal Metabolizer,-,2,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Normal Exposure,-,-,-,No recommendation,-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (2.0) | CYP2C19: Intermediate Metabolizer (n/a),Normal Metabolizer,-,2,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Use with Caution,-,‚ö†Ô∏è,Use recommended starting dose.,-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (2.0) | CYP2C19: Likely Intermediate Metabolizer (n/a),Normal Metabolizer,-,2,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Use with Caution,-,‚ö†Ô∏è,Use recommended starting dose.,-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (2.0) | CYP2C19: Likely Poor Metabolizer (n/a),Normal Metabolizer,-,2,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid imipramine amines. If imipramine is warranted, reduce initial dose to 50%. Adjust dosage based on therapeutic drug monitoting.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (2.0) | CYP2C19: No Result (n/a),Normal Metabolizer,-,2,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,Use recommended starting dose,-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (2.0) | CYP2C19: Normal Metabolizer (n/a),Normal Metabolizer,-,2,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,Use recommended starting dose,-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (2.0) | CYP2C19: Poor Metabolizer (n/a),Normal Metabolizer,-,2,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid imipramine amines. If imipramine is warranted, reduce initial dose to 50%. Adjust dosage based on therapeutic drug monitoting.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (2.0) | CYP2C19: Rapid Metabolizer (n/a),Normal Metabolizer,-,2,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,Consider using an alternative agent. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (2.0) | CYP2C19: Ultrarapid Metabolizer (n/a),Normal Metabolizer,-,2,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,Consider using an alternative agent. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (2.25) | CYP2C19: Indeterminate (n/a),Normal Metabolizer,-,2.25,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Normal Exposure,-,-,-,No recommendation,-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (2.25) | CYP2C19: Intermediate Metabolizer (n/a),Normal Metabolizer,-,2.25,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Use with Caution,-,‚ö†Ô∏è,Use recommended starting dose.,-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (2.25) | CYP2C19: Likely Intermediate Metabolizer (n/a),Normal Metabolizer,-,2.25,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Use with Caution,-,‚ö†Ô∏è,Use recommended starting dose.,-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (2.25) | CYP2C19: Likely Poor Metabolizer (n/a),Normal Metabolizer,-,2.25,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid imipramine amines. If imipramine is warranted, reduce initial dose to 50%. Adjust dosage based on therapeutic drug monitoting.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (2.25) | CYP2C19: No Result (n/a),Normal Metabolizer,-,2.25,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,Use recommended starting dose,-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (2.25) | CYP2C19: Normal Metabolizer (n/a),Normal Metabolizer,-,2.25,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,Use recommended starting dose,-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (2.25) | CYP2C19: Poor Metabolizer (n/a),Normal Metabolizer,-,2.25,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid imipramine amines. If imipramine is warranted, reduce initial dose to 50%. Adjust dosage based on therapeutic drug monitoting.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (2.25) | CYP2C19: Rapid Metabolizer (n/a),Normal Metabolizer,-,2.25,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,Consider using an alternative agent. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Normal Metabolizer (2.25) | CYP2C19: Ultrarapid Metabolizer (n/a),Normal Metabolizer,-,2.25,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,Consider using an alternative agent. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (2.5) | CYP2C19: Indeterminate (n/a),Ultrarapid Metabolizer,-,2.5,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (2.5) | CYP2C19: Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,2.5,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid imipramine use. If imipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (2.5) | CYP2C19: Likely Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,2.5,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid imipramine use. If imipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (2.5) | CYP2C19: Likely Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,2.5,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid imipramine use. If imipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (2.5) | CYP2C19: No Result (n/a),Ultrarapid Metabolizer,-,2.5,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (2.5) | CYP2C19: Normal Metabolizer (n/a),Ultrarapid Metabolizer,-,2.5,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid imipramine use. If imipramine is warranted, consider titrating to a higher target dose. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (2.5) | CYP2C19: Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,2.5,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid imipramine use. If imipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (2.5) | CYP2C19: Rapid Metabolizer (n/a),Ultrarapid Metabolizer,-,2.5,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid imipramine use. If imipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (2.5) | CYP2C19: Ultrarapid Metabolizer (n/a),Ultrarapid Metabolizer,-,2.5,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid imipramine use. If imipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.0) | CYP2C19: Indeterminate (n/a),Ultrarapid Metabolizer,-,‚â•3.0,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.0) | CYP2C19: Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.0,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid imipramine use. If imipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.0) | CYP2C19: Likely Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.0,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid imipramine use. If imipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.0) | CYP2C19: Likely Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.0,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid imipramine use. If imipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.0) | CYP2C19: No Result (n/a),Ultrarapid Metabolizer,-,‚â•3.0,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.0) | CYP2C19: Normal Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.0,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid imipramine use. If imipramine is warranted, consider titrating to a higher target dose. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.0) | CYP2C19: Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.0,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid imipramine use. If imipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.0) | CYP2C19: Rapid Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.0,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid imipramine use. If imipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.0) | CYP2C19: Ultrarapid Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.0,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid imipramine use. If imipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (3.0) | CYP2C19: Indeterminate (n/a),Ultrarapid Metabolizer,-,3,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (3.0) | CYP2C19: Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,3,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid imipramine use. If imipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (3.0) | CYP2C19: Likely Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,3,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid imipramine use. If imipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (3.0) | CYP2C19: Likely Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,3,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid imipramine use. If imipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (3.0) | CYP2C19: No Result (n/a),Ultrarapid Metabolizer,-,3,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (3.0) | CYP2C19: Normal Metabolizer (n/a),Ultrarapid Metabolizer,-,3,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid imipramine use. If imipramine is warranted, consider titrating to a higher target dose. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (3.0) | CYP2C19: Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,3,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid imipramine use. If imipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (3.0) | CYP2C19: Rapid Metabolizer (n/a),Ultrarapid Metabolizer,-,3,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid imipramine use. If imipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (3.0) | CYP2C19: Ultrarapid Metabolizer (n/a),Ultrarapid Metabolizer,-,3,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid imipramine use. If imipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.25) | CYP2C19: Indeterminate (n/a),Ultrarapid Metabolizer,-,‚â•3.25,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.25) | CYP2C19: Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.25,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid imipramine use. If imipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.25) | CYP2C19: Likely Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.25,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid imipramine use. If imipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.25) | CYP2C19: Likely Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.25,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid imipramine use. If imipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.25) | CYP2C19: No Result (n/a),Ultrarapid Metabolizer,-,‚â•3.25,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.25) | CYP2C19: Normal Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.25,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid imipramine use. If imipramine is warranted, consider titrating to a higher target dose. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.25) | CYP2C19: Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.25,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid imipramine use. If imipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.25) | CYP2C19: Rapid Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.25,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid imipramine use. If imipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.25) | CYP2C19: Ultrarapid Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.25,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid imipramine use. If imipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.5) | CYP2C19: Indeterminate (n/a),Ultrarapid Metabolizer,-,‚â•3.5,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.5) | CYP2C19: Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.5,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid imipramine use. If imipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.5) | CYP2C19: Likely Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.5,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid imipramine use. If imipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.5) | CYP2C19: Likely Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.5,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid imipramine use. If imipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.5) | CYP2C19: No Result (n/a),Ultrarapid Metabolizer,-,‚â•3.5,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.5) | CYP2C19: Normal Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.5,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid imipramine use. If imipramine is warranted, consider titrating to a higher target dose. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.5) | CYP2C19: Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.5,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid imipramine use. If imipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.5) | CYP2C19: Rapid Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.5,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid imipramine use. If imipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•3.5) | CYP2C19: Ultrarapid Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.5,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid imipramine use. If imipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (3.5) | CYP2C19: Indeterminate (n/a),Ultrarapid Metabolizer,-,3.5,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (3.5) | CYP2C19: Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,3.5,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid imipramine use. If imipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (3.5) | CYP2C19: Likely Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,3.5,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid imipramine use. If imipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (3.5) | CYP2C19: Likely Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,3.5,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid imipramine use. If imipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (3.5) | CYP2C19: No Result (n/a),Ultrarapid Metabolizer,-,3.5,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (3.5) | CYP2C19: Normal Metabolizer (n/a),Ultrarapid Metabolizer,-,3.5,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid imipramine use. If imipramine is warranted, consider titrating to a higher target dose. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (3.5) | CYP2C19: Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,3.5,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid imipramine use. If imipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (3.5) | CYP2C19: Rapid Metabolizer (n/a),Ultrarapid Metabolizer,-,3.5,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid imipramine use. If imipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (3.5) | CYP2C19: Ultrarapid Metabolizer (n/a),Ultrarapid Metabolizer,-,3.5,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid imipramine use. If imipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•4.0) | CYP2C19: Indeterminate (n/a),Ultrarapid Metabolizer,-,‚â•4.0,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•4.0) | CYP2C19: Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•4.0,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid imipramine use. If imipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•4.0) | CYP2C19: Likely Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•4.0,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid imipramine use. If imipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•4.0) | CYP2C19: Likely Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•4.0,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid imipramine use. If imipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•4.0) | CYP2C19: No Result (n/a),Ultrarapid Metabolizer,-,‚â•4.0,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•4.0) | CYP2C19: Normal Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•4.0,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid imipramine use. If imipramine is warranted, consider titrating to a higher target dose. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•4.0) | CYP2C19: Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•4.0,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid imipramine use. If imipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•4.0) | CYP2C19: Rapid Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•4.0,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid imipramine use. If imipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•4.0) | CYP2C19: Ultrarapid Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•4.0,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid imipramine use. If imipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (4.0) | CYP2C19: Indeterminate (n/a),Ultrarapid Metabolizer,-,4,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (4.0) | CYP2C19: Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,4,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid imipramine use. If imipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (4.0) | CYP2C19: Likely Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,4,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid imipramine use. If imipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (4.0) | CYP2C19: Likely Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,4,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid imipramine use. If imipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (4.0) | CYP2C19: No Result (n/a),Ultrarapid Metabolizer,-,4,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (4.0) | CYP2C19: Normal Metabolizer (n/a),Ultrarapid Metabolizer,-,4,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid imipramine use. If imipramine is warranted, consider titrating to a higher target dose. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (4.0) | CYP2C19: Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,4,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid imipramine use. If imipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (4.0) | CYP2C19: Rapid Metabolizer (n/a),Ultrarapid Metabolizer,-,4,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid imipramine use. If imipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (4.0) | CYP2C19: Ultrarapid Metabolizer (n/a),Ultrarapid Metabolizer,-,4,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid imipramine use. If imipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•4.5) | CYP2C19: Indeterminate (n/a),Ultrarapid Metabolizer,-,‚â•4.5,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•4.5) | CYP2C19: Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•4.5,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid imipramine use. If imipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•4.5) | CYP2C19: Likely Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•4.5,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid imipramine use. If imipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•4.5) | CYP2C19: Likely Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•4.5,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid imipramine use. If imipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•4.5) | CYP2C19: No Result (n/a),Ultrarapid Metabolizer,-,‚â•4.5,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•4.5) | CYP2C19: Normal Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•4.5,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid imipramine use. If imipramine is warranted, consider titrating to a higher target dose. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•4.5) | CYP2C19: Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•4.5,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid imipramine use. If imipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•4.5) | CYP2C19: Rapid Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•4.5,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid imipramine use. If imipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•4.5) | CYP2C19: Ultrarapid Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•4.5,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid imipramine use. If imipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•5.0) | CYP2C19: Indeterminate (n/a),Ultrarapid Metabolizer,-,‚â•5.0,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•5.0) | CYP2C19: Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•5.0,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid imipramine use. If imipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•5.0) | CYP2C19: Likely Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•5.0,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid imipramine use. If imipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•5.0) | CYP2C19: Likely Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•5.0,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid imipramine use. If imipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•5.0) | CYP2C19: No Result (n/a),Ultrarapid Metabolizer,-,‚â•5.0,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•5.0) | CYP2C19: Normal Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•5.0,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid imipramine use. If imipramine is warranted, consider titrating to a higher target dose. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•5.0) | CYP2C19: Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•5.0,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid imipramine use. If imipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•5.0) | CYP2C19: Rapid Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•5.0,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid imipramine use. If imipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•5.0) | CYP2C19: Ultrarapid Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•5.0,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid imipramine use. If imipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•6.0) | CYP2C19: Indeterminate (n/a),Ultrarapid Metabolizer,-,‚â•6.0,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•6.0) | CYP2C19: Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•6.0,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid imipramine use. If imipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•6.0) | CYP2C19: Likely Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•6.0,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid imipramine use. If imipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•6.0) | CYP2C19: Likely Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•6.0,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid imipramine use. If imipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•6.0) | CYP2C19: No Result (n/a),Ultrarapid Metabolizer,-,‚â•6.0,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•6.0) | CYP2C19: Normal Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•6.0,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid imipramine use. If imipramine is warranted, consider titrating to a higher target dose. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•6.0) | CYP2C19: Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•6.0,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Avoid imipramine use. If imipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•6.0) | CYP2C19: Rapid Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•6.0,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid imipramine use. If imipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Ultrarapid Metabolizer (‚â•6.0) | CYP2C19: Ultrarapid Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•6.0,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid imipramine use. If imipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Indeterminate (n/a) | CYP2C19: Indeterminate (n/a),Indeterminate,-,n/a,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,No recommendation,No recommendation,-,-,No recommendation,-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Indeterminate (n/a) | CYP2C19: Intermediate Metabolizer (n/a),Indeterminate,-,n/a,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,No recommendation,-,-,No recommendation,-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Indeterminate (n/a) | CYP2C19: Likely Intermediate Metabolizer (n/a),Indeterminate,-,n/a,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,No recommendation,-,-,No recommendation,-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Indeterminate (n/a) | CYP2C19: Likely Poor Metabolizer (n/a),Indeterminate,-,n/a,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tertiary amine use. Consider alternative agents: Secondary amines nortriptyline and desipramine. If tertiary amine is warranted, reduce initial dose to 50%. Adjust dosage based on therapeutic drug monitoting. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Indeterminate (n/a) | CYP2C19: No Result (n/a),Indeterminate,-,n/a,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,No recommendation,No recommendation,-,-,No recommendation,-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Indeterminate (n/a) | CYP2C19: Normal Metabolizer (n/a),Indeterminate,-,n/a,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Normal Exposure,No recommendation,-,-,No recommendation,-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Indeterminate (n/a) | CYP2C19: Poor Metabolizer (n/a),Indeterminate,-,n/a,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tertiary amine use. Consider alternative agents: Secondary amines nortriptyline and desipramine. If tertiary amine is warranted, reduce initial dose to 50%. Adjust dosage based on therapeutic drug monitoting. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Indeterminate (n/a) | CYP2C19: Rapid Metabolizer (n/a),Indeterminate,-,n/a,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tertiary amine use. Consider alternative agents: Secondary amines nortriptyline and desipramine. If tertiary amine is warranted, adjust dosage based on therapeutic drug monitoting.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: Indeterminate (n/a) | CYP2C19: Ultrarapid Metabolizer (n/a),Indeterminate,-,n/a,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tertiary amine use. Consider alternative agents: Secondary amines nortriptyline and desipramine. If tertiary amine is warranted, adjust dosage based on therapeutic drug monitoting.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: No Result (No Result) | CYP2C19: Indeterminate (n/a),No Result,-,n/a,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,No recommendation,No recommendation,-,-,No recommendation,-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: No Result (No Result) | CYP2C19: Intermediate Metabolizer (n/a),No Result,-,n/a,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Use as Directed,-,‚úÖ,Use recommended starting dose.,-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: No Result (No Result) | CYP2C19: Likely Intermediate Metabolizer (n/a),No Result,-,n/a,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Use as Directed,-,‚úÖ,Use recommended starting dose.,-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: No Result (No Result) | CYP2C19: Likely Poor Metabolizer (n/a),No Result,-,n/a,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tertiary amine use. Consider alternative agents: Secondary amines nortriptyline and desipramine. If tertiary amine is warranted, reduce initial dose to 50%. Adjust dosage based on therapeutic drug monitoting. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: No Result (No Result) | CYP2C19: Normal Metabolizer (n/a),No Result,-,n/a,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,Use recommended starting dose,-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: No Result (No Result) | CYP2C19: Poor Metabolizer (n/a),No Result,-,n/a,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tertiary amine use. Consider alternative agents: Secondary amines nortriptyline and desipramine. If tertiary amine is warranted, reduce initial dose to 50%. Adjust dosage based on therapeutic drug monitoting. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: No Result (No Result) | CYP2C19: Rapid Metabolizer (n/a),No Result,-,n/a,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tertiary amine use. Consider alternative agents: Secondary amines nortriptyline and desipramine. If tertiary amine is warranted, adjust dosage based on therapeutic drug monitoting.",-,-,-
Imipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC; DPWG,CYP2D6: No Result (No Result) | CYP2C19: Ultrarapid Metabolizer (n/a),No Result,-,n/a,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"Avoid tertiary amine use. Consider alternative agents: Secondary amines nortriptyline and desipramine. If tertiary amine is warranted, adjust dosage based on therapeutic drug monitoting.",-,-,-
Levomilnacipran,Actionable,PSYCHIATRY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,CPIC (No Recommendation),Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Levomilnacipran,Actionable,PSYCHIATRY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,CPIC (No Recommendation),Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK and Clinical Effects,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Levomilnacipran,Actionable,PSYCHIATRY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,CPIC (No Recommendation),Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK and Clinical Effects,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Lurasidone,Actionable,PSYCHIATRY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Lurasidone,Actionable,PSYCHIATRY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK and Clinical Effects,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Lurasidone,Actionable,PSYCHIATRY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK and Clinical Effects,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Mirtazapine,Actionable,PSYCHIATRY,Level 2A,CYP2D6,Yes,CYP2D6,-,-,-,DPWG (No Recommendation),Ultrarapid Metabolizer (>2),Ultrarapid Metabolizer,-,>2,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,"Increased Exposure, Increased Risk of ADR(QTc prolongation)",Use with Caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Mirtazapine,Actionable,PSYCHIATRY,Level 2A,CYP2D6,Yes,CYP2D6,-,-,-,DPWG (No Recommendation),Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Mirtazapine,Actionable,PSYCHIATRY,Level 2A,CYP2D6,Yes,CYP2D6,-,-,-,DPWG (No Recommendation),Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,"Increased Exposure, Increased Risk of ADR(QTc prolongation)",Use with Caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Mirtazapine,Actionable,PSYCHIATRY,Level 2A,CYP2D6,Yes,CYP2D6,-,-,-,DPWG (No Recommendation),Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,"Increased Exposure, Increased Risk of ADR (short-lived discomforts)",Use with Caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Nefazodone,Actionable,PSYCHIATRY,Level 1B,CYP2D6,Yes,CYP2D6,-,-,FDA evidence,-,Ultrarapid Metabolizer (>2),Ultrarapid Metabolizer,-,>2,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Nefazodone,Actionable,PSYCHIATRY,Level 1B,CYP2D6,Yes,CYP2D6,-,-,FDA evidence,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Nefazodone,Actionable,PSYCHIATRY,Level 1B,CYP2D6,Yes,CYP2D6,-,-,FDA evidence,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Nefazodone,Actionable,PSYCHIATRY,Level 1B,CYP2D6,Yes,CYP2D6,-,-,FDA evidence,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Nortriptyline,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6,Yes,CYP2D6,-,-,Professional guideline; FDA evidence,CPIC; DPWG,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Avoid tricyclic use. Consider alternative drug not metabolized by CYP2D6. If a tricyclic use is warranted, consider a 50% reduction of recommended starting dose.",-,-,-
Nortriptyline,Actionable,PSYCHIATRY,Level 1A(Moderate),CYP2D6,Yes,CYP2D6,-,-,Professional guideline; FDA evidence,CPIC; DPWG,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,Consider a 25% reduction of recommended starting dose.,-,-,-
Nortriptyline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6,Yes,CYP2D6,-,-,Professional guideline; FDA evidence,CPIC; DPWG,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,Consider a 25% reduction of recommended starting dose.,-,-,-
Nortriptyline,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6,Yes,CYP2D6,-,-,Professional guideline; FDA evidence,CPIC; DPWG,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,Initiate therapy with recommended starting dose,-,-,-
Nortriptyline,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6,Yes,CYP2D6,-,-,Professional guideline; FDA evidence,CPIC; DPWG,Ultrarapid Metabolizer (>2),Ultrarapid Metabolizer,-,>2,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure,Increased Caution/Avoid,Efficacy,üõë,"Avoid tricyclic use due. Consider alternative drug not metabolized by CYP2D6. If a tricyclic use is warranted, consider titrating to a higher target dose.",-,-,-
Nortriptyline,Actionable,PSYCHIATRY,n/a,CYP2D6,Yes,CYP2D6,-,-,Professional guideline; FDA evidence,CPIC; DPWG,Indeterminate,Indeterminate,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,n/a,No recommendation,-,-,No recommendation,-,-,-
Olanzapine,Actionable,PSYCHIATRY,Level 2A,CYP1A2 + HTR2C,No,CYP1A2,HTR2C,-,-,DPWG (No Recommendation),"CYP1A2: rs762551,AA; Fast Metabolizer + HTR2C: rs3813929,C",Fast Metabolizer,"rs762551,AA",-,-,-,-,-,-,-,-,-,-,-,-,"rs3813929,C",-,-,-,-,Reduced Response; Increased Risk of ADR(weight gain),Use with Caution,-,‚ö†Ô∏è,Reduced Response; Increased Risk of ADR(weight gain),-,-,-
Olanzapine,Actionable,PSYCHIATRY,Level 2A,CYP1A2 + HTR2C,No,CYP1A2,HTR2C,-,-,DPWG (No Recommendation),"CYP1A2: rs762551,AC; Slow Metabolizer + HTR2C: rs3813929,C",Slow Metabolizer,"rs762551,AC",-,-,-,-,-,-,-,-,-,-,-,-,"rs3813929,C",-,-,-,-,Increased Risk of ADR(weight gain),Use with Caution,-,‚ö†Ô∏è,Increased Risk of ADR(weight gain),-,-,-
Olanzapine,Actionable,PSYCHIATRY,Level 2A,CYP1A2 + HTR2C,No,CYP1A2,HTR2C,-,-,DPWG (No Recommendation),"CYP1A2: rs762551,CC; Slow Metabolizer + HTR2C: rs3813929,C",Slow Metabolizer,"rs762551,CC",-,-,-,-,-,-,-,-,-,-,-,-,"rs3813929,C",-,-,-,-,Increased Risk of ADR(weight gain),Use with Caution,-,‚ö†Ô∏è,Increased Risk of ADR(weight gain),-,-,-
Paroxetine,Actionable,PSYCHIATRY,Level 1A(Moderate),CYP2D6,Yes,CYP2D6,-,-,Professional guideline; FDA evidence,CPIC; DPWG,Ultrarapid Metabolizer (>2),Ultrarapid Metabolizer,-,>2,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure,Increased Caution/Avoid,Efficacy,üõë,Select alternative drug not predominantly metabolized by CYP2D6.,-,-,-
Paroxetine,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6,Yes,CYP2D6,-,-,Professional guideline; FDA evidence,CPIC; DPWG,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Paroxetine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6,Yes,CYP2D6,-,-,Professional guideline; FDA evidence,CPIC; DPWG,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure;  Minimal Evidence for Clinical impact,Increased Caution/Avoid,Toxicity,üõë,Consider a lower starting dose and slower titration schedule as compared to normal metabolizers.,-,-,-
Paroxetine,Actionable,PSYCHIATRY,Level 1A(Moderate),CYP2D6,Yes,CYP2D6,-,-,Professional guideline; FDA evidence,CPIC; DPWG,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Risk of ADR,Increased Caution/Avoid,Toxicity,üõë,"Consider a 50% reduction in recommended starting dose, slower titration schedule, and a 50% lower maintenance dose as compared to normal metabolizers.",-,-,-
Perphenazine,Actionable,PSYCHIATRY,Level 1BB,CYP2D6,Yes,CYP2D6,-,-,FDA evidence,-,Ultrarapid Metabolizer (>2),Ultrarapid Metabolizer,-,>2,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure,Use with Caution,Efficacy,‚ö†Ô∏è,-,-,-,-
Perphenazine,Actionable,PSYCHIATRY,Level 1BB,CYP2D6,Yes,CYP2D6,-,-,FDA evidence,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Perphenazine,Actionable,PSYCHIATRY,Level 1BB,CYP2D6,Yes,CYP2D6,-,-,FDA evidence,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Perphenazine,Actionable,PSYCHIATRY,Level 1B,CYP2D6,Yes,CYP2D6,-,-,FDA evidence,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Protriptyline,Actionable,PSYCHIATRY,Level 1BB,CYP2D6,Yes,CYP2D6,-,-,FDA evidence,-,Ultrarapid Metabolizer (>2),Ultrarapid Metabolizer,-,>2,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure; Minimal Evidence for clinical Impact,Use with Caution,Efficacy,‚ö†Ô∏è,-,-,-,-
Protriptyline,Actionable,PSYCHIATRY,Level 1BB,CYP2D6,Yes,CYP2D6,-,-,FDA evidence,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Protriptyline,Actionable,PSYCHIATRY,Level 1BB,CYP2D6,Yes,CYP2D6,-,-,FDA evidence,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure;  Minimal Evidence for Clinical impact,Use with Caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Protriptyline,Actionable,PSYCHIATRY,Level 1B,CYP2D6,Yes,CYP2D6,-,-,FDA evidence,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure;  Minimal Evidence for Clinical impact,Use with Caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Sertraline,Actionable,PSYCHIATRY,n/a,CYP2B6 + CYP2C19,No,CYP2B6,CYP2C19,-,Professional guideline,CPIC; DPWG,CYP2B6: Indeterminate (n/a) | CYP2C19: Indeterminate (n/a),Indeterminate,-,n/a,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,No recommendation,-,-,-,No recommendation,-,-,-
Sertraline,Actionable,PSYCHIATRY,Level 1A(Moderate),CYP2B6 + CYP2C19,No,CYP2B6,CYP2C19,-,Professional guideline,CPIC; DPWG,CYP2B6: Indeterminate (n/a) | CYP2C19: Intermediate Metabolizer (n/a),Indeterminate,-,n/a,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Use as Directed,-,‚úÖ,Use recommended starting dose. Consider slower titration schedule and lower maintenance dose.,-,-,-
Sertraline,Actionable,PSYCHIATRY,Level 1A(Moderate),CYP2B6 + CYP2C19,No,CYP2B6,CYP2C19,-,Professional guideline,CPIC; DPWG,CYP2B6: Indeterminate (n/a) | CYP2C19: Likely Intermediate Metabolizer (n/a),Indeterminate,-,n/a,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Use as Directed,-,‚úÖ,Use recommended starting dose. Consider slower titration schedule and lower maintenance dose.,-,-,-
Sertraline,Actionable,PSYCHIATRY,Level 1A(Moderate),CYP2B6 + CYP2C19,No,CYP2B6,CYP2C19,-,Professional guideline,CPIC; DPWG,CYP2B6: Indeterminate (n/a) | CYP2C19: Likely Poor Metabolizer (n/a),Indeterminate,-,n/a,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Consider a lower starting dose, slower titration schedule. Reduce standard maintenance dose to 50% or consider clinically appropriate alternative antidepressant.",-,-,-
Sertraline,Actionable,PSYCHIATRY,n/a,CYP2B6 + CYP2C19,No,CYP2B6,CYP2C19,-,Professional guideline,CPIC; DPWG,CYP2B6: Indeterminate (n/a) | CYP2C19: No Result (n/a),Indeterminate,-,n/a,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,No recommendation,-,-,-,No recommendation,-,-,-
Sertraline,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2B6 + CYP2C19,No,CYP2B6,CYP2C19,-,Professional guideline,CPIC; DPWG,CYP2B6: Indeterminate (n/a) | CYP2C19: Normal Metabolizer (n/a),Indeterminate,-,n/a,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Normal Exposure,-,-,-,Use recommended starting dose,-,-,-
Sertraline,Actionable,PSYCHIATRY,Level 1A(Moderate),CYP2B6 + CYP2C19,No,CYP2B6,CYP2C19,-,Professional guideline,CPIC; DPWG,CYP2B6: Indeterminate (n/a) | CYP2C19: Poor Metabolizer (n/a),Indeterminate,-,n/a,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Consider a lower starting dose, slower titration schedule. Reduce standard maintenance dose to 50% or consider clinically appropriate alternative antidepressant.",-,-,-
Sertraline,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2B6 + CYP2C19,No,CYP2B6,CYP2C19,-,Professional guideline,CPIC; DPWG,CYP2B6: Indeterminate (n/a) | CYP2C19: Rapid Metabolizer (n/a),Indeterminate,-,n/a,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Use as Directed,-,‚úÖ,Use recommended starting dose,-,-,-
Sertraline,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2B6 + CYP2C19,No,CYP2B6,CYP2C19,-,Professional guideline,CPIC; DPWG,CYP2B6: Indeterminate (n/a) | CYP2C19: Ultrarapid Metabolizer (n/a),Indeterminate,-,n/a,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Use as Directed,-,‚úÖ,Use recommended starting dose,-,-,-
Sertraline,Actionable,PSYCHIATRY,Level 1A(Moderate),CYP2B6 + CYP2C19,No,CYP2B6,CYP2C19,-,Professional guideline,CPIC; DPWG,CYP2B6: Intermediate Metabolizer (n/a) | CYP2C19: Indeterminate (n/a),Intermediate Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Increased Exposure,Use with Caution,-,‚ö†Ô∏è,Use recommended starting dose. Consider slower titration schedule and lower maintenance dose.,-,-,-
Sertraline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2B6 + CYP2C19,No,CYP2B6,CYP2C19,-,Professional guideline,CPIC; DPWG,CYP2B6: Intermediate Metabolizer (n/a) | CYP2C19: Intermediate Metabolizer (n/a),Intermediate Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Use with Caution,-,‚ö†Ô∏è,Use recommended starting dose. Consider slower titration schedule and lower maintenance dose.,-,-,-
Sertraline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2B6 + CYP2C19,No,CYP2B6,CYP2C19,-,Professional guideline,CPIC; DPWG,CYP2B6: Intermediate Metabolizer (n/a) | CYP2C19: Likely Intermediate Metabolizer (n/a),Intermediate Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Use with Caution,-,‚ö†Ô∏è,Use recommended starting dose. Consider slower titration schedule and lower maintenance dose.,-,-,-
Sertraline,Actionable,PSYCHIATRY,Level 1A(Moderate),CYP2B6 + CYP2C19,No,CYP2B6,CYP2C19,-,Professional guideline,CPIC; DPWG,CYP2B6: Intermediate Metabolizer (n/a) | CYP2C19: Likely Poor Metabolizer (n/a),Intermediate Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Consider a lower starting dose, slower titration schedule. Reduce standard maintenance dose to 50% or consider clinically appropriate alternative antidepressant.",-,-,-
Sertraline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2B6 + CYP2C19,No,CYP2B6,CYP2C19,-,Professional guideline,CPIC; DPWG,CYP2B6: Intermediate Metabolizer (n/a) | CYP2C19: No Result (n/a),Intermediate Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Increased Exposure,Use with Caution,-,‚ö†Ô∏è,Use recommended starting dose. Consider slower titration schedule and lower maintenance dose.,-,-,-
Sertraline,Actionable,PSYCHIATRY,Level 1A(Moderate),CYP2B6 + CYP2C19,No,CYP2B6,CYP2C19,-,Professional guideline,CPIC; DPWG,CYP2B6: Intermediate Metabolizer (n/a) | CYP2C19: Normal Metabolizer (n/a),Intermediate Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Increased Exposure,Use with Caution,-,‚ö†Ô∏è,Use recommended starting dose. Consider slower titration schedule and lower maintenance dose.,-,-,-
Sertraline,Actionable,PSYCHIATRY,Level 1A(Moderate),CYP2B6 + CYP2C19,No,CYP2B6,CYP2C19,-,Professional guideline,CPIC; DPWG,CYP2B6: Intermediate Metabolizer (n/a) | CYP2C19: Poor Metabolizer (n/a),Intermediate Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Consider a lower starting dose, slower titration schedule. Reduce standard maintenance dose to 50% or consider clinically appropriate alternative antidepressant.",-,-,-
Sertraline,Actionable,PSYCHIATRY,Level 1A(Moderate),CYP2B6 + CYP2C19,No,CYP2B6,CYP2C19,-,Professional guideline,CPIC; DPWG,CYP2B6: Intermediate Metabolizer (n/a) | CYP2C19: Rapid Metabolizer (n/a),Intermediate Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Use as Directed,-,‚úÖ,Use recommended starting dose.,-,-,-
Sertraline,Actionable,PSYCHIATRY,Level 1A(Moderate),CYP2B6 + CYP2C19,No,CYP2B6,CYP2C19,-,Professional guideline,CPIC; DPWG,CYP2B6: Intermediate Metabolizer (n/a) | CYP2C19: Ultrarapid Metabolizer (n/a),Intermediate Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Use as Directed,-,‚úÖ,Use recommended starting dose.,-,-,-
Sertraline,Actionable,PSYCHIATRY,n/a,CYP2B6 + CYP2C19,No,CYP2B6,CYP2C19,-,Professional guideline,CPIC; DPWG,CYP2B6: No Result (n/a) | CYP2C19: Indeterminate (n/a),No Result,-,n/a,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,No recommendation,-,-,-,No recommendation,-,-,-
Sertraline,Actionable,PSYCHIATRY,Level 1A(Moderate),CYP2B6 + CYP2C19,No,CYP2B6,CYP2C19,-,Professional guideline,CPIC; DPWG,CYP2B6: No Result (n/a) | CYP2C19: Intermediate Metabolizer (n/a),No Result,-,n/a,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Use as Directed,-,‚úÖ,Use recommended starting dose. Consider slower titration schedule and lower maintenance dose.,-,-,-
Sertraline,Actionable,PSYCHIATRY,Level 1A(Moderate),CYP2B6 + CYP2C19,No,CYP2B6,CYP2C19,-,Professional guideline,CPIC; DPWG,CYP2B6: No Result (n/a) | CYP2C19: Likely Intermediate Metabolizer (n/a),No Result,-,n/a,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Use as Directed,-,‚úÖ,Use recommended starting dose. Consider slower titration schedule and lower maintenance dose.,-,-,-
Sertraline,Actionable,PSYCHIATRY,Level 1A(Moderate),CYP2B6 + CYP2C19,No,CYP2B6,CYP2C19,-,Professional guideline,CPIC; DPWG,CYP2B6: No Result (n/a) | CYP2C19: Likely Poor Metabolizer (n/a),No Result,-,n/a,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Consider a lower starting dose, slower titration schedule. Reduce standard maintenance dose to 50% or consider clinically appropriate alternative antidepressant.",-,-,-
Sertraline,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2B6 + CYP2C19,No,CYP2B6,CYP2C19,-,Professional guideline,CPIC; DPWG,CYP2B6: No Result (n/a) | CYP2C19: Normal Metabolizer (n/a),No Result,-,n/a,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,Use recommended starting dose,-,-,-
Sertraline,Actionable,PSYCHIATRY,Level 1A(Moderate),CYP2B6 + CYP2C19,No,CYP2B6,CYP2C19,-,Professional guideline,CPIC; DPWG,CYP2B6: No Result (n/a) | CYP2C19: Poor Metabolizer (n/a),No Result,-,n/a,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Consider a lower starting dose, slower titration schedule. Reduce standard maintenance dose to 50% or consider clinically appropriate alternative antidepressant.",-,-,-
Sertraline,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2B6 + CYP2C19,No,CYP2B6,CYP2C19,-,Professional guideline,CPIC; DPWG,CYP2B6: No Result (n/a) | CYP2C19: Rapid Metabolizer (n/a),No Result,-,n/a,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Use as Directed,-,‚úÖ,Use recommended starting dose,-,-,-
Sertraline,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2B6 + CYP2C19,No,CYP2B6,CYP2C19,-,Professional guideline,CPIC; DPWG,CYP2B6: No Result (n/a) | CYP2C19: Ultrarapid Metabolizer (n/a),No Result,-,n/a,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Use as Directed,-,‚úÖ,Use recommended starting dose,-,-,-
Sertraline,Actionable,PSYCHIATRY,Level 1A(Moderate),CYP2B6 + CYP2C19,No,CYP2B6,CYP2C19,-,Professional guideline,CPIC; DPWG,CYP2B6: Normal Metabolizer (n/a) | CYP2C19: Indeterminate (n/a),Normal Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,Use recommended starting dose,-,-,-
Sertraline,Actionable,PSYCHIATRY,Level 1A(Moderate),CYP2B6 + CYP2C19,No,CYP2B6,CYP2C19,-,Professional guideline,CPIC; DPWG,CYP2B6: Normal Metabolizer (n/a) | CYP2C19: Intermediate Metabolizer (n/a),Normal Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Use as Directed,-,‚úÖ,Use recommended starting dose. Consider slower titration schedule and lower maintenance dose.,-,-,-
Sertraline,Actionable,PSYCHIATRY,Level 1A(Moderate),CYP2B6 + CYP2C19,No,CYP2B6,CYP2C19,-,Professional guideline,CPIC; DPWG,CYP2B6: Normal Metabolizer (n/a) | CYP2C19: Likely Intermediate Metabolizer (n/a),Normal Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Use as Directed,-,‚úÖ,Use recommended starting dose. Consider slower titration schedule and lower maintenance dose.,-,-,-
Sertraline,Actionable,PSYCHIATRY,Level 1A(Moderate),CYP2B6 + CYP2C19,No,CYP2B6,CYP2C19,-,Professional guideline,CPIC; DPWG,CYP2B6: Normal Metabolizer (n/a) | CYP2C19: Likely Poor Metabolizer (n/a),Normal Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Consider a lower starting dose, slower titration schedule. Reduce standard maintenance dose to 50% or consider clinically appropriate alternative antidepressant.",-,-,-
Sertraline,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2B6 + CYP2C19,No,CYP2B6,CYP2C19,-,Professional guideline,CPIC; DPWG,CYP2B6: Normal Metabolizer (n/a) | CYP2C19: No Result (n/a),Normal Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,Use recommended starting dose,-,-,-
Sertraline,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2B6 + CYP2C19,No,CYP2B6,CYP2C19,-,Professional guideline,CPIC; DPWG,CYP2B6: Normal Metabolizer (n/a) | CYP2C19: Normal Metabolizer (n/a),Normal Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,Use recommended starting dose,-,-,-
Sertraline,Actionable,PSYCHIATRY,Level 1A(Moderate),CYP2B6 + CYP2C19,No,CYP2B6,CYP2C19,-,Professional guideline,CPIC; DPWG,CYP2B6: Normal Metabolizer (n/a) | CYP2C19: Poor Metabolizer (n/a),Normal Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Consider a lower starting dose, slower titration schedule. Reduce standard maintenance dose to 50% or consider clinically appropriate alternative antidepressant.",-,-,-
Sertraline,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2B6 + CYP2C19,No,CYP2B6,CYP2C19,-,Professional guideline,CPIC; DPWG,CYP2B6: Normal Metabolizer (n/a) | CYP2C19: Rapid Metabolizer (n/a),Normal Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Use as Directed,-,‚úÖ,Use recommended starting dose,-,-,-
Sertraline,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2B6 + CYP2C19,No,CYP2B6,CYP2C19,-,Professional guideline,CPIC; DPWG,CYP2B6: Normal Metabolizer (n/a) | CYP2C19: Ultrarapid Metabolizer (n/a),Normal Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Use as Directed,-,‚úÖ,Use recommended starting dose,-,-,-
Sertraline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2B6 + CYP2C19,No,CYP2B6,CYP2C19,-,Professional guideline,CPIC; DPWG,CYP2B6: Poor Metabolizer (n/a) | CYP2C19: Indeterminate (n/a),Poor Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Consider a lower starting dose, slower titration schedule. Reduce standard maintenance dose to 25% or consider clinically appropriate alternative antidepressant.",-,-,-
Sertraline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2B6 + CYP2C19,No,CYP2B6,CYP2C19,-,Professional guideline,CPIC; DPWG,CYP2B6: Poor Metabolizer (n/a) | CYP2C19: Intermediate Metabolizer (n/a),Poor Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Consider a lower starting dose, slower titration schedule. Reduce standard maintenance dose to 50%.",-,-,-
Sertraline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2B6 + CYP2C19,No,CYP2B6,CYP2C19,-,Professional guideline,CPIC; DPWG,CYP2B6: Poor Metabolizer (n/a) | CYP2C19: Likely Intermediate Metabolizer (n/a),Poor Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Consider a lower starting dose, slower titration schedule. Reduce standard maintenance dose to 50%.",-,-,-
Sertraline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2B6 + CYP2C19,No,CYP2B6,CYP2C19,-,Professional guideline,CPIC; DPWG,CYP2B6: Poor Metabolizer (n/a) | CYP2C19: Likely Poor Metabolizer (n/a),Poor Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,Consider an alternative antidepressant.,-,-,-
Sertraline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2B6 + CYP2C19,No,CYP2B6,CYP2C19,-,Professional guideline,CPIC; DPWG,CYP2B6: Poor Metabolizer (n/a) | CYP2C19: No Result (n/a),Poor Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Consider a lower starting dose, slower titration schedule. Reduce standard maintenance dose to 25% or consider clinically appropriate alternative antidepressant.",-,-,-
Sertraline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2B6 + CYP2C19,No,CYP2B6,CYP2C19,-,Professional guideline,CPIC; DPWG,CYP2B6: Poor Metabolizer (n/a) | CYP2C19: Normal Metabolizer (n/a),Poor Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,"Consider a lower starting dose, slower titration schedule. Reduce standard maintenance dose to 25% or consider clinically appropriate alternative antidepressant.",-,-,-
Sertraline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2B6 + CYP2C19,No,CYP2B6,CYP2C19,-,Professional guideline,CPIC; DPWG,CYP2B6: Poor Metabolizer (n/a) | CYP2C19: Poor Metabolizer (n/a),Poor Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,-,üõë,Consider an alternative antidepressant.,-,-,-
Sertraline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2B6 + CYP2C19,No,CYP2B6,CYP2C19,-,Professional guideline,CPIC; DPWG,CYP2B6: Poor Metabolizer (n/a) | CYP2C19: Rapid Metabolizer (n/a),Poor Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Use as Directed,-,‚úÖ,Use recommended starting dose.,-,-,-
Sertraline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2B6 + CYP2C19,No,CYP2B6,CYP2C19,-,Professional guideline,CPIC; DPWG,CYP2B6: Poor Metabolizer (n/a) | CYP2C19: Ultrarapid Metabolizer (n/a),Poor Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Use as Directed,-,‚úÖ,Use recommended starting dose.,-,-,-
Sertraline,Actionable,PSYCHIATRY,Level 1A(Moderate),CYP2B6 + CYP2C19,No,CYP2B6,CYP2C19,-,Professional guideline,CPIC; DPWG,CYP2B6: Rapid Metabolizer (n/a) | CYP2C19: Indeterminate (n/a),Rapid Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Decreased Exposure,Use as Directed,-,‚úÖ,Use recommended starting dose,-,-,-
Sertraline,Actionable,PSYCHIATRY,Level 1A(Moderate),CYP2B6 + CYP2C19,No,CYP2B6,CYP2C19,-,Professional guideline,CPIC; DPWG,CYP2B6: Rapid Metabolizer (n/a) | CYP2C19: Intermediate Metabolizer (n/a),Rapid Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Use as Directed,-,‚úÖ,Use recommended starting dose.,-,-,-
Sertraline,Actionable,PSYCHIATRY,Level 1A(Moderate),CYP2B6 + CYP2C19,No,CYP2B6,CYP2C19,-,Professional guideline,CPIC; DPWG,CYP2B6: Rapid Metabolizer (n/a) | CYP2C19: Likely Intermediate Metabolizer (n/a),Rapid Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Use as Directed,-,‚úÖ,Use recommended starting dose.,-,-,-
Sertraline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2B6 + CYP2C19,No,CYP2B6,CYP2C19,-,Professional guideline,CPIC; DPWG,CYP2B6: Rapid Metabolizer (n/a) | CYP2C19: Likely Poor Metabolizer (n/a),Rapid Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Consider a lower starting dose, slower titration schedule. Reduce standard maintenance dose to 50% or consider clinically appropriate alternative antidepressant.",-,-,-
Sertraline,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2B6 + CYP2C19,No,CYP2B6,CYP2C19,-,Professional guideline,CPIC; DPWG,CYP2B6: Rapid Metabolizer (n/a) | CYP2C19: No Result (n/a),Rapid Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Decreased Exposure,Use as Directed,-,‚úÖ,Use recommended starting dose,-,-,-
Sertraline,Actionable,PSYCHIATRY,Level 1A(Moderate),CYP2B6 + CYP2C19,No,CYP2B6,CYP2C19,-,Professional guideline,CPIC; DPWG,CYP2B6: Rapid Metabolizer (n/a) | CYP2C19: Normal Metabolizer (n/a),Rapid Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Decreased Exposure,Use as Directed,-,‚úÖ,Use recommended starting dose,-,-,-
Sertraline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2B6 + CYP2C19,No,CYP2B6,CYP2C19,-,Professional guideline,CPIC; DPWG,CYP2B6: Rapid Metabolizer (n/a) | CYP2C19: Poor Metabolizer (n/a),Rapid Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Consider a lower starting dose, slower titration schedule. Reduce standard maintenance dose to 50% or consider clinically appropriate alternative antidepressant.",-,-,-
Sertraline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2B6 + CYP2C19,No,CYP2B6,CYP2C19,-,Professional guideline,CPIC; DPWG,CYP2B6: Rapid Metabolizer (n/a) | CYP2C19: Rapid Metabolizer (n/a),Rapid Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Use with Caution,-,‚ö†Ô∏è,"Use recommended starting dose. If patient does not respond, consider titrating to a higher maintenance dose or switch to clinically appropriate alternative antidepressant.",-,-,-
Sertraline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2B6 + CYP2C19,No,CYP2B6,CYP2C19,-,Professional guideline,CPIC; DPWG,CYP2B6: Rapid Metabolizer (n/a) | CYP2C19: Ultrarapid Metabolizer (n/a),Rapid Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Use with Caution,-,‚ö†Ô∏è,"Use recommended starting dose. If patient does not respond, consider titrating to a higher maintenance dose or switch to clinically appropriate alternative antidepressant.",-,-,-
Sertraline,Actionable,PSYCHIATRY,Level 1A(Moderate),CYP2B6 + CYP2C19,No,CYP2B6,CYP2C19,-,Professional guideline,CPIC; DPWG,CYP2B6: Ultrarapid Metabolizer (n/a) | CYP2C19: Indeterminate (n/a),Ultrarapid Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Decreased Exposure,Use as Directed,-,‚úÖ,Use recommended starting dose,-,-,-
Sertraline,Actionable,PSYCHIATRY,Level 1A(Moderate),CYP2B6 + CYP2C19,No,CYP2B6,CYP2C19,-,Professional guideline,CPIC; DPWG,CYP2B6: Ultrarapid Metabolizer (n/a) | CYP2C19: Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Use as Directed,-,‚úÖ,Use recommended starting dose.,-,-,-
Sertraline,Actionable,PSYCHIATRY,Level 1A(Moderate),CYP2B6 + CYP2C19,No,CYP2B6,CYP2C19,-,Professional guideline,CPIC; DPWG,CYP2B6: Ultrarapid Metabolizer (n/a) | CYP2C19: Likely Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Use as Directed,-,‚úÖ,Use recommended starting dose.,-,-,-
Sertraline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2B6 + CYP2C19,No,CYP2B6,CYP2C19,-,Professional guideline,CPIC; DPWG,CYP2B6: Ultrarapid Metabolizer (n/a) | CYP2C19: Likely Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Consider a lower starting dose, slower titration schedule. Reduce standard maintenance dose to 50% or consider clinically appropriate alternative antidepressant.",-,-,-
Sertraline,Actionable,PSYCHIATRY,Level 1A(Moderate),CYP2B6 + CYP2C19,No,CYP2B6,CYP2C19,-,Professional guideline,CPIC; DPWG,CYP2B6: Ultrarapid Metabolizer (n/a) | CYP2C19: No Result (n/a),Ultrarapid Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Decreased Exposure,Use as Directed,-,‚úÖ,Use recommended starting dose,-,-,-
Sertraline,Actionable,PSYCHIATRY,Level 1A(Moderate),CYP2B6 + CYP2C19,No,CYP2B6,CYP2C19,-,Professional guideline,CPIC; DPWG,CYP2B6: Ultrarapid Metabolizer (n/a) | CYP2C19: Normal Metabolizer (n/a),Ultrarapid Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Decreased Exposure,Use with Caution,-,‚ö†Ô∏è,Use recommended starting dose,-,-,-
Sertraline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2B6 + CYP2C19,No,CYP2B6,CYP2C19,-,Professional guideline,CPIC; DPWG,CYP2B6: Ultrarapid Metabolizer (n/a) | CYP2C19: Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,-,üõë,"Consider a lower starting dose, slower titration schedule. Reduce standard maintenance dose to 50% or consider clinically appropriate alternative antidepressant.",-,-,-
Sertraline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2B6 + CYP2C19,No,CYP2B6,CYP2C19,-,Professional guideline,CPIC; DPWG,CYP2B6: Ultrarapid Metabolizer (n/a) | CYP2C19: Rapid Metabolizer (n/a),Ultrarapid Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Use with Caution,-,‚ö†Ô∏è,"Use recommended starting dose. If patient does not respond, consider titrating to a higher maintenance dose or switch to clinically appropriate alternative antidepressant.",-,-,-
Sertraline,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2B6 + CYP2C19,No,CYP2B6,CYP2C19,-,Professional guideline,CPIC; DPWG,CYP2B6: Ultrarapid Metabolizer (n/a) | CYP2C19: Ultrarapid Metabolizer (n/a),Ultrarapid Metabolizer,-,n/a,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Use with Caution,-,‚ö†Ô∏è,"Use recommended starting dose. If patient does not respond, consider titrating to a higher maintenance dose or switch to clinically appropriate alternative antidepressant.",-,-,-
Thioridazine,Actionable,PSYCHIATRY,Level 1AA,CYP2D6,Yes,CYP2D6,-,-,FDA evidence,-,Ultrarapid Metabolizer (>2),Ultrarapid Metabolizer,-,>2,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure,Use with Caution,Efficacy,‚ö†Ô∏è,-,-,-,-
Thioridazine,Actionable,PSYCHIATRY,Level 1AA,CYP2D6,Yes,CYP2D6,-,-,FDA evidence,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Thioridazine,Actionable,PSYCHIATRY,Level 1AA,CYP2D6,Yes,CYP2D6,-,-,FDA evidence,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Thioridazine,Actionable,PSYCHIATRY,Level 1A,CYP2D6,Yes,CYP2D6,-,-,FDA evidence,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Risk of ADR (QT prolongation),Increased Caution/Avoid,Toxicity,üõë,Contraindicated in poor metabolizers.,-,-,-
Trazodone,Actionable,PSYCHIATRY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Trazodone,Actionable,PSYCHIATRY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK or Clinical Effects,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Trazodone,Actionable,PSYCHIATRY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK or Clinical Effects,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Poor Metabolizer (0.0) | CYP2C19: Indeterminate (n/a),Poor Metabolizer,-,0,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, reduce initial dose to 50%. Adjust dosage based on therapeutic drug monitoring. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Poor Metabolizer (0.0) | CYP2C19: Intermediate Metabolizer (n/a),Poor Metabolizer,-,0,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, consider 50% reduction of recommended starting dose. Adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Poor Metabolizer (0.0) | CYP2C19: Likely Intermediate Metabolizer (n/a),Poor Metabolizer,-,0,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, consider 50% reduction of recommended starting dose. Adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Poor Metabolizer (0.0) | CYP2C19: Likely Poor Metabolizer (n/a),Poor Metabolizer,-,0,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Poor Metabolizer (0.0) | CYP2C19: No Result (n/a),Poor Metabolizer,-,0,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, reduce initial dose to 50%. Adjust dosage based on therapeutic drug monitoring. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Poor Metabolizer (0.0) | CYP2C19: Normal Metabolizer (n/a),Poor Metabolizer,-,0,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, reduce initial dose to 50%. Adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Poor Metabolizer (0.0) | CYP2C19: Poor Metabolizer (n/a),Poor Metabolizer,-,0,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Poor Metabolizer (0.0) | CYP2C19: Rapid Metabolizer (n/a),Poor Metabolizer,-,0,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Poor Metabolizer (0.0) | CYP2C19: Ultrarapid Metabolizer (n/a),Poor Metabolizer,-,0,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Intermediate Metabolizer (0.25) | CYP2C19: Indeterminate (n/a),Intermediate Metabolizer,-,0.25,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,Reduce initial dose to 25%. Adjust dosage based on therapeutic drug monitoring. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.,-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Intermediate Metabolizer (0.25) | CYP2C19: Intermediate Metabolizer (n/a),Intermediate Metabolizer,-,0.25,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,Reduce initial dose to 25%. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Intermediate Metabolizer (0.25) | CYP2C19: Likely Intermediate Metabolizer (n/a),Intermediate Metabolizer,-,0.25,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,Reduce initial dose to 25%. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Intermediate Metabolizer (0.25) | CYP2C19: Likely Poor Metabolizer (n/a),Intermediate Metabolizer,-,0.25,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Intermediate Metabolizer (0.25) | CYP2C19: No Result (n/a),Intermediate Metabolizer,-,0.25,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,Reduce initial dose to 25%. Adjust dosage based on therapeutic drug monitoring. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.,-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Intermediate Metabolizer (0.25) | CYP2C19: Normal Metabolizer (n/a),Intermediate Metabolizer,-,0.25,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,Reduce initial dose to 25%. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Intermediate Metabolizer (0.25) | CYP2C19: Poor Metabolizer (n/a),Intermediate Metabolizer,-,0.25,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Intermediate Metabolizer (0.25) | CYP2C19: Rapid Metabolizer (n/a),Intermediate Metabolizer,-,0.25,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,Efficacy,üõë,"Consider using an alternative agent. If trimipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Intermediate Metabolizer (0.25) | CYP2C19: Ultrarapid Metabolizer (n/a),Intermediate Metabolizer,-,0.25,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,Efficacy,üõë,"Consider using an alternative agent. If trimipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Intermediate Metabolizer (0.5) | CYP2C19: Indeterminate (n/a),Intermediate Metabolizer,-,0.5,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,Reduce initial dose to 25%. Adjust dosage based on therapeutic drug monitoring. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.,-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Intermediate Metabolizer (0.5) | CYP2C19: Intermediate Metabolizer (n/a),Intermediate Metabolizer,-,0.5,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,Reduce initial dose to 25%. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Intermediate Metabolizer (0.5) | CYP2C19: Likely Intermediate Metabolizer (n/a),Intermediate Metabolizer,-,0.5,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,Reduce initial dose to 25%. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Intermediate Metabolizer (0.5) | CYP2C19: Likely Poor Metabolizer (n/a),Intermediate Metabolizer,-,0.5,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Intermediate Metabolizer (0.5) | CYP2C19: No Result (n/a),Intermediate Metabolizer,-,0.5,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,Reduce initial dose to 25%. Adjust dosage based on therapeutic drug monitoring. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.,-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Intermediate Metabolizer (0.5) | CYP2C19: Normal Metabolizer (n/a),Intermediate Metabolizer,-,0.5,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,Reduce initial dose to 25%. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Intermediate Metabolizer (0.5) | CYP2C19: Poor Metabolizer (n/a),Intermediate Metabolizer,-,0.5,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Intermediate Metabolizer (0.5) | CYP2C19: Rapid Metabolizer (n/a),Intermediate Metabolizer,-,0.5,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,Efficacy,üõë,"Consider using an alternative agent. If trimipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Intermediate Metabolizer (0.5) | CYP2C19: Ultrarapid Metabolizer (n/a),Intermediate Metabolizer,-,0.5,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,Efficacy,üõë,"Consider using an alternative agent. If trimipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Intermediate Metabolizer (0.75) | CYP2C19: Indeterminate (n/a),Intermediate Metabolizer,-,0.75,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,Reduce initial dose to 25%. Adjust dosage based on therapeutic drug monitoring. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.,-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Intermediate Metabolizer (0.75) | CYP2C19: Intermediate Metabolizer (n/a),Intermediate Metabolizer,-,0.75,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,Reduce initial dose to 25%. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Intermediate Metabolizer (0.75) | CYP2C19: Likely Intermediate Metabolizer (n/a),Intermediate Metabolizer,-,0.75,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,Reduce initial dose to 25%. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Intermediate Metabolizer (0.75) | CYP2C19: Likely Poor Metabolizer (n/a),Intermediate Metabolizer,-,0.75,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Intermediate Metabolizer (0.75) | CYP2C19: No Result (n/a),Intermediate Metabolizer,-,0.75,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,Reduce initial dose to 25%. Adjust dosage based on therapeutic drug monitoring. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.,-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Intermediate Metabolizer (0.75) | CYP2C19: Normal Metabolizer (n/a),Intermediate Metabolizer,-,0.75,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,Reduce initial dose to 25%. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Intermediate Metabolizer (0.75) | CYP2C19: Poor Metabolizer (n/a),Intermediate Metabolizer,-,0.75,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Intermediate Metabolizer (0.75) | CYP2C19: Rapid Metabolizer (n/a),Intermediate Metabolizer,-,0.75,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,Efficacy,üõë,"Consider using an alternative agent. If trimipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Intermediate Metabolizer (0.75) | CYP2C19: Ultrarapid Metabolizer (n/a),Intermediate Metabolizer,-,0.75,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,Efficacy,üõë,"Consider using an alternative agent. If trimipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Intermediate Metabolizer (1.0) | CYP2C19: Indeterminate (n/a),Intermediate Metabolizer,-,1,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,Reduce initial dose to 25%. Adjust dosage based on therapeutic drug monitoring. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.,-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Intermediate Metabolizer (1.0) | CYP2C19: Intermediate Metabolizer (n/a),Intermediate Metabolizer,-,1,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,Reduce initial dose to 25%. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Intermediate Metabolizer (1.0) | CYP2C19: Likely Intermediate Metabolizer (n/a),Intermediate Metabolizer,-,1,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,Reduce initial dose to 25%. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Intermediate Metabolizer (1.0) | CYP2C19: Likely Poor Metabolizer (n/a),Intermediate Metabolizer,-,1,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Intermediate Metabolizer (1.0) | CYP2C19: No Result (n/a),Intermediate Metabolizer,-,1,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,Reduce initial dose to 25%. Adjust dosage based on therapeutic drug monitoring. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.,-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Intermediate Metabolizer (1.0) | CYP2C19: Normal Metabolizer (n/a),Intermediate Metabolizer,-,1,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,Reduce initial dose to 25%. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Intermediate Metabolizer (1.0) | CYP2C19: Poor Metabolizer (n/a),Intermediate Metabolizer,-,1,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Intermediate Metabolizer (1.0) | CYP2C19: Rapid Metabolizer (n/a),Intermediate Metabolizer,-,1,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,Efficacy,üõë,"Consider using an alternative agent. If trimipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Intermediate Metabolizer (1.0) | CYP2C19: Ultrarapid Metabolizer (n/a),Intermediate Metabolizer,-,1,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,Efficacy,üõë,"Consider using an alternative agent. If trimipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Normal Metabolizer (1.25) | CYP2C19: Indeterminate (n/a),Normal Metabolizer,-,1.25,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Normal Exposure,No recommendation,-,-,No recommendation,-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Normal Metabolizer (1.25) | CYP2C19: Intermediate Metabolizer (n/a),Normal Metabolizer,-,1.25,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Use with Caution,-,‚ö†Ô∏è,Use recommended starting dose.,-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Normal Metabolizer (1.25) | CYP2C19: Likely Intermediate Metabolizer (n/a),Normal Metabolizer,-,1.25,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Use with Caution,-,‚ö†Ô∏è,Use recommended starting dose.,-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Normal Metabolizer (1.25) | CYP2C19: Likely Poor Metabolizer (n/a),Normal Metabolizer,-,1.25,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, reduce initial dose to 50%. Adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Normal Metabolizer (1.25) | CYP2C19: No Result (n/a),Normal Metabolizer,-,1.25,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Normal Exposure,Use with Caution,-,‚ö†Ô∏è,Use recommended starting dose,-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Normal Metabolizer (1.25) | CYP2C19: Normal Metabolizer (n/a),Normal Metabolizer,-,1.25,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,Use recommended starting dose,-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Normal Metabolizer (1.25) | CYP2C19: Poor Metabolizer (n/a),Normal Metabolizer,-,1.25,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, reduce initial dose to 50%. Adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Normal Metabolizer (1.25) | CYP2C19: Rapid Metabolizer (n/a),Normal Metabolizer,-,1.25,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,Efficacy,üõë,Consider using an alternative agent. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Normal Metabolizer (1.25) | CYP2C19: Ultrarapid Metabolizer (n/a),Normal Metabolizer,-,1.25,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,Efficacy,üõë,Consider using an alternative agent. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Normal Metabolizer (1.5) | CYP2C19: Indeterminate (n/a),Normal Metabolizer,-,1.5,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Normal Exposure,No recommendation,-,-,No recommendation,-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Normal Metabolizer (1.5) | CYP2C19: Intermediate Metabolizer (n/a),Normal Metabolizer,-,1.5,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Use with Caution,-,‚ö†Ô∏è,Use recommended starting dose.,-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Normal Metabolizer (1.5) | CYP2C19: Likely Intermediate Metabolizer (n/a),Normal Metabolizer,-,1.5,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Use with Caution,-,‚ö†Ô∏è,Use recommended starting dose.,-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Normal Metabolizer (1.5) | CYP2C19: Likely Poor Metabolizer (n/a),Normal Metabolizer,-,1.5,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, reduce initial dose to 50%. Adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Normal Metabolizer (1.5) | CYP2C19: No Result (n/a),Normal Metabolizer,-,1.5,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Normal Exposure,Use with Caution,-,‚ö†Ô∏è,Use recommended starting dose,-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Normal Metabolizer (1.5) | CYP2C19: Normal Metabolizer (n/a),Normal Metabolizer,-,1.5,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,Use recommended starting dose,-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Normal Metabolizer (1.5) | CYP2C19: Poor Metabolizer (n/a),Normal Metabolizer,-,1.5,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, reduce initial dose to 50%. Adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Normal Metabolizer (1.5) | CYP2C19: Rapid Metabolizer (n/a),Normal Metabolizer,-,1.5,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,Efficacy,üõë,Consider using an alternative agent. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Normal Metabolizer (1.5) | CYP2C19: Ultrarapid Metabolizer (n/a),Normal Metabolizer,-,1.5,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,Efficacy,üõë,Consider using an alternative agent. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Normal Metabolizer (1.75) | CYP2C19: Indeterminate (n/a),Normal Metabolizer,-,1.75,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Normal Exposure,No recommendation,-,-,No recommendation,-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Normal Metabolizer (1.75) | CYP2C19: Intermediate Metabolizer (n/a),Normal Metabolizer,-,1.75,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Use with Caution,-,‚ö†Ô∏è,Use recommended starting dose.,-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Normal Metabolizer (1.75) | CYP2C19: Likely Intermediate Metabolizer (n/a),Normal Metabolizer,-,1.75,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Use with Caution,-,‚ö†Ô∏è,Use recommended starting dose.,-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Normal Metabolizer (1.75) | CYP2C19: Likely Poor Metabolizer (n/a),Normal Metabolizer,-,1.75,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, reduce initial dose to 50%. Adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Normal Metabolizer (1.75) | CYP2C19: No Result (n/a),Normal Metabolizer,-,1.75,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Normal Exposure,Use with Caution,-,‚ö†Ô∏è,Use recommended starting dose,-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Normal Metabolizer (1.75) | CYP2C19: Normal Metabolizer (n/a),Normal Metabolizer,-,1.75,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,Use recommended starting dose,-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Normal Metabolizer (1.75) | CYP2C19: Poor Metabolizer (n/a),Normal Metabolizer,-,1.75,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, reduce initial dose to 50%. Adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Normal Metabolizer (1.75) | CYP2C19: Rapid Metabolizer (n/a),Normal Metabolizer,-,1.75,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,Efficacy,üõë,Consider using an alternative agent. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Normal Metabolizer (1.75) | CYP2C19: Ultrarapid Metabolizer (n/a),Normal Metabolizer,-,1.75,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,Efficacy,üõë,Consider using an alternative agent. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Normal Metabolizer (2.0) | CYP2C19: Indeterminate (n/a),Normal Metabolizer,-,2,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Normal Exposure,No recommendation,-,-,No recommendation,-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Normal Metabolizer (2.0) | CYP2C19: Intermediate Metabolizer (n/a),Normal Metabolizer,-,2,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Use with Caution,-,‚ö†Ô∏è,Use recommended starting dose.,-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Normal Metabolizer (2.0) | CYP2C19: Likely Intermediate Metabolizer (n/a),Normal Metabolizer,-,2,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Use with Caution,-,‚ö†Ô∏è,Use recommended starting dose.,-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Normal Metabolizer (2.0) | CYP2C19: Likely Poor Metabolizer (n/a),Normal Metabolizer,-,2,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, reduce initial dose to 50%. Adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Normal Metabolizer (2.0) | CYP2C19: No Result (n/a),Normal Metabolizer,-,2,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Normal Exposure,Use with Caution,-,‚ö†Ô∏è,Use recommended starting dose,-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Normal Metabolizer (2.0) | CYP2C19: Normal Metabolizer (n/a),Normal Metabolizer,-,2,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,Use recommended starting dose,-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Normal Metabolizer (2.0) | CYP2C19: Poor Metabolizer (n/a),Normal Metabolizer,-,2,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, reduce initial dose to 50%. Adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Normal Metabolizer (2.0) | CYP2C19: Rapid Metabolizer (n/a),Normal Metabolizer,-,2,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,Efficacy,üõë,Consider using an alternative agent. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Normal Metabolizer (2.0) | CYP2C19: Ultrarapid Metabolizer (n/a),Normal Metabolizer,-,2,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,Efficacy,üõë,Consider using an alternative agent. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Normal Metabolizer (2.25) | CYP2C19: Indeterminate (n/a),Normal Metabolizer,-,2.25,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Normal Exposure,No recommendation,-,-,No recommendation,-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Normal Metabolizer (2.25) | CYP2C19: Intermediate Metabolizer (n/a),Normal Metabolizer,-,2.25,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Use with Caution,-,‚ö†Ô∏è,Use recommended starting dose.,-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Normal Metabolizer (2.25) | CYP2C19: Likely Intermediate Metabolizer (n/a),Normal Metabolizer,-,2.25,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Use with Caution,-,‚ö†Ô∏è,Use recommended starting dose.,-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Normal Metabolizer (2.25) | CYP2C19: Likely Poor Metabolizer (n/a),Normal Metabolizer,-,2.25,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, reduce initial dose to 50%. Adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Normal Metabolizer (2.25) | CYP2C19: No Result (n/a),Normal Metabolizer,-,2.25,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Normal Exposure,Use with Caution,-,‚ö†Ô∏è,Use recommended starting dose,-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Normal Metabolizer (2.25) | CYP2C19: Normal Metabolizer (n/a),Normal Metabolizer,-,2.25,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,Use recommended starting dose,-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Normal Metabolizer (2.25) | CYP2C19: Poor Metabolizer (n/a),Normal Metabolizer,-,2.25,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, reduce initial dose to 50%. Adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Normal Metabolizer (2.25) | CYP2C19: Rapid Metabolizer (n/a),Normal Metabolizer,-,2.25,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,Efficacy,üõë,Consider using an alternative agent. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Normal Metabolizer (2.25) | CYP2C19: Ultrarapid Metabolizer (n/a),Normal Metabolizer,-,2.25,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,Efficacy,üõë,Consider using an alternative agent. Adjust dosage based on therapeutic drug monitoring.,-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (2.5) | CYP2C19: Indeterminate (n/a),Ultrarapid Metabolizer,-,2.5,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (2.5) | CYP2C19: Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,2.5,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (2.5) | CYP2C19: Likely Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,2.5,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (2.5) | CYP2C19: Likely Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,2.5,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (2.5) | CYP2C19: No Result (n/a),Ultrarapid Metabolizer,-,2.5,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (2.5) | CYP2C19: Normal Metabolizer (n/a),Ultrarapid Metabolizer,-,2.5,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, titrate to a higher target dose. Adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (2.5) | CYP2C19: Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,2.5,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (2.5) | CYP2C19: Rapid Metabolizer (n/a),Ultrarapid Metabolizer,-,2.5,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (2.5) | CYP2C19: Ultrarapid Metabolizer (n/a),Ultrarapid Metabolizer,-,2.5,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (‚â•3.0) | CYP2C19: Indeterminate (n/a),Ultrarapid Metabolizer,-,‚â•3.0,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (‚â•3.0) | CYP2C19: Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.0,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (‚â•3.0) | CYP2C19: Likely Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.0,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (‚â•3.0) | CYP2C19: Likely Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.0,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (‚â•3.0) | CYP2C19: No Result (n/a),Ultrarapid Metabolizer,-,‚â•3.0,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (‚â•3.0) | CYP2C19: Normal Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.0,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, titrate to a higher target dose. Adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (‚â•3.0) | CYP2C19: Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.0,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (‚â•3.0) | CYP2C19: Rapid Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.0,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (‚â•3.0) | CYP2C19: Ultrarapid Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.0,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (3.0) | CYP2C19: Indeterminate (n/a),Ultrarapid Metabolizer,-,3,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (3.0) | CYP2C19: Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,3,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (3.0) | CYP2C19: Likely Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,3,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (3.0) | CYP2C19: Likely Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,3,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (3.0) | CYP2C19: No Result (n/a),Ultrarapid Metabolizer,-,3,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (3.0) | CYP2C19: Normal Metabolizer (n/a),Ultrarapid Metabolizer,-,3,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, titrate to a higher target dose. Adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (3.0) | CYP2C19: Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,3,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (3.0) | CYP2C19: Rapid Metabolizer (n/a),Ultrarapid Metabolizer,-,3,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (3.0) | CYP2C19: Ultrarapid Metabolizer (n/a),Ultrarapid Metabolizer,-,3,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (‚â•3.25) | CYP2C19: Indeterminate (n/a),Ultrarapid Metabolizer,-,‚â•3.25,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (‚â•3.25) | CYP2C19: Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.25,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (‚â•3.25) | CYP2C19: Likely Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.25,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (‚â•3.25) | CYP2C19: Likely Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.25,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (‚â•3.25) | CYP2C19: No Result (n/a),Ultrarapid Metabolizer,-,‚â•3.25,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (‚â•3.25) | CYP2C19: Normal Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.25,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, titrate to a higher target dose. Adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (‚â•3.25) | CYP2C19: Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.25,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (‚â•3.25) | CYP2C19: Rapid Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.25,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (‚â•3.25) | CYP2C19: Ultrarapid Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.25,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (‚â•3.5) | CYP2C19: Indeterminate (n/a),Ultrarapid Metabolizer,-,‚â•3.5,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (‚â•3.5) | CYP2C19: Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.5,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (‚â•3.5) | CYP2C19: Likely Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.5,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (‚â•3.5) | CYP2C19: Likely Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.5,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (‚â•3.5) | CYP2C19: No Result (n/a),Ultrarapid Metabolizer,-,‚â•3.5,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (‚â•3.5) | CYP2C19: Normal Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.5,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, titrate to a higher target dose. Adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (‚â•3.5) | CYP2C19: Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.5,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (‚â•3.5) | CYP2C19: Rapid Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.5,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (‚â•3.5) | CYP2C19: Ultrarapid Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•3.5,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (3.5) | CYP2C19: Indeterminate (n/a),Ultrarapid Metabolizer,-,3.5,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (3.5) | CYP2C19: Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,3.5,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (3.5) | CYP2C19: Likely Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,3.5,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (3.5) | CYP2C19: Likely Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,3.5,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (3.5) | CYP2C19: No Result (n/a),Ultrarapid Metabolizer,-,3.5,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (3.5) | CYP2C19: Normal Metabolizer (n/a),Ultrarapid Metabolizer,-,3.5,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, titrate to a higher target dose. Adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (3.5) | CYP2C19: Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,3.5,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (3.5) | CYP2C19: Rapid Metabolizer (n/a),Ultrarapid Metabolizer,-,3.5,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (3.5) | CYP2C19: Ultrarapid Metabolizer (n/a),Ultrarapid Metabolizer,-,3.5,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (‚â•4.0) | CYP2C19: Indeterminate (n/a),Ultrarapid Metabolizer,-,‚â•4.0,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (‚â•4.0) | CYP2C19: Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•4.0,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (‚â•4.0) | CYP2C19: Likely Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•4.0,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (‚â•4.0) | CYP2C19: Likely Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•4.0,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (‚â•4.0) | CYP2C19: No Result (n/a),Ultrarapid Metabolizer,-,‚â•4.0,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (‚â•4.0) | CYP2C19: Normal Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•4.0,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, titrate to a higher target dose. Adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (‚â•4.0) | CYP2C19: Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•4.0,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (‚â•4.0) | CYP2C19: Rapid Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•4.0,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (‚â•4.0) | CYP2C19: Ultrarapid Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•4.0,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (4.0) | CYP2C19: Indeterminate (n/a),Ultrarapid Metabolizer,-,4,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (4.0) | CYP2C19: Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,4,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (4.0) | CYP2C19: Likely Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,4,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (4.0) | CYP2C19: Likely Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,4,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (4.0) | CYP2C19: No Result (n/a),Ultrarapid Metabolizer,-,4,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (4.0) | CYP2C19: Normal Metabolizer (n/a),Ultrarapid Metabolizer,-,4,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, titrate to a higher target dose. Adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (4.0) | CYP2C19: Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,4,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (4.0) | CYP2C19: Rapid Metabolizer (n/a),Ultrarapid Metabolizer,-,4,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (4.0) | CYP2C19: Ultrarapid Metabolizer (n/a),Ultrarapid Metabolizer,-,4,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (‚â•4.5) | CYP2C19: Indeterminate (n/a),Ultrarapid Metabolizer,-,‚â•4.5,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (‚â•4.5) | CYP2C19: Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•4.5,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (‚â•4.5) | CYP2C19: Likely Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•4.5,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (‚â•4.5) | CYP2C19: Likely Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•4.5,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (‚â•4.5) | CYP2C19: No Result (n/a),Ultrarapid Metabolizer,-,‚â•4.5,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (‚â•4.5) | CYP2C19: Normal Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•4.5,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, titrate to a higher target dose. Adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (‚â•4.5) | CYP2C19: Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•4.5,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (‚â•4.5) | CYP2C19: Rapid Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•4.5,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (‚â•4.5) | CYP2C19: Ultrarapid Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•4.5,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (‚â•5.0) | CYP2C19: Indeterminate (n/a),Ultrarapid Metabolizer,-,‚â•5.0,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (‚â•5.0) | CYP2C19: Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•5.0,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (‚â•5.0) | CYP2C19: Likely Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•5.0,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (‚â•5.0) | CYP2C19: Likely Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•5.0,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (‚â•5.0) | CYP2C19: No Result (n/a),Ultrarapid Metabolizer,-,‚â•5.0,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (‚â•5.0) | CYP2C19: Normal Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•5.0,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, titrate to a higher target dose. Adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (‚â•5.0) | CYP2C19: Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•5.0,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (‚â•5.0) | CYP2C19: Rapid Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•5.0,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (‚â•5.0) | CYP2C19: Ultrarapid Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•5.0,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (‚â•6.0) | CYP2C19: Indeterminate (n/a),Ultrarapid Metabolizer,-,‚â•6.0,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (‚â•6.0) | CYP2C19: Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•6.0,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (‚â•6.0) | CYP2C19: Likely Intermediate Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•6.0,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (‚â•6.0) | CYP2C19: Likely Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•6.0,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (‚â•6.0) | CYP2C19: No Result (n/a),Ultrarapid Metabolizer,-,‚â•6.0,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Avoid tricyclic use. Consider using an alternative agent. If TCA is warranted, consider titrating to a higher target dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Adjust dosage based on therapeutic drug monitoring.
",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (‚â•6.0) | CYP2C19: Normal Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•6.0,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, titrate to a higher target dose. Adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (‚â•6.0) | CYP2C19: Poor Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•6.0,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Total exposure to active compound(s) is difficult to predict,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (‚â•6.0) | CYP2C19: Rapid Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•6.0,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Ultrarapid Metabolizer (‚â•6.0) | CYP2C19: Ultrarapid Metabolizer (n/a),Ultrarapid Metabolizer,-,‚â•6.0,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Avoid trimipramine use. If trimipramine is warranted, adjust dosage based on therapeutic drug monitoring.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Indeterminate (n/a) | CYP2C19: Indeterminate (n/a),Indeterminate,-,n/a,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,No recommendation,No recommendation,-,-,No recommendation,-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Indeterminate (n/a) | CYP2C19: Intermediate Metabolizer (n/a),Indeterminate,-,n/a,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Use with Caution,-,-,-,-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Indeterminate (n/a) | CYP2C19: Likely Intermediate Metabolizer (n/a),Indeterminate,-,n/a,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Use with Caution,-,-,-,-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Indeterminate (n/a) | CYP2C19: Likely Poor Metabolizer (n/a),Indeterminate,-,n/a,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Avoid tertiary amine use. Consider alternative agents: Secondary amines nortriptyline and desipramine. If tertiary amine is warranted, reduce initial dose to 50%. Adjust dosage based on therapeutic drug monitoting. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Indeterminate (n/a) | CYP2C19: No Result (n/a),Indeterminate,-,n/a,-,-,-,-,-,-,-,-,-,-,No Result,-,n/a,-,-,-,No recommendation,No recommendation,-,-,No recommendation,-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Indeterminate (n/a) | CYP2C19: Normal Metabolizer (n/a),Indeterminate,-,n/a,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Normal Exposure,No recommendation,-,-,No recommendation,-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Indeterminate (n/a) | CYP2C19: Poor Metabolizer (n/a),Indeterminate,-,n/a,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Avoid tertiary amine use. Consider alternative agents: Secondary amines nortriptyline and desipramine. If tertiary amine is warranted, reduce initial dose to 50%. Adjust dosage based on therapeutic drug monitoting. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Indeterminate (n/a) | CYP2C19: Rapid Metabolizer (n/a),Indeterminate,-,n/a,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Avoid tertiary amine use. Consider alternative agents: Secondary amines nortriptyline and desipramine. If tertiary amine is warranted, adjust dosage based on therapeutic drug monitoting.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: Indeterminate (n/a) | CYP2C19: Ultrarapid Metabolizer (n/a),Indeterminate,-,n/a,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Avoid tertiary amine use. Consider alternative agents: Secondary amines nortriptyline and desipramine. If tertiary amine is warranted, adjust dosage based on therapeutic drug monitoting.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: No Result (No Result) | CYP2C19: Indeterminate (n/a),No Result,-,n/a,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,n/a,-,-,-,No recommendation,No recommendation,-,-,No recommendation,-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: No Result (No Result) | CYP2C19: Intermediate Metabolizer (n/a),No Result,-,n/a,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Use with Caution,-,‚ö†Ô∏è,Use recommended starting dose.,-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: No Result (No Result) | CYP2C19: Likely Intermediate Metabolizer (n/a),No Result,-,n/a,-,-,-,-,-,-,-,-,-,-,Likely Intermediate Metabolizer,-,n/a,-,-,-,Increased Exposure,Use with Caution,-,‚ö†Ô∏è,Use recommended starting dose.,-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: No Result (No Result) | CYP2C19: Likely Poor Metabolizer (n/a),No Result,-,n/a,-,-,-,-,-,-,-,-,-,-,Likely Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Avoid tertiary amine use. Consider alternative agents: Secondary amines nortriptyline and desipramine. If tertiary amine is warranted, reduce initial dose to 50%. Adjust dosage based on therapeutic drug monitoting. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: No Result (No Result) | CYP2C19: Normal Metabolizer (n/a),No Result,-,n/a,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,n/a,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,Use recommended starting dose,-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: No Result (No Result) | CYP2C19: Poor Metabolizer (n/a),No Result,-,n/a,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,n/a,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Avoid tertiary amine use. Consider alternative agents: Secondary amines nortriptyline and desipramine. If tertiary amine is warranted, reduce initial dose to 50%. Adjust dosage based on therapeutic drug monitoting. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: No Result (No Result) | CYP2C19: Rapid Metabolizer (n/a),No Result,-,n/a,-,-,-,-,-,-,-,-,-,-,Rapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Avoid tertiary amine use. Consider alternative agents: Secondary amines nortriptyline and desipramine. If tertiary amine is warranted, adjust dosage based on therapeutic drug monitoting.",-,-,-
Trimipramine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6 + CYP2C19,No,CYP2D6,CYP2C19,-,Professional guideline; FDA evidence,CPIC,CYP2D6: No Result (No Result) | CYP2C19: Ultrarapid Metabolizer (n/a),No Result,-,n/a,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,n/a,-,-,-,Decreased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Avoid tertiary amine use. Consider alternative agents: Secondary amines nortriptyline and desipramine. If tertiary amine is warranted, adjust dosage based on therapeutic drug monitoting.",-,-,-
Venlafaxine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6,Yes,CYP2D6,-,-,Professional guideline; FDA evidence,CPIC; DPWG,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure; Increased Risk of ADR,Increased Caution/Avoid,Efficacy/Toxicity,üõë,Consider non-CYP2D6-metabolized drug,-,-,-
Venlafaxine,Actionable,PSYCHIATRY,Level 1A(No Recommendation),CYP2D6,Yes,CYP2D6,-,-,Professional guideline; FDA evidence,CPIC; DPWG,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure,Use with Caution,-,‚ö†Ô∏è,No recommendation,-,-,-
Venlafaxine,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6,Yes,CYP2D6,-,-,Professional guideline; FDA evidence,CPIC; DPWG,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,Use recommended starting dose,-,-,-
Venlafaxine,Actionable,PSYCHIATRY,Level 1A(No Recommendation),CYP2D6,Yes,CYP2D6,-,-,Professional guideline; FDA evidence,CPIC; DPWG,Ultrarapid Metabolizer (>2),Ultrarapid Metabolizer,-,>2,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,-,‚ö†Ô∏è,No recommendation,-,-,-
Venlafaxine,Actionable,PSYCHIATRY,Level 1A(No Recommendation),CYP2D6,Yes,CYP2D6,-,-,Professional guideline; FDA evidence,CPIC; DPWG,Indeterminate,Indeterminate,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,n/a,No recommendation,-,-,No recommendation,-,-,-
Vilazodone,Actionable,PSYCHIATRY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,CPIC (No Recommendation),Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Vilazodone,Actionable,PSYCHIATRY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,CPIC (No Recommendation),Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK or Clinical Effects,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Vilazodone,Actionable,PSYCHIATRY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,CPIC (No Recommendation),Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK or Clinical Effects,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Vortioxetine,Actionable,PSYCHIATRY,Level 1A(Moderate),CYP2D6,Yes,CYP2D6,-,-,Professional guideline; FDA evidence,CPIC,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Start at 50% of the initial dose, increase to 10 mg maximum, or try a different antidepressant not heavily metabolized by CYP2D6",-,-,-
Vortioxetine,Actionable,PSYCHIATRY,Level 1A(Moderate),CYP2D6,Yes,CYP2D6,-,-,Professional guideline; FDA evidence,CPIC,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,Toxicity,‚ö†Ô∏è,Use recommended starting dose,-,-,-
Vortioxetine,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2D6,Yes,CYP2D6,-,-,Professional guideline; FDA evidence,CPIC,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,Use recommended starting dose,-,-,-
Vortioxetine,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2D6,Yes,CYP2D6,-,-,Professional guideline; FDA evidence,CPIC,Ultrarapid Metabolizer (>2),Ultrarapid Metabolizer,-,>2,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure,Increased Caution/Avoid,Efficacy,üõë,"Consider non-CYP2D6-metabolized drug. If using vortioxetine, start at standard dose, adjust based on effectiveness and side effects. Higher maintenance dose may be required for efficacy.",-,-,-
Vortioxetine,Actionable,PSYCHIATRY,n/a,CYP2D6,Yes,CYP2D6,-,-,Professional guideline; FDA evidence,CPIC,Indeterminate,Indeterminate,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,n/a,No recommendation,-,-,No recommendation,-,-,-
Alprazolam,Actionable,PSYCHIATRY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Alprazolam,Actionable,PSYCHIATRY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure; Increased risk of ADR,Use with Caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Alprazolam,Actionable,PSYCHIATRY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure; Increased risk of ADR,Use with Caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Aripiprazole,Actionable,PSYCHIATRY,Level 1A,CYP2D6,Yes,CYP2D6,-,-,FDA evidence; Professional guideline,DPWG,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,Administer no more than 10 mg/day or 300 mg/month [DPWG]; Administer half of usual dose [FDA for ABILIFY]; Administer 300mg of ABILIFY MAINTENA],-,-,-
Aripiprazole,Actionable,PSYCHIATRY,Level 1A,CYP2D6,Yes,CYP2D6,-,-,FDA evidence; Professional guideline,DPWG,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,Toxicity,‚ö†Ô∏è,Use recommended starting dose,-,-,-
Aripiprazole,Actionable,PSYCHIATRY,Level 1A,CYP2D6,Yes,CYP2D6,-,-,FDA evidence; Professional guideline,DPWG,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,Use recommended starting dose,-,-,-
Aripiprazole,Actionable,PSYCHIATRY,Level 1A,CYP2D6,Yes,CYP2D6,-,-,FDA evidence; Professional guideline,DPWG,Ultrarapid Metabolizer (>2),Ultrarapid Metabolizer,-,>2,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure,Use with Caution,Toxicity,‚ö†Ô∏è,Use recommended starting dose,-,-,-
Aripiprazole,Actionable,PSYCHIATRY,Level 1A,CYP2D6,Yes,CYP2D6,-,-,FDA evidence; Professional guideline,DPWG,Indeterminate,Indeterminate,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,n/a,No recommendation,-,-,No recommendation,-,-,-
Nicotine,Actionable,PSYCHIATRY,Level 1B,CYP2A6,Yes,CYP2A6,-,-,-,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Nicotine,Actionable,PSYCHIATRY,Level 1B,CYP2A6,Yes,CYP2A6,-,-,-,-,Slow Metabolizer,Slow Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Nicotine,Actionable,PSYCHIATRY,Level 1B,CYP2A6,Yes,CYP2A6,-,-,-,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Nicotine,Actionable,PSYCHIATRY,Level 1B,CYP2A6,Yes,CYP2A6,-,-,-,-,Normal/Extensive Metabolizer,Normal/Extensive Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,PK,‚úÖ,-,-,-,-
Nicotine,Actionable,PSYCHIATRY,Level 1B,CYP2A6,Yes,CYP2A6,-,-,-,-,Ultrarapid Metabolizer,Ultrarapid Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Pimozide,Actionable,PSYCHIATRY,Level 1A,CYP2D6,Yes,CYP2D6,-,-,Professional guideline; FDA evidence,DPWG,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure; Increased risk of ADR (QT-prolongation),Increased Caution/Avoid,Toxicity,üõë,Use maximum of 10 mg/day for 12 years and older and 0.05 mg/kg per day to a maximum of 2 mg/day for younger than 12 years [DPWG] Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults and dosages should not be increased earlier than 14 days [FDA].,-,-,-
Pimozide,Actionable,PSYCHIATRY,Level 1A,CYP2D6,Yes,CYP2D6,-,-,Professional guideline; FDA evidence,DPWG,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure; Increased risk of ADR (QT-prolongation),Increased Caution/Avoid,Toxicity,üõë,Use maximum of 16 mg/day for 12 years and older and 0.08 mg/kg per day to a maximum of 3 mg/day for younger than 12 years [DPWG],-,-,-
Pimozide,Actionable,PSYCHIATRY,Level 1A,CYP2D6,Yes,CYP2D6,-,-,Professional guideline; FDA evidence,DPWG,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Pimozide,Actionable,PSYCHIATRY,Level 1A,CYP2D6,Yes,CYP2D6,-,-,Professional guideline; FDA evidence,DPWG,Ultrarapid Metabolizer (>2),Ultrarapid Metabolizer,-,>2,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure; Minimal evidence for clinical Effect,Use with caution,Efficacy,‚ö†Ô∏è,-,-,-,-
Pimozide,Actionable,PSYCHIATRY,Level 1A,CYP2D6,Yes,CYP2D6,-,-,Professional guideline; FDA evidence,DPWG,Indeterminate,Indeterminate,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,-,No recommendation,-,-,-
Quetiapine,Actionable,PSYCHIATRY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,Professional guideline,DPWG,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Quetiapine,Actionable,PSYCHIATRY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,Professional guideline,DPWG,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Quetiapine,Actionable,PSYCHIATRY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,Professional guideline,DPWG,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure,Increased Caution/Avoid,-,üõë,"For Depression: Choose an alternative [e.g. Aripiprazole, Olanzapine]; For other Indications: use 30% of the normal dose [DPWG]",-,"Aripiprazole, Olanzapine",-
Dextromethorphan Hydrobromide / Bupropion Hydrochloride,Actionable,PULMONARY,Level 1BB,CYP2D6,Yes,CYP2D6,-,-,-,-,Ultrarapid Metabolizer (>2),Ultrarapid Metabolizer,-,>2,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure; Minimal Evidence for clinical Impact,Use with Caution,Efficacy,‚ö†Ô∏è,-,-,-,-
Dextromethorphan Hydrobromide / Bupropion Hydrochloride,Actionable,PULMONARY,Level 1BB,CYP2D6,Yes,CYP2D6,-,-,-,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Dextromethorphan Hydrobromide / Bupropion Hydrochloride,Actionable,PULMONARY,Level 1BB,CYP2D6,Yes,CYP2D6,-,-,-,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure;  Minimal Evidence for Clinical impact,Use with Caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Dextromethorphan Hydrobromide / Bupropion Hydrochloride,Actionable,PULMONARY,Level 1B,CYP2D6,Yes,CYP2D6,-,-,-,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Risk of ADR,Increased Caution/Avoid,Toxicity,üõë,one tablet once daily in the morning [FDA],-,-,-
Indacaterol,Actionable,PULMONARY,Level 1B,UGT1A1,Yes,UGT1A1,-,-,FDA evidence,-,Extensive Metabolizer,Extensive Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Risk of ADR,Use as Directed,-,‚úÖ,-,-,-,-
Indacaterol,Actionable,PULMONARY,Level 1B,UGT1A1,Yes,UGT1A1,-,-,FDA evidence,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Risk of ADR,Use as Directed,-,‚úÖ,-,-,-,-
Indacaterol,Actionable,PULMONARY,Level 1B,UGT1A1,Yes,UGT1A1,-,-,FDA evidence,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Risk of ADR,Use as Directed,-,‚úÖ,-,-,-,-
Salmeterol,Actionable,PULMONARY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Salmeterol,Actionable,PULMONARY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK or Clinical Effects,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Salmeterol,Actionable,PULMONARY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK or Clinical Effects,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Salmeterol,Actionable,PULMONARY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Salmeterol,Actionable,PULMONARY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Salmeterol,Actionable,PULMONARY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Salmeterol,Actionable,PULMONARY,Level 2A + Level 2A,CYP3A4 + ADRB2,No,CYP3A4,ADRB2,-,-,-,"CYP3A4: Normal Metabolizer + rs1042713, AA",Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,"rs1042713, AA",-,-,-,-,Reduced Response,Use with Caution,Toxicity/Efficacy,‚ö†Ô∏è,-,-,-,-
Salmeterol,Actionable,PULMONARY,Level 2A + Level 2A,CYP3A4 + ADRB2,No,CYP3A4,ADRB2,-,-,-,"CYP3A4: Normal Metabolizer + rs1042713, AG",Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,"rs1042713, AG",-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Salmeterol,Actionable,PULMONARY,Level 2A + Level 2A,CYP3A4 + ADRB2,No,CYP3A4,ADRB2,-,-,-,"CYP3A4: Normal Metabolizer + rs1042713, GG",Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,"rs1042713, GG",-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Salmeterol,Actionable,PULMONARY,Level 2A + Level 2A,CYP3A4 + ADRB2,No,CYP3A4,ADRB2,-,-,-,"CYP3A4: Intermediate Metabolizer + rs1042713, AA",Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,"rs1042713, AA",-,-,-,-,Reduced Response,Use with Caution,Toxicity/Efficacy,‚ö†Ô∏è,-,-,-,-
Salmeterol,Actionable,PULMONARY,Level 2A + Level 2A,CYP3A4 + ADRB2,No,CYP3A4,ADRB2,-,-,-,"CYP3A4: Intermediate Metabolizer + rs1042713, AG ",Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,"rs1042713, AG",-,-,-,-,Increased Exposure,Use with Caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Salmeterol,Actionable,PULMONARY,Level 2A + Level 2A,CYP3A4 + ADRB2,No,CYP3A4,ADRB2,-,-,-,"CYP3A4: Intermediate Metabolizer + rs1042713, GG",Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,"rs1042713, GG",-,-,-,-,Increased Exposure,Use with Caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Salmeterol,Actionable,PULMONARY,Level 2A + Level 2A,CYP3A4 + ADRB2,No,CYP3A4,ADRB2,-,-,-,"CYP3A4: Poor Metabolizer + rs1042713, AA",Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,"rs1042713, AA",-,-,-,-,Reduced Response,Use with Caution,Toxicity/Efficacy,‚ö†Ô∏è,-,-,-,-
Salmeterol,Actionable,PULMONARY,Level 2A + Level 2A,CYP3A4 + ADRB2,No,CYP3A4,ADRB2,-,-,-,"CYP3A4: Poor Metabolizer + rs1042713, AG",Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,"rs1042713, AG",-,-,-,-,Increased Exposure,Use with Caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Salmeterol,Actionable,PULMONARY,Level 2A + Level 2A,CYP3A4 + ADRB2,No,CYP3A4,ADRB2,-,-,-,"CYP3A4: Poor Metabolizer + rs1042713, GG",Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,"rs1042713, GG",-,-,-,-,Increased Exposure,Use with Caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Sildenafil,Actionable,"UROLOGY, PULMONARY",Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Sildenafil,Actionable,"UROLOGY, PULMONARY",Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure; Minimal Evidence for Clinical Impact,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Sildenafil,Actionable,"UROLOGY, PULMONARY",Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure; Minimal Evidence for Clinical Impact,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Dextromethorphan,Actionable,PULMONARY,Level 2C,CYP2D6,Yes,CYP2D6,-,-,-,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Dextromethorphan,Actionable,PULMONARY,Level 2C,CYP2D6,Yes,CYP2D6,-,-,-,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Dextromethorphan,Actionable,PULMONARY,Level 2C,CYP2D6,Yes,CYP2D6,-,-,-,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Dextromethorphan,Actionable,PULMONARY,Level 2C,CYP2D6,Yes,CYP2D6,-,-,-,-,Ultrarapid Metabolizer (>2),Ultrarapid Metabolizer,-,>2,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure,Use with caution,Efficacy,‚ö†Ô∏è,-,-,-,-
Dextromethorphan,Actionable,PULMONARY,Level 2C,CYP2D6,Yes,CYP2D6,-,-,-,-,Indeterminate,Indeterminate,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,No recommendation,-,-,-
Allopurinol,Actionable,RHEUMATOLOGY,Level 1A(Strong),HLA-B,Yes,HLA-B,-,-,Professional guideline; FDA evidence,CPIC; DPWG,Normal Risk,Normal Risk,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Risk of ADR (SCAR),Use as Directed,Toxicity,‚úÖ,Use label specified dosing,-,-,-
Allopurinol,Actionable,RHEUMATOLOGY,Level 1A(Strong),HLA-B,Yes,HLA-B,-,-,Professional guideline; FDA evidence,CPIC; DPWG,Increased Risk,Increased Risk,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Risk of ADR (SCAR),Increased Caution/Avoid,Toxicity,üõë,Allopurinol is contraindicated,-,-,-
Allopurinol,Actionable,RHEUMATOLOGY,Level 1A(Strong),HLA-B,Yes,HLA-B,-,-,Professional guideline; FDA evidence,CPIC; DPWG,Increased Risk,Increased Risk,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Risk of ADR (SCAR),Increased Caution/Avoid,Toxicity,üõë,Allopurinol is contraindicated,-,-,-
Cevimeline,Actionable,RHEUMATOLOGY,Level 1BB,CYP2D6,Yes,CYP2D6,-,-,FDA evidence,-,Ultrarapid Metabolizer (>2),Ultrarapid Metabolizer,-,>2,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure; Minimal Evidence for clinical Impact,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Cevimeline,Actionable,RHEUMATOLOGY,Level 1BB,CYP2D6,Yes,CYP2D6,-,-,FDA evidence,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Cevimeline,Actionable,RHEUMATOLOGY,Level 1BB,CYP2D6,Yes,CYP2D6,-,-,FDA evidence,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Cevimeline,Actionable,RHEUMATOLOGY,Level 1B,CYP2D6,Yes,CYP2D6,-,-,FDA evidence,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Risk of ADR,Use with Caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Colchicine,Actionable,RHEUMATOLOGY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Colchicine,Actionable,RHEUMATOLOGY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK and Clinical impact,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Colchicine,Actionable,RHEUMATOLOGY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK and Clinical impact,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Lesinurad,Actionable,RHEUMATOLOGY,Level 1BB,CYP2C9,Yes,CYP2C9,-,-,FDA evidence,-,Normal Metabolizer(2.0),Normal Metabolizer,-,2,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Lesinurad,Actionable,RHEUMATOLOGY,Level 1BB,CYP2C9,Yes,CYP2C9,-,-,FDA evidence,-,Intermediate Metabolizer(1.5),Intermediate Metabolizer,-,1.5,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,"The action of Intermediate Metabolizer 1.5 is inferred based on phenytoin, which also utilizes CYP2C9 as its primary metabolizer. It appears that there will be a slight reduction in metabolism, but this may not have a significant clinical effect."
Lesinurad,Actionable,RHEUMATOLOGY,Level 1B,CYP2C9,Yes,CYP2C9,-,-,FDA evidence,-,Intermediate Metabolizer (1.0),Intermediate Metabolizer,-,1,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Lesinurad,Actionable,RHEUMATOLOGY,Level 1B,CYP2C9,Yes,CYP2C9,-,-,FDA evidence,-,"Poor Metabolizer (0.0, 0.5)",Poor Metabolizer,-,0,0.5,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Lesinurad,Actionable,RHEUMATOLOGY,Level 1BB,CYP2C9,Yes,CYP2C9,-,-,FDA evidence,-,Indeterminate(n/a),Indeterminate,-,n/a,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,No Recommendation,-,-,-,-,-,-
Tofacitinib,Actionable,RHEUMATOLOGY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Tofacitinib,Actionable,RHEUMATOLOGY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK and Clinical impact,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Tofacitinib,Actionable,RHEUMATOLOGY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK and Clinical impact,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Armodafinil,Actionable,SLEEP MEDICINE,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Armodafinil,Actionable,SLEEP MEDICINE,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK and Clinical impact,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Armodafinil,Actionable,SLEEP MEDICINE,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK and Clinical impact,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Eszopiclone,Actionable,SLEEP MEDICINE,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Eszopiclone,Actionable,SLEEP MEDICINE,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK or Clinical Effects,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Eszopiclone,Actionable,SLEEP MEDICINE,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK or Clinical Effects,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Chlorpromazine,Actionable,PSYCHIATRY,Level 2A,CYP1A2,Yes,CYP1A2,-,-,-,-,Poor metabolizer,Poor metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Ramelteon,Actionable,SLEEP MEDICINE,Level 2A,CYP1A2,Yes,CYP1A2,-,-,-,-,Extensive Metabolizer,Extensive Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Ramelteon,Actionable,SLEEP MEDICINE,Level 2A,CYP1A2,Yes,CYP1A2,-,-,-,-,High Inducibility,High Inducibility,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Ramelteon,Actionable,SLEEP MEDICINE,Level 2A,CYP1A2,Yes,CYP1A2,-,-,-,-,Slow metabolizers; *1C heterozygous,Slow metabolizers,*1C Heterozygous,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Ramelteon,Actionable,SLEEP MEDICINE,Level 2A,CYP1A2,Yes,CYP1A2,-,-,-,-,Intermediate metabolizer,Intermediate metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Ramelteon,Actionable,SLEEP MEDICINE,Level 2A,CYP1A2,Yes,CYP1A2,-,-,-,-,Slow metabolizers; *1C Homozygous,Slow metabolizers,*1C Homozygous,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Ramelteon,Actionable,SLEEP MEDICINE,Level 2A,CYP1A2,Yes,CYP1A2,-,-,-,-,Poor metabolizer,Poor metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Triazolam,Actionable,SLEEP MEDICINE,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Triazolam,Actionable,SLEEP MEDICINE,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK or Clinical Effects,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Triazolam,Actionable,SLEEP MEDICINE,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK or Clinical Effects,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Zolpidem,Actionable,SLEEP MEDICINE,Level 2B,CYP3A4,Yes,CYP3A4,-,-,-,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Zolpidem,Actionable,SLEEP MEDICINE,Level 2B,CYP3A4,Yes,CYP3A4,-,-,-,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK or Clinical Effects,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Zolpidem,Actionable,SLEEP MEDICINE,Level 2B,CYP3A4,Yes,CYP3A4,-,-,-,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK or Clinical Effects,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Modafinil,Actionable,SLEEP MEDICINE,Level 2C,CYP2D6,Yes,CYP2D6,-,-,FDA evidence,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Possible Increased Exposure,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Modafinil,Actionable,SLEEP MEDICINE,Level 2C,CYP2D6,Yes,CYP2D6,-,-,FDA evidence,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Modafinil,Actionable,SLEEP MEDICINE,Level 2C,CYP2D6,Yes,CYP2D6,-,-,FDA evidence,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Modafinil,Actionable,SLEEP MEDICINE,Level 2C,CYP2D6,Yes,CYP2D6,-,-,FDA evidence,-,Ultrarapid Metabolizer (>2),Ultrarapid Metabolizer,-,>2,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Possible Decreased Exposure,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Modafinil,Actionable,SLEEP MEDICINE,Level 2C,CYP2D6,Yes,CYP2D6,-,-,FDA evidence,-,Indeterminate,Indeterminate,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,-,No recommendation,-,-,-
Darifenacin,Actionable,UROLOGY,Level 1BB,CYP2D6,Yes,CYP2D6,-,-,FDA evidence,-,Ultrarapid Metabolizer (>2),Ultrarapid Metabolizer,-,>2,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure;  Minimal Evidence for Clinical impact,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Darifenacin,Actionable,UROLOGY,Level 1BB,CYP2D6,Yes,CYP2D6,-,-,FDA evidence,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Darifenacin,Actionable,UROLOGY,Level 1BB,CYP2D6,Yes,CYP2D6,-,-,FDA evidence,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Darifenacin,Actionable,UROLOGY,Level 1B,CYP2D6,Yes,CYP2D6,-,-,FDA evidence,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure;  Minimal Evidence for Clinical impact,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Fesoterodine,Actionable,UROLOGY,Level 1BB,CYP2D6,Yes,CYP2D6,-,-,FDA evidence,-,Ultrarapid Metabolizer (>2),Ultrarapid Metabolizer,-,>2,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure; Minimal Evidence for clinical Impact,Use with Caution,Toxicity/Efficacy,‚ö†Ô∏è,-,-,-,-
Fesoterodine,Actionable,UROLOGY,Level 1BB,CYP2D6,Yes,CYP2D6,-,-,FDA evidence,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Fesoterodine,Actionable,UROLOGY,Level 1BB,CYP2D6,Yes,CYP2D6,-,-,FDA evidence,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Fesoterodine,Actionable,UROLOGY,Level 1B,CYP2D6,Yes,CYP2D6,-,-,FDA evidence,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Finasteride,Actionable,UROLOGY,Level 2B,CYP3A4,Yes,CYP3A4,-,-,-,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Finasteride,Actionable,UROLOGY,Level 2B,CYP3A4,Yes,CYP3A4,-,-,-,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK or Clinical effects,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Finasteride,Actionable,UROLOGY,Level 2B,CYP3A4,Yes,CYP3A4,-,-,-,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK or Clinical effects,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Oxybutynin,Actionable,UROLOGY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Oxybutynin,Actionable,UROLOGY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK or clinical effects,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Oxybutynin,Actionable,UROLOGY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK or clinical effects,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Tamsulosin,Actionable,UROLOGY,Level 1BB,CYP2D6,Yes,CYP2D6,-,-,FDA evidence,-,Ultrarapid Metabolizer (>2),Ultrarapid Metabolizer,-,>2,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure,Use with Caution,Toxicity/Efficacy,‚ö†Ô∏è,-,-,-,-
Tamsulosin,Actionable,UROLOGY,Level 1BB,CYP2D6,Yes,CYP2D6,-,-,FDA evidence,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Tamsulosin,Actionable,UROLOGY,Level 1BB,CYP2D6,Yes,CYP2D6,-,-,FDA evidence,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Tamsulosin,Actionable,UROLOGY,Level 1B,CYP2D6,Yes,CYP2D6,-,-,FDA evidence,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Tolterodine,Actionable,UROLOGY,Level 2A,CYP2D6,Yes,CYP2D6,-,-,FDA evidence,-,Ultrarapid Metabolizer (>2),Ultrarapid Metabolizer,-,>2,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure;  Minimal Evidence for Clinical impact,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Tolterodine,Actionable,UROLOGY,Level 2A,CYP2D6,Yes,CYP2D6,-,-,FDA evidence,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Tolterodine,Actionable,UROLOGY,Level 2A,CYP2D6,Yes,CYP2D6,-,-,FDA evidence,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure;  Minimal Evidence for Clinical impact,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Tolterodine,Actionable,UROLOGY,Level 2A,CYP2D6,Yes,CYP2D6,-,-,FDA evidence,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Risk of ADR (QT prolongation).,Use with Caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Vardenafil,Actionable,"UROLOGY, PULMONARY",Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure; Minimal Evidence for clinical Impact,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Vardenafil,Actionable,"UROLOGY, PULMONARY",Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure; Minimal Evidence for clinical Impact,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Vardenafil,Actionable,"UROLOGY, PULMONARY",Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Tadalafil,Actionable,"UROLOGY, PULMONARY",Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Tadalafil,Actionable,"UROLOGY, PULMONARY",Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK or Clinical effects,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Tadalafil,Actionable,"UROLOGY, PULMONARY",Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK or Clinical effects,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Abacavir,Actionable,INFECTIOUS DISEASE,Level 1A,HLA-B,Yes,HLA-B,-,-,Professional guideline; FDA evidence,CPIC / DPWG,Normal Risk,Normal Risk,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Risk of ADR (Hypersensitivity),Use as Directed,Toxicity,‚úÖ,Use label specified dosing,-,-,-
Abacavir,Actionable,INFECTIOUS DISEASE,Level 1A,HLA-B,Yes,HLA-B,-,-,Professional guideline; FDA evidence,CPIC / DPWG,Increased Risk,Increased Risk,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Risk of ADR (Hypersensitivity),Increased Caution/Avoid,Toxicity,üõë,Avoid Abacavir,-,-,-
Abacavir,Actionable,INFECTIOUS DISEASE,Level 1A,HLA-B,Yes,HLA-B,-,-,Professional guideline; FDA evidence,CPIC / DPWG,Increased Risk,Increased Risk,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Risk of ADR (Hypersensitivity),Increased Caution/Avoid,Toxicity,üõë,Avoid Abacavir,-,-,-
Ivacaftor / Tezacaftor,Actionable,GENETIC DISEASE,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Ivacaftor / Tezacaftor,Actionable,GENETIC DISEASE,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal evidence for PK or Clinical effects,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Ivacaftor / Tezacaftor,Actionable,GENETIC DISEASE,Level 2A,CYP3A4,Yes,CYP3A4,-,-,-,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal evidence for PK or Clinical effects,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Lapatinib,Actionable,ONCOLOGY,Level 1B,HLA-DQA1*02:01 + HLA-DRB1*07:01,No,HLA-DQA1,HLA-DRB1,-,Additional testing,-,HLA-DRB1*07:01: Positive| HLA-DQA1*02:01: Positive,Positive,*02:01,-,-,-,-,-,-,-,-,-,-,-,Positive,*07:01,-,-,-,-,Increased Risk of ADR (hepatotoxicity),Use with Caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Lapatinib,Actionable,ONCOLOGY,Level 1B,HLA-DQA1*02:01 + HLA-DRB1*07:01,No,HLA-DQA1,HLA-DRB1,-,Additional testing,-,HLA-DRB1*07:01: Positive| HLA-DQA1*02:01: Negative,Negative,*02:01,-,-,-,-,-,-,-,-,-,-,-,Positive,*07:01,-,-,-,-,Increased Risk of ADR (hepatotoxicity),Use with Caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Lapatinib,Actionable,ONCOLOGY,Level 1B,HLA-DQA1*02:01 + HLA-DRB1*07:01,No,HLA-DQA1,HLA-DRB1,-,Additional testing,-,HLA-DRB1*07:01: Negative| HLA-DQA1*02:01: Positive,Positive,*02:01,-,-,-,-,-,-,-,-,-,-,-,Negative,*07:01,-,-,-,-,Increased Risk of ADR (hepatotoxicity),Use with Caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Lapatinib,Actionable,ONCOLOGY,Level 1B,HLA-DQA1*02:01 + HLA-DRB1*07:01,No,HLA-DQA1,HLA-DRB1,-,Additional testing,-,HLA-DRB1*07:01: Negative| HLA-DQA1*02:01: Negative,Negative,*02:01,-,-,-,-,-,-,-,-,-,-,-,Negative,*07:01,-,-,-,-,Normal Risk of ADR (hepatotoxicity),Use as Directed,Toxicity,‚úÖ,-,-,-,-
Fluoxetine / Olanzapine,Actionable,Psychiatry,Level 1BB,CYP2D6,Yes,CYP2D6,-,-,-,-,Ultrarapid Metabolizer (>2),Ultrarapid Metabolizer,-,>2,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure,Use with Caution,Efficacy,‚ö†Ô∏è,-,-,-,-
Fluoxetine / Olanzapine,Actionable,Psychiatry,Level 1BB,CYP2D6,Yes,CYP2D6,-,-,-,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Fluoxetine / Olanzapine,Actionable,Psychiatry,Level 1BB,CYP2D6,Yes,CYP2D6,-,-,-,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Fluoxetine / Olanzapine,Actionable,Psychiatry,Level 1B,CYP2D6,Yes,CYP2D6,-,-,-,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Sulfamethoxazole/trimethoprim,Actionable,INFECTIOUS DISEASE,Level 1B,G6PD,Yes,G6PD,-,-,FDA evidence,CPIC (No Recommendation),Normal,Normal,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Risk of ADR (acute hemolytic anemia),Use as Directed,-,‚úÖ,-,-,-,-
Sulfamethoxazole/trimethoprim,Actionable,INFECTIOUS DISEASE,Level 1B,G6PD,Yes,G6PD,-,-,FDA evidence,CPIC (No Recommendation),Deficient,Deficient,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Risk of ADR (acute hemolytic anemia),Use with Caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Sulfamethoxazole/trimethoprim,Actionable,INFECTIOUS DISEASE,Level 1B,G6PD,Yes,G6PD,-,-,FDA evidence,CPIC (No Recommendation),Deficient with CNSHA,Deficient with CNSHA,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Risk of ADR (acute hemolytic anemia),Use with Caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Sulfamethoxazole/trimethoprim,Actionable,INFECTIOUS DISEASE,Level 1B,G6PD,Yes,G6PD,-,-,FDA evidence,CPIC (No Recommendation),Variable,Variable,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Risk of ADR (acute hemolytic anemia),Use as Directed,Toxicity,‚úÖ,-,-,-,-
Sulfamethoxazole/trimethoprim,Actionable,INFECTIOUS DISEASE,Level 1B,G6PD,Yes,G6PD,-,-,FDA evidence,CPIC (No Recommendation),Indeterminate,Indeterminate,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Unknown Risk of ADR (acute hemolytic anemia),-,-,-,-,-,-,-
Dasatinib,Actionable,ONCOLOGY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,Additional testing,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Dasatinib,Actionable,ONCOLOGY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,Additional testing,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal evidence for impact on PK or clinical effect,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Dasatinib,Actionable,ONCOLOGY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,Additional testing,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal evidence for impact on PK or clinical effect,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Doxorubicin,Actionable,ONCOLOGY,Level 2A,CYP3A4 + CYP2D6,No,CYP3A4,CYP2D6,-,Professional guideline,CPIC (No recommendation),CYP3A4: Normal Metabolizer| CYP2D6: Poor Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,-,-,-,-,Increased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Doxorubicin,Actionable,ONCOLOGY,Level 2A,CYP3A4 + CYP2D6,No,CYP3A4,CYP2D6,-,Professional guideline,CPIC (No recommendation),CYP3A4: Normal Metabolizer| CYP2D6: Intermediate Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,-,-,-,-,Increased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Doxorubicin,Actionable,ONCOLOGY,Level 2A,CYP3A4 + CYP2D6,No,CYP3A4,CYP2D6,-,Professional guideline,CPIC (No recommendation),CYP3A4: Normal Metabolizer| CYP2D6: Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,-,-,-,-,Normal Exposure,Use as Directed,PK,‚úÖ,-,-,-,-
Doxorubicin,Actionable,ONCOLOGY,Level 2A,CYP3A4 + CYP2D6,No,CYP3A4,CYP2D6,-,Professional guideline,CPIC (No recommendation),CYP3A4: Normal Metabolizer| CYP2D6: Ultrarapid Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,-,-,-,-,Increased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Doxorubicin,Actionable,ONCOLOGY,Level 2A,CYP3A4 + CYP2D6,No,CYP3A4,CYP2D6,-,Professional guideline,CPIC (No recommendation),CYP3A4: Normal Metabolizer| CYP2D6: Indeterminate,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,-,-,-,-,Normal Exposure,Use as Directed,PK,‚úÖ,-,-,-,-
Doxorubicin,Actionable,ONCOLOGY,Level 2A,CYP3A4 + CYP2D6,No,CYP3A4,CYP2D6,-,Professional guideline,CPIC (No recommendation),CYP3A4: Intermediate Metabolizer| CYP2D6: Poor Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,-,-,-,-,Increased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Doxorubicin,Actionable,ONCOLOGY,Level 2A,CYP3A4 + CYP2D6,No,CYP3A4,CYP2D6,-,Professional guideline,CPIC (No recommendation),CYP3A4: Intermediate Metabolizer| CYP2D6: Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,-,-,-,-,Increased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Doxorubicin,Actionable,ONCOLOGY,Level 2A,CYP3A4 + CYP2D6,No,CYP3A4,CYP2D6,-,Professional guideline,CPIC (No recommendation),CYP3A4: Intermediate Metabolizer| CYP2D6: Normal Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,-,-,-,-,Increased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Doxorubicin,Actionable,ONCOLOGY,Level 2A,CYP3A4 + CYP2D6,No,CYP3A4,CYP2D6,-,Professional guideline,CPIC (No recommendation),CYP3A4: Intermediate Metabolizer| CYP2D6: Ultrarapid Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,-,-,-,-,Increased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Doxorubicin,Actionable,ONCOLOGY,Level 2A,CYP3A4 + CYP2D6,No,CYP3A4,CYP2D6,-,Professional guideline,CPIC (No recommendation),CYP3A4: Intermediate Metabolizer| CYP2D6: Indeterminate,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,-,-,-,-,Increased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Doxorubicin,Actionable,ONCOLOGY,Level 2A,CYP3A4 + CYP2D6,No,CYP3A4,CYP2D6,-,Professional guideline,CPIC (No recommendation),CYP3A4: Poor Metabolizer| CYP2D6: Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,Poor Metabolizer,-,-,-,-,-,Increased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Doxorubicin,Actionable,ONCOLOGY,Level 2A,CYP3A4 + CYP2D6,No,CYP3A4,CYP2D6,-,Professional guideline,CPIC (No recommendation),CYP3A4: Poor Metabolizer| CYP2D6: Intermediate Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,Intermediate Metabolizer,-,-,-,-,-,Increased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Doxorubicin,Actionable,ONCOLOGY,Level 2A,CYP3A4 + CYP2D6,No,CYP3A4,CYP2D6,-,Professional guideline,CPIC (No recommendation),CYP3A4: Poor Metabolizer| CYP2D6: Normal Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,Normal Metabolizer,-,-,-,-,-,Increased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Doxorubicin,Actionable,ONCOLOGY,Level 2A,CYP3A4 + CYP2D6,No,CYP3A4,CYP2D6,-,Professional guideline,CPIC (No recommendation),CYP3A4: Poor Metabolizer| CYP2D6: Ultrarapid Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,Ultrarapid Metabolizer,-,-,-,-,-,Increased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Doxorubicin,Actionable,ONCOLOGY,Level 2A,CYP3A4 + CYP2D6,No,CYP3A4,CYP2D6,-,Professional guideline,CPIC (No recommendation),CYP3A4: Poor Metabolizer| CYP2D6: Indeterminate,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,Indeterminate,-,-,-,-,-,Increased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Terbinafine,Actionable,INFECTIOUS DISEASE,Level 2C,CYP2C9,Yes,CYP2C9,-,-,FDA label,-,Normal Metabolizer(2.0),Normal Metabolizer,-,2,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Terbinafine,Actionable,INFECTIOUS DISEASE,Level 2C,CYP2C9,Yes,CYP2C9,-,-,FDA label,-,Intermediate Metabolizer(1.5),Intermediate Metabolizer,-,1.5,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,"The action of Intermediate Metabolizer 1.5 is inferred based on phenytoin, which also utilizes CYP2C9 as its primary metabolizer. It appears that there will be a slight reduction in metabolism, but this may not have a significant clinical effect."
Terbinafine,Actionable,INFECTIOUS DISEASE,Level 2C,CYP2C9,Yes,CYP2C9,-,-,FDA label,-,Intermediate Metabolizer (1.0),Intermediate Metabolizer,-,1,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Terbinafine,Actionable,INFECTIOUS DISEASE,Level 2C,CYP2C9,Yes,CYP2C9,-,-,FDA label,-,"Poor Metabolizer (0.0, 0.5)",Poor Metabolizer,-,0,0.5,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Terbinafine,Actionable,INFECTIOUS DISEASE,Level 2C,CYP2C9,Yes,CYP2C9,-,-,FDA label,-,Indeterminate(n/a),Indeterminate,-,n/a,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,No Recommendation,-,-,-,-,-,-
Ponatinib,Actionable,ONCOLOGY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,Additional testing,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Ponatinib,Actionable,ONCOLOGY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,Additional testing,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK and Clincial Effects,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Ponatinib,Actionable,ONCOLOGY,Level 2A,CYP3A4,Yes,CYP3A4,-,-,Additional testing,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK and Clincial Effects,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Lamotrigine,Actionable,NEUROLOGY,Level 1A,HLA-B,Yes,HLA-B,-,-,Professional guideline,DPWG,Increased Risk,Increased Risk,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Risk of ADR (cutaneous side effect: Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN)),Increased Caution/Avoid,Toxicity,üõë,Avoid lamotrigine,"Carbamazepine, Phenytoin, Oxcarbazepine",-,-
Lamotrigine,Actionable,NEUROLOGY,Level 1A,HLA-B,Yes,HLA-B,-,-,Professional guideline,DPWG,Increased Risk,Increased Risk,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Risk of ADR (cutaneous side effect: Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN)),Increased Caution/Avoid,Toxicity,üõë,Avoid lamotrigine,"Carbamazepine, Phenytoin, Oxcarbazepine",-,-
Lamotrigine,Actionable,NEUROLOGY,Level 1A,HLA-B,Yes,HLA-B,-,-,Professional guideline,DPWG,Normal Risk,Normal Risk,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Risk of ADR,Use as Directed,Toxicity,‚úÖ,-,-,-,-
Lomitapide,Actionable,CARDIOVASCULAR,Level 2A,CYP3A4,Yes,CYP3A4,-,-,Additional testing,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Lomitapide,Actionable,CARDIOVASCULAR,Level 2A,CYP3A4,Yes,CYP3A4,-,-,Additional testing,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK and Clincial Effects,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Lomitapide,Actionable,CARDIOVASCULAR,Level 2A,CYP3A4,Yes,CYP3A4,-,-,Additional testing,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Minimal Evidence for PK and Clincial Effects,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Maraviroc,Actionable,INFECTIOUS DISEASE,Level 2A,CYP3A5,Yes,CYP3A5,-,-,Additional testing,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure; Minimal Evidence for clinical Impact,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Maraviroc,Actionable,INFECTIOUS DISEASE,Level 2A,CYP3A5,Yes,CYP3A5,-,-,Additional testing,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure; Minimal Evidence for clinical Impact,Use with Caution,PK,‚ö†Ô∏è,-,-,-,-
Maraviroc,Actionable,INFECTIOUS DISEASE,Level 2A,CYP3A5,Yes,CYP3A5,-,-,Additional testing,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Nevirapine,Actionable,INFECTIOUS DISEASE,Level 2C,CYP2B6,Yes,CYP2B6,-,-,-,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Nevirapine,Actionable,INFECTIOUS DISEASE,Level 2C,CYP2B6,Yes,CYP2B6,-,-,-,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Nevirapine,Actionable,INFECTIOUS DISEASE,Level 2C,CYP2B6,Yes,CYP2B6,-,-,-,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Nevirapine,Actionable,INFECTIOUS DISEASE,Level 2C,CYP2B6,Yes,CYP2B6,-,-,-,-,Rapid Metabolizer,Rapid Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure,Use with Caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Nevirapine,Actionable,INFECTIOUS DISEASE,Level 2C,CYP2B6,Yes,CYP2B6,-,-,-,-,Ultrarapid Metabolizer,Ultrarapid Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure,Use with Caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Oxcarbazepine,Actionable,NEUROLOGY,Level 1A(Strong),HLA-B,Yes,HLA-B,-,-,FDA evidence; Professional guideline,CPIC/DPWG,Increased Risk,Increased Risk,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Risk of ADR (oxcarbazepine-induced SJS/TEN),Increased Caution/Avoid,Toxicity,üõë,"A. If patient is oxcarbazepine-naive- do not use oxcarbazepine.
B. If the patient has previously used oxcarbazepine consistently for longer than 3 months without incidence of cutaneous adverse reactions, cautiously consider use of oxcarbazepine in the future. [CPIC]",-,-,-
Oxcarbazepine,Actionable,NEUROLOGY,Level 1A(Strong),HLA-B,Yes,HLA-B,-,-,FDA evidence; Professional guideline,CPIC/DPWG,Increased Risk,Increased Risk,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Risk of ADR (oxcarbazepine-induced SJS/TEN),Increased Caution/Avoid,Toxicity,üõë,"A. If patient is oxcarbazepine-naive- do not use oxcarbazepine.
B. If the patient has previously used oxcarbazepine consistently for longer than 3 months without incidence of cutaneous adverse reactions, cautiously consider use of oxcarbazepine in the future. [CPIC]",-,-,-
Oxcarbazepine,Actionable,NEUROLOGY,Level 1A(Strong),HLA-B,Yes,HLA-B,-,-,FDA evidence; Professional guideline,CPIC/DPWG,Normal Risk,Normal Risk,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Risk of ADR,Use as Directed,Toxicity,‚úÖ,-,-,-,-
Vemurafenib,Actionable,ONCOLOGY,Level 2C,CYP3A4,Yes,CYP3A4,-,-,Additional testing,-,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Vemurafenib,Actionable,ONCOLOGY,Level 2C,CYP3A4,Yes,CYP3A4,-,-,Additional testing,-,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Risk of ADR(Hyperbilirubinemia or Nausea),Use with Caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Vemurafenib,Actionable,ONCOLOGY,Level 2C,CYP3A4,Yes,CYP3A4,-,-,Additional testing,-,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Risk of ADR(Hyperbilirubinemia or Nausea),Use with Caution,Toxicity,‚ö†Ô∏è,-,-,-,-
Carbamazepine,Actionable,NEUROLOGY,Level 1A(Strong),HLA-A + HLA-B,No,HLA-A,HLA-B,-,Professional guideline; FDA evidence,CPIC/DPWG,HLA-A (Normal Risk) + HLA-B (Normal Risk),Normal Risk,-,-,-,-,-,-,-,-,-,-,-,-,Normal Risk,-,-,-,-,-,Normal risk of ADR (carbamazepine-induced SJS/TEN),Use as Directed,-,‚úÖ,Use as per standard dosing guidelines.,-,-,-
Carbamazepine,Actionable,NEUROLOGY,Level 1A(Strong),HLA-A + HLA-B,No,HLA-A,HLA-B,-,Professional guideline; FDA evidence,CPIC/DPWG,HLA-B (Increased Risk) + HLA-A (Normal Risk),Normal Risk,-,-,-,-,-,-,-,-,-,-,-,-,Increased Risk,-,-,-,-,-,Increased risk of ADR (carbamazepine-induced SJS/TEN),Increased Caution/Avoid,Toxicity,üõë,"A. If patient is carbamazepine-naive and alternative agents are available, do not use carbamazepine.
B. If patient is carbamazepine-naive and alternative agents are not available, consider the use of carbamazepine with increased frequency of clinical monitoring. Discontinue therapy at first evidence of a cutaneous adverse reaction.
C. The latency period for cutaneous adverse drug reactions is variable depending on phenotype; however, all usually occur within 3 months of regular dosing. Therefore, if patient has previously used carbamazepine for longer than 3 months without incidence of cutaneous adverse reactions, cautiously consider use of carbamazepine.",-,-,-
Carbamazepine,Actionable,NEUROLOGY,Level 1A(Strong),HLA-A + HLA-B,No,HLA-A,HLA-B,-,Professional guideline; FDA evidence,CPIC/DPWG,HLA-A (Increased Risk) + HLA-B (Normal Risk),Increased Risk,-,-,-,-,-,-,-,-,-,-,-,-,Normal Risk,-,-,-,-,-,Increased risk of ADR (carbamazepine-induced SJS/TEN),Increased Caution/Avoid,Toxicity,üõë,"A. If patient is carbamazepine-naive, do not use carbamazepine.
B. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (~4-28 days), and cases usually occur within 3 months of dosing; therefore, if the patient has previously used carbamazepine consistently for longer than 3 months without incidence of cutaneous adverse reactions, cautiously consider use of carbamazepine in the future.",-,-,-
Carbamazepine,Actionable,NEUROLOGY,Level 1A(Strong),HLA-A + HLA-B,No,HLA-A,HLA-B,-,Professional guideline; FDA evidence,CPIC/DPWG,HLA-A (Increased Risk) + HLA-B (unknown Risk),Increased Risk,-,-,-,-,-,-,-,-,-,-,-,-,Unknown Risk,-,-,-,-,-,Increased risk of ADR (carbamazepine-induced SJS/TEN),Increased Caution/Avoid,Toxicity,üõë,"A. If patient is carbamazepine-naive, do not use carbamazepine.
B. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (~4-28 days), and cases usually occur within 3 months of dosing; therefore, if the patient has previously used carbamazepine consistently for longer than 3 months without incidence of cutaneous adverse reactions, cautiously consider use of carbamazepine in the future.",-,-,-
Carbamazepine,Actionable,NEUROLOGY,Level 1A(Strong),HLA-A + HLA-B,No,HLA-A,HLA-B,-,Professional guideline; FDA evidence,CPIC/DPWG,HLA-A (Increased Risk) + HLA-B (Increased Risk),Increased Risk,-,-,-,-,-,-,-,-,-,-,-,-,Increased Risk,-,-,-,-,-,Increased risk of ADR (carbamazepine-induced SJS/TEN),Increased Caution/Avoid,Toxicity,üõë,"A. If patient is carbamazepine-naive, do not use carbamazepine.
B. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (~4-28 days), and cases usually occur within 3 months of dosing; therefore, if the patient has previously used carbamazepine consistently for longer than 3 months without incidence of cutaneous adverse reactions, cautiously consider use of carbamazepine in the future.",-,-,-
Leuocovorin,Actionable,ONCOLOGY,Level 2A,MTHFR,Yes,MTHFR,-,-,-,-,GG Genotype,-,GG Genotype,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Reduced Response,Use with Caution,Efficacy,‚ö†Ô∏è,-,-,-,-
Tamoxifen,Actionable,ONCOLOGY,Level 1A(Strong),CYP2D6 + F2 + F5,No,CYP2D6,F2,F5,Professional guideline; FDA evidence,CPIC/DPWG,CYP2D6: Poor Metabolizer (0) + F2: Increased Risk + F5: Normal Risk,Poor Metabolizer,-,0,-,-,-,-,-,-,-,-,-,-,Increased Risk,-,-,Normal Risk,-,-,Decreased Exposure; Reduced Response (higher risk of breast cancer recurrence); Increased Risk of ADR,Increased Caution/Avoid,Efficacy,üõë,"Recommend alternative hormonal therapy such as an aromatase inhibitor for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women. If aromatase inhibitor therapy is contraindicted, use higher dose tamoxifen (40 mg/day), though it increases but does not normalize endoxifen concentrations.",-,-,-
Tamoxifen,Actionable,ONCOLOGY,Level 1A(Strong),CYP2D6 + F2 + F5,No,CYP2D6,F2,F5,Professional guideline; FDA evidence,CPIC/DPWG,CYP2D6: Poor Metabolizer (0) + F2: Increased Risk + F5: Increased Risk,Poor Metabolizer,-,0,-,-,-,-,-,-,-,-,-,-,Increased Risk,-,-,Increased Risk,-,-,Decreased Exposure; Reduced Response (higher risk of breast cancer recurrence); Increased Risk of ADR,Increased Caution/Avoid,Efficacy,üõë,"Recommend alternative hormonal therapy such as an aromatase inhibitor for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women. If aromatase inhibitor therapy is contraindicted, use higher dose tamoxifen (40 mg/day), though it increases but does not normalize endoxifen concentrations.",-,-,-
Tamoxifen,Actionable,ONCOLOGY,Level 1A(Strong),CYP2D6 + F2 + F5,No,CYP2D6,F2,F5,Professional guideline; FDA evidence,CPIC/DPWG,CYP2D6: Poor Metabolizer (0) + F2: Normal Risk + F5: Normal Risk,Poor Metabolizer,-,0,-,-,-,-,-,-,-,-,-,-,Normal Risk,-,-,Normal Risk,-,-,Decreased Exposure; Reduced Response (higher risk of breast cancer recurrence); Increased Risk of ADR,Increased Caution/Avoid,Efficacy,üõë,"Recommend alternative hormonal therapy such as an aromatase inhibitor for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women. If aromatase inhibitor therapy is contraindicted, use higher dose tamoxifen (40 mg/day), though it increases but does not normalize endoxifen concentrations.",-,-,-
Tamoxifen,Actionable,ONCOLOGY,Level 1A(Strong),CYP2D6 + F2 + F5,No,CYP2D6,F2,F5,Professional guideline; FDA evidence,CPIC/DPWG,CYP2D6: Poor Metabolizer (0) + F2: Normal Risk + F5: Increased Risk,Poor Metabolizer,-,0,-,-,-,-,-,-,-,-,-,-,Normal Risk,-,-,Increased Risk,-,-,Decreased Exposure; Reduced Response (higher risk of breast cancer recurrence); Increased Risk of ADR,Increased Caution/Avoid,Efficacy,üõë,"Recommend alternative hormonal therapy such as an aromatase inhibitor for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women. If aromatase inhibitor therapy is contraindicted, use higher dose tamoxifen (40 mg/day), though it increases but does not normalize endoxifen concentrations.",-,-,-
Tamoxifen,Actionable,ONCOLOGY,Level 1A(Moderate),CYP2D6 + F2 + F5,No,CYP2D6,F2,F5,Professional guideline; FDA evidence,CPIC/DPWG,"CYP2D6: Intermediate Metabolizer (0.25, 0.5, 0.75) + F2: Increased Risk + F5: Normal Risk",Intermediate Metabolizer,-,0.25,0.5,0.75,-,-,-,-,-,-,-,-,Increased Risk,-,-,Normal Risk,-,-,Decreased Exposure; Reduced Response (higher risk of breast cancer recurrence); Increased Risk of ADR,Increased Caution/Avoid,Efficacy,üõë,"Consider hormonal therapy such as an aromatase inhibitor for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women. If aromatase inhibitor use is contraindicated, consideration should be given to use a higher but FDA approved tamoxifen dose (40 mg/day)(PMID 27226358). Avoid CYP2D6 strong to weak inhibitors.",-,-,-
Tamoxifen,Actionable,ONCOLOGY,Level 1A(Moderate),CYP2D6 + F2 + F5,No,CYP2D6,F2,F5,Professional guideline; FDA evidence,CPIC/DPWG,"CYP2D6: Intermediate Metabolizer (0.25, 0.5, 0.75) + F2: Increased Risk + F5: Increased Risk",Intermediate Metabolizer,-,0.25,0.5,0.75,-,-,-,-,-,-,-,-,Increased Risk,-,-,Increased Risk,-,-,Decreased Exposure; Reduced Response (higher risk of breast cancer recurrence); Increased Risk of ADR,Increased Caution/Avoid,Efficacy,üõë,"Consider hormonal therapy such as an aromatase inhibitor for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women. If aromatase inhibitor use is contraindicated, consideration should be given to use a higher but FDA approved tamoxifen dose (40 mg/day)(PMID 27226358). Avoid CYP2D6 strong to weak inhibitors.",-,-,-
Tamoxifen,Actionable,ONCOLOGY,Level 1A(Moderate),CYP2D6 + F2 + F5,No,CYP2D6,F2,F5,Professional guideline; FDA evidence,CPIC/DPWG,"CYP2D6: Intermediate Metabolizer (0.25, 0.5, 0.75) + F2: Normal Risk + F5: Normal Risk",Intermediate Metabolizer,-,0.25,0.5,0.75,-,-,-,-,-,-,-,-,Normal Risk,-,-,Normal Risk,-,-,Decreased Exposure; Reduced Response (higher risk of breast cancer recurrence),Increased Caution/Avoid,Efficacy,üõë,"Consider hormonal therapy such as an aromatase inhibitor for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women. If aromatase inhibitor use is contraindicated, consideration should be given to use a higher but FDA approved tamoxifen dose (40 mg/day)(PMID 27226358). Avoid CYP2D6 strong to weak inhibitors.",-,-,-
Tamoxifen,Actionable,ONCOLOGY,Level 1A(Moderate),CYP2D6 + F2 + F5,No,CYP2D6,F2,F5,Professional guideline; FDA evidence,CPIC/DPWG,"CYP2D6: Intermediate Metabolizer (0.25, 0.5, 0.75) + F2: Normal Risk + F5: Increased Risk",Intermediate Metabolizer,-,0.25,0.5,0.75,-,-,-,-,-,-,-,-,Normal Risk,-,-,Increased Risk,-,-,Decreased Exposure; Reduced Response (higher risk of breast cancer recurrence); Increased Risk of ADR,Increased Caution/Avoid,Efficacy,üõë,"Consider hormonal therapy such as an aromatase inhibitor for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women. If aromatase inhibitor use is contraindicated, consideration should be given to use a higher but FDA approved tamoxifen dose (40 mg/day)(PMID 27226358). Avoid CYP2D6 strong to weak inhibitors.",-,-,-
Tamoxifen,Actionable,ONCOLOGY,Level 1A(Optional),CYP2D6 + F2 + F5,No,CYP2D6,F2,F5,Professional guideline; FDA evidence,CPIC/DPWG,CYP2D6: Intermediate Metabolizer (1) + F2: Increased Risk + F5: Normal Risk,Intermediate Metabolizer,-,1,-,-,-,-,-,-,-,-,-,-,Increased Risk,-,-,Normal Risk,-,-,Decreased Exposure; Reduced Response (higher risk of breast cancer recurrence); Increased Risk of ADR,Increased Caution/Avoid,Efficacy,üõë,"Consider hormonal therapy such as an aromatase inhibitor for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women. If aromatase inhibitor use is contraindicated, consideration should be given to use a higher but FDA approved tamoxifen dose (40 mg/day). Avoid CYP2D6 strong to weak inhibitors.",-,-,-
Tamoxifen,Actionable,ONCOLOGY,Level 1A(Optional),CYP2D6 + F2 + F5,No,CYP2D6,F2,F5,Professional guideline; FDA evidence,CPIC/DPWG,CYP2D6: Intermediate Metabolizer (1) + F2: Increased Risk + F5: Increased Risk,Intermediate Metabolizer,-,1,-,-,-,-,-,-,-,-,-,-,Increased Risk,-,-,Increased Risk,-,-,Decreased Exposure; Reduced Response (higher risk of breast cancer recurrence); Increased Risk of ADR,Increased Caution/Avoid,Efficacy,üõë,"Consider hormonal therapy such as an aromatase inhibitor for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women. If aromatase inhibitor use is contraindicated, consideration should be given to use a higher but FDA approved tamoxifen dose (40 mg/day). Avoid CYP2D6 strong to weak inhibitors.",-,-,-
Tamoxifen,Actionable,ONCOLOGY,Level 1A(Optional),CYP2D6 + F2 + F5,No,CYP2D6,F2,F5,Professional guideline; FDA evidence,CPIC/DPWG,CYP2D6: Intermediate Metabolizer (1) + F2: Normal Risk + F5: Normal Risk,Intermediate Metabolizer,-,1,-,-,-,-,-,-,-,-,-,-,Normal Risk,-,-,Normal Risk,-,-,Decreased Exposure; Reduced Response (higher risk of breast cancer recurrence),Increased Caution/Avoid,Efficacy,üõë,"Consider hormonal therapy such as an aromatase inhibitor for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women. If aromatase inhibitor use is contraindicated, consideration should be given to use a higher but FDA approved tamoxifen dose (40 mg/day). Avoid CYP2D6 strong to weak inhibitors.",-,-,-
Tamoxifen,Actionable,ONCOLOGY,Level 1A(Optional),CYP2D6 + F2 + F5,No,CYP2D6,F2,F5,Professional guideline; FDA evidence,CPIC/DPWG,CYP2D6: Intermediate Metabolizer (1) + F2: Normal Risk + F5: Increased Risk,Intermediate Metabolizer,-,1,-,-,-,-,-,-,-,-,-,-,Normal Risk,-,-,Increased Risk,-,-,Decreased Exposure; Reduced Response (higher risk of breast cancer recurrence); Increased Risk of ADR,Increased Caution/Avoid,Efficacy,üõë,"Consider hormonal therapy such as an aromatase inhibitor for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women. If aromatase inhibitor use is contraindicated, consideration should be given to use a higher but FDA approved tamoxifen dose (40 mg/day). Avoid CYP2D6 strong to weak inhibitors.",-,-,-
Tamoxifen,Actionable,ONCOLOGY,Level 1A(Strong),CYP2D6 + F2 + F5,No,CYP2D6,F2,F5,Professional guideline; FDA evidence,CPIC/DPWG,"CYP2D6: Normal Metabolizer (1.25, 1.5, 1.75, 2, 2.25) + F2: Increased Risk + F5: Normal Risk",Normal Metabolizer,-,1.25,1.5,1.75,2,2.25,-,-,-,-,-,-,Increased Risk,-,-,Normal Risk,-,-,Normal Exposure; Increased Risk of ADR,Use with Caution,Toxicity,‚ö†Ô∏è,Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).,-,-,-
Tamoxifen,Actionable,ONCOLOGY,Level 1A(Strong),CYP2D6 + F2 + F5,No,CYP2D6,F2,F5,Professional guideline; FDA evidence,CPIC/DPWG,"CYP2D6: Normal Metabolizer (1.25, 1.5, 1.75, 2, 2.25) + F2: Increased Risk + F5: Increased Risk",Normal Metabolizer,-,1.25,1.5,1.75,2,2.25,-,-,-,-,-,-,Increased Risk,-,-,Increased Risk,-,-,Normal Exposure;  Increased Risk of ADR,Use with Caution,Toxicity,‚ö†Ô∏è,Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).,-,-,-
Tamoxifen,Actionable,ONCOLOGY,Level 1A(Strong),CYP2D6 + F2 + F5,No,CYP2D6,F2,F5,Professional guideline; FDA evidence,CPIC/DPWG,"CYP2D6: Normal Metabolizer (1.25, 1.5, 1.75, 2, 2.25) + F2: Normal Risk + F5: Normal Risk",Normal Metabolizer,-,1.25,1.5,1.75,2,2.25,-,-,-,-,-,-,Normal Risk,-,-,Normal Risk,-,-,Normal Exposure,Use as Directed,Efficacy,‚úÖ,Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).,-,-,-
Tamoxifen,Actionable,ONCOLOGY,Level 1A(Strong),CYP2D6 + F2 + F5,No,CYP2D6,F2,F5,Professional guideline; FDA evidence,CPIC/DPWG,"CYP2D6: Normal Metabolizer (1.25, 1.5, 1.75, 2, 2.25) + F2: Normal Risk + F5: Increased Risk",Normal Metabolizer,-,1.25,1.5,1.75,2,2.25,-,-,-,-,-,-,Normal Risk,-,-,Increased Risk,-,-,Normal Exposure;  Increased Risk of ADR,Use with Caution,Toxicity,‚ö†Ô∏è,Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).,-,-,-
Tamoxifen,Actionable,ONCOLOGY,Level 1A(Strong),CYP2D6 + F2 + F5,No,CYP2D6,F2,F5,Professional guideline; FDA evidence,CPIC/DPWG,"CYP2D6: Ultrarapid Metabolizer (2.5, ‚â•3.0, 3, ‚â•3.25, ‚â•3.5, 3.5, ‚â•4.0, 4, ‚â•4.5, ‚â•5.0, ‚â•6.0) + F2: Increased Risk + F5: Normal Risk",Ultrarapid Metabolizer,-,2.5,‚â•3.0,3,‚â•3.25,‚â•3.5,3.5,‚â•4.0,4,‚â•4.5,‚â•5.0,‚â•6.0,Increased Risk,-,-,Normal Risk,-,-,Normal Exposure; Increased Risk of ADR,Use with Caution,Toxicity,‚ö†Ô∏è,Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).,-,-,-
Tamoxifen,Actionable,ONCOLOGY,Level 1A(Strong),CYP2D6 + F2 + F5,No,CYP2D6,F2,F5,Professional guideline; FDA evidence,CPIC/DPWG,"CYP2D6: Ultrarapid Metabolizer (2.5, ‚â•3.0, 3, ‚â•3.25, ‚â•3.5, 3.5, ‚â•4.0, 4, ‚â•4.5, ‚â•5.0, ‚â•6.0) + F2: Increased Risk + F5: Increased Risk",Ultrarapid Metabolizer,-,2.5,‚â•3.0,3,‚â•3.25,‚â•3.5,3.5,‚â•4.0,4,‚â•4.5,‚â•5.0,‚â•6.0,Increased Risk,-,-,Increased Risk,-,-,Normal Exposure;  Increased Risk of ADR,Use with Caution,Toxicity,‚ö†Ô∏è,Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).,-,-,-
Tamoxifen,Actionable,ONCOLOGY,Level 1A(Strong),CYP2D6 + F2 + F5,No,CYP2D6,F2,F5,Professional guideline; FDA evidence,CPIC/DPWG,"CYP2D6: Ultrarapid Metabolizer (2.5, ‚â•3.0, 3, ‚â•3.25, ‚â•3.5, 3.5, ‚â•4.0, 4, ‚â•4.5, ‚â•5.0, ‚â•6.0) + F2: Normal Risk + F5: Normal Risk",Ultrarapid Metabolizer,-,2.5,‚â•3.0,3,‚â•3.25,‚â•3.5,3.5,‚â•4.0,4,‚â•4.5,‚â•5.0,‚â•6.0,Normal Risk,-,-,Normal Risk,-,-,Normal Exposure,Use as Directed,Efficacy,‚úÖ,Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).,-,-,-
Tamoxifen,Actionable,ONCOLOGY,Level 1A(Strong),CYP2D6 + F2 + F5,No,CYP2D6,F2,F5,Professional guideline; FDA evidence,CPIC/DPWG,"CYP2D6: Ultrarapid Metabolizer (2.5, ‚â•3.0, 3, ‚â•3.25, ‚â•3.5, 3.5, ‚â•4.0, 4, ‚â•4.5, ‚â•5.0, ‚â•6.0) + F2: Normal Risk + F5: Increased Risk",Ultrarapid Metabolizer,-,2.5,‚â•3.0,3,‚â•3.25,‚â•3.5,3.5,‚â•4.0,4,‚â•4.5,‚â•5.0,‚â•6.0,Normal Risk,-,-,Increased Risk,-,-,Normal Exposure;  Increased Risk of ADR,Use with Caution,Toxicity,‚ö†Ô∏è,Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).,-,-,-
Tamoxifen,Actionable,ONCOLOGY,Level 1A(No Recommendation),CYP2D6 + F2 + F5,No,CYP2D6,F2,F5,Professional guideline; FDA evidence,CPIC/DPWG,CYP2D6: Indeterminate  + F2: Increased Risk + F5: Normal Risk,Indeterminate,-,-,-,-,-,-,-,-,-,-,-,-,Increased Risk,-,-,Normal Risk,-,-,Increased Risk of ADR,Use with Caution,Toxicity,‚ö†Ô∏è,No recommendation,-,-,-
Tamoxifen,Actionable,ONCOLOGY,Level 1A(No Recommendation),CYP2D6 + F2 + F5,No,CYP2D6,F2,F5,Professional guideline; FDA evidence,CPIC/DPWG,CYP2D6: Indeterminate + F2: Increased Risk + F5: Increased Risk,Indeterminate,-,-,-,-,-,-,-,-,-,-,-,-,Increased Risk,-,-,Increased Risk,-,-,Increased Risk of ADR,Use with Caution,Toxicity,‚ö†Ô∏è,No recommendation,-,-,-
Tamoxifen,Actionable,ONCOLOGY,Level 1A(No Recommendation),CYP2D6 + F2 + F5,No,CYP2D6,F2,F5,Professional guideline; FDA evidence,CPIC/DPWG,CYP2D6: Indeterminate + F2: Normal Risk + F5: Normal Risk,Indeterminate,-,-,-,-,-,-,-,-,-,-,-,-,Normal Risk,-,-,Normal Risk,-,-,Normal Risk,No recommendation,-,‚úÖ,No recommendation,-,-,-
Tamoxifen,Actionable,ONCOLOGY,Level 1A(No Recommendation),CYP2D6 + F2 + F5,No,CYP2D6,F2,F5,Professional guideline; FDA evidence,CPIC/DPWG,CYP2D6: Indeterminate + F2: Normal Risk + F5: Increased Risk,Indeterminate,-,-,-,-,-,-,-,-,-,-,-,-,Normal Risk,-,-,Increased Risk,-,-,Increased Risk of ADR,Use with Caution,Toxicity,‚ö†Ô∏è,No recommendation,-,-,-
Leuocovorin,Actionable,ONCOLOGY,Level 2A,MTHFR,Yes,MTHFR,-,-,-,-,AA Genotype,-,AA Genotype,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Response,Use as Directed,-,‚úÖ,-,-,-,-
Leuocovorin,Actionable,ONCOLOGY,Level 2A,MTHFR,Yes,MTHFR,-,-,-,-,AG Genotype,-,AG Genotype,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Response,Use as Directed,-,‚úÖ,-,-,-,-
Oxaliplatin,Actionable,ONCOLOGY,Level 2A,MTHFR,Yes,MTHFR,-,-,-,-,AA Genotype,-,AA Genotype,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Response,Use as Directed,-,‚úÖ,-,-,-,-
Oxaliplatin,Actionable,ONCOLOGY,Level 2A,MTHFR,Yes,MTHFR,-,-,-,-,AG Genotype,-,AG Genotype,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Response,Use as Directed,-,‚úÖ,-,-,-,-
Oxaliplatin,Actionable,ONCOLOGY,Level 2A,MTHFR,Yes,MTHFR,-,-,-,-,GG Genotype,-,GG Genotype,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Reduced Response,Use with Caution,Efficacy,‚ö†Ô∏è,-,-,-,-
Risperidone,Actionable,PSYCHIATRY,Level 1A,CYP2D6,Yes,CYP2D6,-,-,Professional guideline; FDA evidence,DPWG,Ultrarapid Metabolizer (>2),Ultrarapid Metabolizer,-,>2,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Risk of ADR,Increased Caution/Avoid,Efficacy,üõë,Choose an alternative or titrate the dose according to the maximum dose for the active metabolite (paliperidone) (oral 12 mg/day for adults and children from 15 years of age weighing at least 51 kg and 6 mg/day for children from 15 years of age weighing less than 51 kg; intramuscular 75 mg per 2 weeks).,-,-,-
Risperidone,Actionable,PSYCHIATRY,Level 1A,CYP2D6,Yes,CYP2D6,-,-,Professional guideline; FDA evidence,DPWG,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Risperidone,Actionable,PSYCHIATRY,Level 1A,CYP2D6,Yes,CYP2D6,-,-,Professional guideline; FDA evidence,DPWG,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Use with Caution,Efficacy,‚ö†Ô∏è,NO action is needed for this gene-drug interaction.,-,-,-
Risperidone,Actionable,PSYCHIATRY,Level 1A,CYP2D6,Yes,CYP2D6,-,-,Professional guideline; FDA evidence,DPWG,Poor metabolizer,Poor metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Risk of ADR,Increased Caution/Avoid,Efficacy,üõë,"Use 67% of the normal dose. If problematic side effects originating in the central nervous system occur despite this reduced dose, then reduce the dose further to 50% of the normal dose.",-,-,-
Risperidone,Actionable,PSYCHIATRY,Level 1A,CYP2D6 + DRD2,No,CYP2D6,DRD2,-,Professional guideline; FDA evidence,DPWG,"CYP2D6: Ultrarapid Metabolizer (>2) + DRD2:rs1799978,CC",Ultrarapid Metabolizer,-,>2,-,-,-,-,-,-,-,-,-,-,-,"rs1799978,CC",-,-,-,-,Increased Risk of ADR; Reduced Response,Increased Caution/Avoid,Efficacy,üõë,Reduced Response; Choose an alternative or titrate the dose according to the maximum dose for the active metabolite (paliperidone) (oral 12 mg/day for adults and children from 15 years of age weighing at least 51 kg and 6 mg/day for children from 15 years of age weighing less than 51 kg; intramuscular 75 mg per 2 weeks).,-,-,-
Risperidone,Actionable,PSYCHIATRY,Level 1A,CYP2D6 + DRD2,No,CYP2D6,DRD2,-,Professional guideline; FDA evidence,DPWG,"CYP2D6: Ultrarapid Metabolizer (>2) + DRD2:rs1799978,CT",Ultrarapid Metabolizer,-,>2,-,-,-,-,-,-,-,-,-,-,-,"rs1799978,CT",-,-,-,-,Increased Risk of ADR; Reduced Response,Increased Caution/Avoid,Efficacy,üõë,Reduced Response; Choose an alternative or titrate the dose according to the maximum dose for the active metabolite (paliperidone) (oral 12 mg/day for adults and children from 15 years of age weighing at least 51 kg and 6 mg/day for children from 15 years of age weighing less than 51 kg; intramuscular 75 mg per 2 weeks).,-,-,-
Risperidone,Actionable,PSYCHIATRY,Level 1A,CYP2D6 + DRD2,No,CYP2D6,DRD2,-,Professional guideline; FDA evidence,DPWG,"CYP2D6: Ultrarapid Metabolizer (>2) + DRD2:rs1799978,TT",Ultrarapid Metabolizer,-,>2,-,-,-,-,-,-,-,-,-,-,-,"rs1799978,TT",-,-,-,-,Increased Risk of ADR,Increased Caution/Avoid,Efficacy,üõë,Choose an alternative or titrate the dose according to the maximum dose for the active metabolite (paliperidone) (oral 12 mg/day for adults and children from 15 years of age weighing at least 51 kg and 6 mg/day for children from 15 years of age weighing less than 51 kg; intramuscular 75 mg per 2 weeks).,-,-,-
Risperidone,Actionable,PSYCHIATRY,Level 1A,CYP2D6 + DRD2,No,CYP2D6,DRD2,-,Professional guideline; FDA evidence,DPWG,"CYP2D6: Normal metabolizer +  DRD2:rs1799978,CC",Normal metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,"rs1799978,CC",-,-,-,-,Reduced Response,Use with Caution,Efficacy,‚ö†Ô∏è,Reduced Response,-,-,-
Risperidone,Actionable,PSYCHIATRY,Level 1A,CYP2D6 + DRD2,No,CYP2D6,DRD2,-,Professional guideline; FDA evidence,DPWG,"CYP2D6: Normal metabolizer +  DRD2:rs1799978,CT",Normal metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,"rs1799978,CT",-,-,-,-,Reduced Response,Use with Caution,Efficacy,‚ö†Ô∏è,Reduced Response,-,-,-
Risperidone,Actionable,PSYCHIATRY,Level 1A,CYP2D6 + DRD2,No,CYP2D6,DRD2,-,Professional guideline; FDA evidence,DPWG,"CYP2D6: Normal metabolizer +  DRD2:rs1799978,TT",Normal metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,"rs1799978,TT",-,-,-,-,Normal Response,Use as Directed,Efficacy,‚úÖ,-,-,-,-
Risperidone,Actionable,PSYCHIATRY,Level 1A,CYP2D6 + DRD2,No,CYP2D6,DRD2,-,Professional guideline; FDA evidence,DPWG,"CYP2D6: Intermediate metabolizer + DRD2:rs1799978,CC",Intermediate metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,"rs1799978,CC",-,-,-,-,Reduced Response,Use with Caution,Efficacy,‚ö†Ô∏è,Reduced Response,-,-,-
Risperidone,Actionable,PSYCHIATRY,Level 1A,CYP2D6 + DRD2,No,CYP2D6,DRD2,-,Professional guideline; FDA evidence,DPWG,"CYP2D6: Intermediate metabolizer + DRD2:rs1799978,CT",Intermediate metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,"rs1799978,CT",-,-,-,-,Reduced Response,Use with Caution,Efficacy,‚ö†Ô∏è,Reduced Response,-,-,-
Risperidone,Actionable,PSYCHIATRY,Level 1A,CYP2D6 + DRD2,No,CYP2D6,DRD2,-,Professional guideline; FDA evidence,DPWG,"CYP2D6: Intermediate metabolizer + DRD2:rs1799978,TT",Intermediate metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,"rs1799978,TT",-,-,-,-,Increased Exposure,Use with Caution,Efficacy,‚ö†Ô∏è,-,-,-,-
Risperidone,Actionable,PSYCHIATRY,Level 1A,CYP2D6 + DRD2,No,CYP2D6,DRD2,-,Professional guideline; FDA evidence,DPWG,"CYP2D6: Poor metabolizer + DRD2:rs1799978,CC",Poor metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,"rs1799978,CC",-,-,-,-,Increased Risk of ADR; Reduced Response,Increased Caution/Avoid,Efficacy,üõë,"Reduced Response; Increased Risk of ADR; Use 67% of the normal dose. If problematic side effects originating in the central nervous system occur despite this reduced dose, then reduce the dose further to 50% of the normal dose.",-,-,-
Risperidone,Actionable,PSYCHIATRY,Level 1A,CYP2D6 + DRD2,No,CYP2D6,DRD2,-,Professional guideline; FDA evidence,DPWG,"CYP2D6: Poor metabolizer + DRD2:rs1799978,CT",Poor metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,"rs1799978,CT",-,-,-,-,Increased Risk of ADR; Reduced Response,Increased Caution/Avoid,Efficacy,üõë,"Reduced Response; Increased Risk of ADR; Use 67% of the normal dose. If problematic side effects originating in the central nervous system occur despite this reduced dose, then reduce the dose further to 50% of the normal dose.",-,-,-
Risperidone,Actionable,PSYCHIATRY,Level 1A,CYP2D6 + DRD2,No,CYP2D6,DRD2,-,Professional guideline; FDA evidence,DPWG,"CYP2D6: Poor metabolizer + DRD2:rs1799978,TT",Poor metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,"rs1799978,TT",-,-,-,-,Increased Risk of ADR,Increased Caution/Avoid,Efficacy,üõë,"Use 67% of the normal dose. If problematic side effects originating in the central nervous system occur despite this reduced dose, then reduce the dose further to 50% of the normal dose.",-,-,-
Citalopram,Actionable,PSYCHIATRY,n/a,CYP2C19 + HTR2A,No,CYP2C19,HTR2A,-,Professional guideline; FDA evidence,CPIC; DPWG,"CYP2C19: Indeterminate + rs7997012, AG",Indeterminate,-,-,-,-,-,-,-,-,-,-,-,-,-,"rs7997012, AG",-,-,-,-,n/a,-,n/a,-,No recommendation,-,-,-
Citalopram,Actionable,PSYCHIATRY,Level 1A(Moderate) + Level 3,CYP2C19 + HTR2A,No,CYP2C19,HTR2A,-,Professional guideline; FDA evidence,CPIC; DPWG,"CYP2C19: Intermediate Metabolizer + rs7997012, AG",Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,"rs7997012, AG",-,-,-,-,Increased Exposure; Minimal evidence for clinical impact,Use with Caution,Efficacy,‚ö†Ô∏è,Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose than normal metabolizers.,-,-,-
Citalopram,Actionable,PSYCHIATRY,Level 1A(Moderate)+ Level 3,CYP2C19 + HTR2A,No,CYP2C19,HTR2A,-,Professional guideline; FDA evidence,CPIC; DPWG,"CYP2C19: Likely Intermediate Metabolizer + rs7997012, AG",Likely Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,"rs7997012, AG",-,-,-,-,Increased Exposure; Minimal evidence for clinical impact,Use with Caution,Efficacy,‚ö†Ô∏è,Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose than normal metabolizers.,-,-,-
Citalopram,Actionable,PSYCHIATRY,Level 1A(Strong)+ Level 3,CYP2C19 + HTR2A,No,CYP2C19,HTR2A,-,Professional guideline; FDA evidence,CPIC; DPWG,"CYP2C19: Likely Poor Metabolizer + rs7997012, AG",Likely Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,"rs7997012, AG",-,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Consider a clinically appropriate antidepressant not predominantly metabolized by CYP2C19. If citalopram or escitalopram are clinically appropriate, consider a lower starting dose, slower titration schedule and 50% reduction of the standard maintenance dose as compared to normal metabolizers.",-,-,-
Citalopram,Actionable,PSYCHIATRY,Level 1A(Strong)+ Level 3,CYP2C19 + HTR2A,No,CYP2C19,HTR2A,-,Professional guideline; FDA evidence,CPIC; DPWG,"CYP2C19: Normal Metabolizer + rs7997012, AG",Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,"rs7997012, AG",-,-,-,-,Normal Exposure,Use as Directed,PK/Toxicity/Efficacy,‚úÖ,Initiate therapy with recommended starting dose,-,-,-
Citalopram,Actionable,PSYCHIATRY,Level 1A(Strong)+ Level 3,CYP2C19 + HTR2A,No,CYP2C19,HTR2A,-,Professional guideline; FDA evidence,CPIC; DPWG,"CYP2C19: Poor Metabolizer + rs7997012, AG",Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,"rs7997012, AG",-,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Consider a clinically appropriate antidepressant not predominantly metabolized by CYP2C19. If citalopram or escitalopram are clinically appropriate, consider a lower starting dose, slower titration schedule and 50% reduction of the standard maintenance dose as compared to normal metabolizers.",-,-,-
Citalopram,Actionable,PSYCHIATRY,Level 1A(Optional)+ Level 3,CYP2C19 + HTR2A,No,CYP2C19,HTR2A,-,Professional guideline; FDA evidence,CPIC; DPWG,"CYP2C19: Rapid Metabolizer + rs7997012, AG",Rapid Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,"rs7997012, AG",-,-,-,-,Decreased Exposure,Use with Caution,Efficacy,‚ö†Ô∏è,"Initiate therapy with recommended starting dose. If patient does not adequately respond to recommended maintenance dosing, consider titrating to a higher maintenance dose or switching to a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.",-,-,-
Citalopram,Actionable,PSYCHIATRY,Level 1A(Strong)+ Level 3,CYP2C19 + HTR2A,No,CYP2C19,HTR2A,-,Professional guideline; FDA evidence,CPIC; DPWG,"CYP2C19: Ultrarapid Metabolizer + rs7997012, AG",Ultrarapid Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,"rs7997012, AG",-,-,-,-,Decreased Exposure,Increased Caution/Avoid,Efficacy,üõë,"Consider a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19. If citalopram or escitalopram are clinically appropriate, and adequate efficacy is not achieved at standard maintenance dosing, consider titrating to a higher maintenance dose.",-,-,-
Citalopram,Actionable,PSYCHIATRY,n/a,CYP2C19 + HTR2A,No,CYP2C19,HTR2A,-,Professional guideline; FDA evidence,CPIC; DPWG,"CYP2C19: Indeterminate + rs7997012, GG",Indeterminate,-,-,-,-,-,-,-,-,-,-,-,-,-,"rs7997012, GG",-,-,-,-,n/a,-,n/a,‚ö†Ô∏è,Reduced Response,-,-,-
Citalopram,Actionable,PSYCHIATRY,Level 1A(Moderate),CYP2C19 + HTR2A,No,CYP2C19,HTR2A,-,Professional guideline; FDA evidence,CPIC; DPWG,"CYP2C19: Intermediate Metabolizer + rs7997012, GG",Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,"rs7997012, GG",-,-,-,-,Increased Exposure; Minimal evidence for clinical impact,Use as Directed,Toxicity,‚ö†Ô∏è,Reduced Response,-,-,-
Citalopram,Actionable,PSYCHIATRY,Level 1A(Moderate),CYP2C19 + HTR2A,No,CYP2C19,HTR2A,-,Professional guideline; FDA evidence,CPIC; DPWG,"CYP2C19: Likely Intermediate Metabolizer + rs7997012, GG",Likely Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,"rs7997012, GG",-,-,-,-,Increased Exposure; Minimal evidence for clinical impact,Use as Directed,Toxicity,‚ö†Ô∏è,Reduced Response,-,-,-
Citalopram,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2C19 + HTR2A,No,CYP2C19,HTR2A,-,Professional guideline; FDA evidence,CPIC; DPWG,"CYP2C19: Likely Poor Metabolizer + rs7997012, GG",Likely Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,"rs7997012, GG",-,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Reduced Response; Increased Risk of Toxicity;Consider a clinically appropriate antidepressant not predominantly metabolized by CYP2C19. If citalopram or escitalopram are clinically appropriate, consider a lower starting dose, slower titration schedule and 50% reduction of the standard maintenance dose as compared to normal metabolizers.",-,-,-
Citalopram,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2C19 + HTR2A,No,CYP2C19,HTR2A,-,Professional guideline; FDA evidence,CPIC; DPWG,"CYP2C19: Normal Metabolizer + rs7997012, GG",Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,"rs7997012, GG",-,-,-,-,Normal Exposure,Use as Directed,PK/Toxicity/Efficacy,‚ö†Ô∏è,Reduced Response,-,-,-
Citalopram,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2C19 + HTR2A,No,CYP2C19,HTR2A,-,Professional guideline; FDA evidence,CPIC; DPWG,"CYP2C19: Poor Metabolizer + rs7997012, GG",Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,"rs7997012, GG",-,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Reduced Response; Increased Risk of Toxicity; Consider a clinically appropriate antidepressant not predominantly metabolized by CYP2C19. If citalopram or escitalopram are clinically appropriate, consider a lower starting dose, slower titration schedule and 50% reduction of the standard maintenance dose as compared to normal metabolizers.",-,-,-
Citalopram,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2C19 + HTR2A,No,CYP2C19,HTR2A,-,Professional guideline; FDA evidence,CPIC; DPWG,"CYP2C19: Rapid Metabolizer + rs7997012, GG",Rapid Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,"rs7997012, GG",-,-,-,-,Decreased Exposure,Use with Caution,Efficacy,‚ö†Ô∏è,"Reduced Response; Initiate therapy with recommended starting dose. If patient does not adequately respond to recommended maintenance dosing, consider titrating to a higher maintenance dose or switching to a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.",-,-,-
Citalopram,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2C19 + HTR2A,No,CYP2C19,HTR2A,-,Professional guideline; FDA evidence,CPIC; DPWG,"CYP2C19: Ultrarapid Metabolizer + rs7997012, GG",Ultrarapid Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,"rs7997012, GG",-,-,-,-,Decreased Exposure,Increased Caution/Avoid,Efficacy,üõë,"Reduced Response; Consider a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19. If citalopram or escitalopram are clinically appropriate, and adequate efficacy is not achieved at standard maintenance dosing, consider titrating to a higher maintenance dose.",-,-,-
Clozapine,Actionable,PSYCHIATRY,Level 1B,CYP2D6 + HTR2C,No,CYP2D6,HTR2C,-,FDA evidence,DPWG (No Recommendation),"CYP2D6: Ultrarapid Metabolizer (>2) + rs3813929,CC",Ultrarapid Metabolizer,-,>2,-,-,-,-,-,-,-,-,-,-,-,"rs3813929,CC",-,-,-,-,Decreased Exposure; Minimal Evidence for clinical Impact,Use with Caution,Toxicity,‚ö†Ô∏è,Increased risk of ADR(Weight Gain),-,-,-
Clozapine,Actionable,PSYCHIATRY,Level 1B,CYP2D6 + HTR2C,No,CYP2D6,HTR2C,-,FDA evidence,DPWG (No Recommendation),"CYP2D6: Normal metabolizer (1.5 and 2) + rs3813929,CC",Normal metabolizer,-,1.5,2,-,-,-,-,-,-,-,-,-,-,"rs3813929,CC",-,-,-,-,Normal Exposure,Use with Caution,Toxicity,‚ö†Ô∏è,Increased risk of ADR(Weight Gain),-,-,-
Clozapine,Actionable,PSYCHIATRY,Level 1B,CYP2D6 + HTR2C,No,CYP2D6,HTR2C,-,FDA evidence,DPWG (No Recommendation),"CYP2D6: Normal metabolizer or Intermediate metabolizer (1 (no *10 allele present)) + rs3813929,CC",Normal metabolizer,-,1,-,-,-,-,-,-,-,-,-,-,-,"rs3813929,CC",-,-,-,-,Normal Exposure,Use with Caution,Toxicity,‚ö†Ô∏è,Increased risk of ADR(Weight Gain),-,-,-
Clozapine,Actionable,PSYCHIATRY,Level 1B,CYP2D6 + HTR2C,No,CYP2D6,HTR2C,-,FDA evidence,DPWG (No Recommendation),"CYP2D6: Normal metabolizer or Intermediate metabolizer (1 (no *10 allele present)) + rs3813929,CC",Intermediate metabolizer,-,1,-,-,-,-,-,-,-,-,-,-,-,"rs3813929,CC",-,-,-,-,Normal Exposure,Use with Caution,Toxicity,‚ö†Ô∏è,Increased risk of ADR(Weight Gain),-,-,-
Clozapine,Actionable,PSYCHIATRY,Level 1B,CYP2D6 + HTR2C,No,CYP2D6,HTR2C,-,FDA evidence,DPWG (No Recommendation),"CYP2D6: Normal metabolizer or Intermediate metabolizer (1 (*10 allele present)) + rs3813929,CC",Normal metabolizer,*10,1,-,-,-,-,-,-,-,-,-,-,-,"rs3813929,CC",-,-,-,-,Normal Exposure,Use with Caution,Toxicity,‚ö†Ô∏è,Increased risk of ADR(Weight Gain),-,-,-
Clozapine,Actionable,PSYCHIATRY,Level 1B,CYP2D6 + HTR2C,No,CYP2D6,HTR2C,-,FDA evidence,DPWG (No Recommendation),"CYP2D6: Normal metabolizer or Intermediate metabolizer (1 (*10 allele present)) + rs3813929,CC",Intermediate metabolizer,*10,1,-,-,-,-,-,-,-,-,-,-,-,"rs3813929,CC",-,-,-,-,Normal Exposure,Use with Caution,Toxicity,‚ö†Ô∏è,Increased risk of ADR(Weight Gain),-,-,-
Clozapine,Actionable,PSYCHIATRY,Level 1B,CYP2D6 + HTR2C,No,CYP2D6,HTR2C,-,FDA evidence,DPWG (No Recommendation),"CYP2D6: Intermediate metabolizer (0.5) + rs3813929,CC",Intermediate metabolizer,-,0.5,-,-,-,-,-,-,-,-,-,-,-,"rs3813929,CC",-,-,-,-,Normal Exposure,Use with Caution,Toxicity,‚ö†Ô∏è,Increased risk of ADR(Weight Gain),-,-,-
Clozapine,Actionable,PSYCHIATRY,Level 1B,CYP2D6 + HTR2C,No,CYP2D6,HTR2C,-,FDA evidence,DPWG (No Recommendation),"CYP2D6: Poor metabolizer (0) + rs3813929,CC",Poor metabolizer,-,0,-,-,-,-,-,-,-,-,-,-,-,"rs3813929,CC",-,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,Increased risk of ADR(Weight Gain); Dosage reductions may be necessary.,-,-,-
Clozapine,Actionable,PSYCHIATRY,Level 1B,CYP2D6 + HTR2C,No,CYP2D6,HTR2C,-,FDA evidence,DPWG (No Recommendation),"CYP2D6: Ultrarapid Metabolizer (>2) + rs3813929,CT",Ultrarapid Metabolizer,-,>2,-,-,-,-,-,-,-,-,-,-,-,"rs3813929,CT",-,-,-,-,Decreased Exposure; Minimal Evidence for clinical Impact,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Clozapine,Actionable,PSYCHIATRY,Level 1B,CYP2D6 + HTR2C,No,CYP2D6,HTR2C,-,FDA evidence,DPWG (No Recommendation),"CYP2D6: Normal metabolizer (1.5 and 2) + rs3813929,CT",Normal metabolizer,-,1.5,2,-,-,-,-,-,-,-,-,-,-,"rs3813929,CT",-,-,-,-,Normal Exposure,Use as Directed,Toxicity,‚úÖ,-,-,-,-
Clozapine,Actionable,PSYCHIATRY,Level 1B,CYP2D6 + HTR2C,No,CYP2D6,HTR2C,-,FDA evidence,DPWG (No Recommendation),"CYP2D6: Normal metabolizer or Intermediate metabolizer (1 (no *10 allele present)) + rs3813929,CT",Normal metabolizer,-,1,-,-,-,-,-,-,-,-,-,-,-,"rs3813929,CT",-,-,-,-,Normal Exposure,Use as Directed,Toxicity,‚úÖ,-,-,-,-
Clozapine,Actionable,PSYCHIATRY,Level 1B,CYP2D6 + HTR2C,No,CYP2D6,HTR2C,-,FDA evidence,DPWG (No Recommendation),"CYP2D6: Normal metabolizer or Intermediate metabolizer (1 (no *10 allele present)) + rs3813929,CT",Intermediate metabolizer,-,1,-,-,-,-,-,-,-,-,-,-,-,"rs3813929,CT",-,-,-,-,Normal Exposure,Use as Directed,Toxicity,‚úÖ,-,-,-,-
Clozapine,Actionable,PSYCHIATRY,Level 1B,CYP2D6 + HTR2C,No,CYP2D6,HTR2C,-,FDA evidence,DPWG (No Recommendation),"CYP2D6: Normal metabolizer or Intermediate metabolizer (1 (*10 allele present)) + rs3813929,CT",Normal metabolizer,*10,1,-,-,-,-,-,-,-,-,-,-,-,"rs3813929,CT",-,-,-,-,Normal Exposure,Use as Directed,Toxicity,‚úÖ,-,-,-,-
Clozapine,Actionable,PSYCHIATRY,Level 1B,CYP2D6 + HTR2C,No,CYP2D6,HTR2C,-,FDA evidence,DPWG (No Recommendation),"CYP2D6: Normal metabolizer or Intermediate metabolizer (1 (*10 allele present)) + rs3813929,CT",Intermediate metabolizer,*10,1,-,-,-,-,-,-,-,-,-,-,-,"rs3813929,CT",-,-,-,-,Normal Exposure,Use as Directed,Toxicity,‚úÖ,-,-,-,-
Clozapine,Actionable,PSYCHIATRY,Level 1B,CYP2D6 + HTR2C,No,CYP2D6,HTR2C,-,FDA evidence,DPWG (No Recommendation),"CYP2D6: Intermediate metabolizer (0.5) + rs3813929,CT",Intermediate metabolizer,-,0.5,-,-,-,-,-,-,-,-,-,-,-,"rs3813929,CT",-,-,-,-,Normal Exposure,Use as Directed,Toxicity,‚úÖ,-,-,-,-
Clozapine,Actionable,PSYCHIATRY,Level 1B,CYP2D6 + HTR2C,No,CYP2D6,HTR2C,-,FDA evidence,DPWG (No Recommendation),"CYP2D6: Poor metabolizer (0) + rs3813929,CT",Poor metabolizer,-,0,-,-,-,-,-,-,-,-,-,-,-,"rs3813929,CT",-,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,Dosage reductions may be necessary.,-,-,-
Clozapine,Actionable,PSYCHIATRY,Level 1B,CYP2D6 + HTR2C,No,CYP2D6,HTR2C,-,FDA evidence,DPWG (No Recommendation),"CYP2D6: Ultrarapid Metabolizer (>2) + rs3813929,T",Ultrarapid Metabolizer,-,>2,-,-,-,-,-,-,-,-,-,-,-,"rs3813929,T",-,-,-,-,Decreased Exposure; Minimal Evidence for clinical Impact,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Clozapine,Actionable,PSYCHIATRY,Level 1B,CYP2D6 + HTR2C,No,CYP2D6,HTR2C,-,FDA evidence,DPWG (No Recommendation),"CYP2D6: Normal metabolizer (1.5 and 2) + rs3813929,T",Normal metabolizer,-,1.5,2,-,-,-,-,-,-,-,-,-,-,"rs3813929,T",-,-,-,-,Normal Exposure,Use as Directed,Toxicity,‚úÖ,-,-,-,-
Clozapine,Actionable,PSYCHIATRY,Level 1B,CYP2D6 + HTR2C,No,CYP2D6,HTR2C,-,FDA evidence,DPWG (No Recommendation),"CYP2D6: Normal metabolizer or Intermediate metabolizer (1 (no *10 allele present)) + rs3813929,T",Normal metabolizer,-,1,-,-,-,-,-,-,-,-,-,-,-,"rs3813929,T",-,-,-,-,Normal Exposure,Use as Directed,Toxicity,‚úÖ,-,-,-,-
Clozapine,Actionable,PSYCHIATRY,Level 1B,CYP2D6 + HTR2C,No,CYP2D6,HTR2C,-,FDA evidence,DPWG (No Recommendation),"CYP2D6: Normal metabolizer or Intermediate metabolizer (1 (no *10 allele present)) + rs3813929,T",Intermediate metabolizer,-,1,-,-,-,-,-,-,-,-,-,-,-,"rs3813929,T",-,-,-,-,Normal Exposure,Use as Directed,Toxicity,‚úÖ,-,-,-,-
Clozapine,Actionable,PSYCHIATRY,Level 1B,CYP2D6 + HTR2C,No,CYP2D6,HTR2C,-,FDA evidence,DPWG (No Recommendation),"CYP2D6: Normal metabolizer or Intermediate metabolizer (1 (*10 allele present)) + rs3813929,T",Normal metabolizer,*10,1,-,-,-,-,-,-,-,-,-,-,-,"rs3813929,T",-,-,-,-,Normal Exposure,Use as Directed,Toxicity,‚úÖ,-,-,-,-
Clozapine,Actionable,PSYCHIATRY,Level 1B,CYP2D6 + HTR2C,No,CYP2D6,HTR2C,-,FDA evidence,DPWG (No Recommendation),"CYP2D6: Normal metabolizer or Intermediate metabolizer (1 (*10 allele present)) + rs3813929,T",Intermediate metabolizer,*10,1,-,-,-,-,-,-,-,-,-,-,-,"rs3813929,T",-,-,-,-,Normal Exposure,Use as Directed,Toxicity,‚úÖ,-,-,-,-
Clozapine,Actionable,PSYCHIATRY,Level 1B,CYP2D6 + HTR2C,No,CYP2D6,HTR2C,-,FDA evidence,DPWG (No Recommendation),"CYP2D6: Intermediate metabolizer (0.5) + rs3813929,T",Intermediate metabolizer,-,0.5,-,-,-,-,-,-,-,-,-,-,-,"rs3813929,T",-,-,-,-,Normal Exposure,Use as Directed,Toxicity,‚úÖ,-,-,-,-
Clozapine,Actionable,PSYCHIATRY,Level 1B,CYP2D6 + HTR2C,No,CYP2D6,HTR2C,-,FDA evidence,DPWG (No Recommendation),"CYP2D6: Poor metabolizer (0) + rs3813929,T",Poor metabolizer,-,0,-,-,-,-,-,-,-,-,-,-,-,"rs3813929,T",-,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,Dosage reductions may be necessary.,-,-,-
Clozapine,Actionable,PSYCHIATRY,Level 1B,CYP2D6 + HTR2C,No,CYP2D6,HTR2C,-,FDA evidence,DPWG (No Recommendation),"CYP2D6: Ultrarapid Metabolizer (>2) + rs3813929,TT",Ultrarapid Metabolizer,-,>2,-,-,-,-,-,-,-,-,-,-,-,"rs3813929,TT",-,-,-,-,Decreased Exposure; Minimal Evidence for clinical Impact,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Clozapine,Actionable,PSYCHIATRY,Level 1B,CYP2D6 + HTR2C,No,CYP2D6,HTR2C,-,FDA evidence,DPWG (No Recommendation),"CYP2D6: Normal metabolizer (1.5 and 2) + rs3813929,TT",Normal metabolizer,-,1.5,2,-,-,-,-,-,-,-,-,-,-,"rs3813929,TT",-,-,-,-,Normal Exposure,Use as Directed,Toxicity,‚úÖ,-,-,-,-
Clozapine,Actionable,PSYCHIATRY,Level 1B,CYP2D6 + HTR2C,No,CYP2D6,HTR2C,-,FDA evidence,DPWG (No Recommendation),"CYP2D6: Normal metabolizer or Intermediate metabolizer (1 (no *10 allele present)) + rs3813929,TT",Normal metabolizer,-,1,-,-,-,-,-,-,-,-,-,-,-,"rs3813929,TT",-,-,-,-,Normal Exposure,Use as Directed,Toxicity,‚úÖ,-,-,-,-
Clozapine,Actionable,PSYCHIATRY,Level 1B,CYP2D6 + HTR2C,No,CYP2D6,HTR2C,-,FDA evidence,DPWG (No Recommendation),"CYP2D6: Normal metabolizer or Intermediate metabolizer (1 (no *10 allele present)) + rs3813929,TT",Intermediate metabolizer,-,1,-,-,-,-,-,-,-,-,-,-,-,"rs3813929,TT",-,-,-,-,Normal Exposure,Use as Directed,Toxicity,‚úÖ,-,-,-,-
Clozapine,Actionable,PSYCHIATRY,Level 1B,CYP2D6 + HTR2C,No,CYP2D6,HTR2C,-,FDA evidence,DPWG (No Recommendation),"CYP2D6: Normal metabolizer or Intermediate metabolizer (1 (*10 allele present)) + rs3813929,TT",Normal metabolizer,*10,1,-,-,-,-,-,-,-,-,-,-,-,"rs3813929,TT",-,-,-,-,Normal Exposure,Use as Directed,Toxicity,‚úÖ,-,-,-,-
Clozapine,Actionable,PSYCHIATRY,Level 1B,CYP2D6 + HTR2C,No,CYP2D6,HTR2C,-,FDA evidence,DPWG (No Recommendation),"CYP2D6: Normal metabolizer or Intermediate metabolizer (1 (*10 allele present)) + rs3813929,TT",Intermediate metabolizer,*10,1,-,-,-,-,-,-,-,-,-,-,-,"rs3813929,TT",-,-,-,-,Normal Exposure,Use as Directed,Toxicity,‚úÖ,-,-,-,-
Clozapine,Actionable,PSYCHIATRY,Level 1B,CYP2D6 + HTR2C,No,CYP2D6,HTR2C,-,FDA evidence,DPWG (No Recommendation),"CYP2D6: Intermediate metabolizer (0.5) + rs3813929,TT",Intermediate metabolizer,-,0.5,-,-,-,-,-,-,-,-,-,-,-,"rs3813929,TT",-,-,-,-,Normal Exposure,Use as Directed,Toxicity,‚úÖ,-,-,-,-
Clozapine,Actionable,PSYCHIATRY,Level 1B,CYP2D6 + HTR2C,No,CYP2D6,HTR2C,-,FDA evidence,DPWG (No Recommendation),"CYP2D6: Poor metabolizer (0) + rs3813929,TT",Poor metabolizer,-,0,-,-,-,-,-,-,-,-,-,-,-,"rs3813929,TT",-,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,Dosage reductions may be necessary.,-,-,-
Clozapine,Actionable,PSYCHIATRY,Level 1B,HTR2C,Yes,HTR2C,-,-,FDA evidence,-,"rs3813929,C",-,"rs3813929,C",-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased risk of weight gain,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Clozapine,Actionable,PSYCHIATRY,Level 1B,HTR2C,Yes,HTR2C,-,-,FDA evidence,-,"rs3813929,CC",-,"rs3813929,CC",-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased risk of weight gain,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Clozapine,Actionable,PSYCHIATRY,Level 1B,HTR2C,Yes,HTR2C,-,-,FDA evidence,-,"rs3813929,CT",-,"rs3813929,CT",-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased risk of weight gain,Use as Directed,Toxicity,‚úÖ,-,-,-,-
Clozapine,Actionable,PSYCHIATRY,Level 1B,HTR2C,Yes,HTR2C,-,-,FDA evidence,-,"rs3813929,T",-,"rs3813929,T",-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased risk of weight gain,Use as Directed,Toxicity,‚úÖ,-,-,-,-
Clozapine,Actionable,PSYCHIATRY,Level 1B,HTR2C,Yes,HTR2C,-,-,FDA evidence,-,"rs3813929,TT",-,"rs3813929,TT",-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased risk of weight gain,Use as Directed,Toxicity,‚úÖ,-,-,-,-
Olanzapine,Actionable,PSYCHIATRY,Level 2A,CYP1A2,Yes,CYP1A2,-,-,-,DPWG (No Recommendation),"rs762551,AA; Fast Metabolizer",Fast Metabolizer,"rs762551,AA",-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Reduced Response,Use with Caution,-,‚ö†Ô∏è,Reduced Response,-,-,-
Olanzapine,Actionable,PSYCHIATRY,Level 2A,CYP1A2,Yes,CYP1A2,-,-,-,DPWG (No Recommendation),"rs762551,AC; Slow Metabolizer",Slow Metabolizer,"rs762551,AC",-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Response,Use as Directed,-,‚úÖ,-,-,-,-
Olanzapine,Actionable,PSYCHIATRY,Level 2A,CYP1A2,Yes,CYP1A2,-,-,-,DPWG (No Recommendation),"rs762551,CC; Slow Metabolizer",Slow Metabolizer,"rs762551,CC",-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Response,Use as Directed,-,‚úÖ,-,-,-,-
Olanzapine,Actionable,PSYCHIATRY,Level 2A,CYP1A2 + HTR2C,No,CYP1A2,HTR2C,-,-,DPWG (No Recommendation),"CYP1A2: rs762551,AA; Fast Metabolizer + HTR2C: rs3813929,CC",Fast Metabolizer,"rs762551,AA",-,-,-,-,-,-,-,-,-,-,-,-,"rs3813929,CC",-,-,-,-,Reduced Response; Increased Risk of ADR(weight gain),Use with Caution,-,‚ö†Ô∏è,Reduced Response; Increased Risk of ADR(weight gain),-,-,-
Olanzapine,Actionable,PSYCHIATRY,Level 2A,CYP1A2 + HTR2C,No,CYP1A2,HTR2C,-,-,DPWG (No Recommendation),"CYP1A2: rs762551,AC; Slow Metabolizer + HTR2C: rs3813929,CC",Slow Metabolizer,"rs762551,AC",-,-,-,-,-,-,-,-,-,-,-,-,"rs3813929,CC",-,-,-,-,Increased Risk of ADR(weight gain),Use with Caution,-,‚ö†Ô∏è,Increased Risk of ADR(weight gain),-,-,-
Olanzapine,Actionable,PSYCHIATRY,Level 2A,CYP1A2 + HTR2C,No,CYP1A2,HTR2C,-,-,DPWG (No Recommendation),"CYP1A2: rs762551,CC; Slow Metabolizer + HTR2C: rs3813929,CC",Slow Metabolizer,"rs762551,CC",-,-,-,-,-,-,-,-,-,-,-,-,"rs3813929,CC",-,-,-,-,Increased Risk of ADR(weight gain),Use with Caution,-,‚ö†Ô∏è,Increased Risk of ADR(weight gain),-,-,-
Olanzapine,Actionable,PSYCHIATRY,Level 2A,CYP1A2 + HTR2C,No,CYP1A2,HTR2C,-,-,DPWG (No Recommendation),"CYP1A2: rs762551,AA; Fast Metabolizer + HTR2C: rs3813929,CT",Fast Metabolizer,"rs762551,AA",-,-,-,-,-,-,-,-,-,-,-,-,"rs3813929,CT",-,-,-,-,Reduced Response,Use with Caution,-,‚ö†Ô∏è,Reduced Response,-,-,-
Olanzapine,Actionable,PSYCHIATRY,Level 2A,CYP1A2 + HTR2C,No,CYP1A2,HTR2C,-,-,DPWG (No Recommendation),"CYP1A2: rs762551,AC; Slow Metabolizer + HTR2C: rs3813929,CT",Slow Metabolizer,"rs762551,AC",-,-,-,-,-,-,-,-,-,-,-,-,"rs3813929,CT",-,-,-,-,Normal Response,Use as Directed,-,‚úÖ,Normal Response,-,-,-
Olanzapine,Actionable,PSYCHIATRY,Level 2A,CYP1A2 + HTR2C,No,CYP1A2,HTR2C,-,-,DPWG (No Recommendation),"CYP1A2: rs762551,CC; Slow Metabolizer + HTR2C: rs3813929,CT",Slow Metabolizer,"rs762551,CC",-,-,-,-,-,-,-,-,-,-,-,-,"rs3813929,CT",-,-,-,-,Normal Response,Use as Directed,-,‚úÖ,Normal Response,-,-,-
Olanzapine,Actionable,PSYCHIATRY,Level 2A,CYP1A2 + HTR2C,No,CYP1A2,HTR2C,-,-,DPWG (No Recommendation),"CYP1A2: rs762551,AA; Fast Metabolizer + HTR2C: rs3813929,T",Fast Metabolizer,"rs762551,AA",-,-,-,-,-,-,-,-,-,-,-,-,"rs3813929,T",-,-,-,-,Reduced Response,Use with Caution,-,‚ö†Ô∏è,Reduced Response,-,-,-
Olanzapine,Actionable,PSYCHIATRY,Level 2A,CYP1A2 + HTR2C,No,CYP1A2,HTR2C,-,-,DPWG (No Recommendation),"CYP1A2: rs762551,AC; Slow Metabolizer + HTR2C: rs3813929,T",Slow Metabolizer,"rs762551,AC",-,-,-,-,-,-,-,-,-,-,-,-,"rs3813929,T",-,-,-,-,Normal Response,Use as Directed,-,‚úÖ,Normal Response,-,-,-
Olanzapine,Actionable,PSYCHIATRY,Level 2A,CYP1A2 + HTR2C,No,CYP1A2,HTR2C,-,-,DPWG (No Recommendation),"CYP1A2: rs762551,CC; Slow Metabolizer + HTR2C: rs3813929,T",Slow Metabolizer,"rs762551,CC",-,-,-,-,-,-,-,-,-,-,-,-,"rs3813929,T",-,-,-,-,Normal Response,Use as Directed,-,‚úÖ,Normal Response,-,-,-
Olanzapine,Actionable,PSYCHIATRY,Level 2A,CYP1A2 + HTR2C,No,CYP1A2,HTR2C,-,-,DPWG (No Recommendation),"CYP1A2: rs762551,AA; Fast Metabolizer + HTR2C: rs3813929,TT",Fast Metabolizer,"rs762551,AA",-,-,-,-,-,-,-,-,-,-,-,-,"rs3813929,TT",-,-,-,-,Reduced Response,Use with Caution,-,‚ö†Ô∏è,Reduced Response,-,-,-
Olanzapine,Actionable,PSYCHIATRY,Level 2A,CYP1A2 + HTR2C,No,CYP1A2,HTR2C,-,-,DPWG (No Recommendation),"CYP1A2: rs762551,AC; Slow Metabolizer + HTR2C: rs3813929,TT",Slow Metabolizer,"rs762551,AC",-,-,-,-,-,-,-,-,-,-,-,-,"rs3813929,TT",-,-,-,-,Normal Response,Use as Directed,-,‚úÖ,Normal Response,-,-,-
Olanzapine,Actionable,PSYCHIATRY,Level 2A,CYP1A2 + HTR2C,No,CYP1A2,HTR2C,-,-,DPWG (No Recommendation),"CYP1A2: rs762551,CC; Slow Metabolizer + HTR2C: rs3813929,TT",Slow Metabolizer,"rs762551,CC",-,-,-,-,-,-,-,-,-,-,-,-,"rs3813929,TT",-,-,-,-,Normal Response,Use as Directed,-,‚úÖ,Normal Response,-,-,-
Clozapine,Actionable,PSYCHIATRY,Level 1B,CYP2D6,Yes,CYP2D6,-,-,FDA evidence,DPWG (No Recommendation),Ultrarapid Metabolizer (>2),Ultrarapid Metabolizer,-,>2,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure; Minimal Evidence for clinical Impact,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Clozapine,Actionable,PSYCHIATRY,Level 1B,CYP2D6,Yes,CYP2D6,-,-,FDA evidence,DPWG (No Recommendation),Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Clozapine,Actionable,PSYCHIATRY,Level 1B,CYP2D6,Yes,CYP2D6,-,-,FDA evidence,DPWG (No Recommendation),Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Clozapine,Actionable,PSYCHIATRY,Level 1B,CYP2D6,Yes,CYP2D6,-,-,FDA evidence,DPWG (No Recommendation),Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,-,-,-,-
Clozapine,Actionable,PSYCHIATRY,Level 1B,CYP2D6,Yes,CYP2D6,-,-,FDA evidence,DPWG (No Recommendation),Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use with Caution,-,‚ö†Ô∏è,-,-,-,-
Clozapine,Actionable,PSYCHIATRY,Level 1B,CYP2D6,Yes,CYP2D6,-,-,FDA evidence,DPWG (No Recommendation),Poor metabolizer,Poor metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,Dosage reductions may be necessary.,-,-,-
Citalopram,Actionable,PSYCHIATRY,Level 3,HTR2A,Yes,HTR2A,-,-,Professional guideline; FDA evidence,-,rs7997012 AA,-,rs7997012 AA,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Response,Use as Directed,-,‚úÖ,-,-,-,-
Citalopram,Actionable,PSYCHIATRY,Level 3,HTR2A,Yes,HTR2A,-,-,Professional guideline; FDA evidence,-,rs7997012 AG,-,rs7997012 AG,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Response,Use as Directed,-,‚úÖ,-,-,-,-
Citalopram,Actionable,PSYCHIATRY,Level 3,HTR2A,Yes,HTR2A,-,-,Professional guideline; FDA evidence,-,rs7997012 GG,-,rs7997012 GG,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Response,Use with Caution,Efficacy,‚ö†Ô∏è,-,-,-,-
Citalopram,Actionable,PSYCHIATRY,n/a,CYP2C19,Yes,CYP2C19,-,-,Professional guideline; FDA evidence,CPIC; DPWG,Indeterminate,Indeterminate,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,n/a,-,n/a,-,No recommendation,-,-,-
Citalopram,Actionable,PSYCHIATRY,Level 1A(Moderate),CYP2C19,Yes,CYP2C19,-,-,Professional guideline; FDA evidence,CPIC; DPWG,Intermediate Metabolizer,Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure; Minimal evidence for clinical impact,Use with Caution,Efficacy,‚ö†Ô∏è,Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose than normal metabolizers.,-,-,-
Citalopram,Actionable,PSYCHIATRY,Level 1A(Moderate),CYP2C19,Yes,CYP2C19,-,-,Professional guideline; FDA evidence,CPIC; DPWG,Likely Intermediate Metabolizer,Likely Intermediate Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure; Minimal evidence for clinical impact,Use with Caution,Efficacy,‚ö†Ô∏è,Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose than normal metabolizers.,-,-,-
Citalopram,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2C19,Yes,CYP2C19,-,-,Professional guideline; FDA evidence,CPIC; DPWG,Likely Poor Metabolizer,Likely Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Consider a clinically appropriate antidepressant not predominantly metabolized by CYP2C19. If citalopram or escitalopram are clinically appropriate, consider a lower starting dose, slower titration schedule and 50% reduction of the standard maintenance dose as compared to normal metabolizers.",-,-,-
Citalopram,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2C19,Yes,CYP2C19,-,-,Professional guideline; FDA evidence,CPIC; DPWG,Normal Metabolizer,Normal Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Normal Exposure,Use as Directed,-,‚úÖ,Initiate therapy with recommended starting dose,-,-,-
Citalopram,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2C19,Yes,CYP2C19,-,-,Professional guideline; FDA evidence,CPIC; DPWG,Poor Metabolizer,Poor Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Increased Exposure,Increased Caution/Avoid,Toxicity,üõë,"Consider a clinically appropriate antidepressant not predominantly metabolized by CYP2C19. If citalopram or escitalopram are clinically appropriate, consider a lower starting dose, slower titration schedule and 50% reduction of the standard maintenance dose as compared to normal metabolizers.",-,-,-
Citalopram,Actionable,PSYCHIATRY,Level 1A(Optional),CYP2C19,Yes,CYP2C19,-,-,Professional guideline; FDA evidence,CPIC; DPWG,Rapid Metabolizer,Rapid Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure,Use with Caution,Efficacy,‚ö†Ô∏è,"Initiate therapy with recommended starting dose. If patient does not adequately respond to recommended maintenance dosing, consider titrating to a higher maintenance dose or switching to a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.",-,-,-
Citalopram,Actionable,PSYCHIATRY,Level 1A(Strong),CYP2C19,Yes,CYP2C19,-,-,Professional guideline; FDA evidence,CPIC; DPWG,Ultrarapid Metabolizer,Ultrarapid Metabolizer,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,Decreased Exposure,Increased Caution/Avoid,Efficacy,üõë,"Consider a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19. If citalopram or escitalopram are clinically appropriate, and adequate efficacy is not achieved at standard maintenance dosing, consider titrating to a higher maintenance dose.",-,-,-
Desloratadine,Limited pharmacogenetic impact,ALLERGY,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-
Montelukast,Limited pharmacogenetic impact,ALLERGY,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-
Dexmedetomidine,Limited pharmacogenetic impact,ANALGESIC / ANESTHESIOLOGY,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-
Naloxone,Limited pharmacogenetic impact,ANALGESIC / ANESTHESIOLOGY,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-
Dalteparin,Limited pharmacogenetic impact,ANTICOAGULANT / ANTIPLATELET,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-
Enoxaparin,Limited pharmacogenetic impact,ANTICOAGULANT / ANTIPLATELET,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-
Prasugrel,Limited pharmacogenetic impact,ANTICOAGULANT / ANTIPLATELET,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-
Tirofiban,Limited pharmacogenetic impact,ANTICOAGULANT / ANTIPLATELET,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-
Alirocumab,Limited pharmacogenetic impact,CARDIOVASCULAR,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-
Colesevelam,Limited pharmacogenetic impact,CARDIOVASCULAR,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-
Digoxin,Limited pharmacogenetic impact,CARDIOVASCULAR,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-
Gemfibrozil,Limited pharmacogenetic impact,CARDIOVASCULAR,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-
Lisinopril,Limited pharmacogenetic impact,CARDIOVASCULAR,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-
Sotalol,Limited pharmacogenetic impact,CARDIOVASCULAR,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-
Spironolactone,Limited pharmacogenetic impact,CARDIOVASCULAR,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-
Telmisartan,Limited pharmacogenetic impact,CARDIOVASCULAR,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-
Exenatide,Limited pharmacogenetic impact,ENDOCRINOLOGY,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-
Ibandronate,Limited pharmacogenetic impact,ENDOCRINOLOGY,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-
Insulin aspart,Limited pharmacogenetic impact,ENDOCRINOLOGY,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-
Insulin aspart protamine/ Insulin aspart,Limited pharmacogenetic impact,ENDOCRINOLOGY,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-
Insulin aspart/Insulin degludec,Limited pharmacogenetic impact,ENDOCRINOLOGY,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-
Insulin degludec,Limited pharmacogenetic impact,ENDOCRINOLOGY,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-
Insulin detemir,Limited pharmacogenetic impact,ENDOCRINOLOGY,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-
Insulin glargine,Limited pharmacogenetic impact,ENDOCRINOLOGY,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-
Insulin glulisine,Limited pharmacogenetic impact,ENDOCRINOLOGY,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-
Insulin lispro,Limited pharmacogenetic impact,ENDOCRINOLOGY,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-
Insulin lispro protamine/ Insulin lispro,Limited pharmacogenetic impact,ENDOCRINOLOGY,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-
Insulin NPH,Limited pharmacogenetic impact,ENDOCRINOLOGY,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-
Insulin NPH/Insulin regular,Limited pharmacogenetic impact,ENDOCRINOLOGY,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-
Insulin regular,Limited pharmacogenetic impact,ENDOCRINOLOGY,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-
Insulin regular (oral inhalation),Limited pharmacogenetic impact,ENDOCRINOLOGY,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-
Levothyroxine,Limited pharmacogenetic impact,ENDOCRINOLOGY,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-
Metformin,Limited pharmacogenetic impact,ENDOCRINOLOGY,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-
Pamidronate,Limited pharmacogenetic impact,ENDOCRINOLOGY,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-
Risedronate,Limited pharmacogenetic impact,ENDOCRINOLOGY,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-
Vasopressin,Limited pharmacogenetic impact,ENDOCRINOLOGY,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-
Sapropterin,Limited pharmacogenetic impact,GENETIC DISEASE,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-
Sodium phenylbutyrate,Limited pharmacogenetic impact,GENETIC DISEASE,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-
Velaglucerase alfa,Limited pharmacogenetic impact,GENETIC DISEASE,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-
Afatinib,Limited pharmacogenetic impact,ONCOLOGY,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-
Alemtuzumab,Limited pharmacogenetic impact,ONCOLOGY,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-
Darbepoetin alfa,Limited pharmacogenetic impact,ONCOLOGY,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-
Epoetin alfa,Limited pharmacogenetic impact,ONCOLOGY,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-
Ibritumomab,Limited pharmacogenetic impact,ONCOLOGY,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-
Obinutuzumab,Limited pharmacogenetic impact,ONCOLOGY,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-
Ofatumumab,Limited pharmacogenetic impact,ONCOLOGY,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-
Panitumumab,Limited pharmacogenetic impact,ONCOLOGY,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-
Pertuzumab,Limited pharmacogenetic impact,ONCOLOGY,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-
Mycophenolate sodium,Limited pharmacogenetic impact,Immunosuppression,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-
Atovaquone,Limited pharmacogenetic impact,INFECTIOUS DISEASE,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-
Cefdinir,Limited pharmacogenetic impact,INFECTIOUS DISEASE,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-
Ceftriaxone,Limited pharmacogenetic impact,INFECTIOUS DISEASE,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-
Fluconazole,Limited pharmacogenetic impact,INFECTIOUS DISEASE,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-
Flucytosine,Limited pharmacogenetic impact,INFECTIOUS DISEASE,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-
Levofloxacin,Limited pharmacogenetic impact,INFECTIOUS DISEASE,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-
Meropenem,Limited pharmacogenetic impact,INFECTIOUS DISEASE,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-
Moxifloxacin,Limited pharmacogenetic impact,INFECTIOUS DISEASE,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-
Nystatin,Limited pharmacogenetic impact,INFECTIOUS DISEASE,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-
Piperacillin,Limited pharmacogenetic impact,INFECTIOUS DISEASE,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-
Posaconazole,Limited pharmacogenetic impact,INFECTIOUS DISEASE,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-
Vancomycin,Limited pharmacogenetic impact,INFECTIOUS DISEASE,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-
Zanamivir,Limited pharmacogenetic impact,INFECTIOUS DISEASE,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-
Gabapentin,Limited pharmacogenetic impact,NEUROLOGY,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-
Levetiracetam,Limited pharmacogenetic impact,NEUROLOGY,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-
Memantine,Limited pharmacogenetic impact,NEUROLOGY,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-
Pramipexole,Limited pharmacogenetic impact,NEUROLOGY,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-
Pregabalin,Limited pharmacogenetic impact,NEUROLOGY,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-
Succimer,Limited pharmacogenetic impact,NEUROLOGY,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-
Vigabatrin,Limited pharmacogenetic impact,NEUROLOGY,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-
Desvenlafaxine,Limited pharmacogenetic impact,PSYCHIATRY,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-
Lithium,Limited pharmacogenetic impact,PSYCHIATRY,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-
Milnacipran,Limited pharmacogenetic impact,PSYCHIATRY,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-
Paliperidone,Limited pharmacogenetic impact,PSYCHIATRY,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-
Varenicline,Limited pharmacogenetic impact,PSYCHIATRY,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-
Belimumab,Limited pharmacogenetic impact,RHEUMATOLOGY,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-
Temazepam,Limited pharmacogenetic impact,SLEEP MEDICINE,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-